PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Arif, N; Al-Jefri, M; Bizzi, IH; Perano, GB; Goldman, M; Haq, I; Chua, KL; Mengozzi, M; Neunez, M; Smith, H; Ghezzi, P				Arif, Nadia; Al-Jefri, Majed; Bizzi, Isabella Harb; Perano, Gianni Boitano; Goldman, Michel; Haq, Inam; Chua, Kee Leng; Mengozzi, Manuela; Neunez, Marie; Smith, Helen; Ghezzi, Pietro			Fake News or Weak Science? Visibility and Characterization of Antivaccine Webpages Returned by Google in Different Languages and Countries (vol 9, 1215, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						information quality; google; Internet; news; news media; vaccines; autism; public understanding of science			[Arif, Nadia; Mengozzi, Manuela; Ghezzi, Pietro] Brighton & Sussex Med Sch, Falmer, England; [Al-Jefri, Majed] Univ Brighton, Sch Comp Engn & Math, Brighton, E Sussex, England; [Bizzi, Isabella Harb] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil; [Perano, Gianni Boitano; Haq, Inam] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Goldman, Michel; Neunez, Marie] Univ Libre Bruxelles, Inst Interdisciplinary Innovat Healthcare, Brussels, Belgium; [Chua, Kee Leng; Smith, Helen] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore	University of Brighton; University of Sussex; University of Brighton; Universidade Federal do Rio Grande do Sul; University of Sydney; Universite Libre de Bruxelles; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Ghezzi, P (corresponding author), Brighton & Sussex Med Sch, Falmer, England.	pietro.ghezzi@gmail.com		Ghezzi, Pietro/0000-0003-0911-8358				Arif N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01215	1	0	0	2	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2019	10								2252	10.3389/fimmu.2019.02252	http://dx.doi.org/10.3389/fimmu.2019.02252			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JN5WH	31616426	gold, Green Accepted, Green Published			2022-12-18	WOS:000496967900001
J	Mayer, JU				Mayer, Johannes U.			Commentary: Spatiotemporal Modeling of the Key Migratory Events During the Initiation of Adaptive Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cell migration; dendritic cells; adaptive immunity; innate immunity; cell tracking; Kaede mice; photoconversion	DENDRITIC CELLS; LYMPH-NODES; MACROPHAGES; DYNAMICS		[Mayer, Johannes U.] Malaghan Inst Med Res, Wellington, New Zealand	Malaghan Institute; Victoria University Wellington	Mayer, JU (corresponding author), Malaghan Inst Med Res, Wellington, New Zealand.	jmayer@malaghan.org.nz		Mayer, Johannes U/0000-0001-6225-7803	Research for Life Foundation	Research for Life Foundation	I would like to thank Prof. Franca Ronchese for providing comments on the manuscript and the Research for Life Foundation for funding.	Allenspach EJ, 2008, IMMUNITY, V29, P795, DOI 10.1016/j.immuni.2008.08.013; Bernhard CA, 2015, P NATL ACAD SCI USA, V112, P5461, DOI 10.1073/pnas.1423356112; Blecher-Gonen R, 2019, CELL SYST, V8, P109, DOI 10.1016/j.cels.2019.01.001; Bravo-Blas A, 2019, J IMMUNOL, V202, P260, DOI 10.4049/jimmunol.1701254; Cabeza-Cabrerizo M, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw1941; Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090; Cerovic V, 2013, MUCOSAL IMMUNOL, V6, P104, DOI 10.1038/mi.2012.53; Cerovic V, 2014, TRENDS IMMUNOL, V35, P270, DOI 10.1016/j.it.2014.04.003; Chow KV, 2016, J IMMUNOL, V196, P624, DOI 10.4049/jimmunol.1501202; Chtanova T, 2008, IMMUNITY, V29, P487, DOI 10.1016/j.immuni.2008.07.012; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; Gerner MY, 2017, J EXP MED, V214, P3105, DOI 10.1084/jem.20170335; Harrell MI, 2008, J IMMUNOL METHODS, V332, P170, DOI 10.1016/j.jim.2007.11.012; Hayes AJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00598; Houston SA, 2016, MUCOSAL IMMUNOL, V9, P468, DOI 10.1038/mi.2015.77; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Mayer JU, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15820; Nemet I, 2015, PHOTOCH PHOTOBIO SCI, V14, P1787, DOI 10.1039/c5pp00174a; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Randolph GJ, 2017, ANNU REV IMMUNOL, V35, P31, DOI 10.1146/annurev-immunol-041015-055354; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Schulz O, 2009, J EXP MED, V206, P3101, DOI 10.1084/jem.20091925; Tomura M, 2008, P NATL ACAD SCI USA, V105, P10871, DOI 10.1073/pnas.0802278105; Tomura M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06030; Worbs T, 2017, NAT REV IMMUNOL, V17, P30, DOI 10.1038/nri.2016.116	26	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 24	2019	10								2311	10.3389/fimmu.2019.02311	http://dx.doi.org/10.3389/fimmu.2019.02311			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	JA1NQ	31681263	Green Published, gold			2022-12-18	WOS:000487584100001
J	Virtanen, T; Rytkonen-Nissinen, M				Virtanen, Tuomas; Rytkonen-Nissinen, Marja			Commentary: Allergen and Epitope Targets of Mouse-Specific T Cell Responses in Allergy and Asthma	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allergenicity; allergen; animal allergen; lipocalin; lipocalin allergen; T cell; T cell recognition; T cell epitope	LIPOCALIN ALLERGEN; DOG ALLERGEN; BOS-D-2		[Virtanen, Tuomas; Rytkonen-Nissinen, Marja] Univ Eastern Finland, Inst Clin Med, Sch Med, Dept Clin Microbiol, Kuopio, Finland	University of Eastern Finland	Virtanen, T (corresponding author), Univ Eastern Finland, Inst Clin Med, Sch Med, Dept Clin Microbiol, Kuopio, Finland.	tuomas.virtanen@uef.fi		Rytkonen-Nissinen, Marja/0000-0002-2014-8315	University of Eastern Finland	University of Eastern Finland	This study was supported by University of Eastern Finland.	Immonen A, 2007, CLIN EXP ALLERGY, V37, P939, DOI 10.1111/j.1365-2222.2007.02722.x; Immonen A, 2003, CLIN EXP ALLERGY, V33, P834, DOI 10.1046/j.1365-2222.2003.01669.x; Immonen A, 2005, J IMMUNOL, V175, P3614, DOI 10.4049/jimmunol.175.6.3614; Jeal H, 2004, CLIN EXP ALLERGY, V34, P1919, DOI 10.1111/j.1365-2222.2004.02126.x; Juntunen R, 2009, MOL IMMUNOL, V46, P3320, DOI 10.1016/j.molimm.2009.07.022; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Kinnunen T, 2003, EUR J IMMUNOL, V33, P1717, DOI 10.1002/eji.200322952; Kinnunen T, 2005, CLIN EXP ALLERGY, V35, P797, DOI 10.1111/j.1365-2222.2005.02247.x; Liukko ALK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098461; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Ronka AL, 2015, J ALLERGY CLIN IMMUN, V136, P1047, DOI 10.1016/j.jaci.2015.02.025; Saarelainen S, 2002, INT IMMUNOL, V14, P401, DOI 10.1093/intimm/14.4.401; Schulten V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00235; Virtanen T, 1999, IMMUNOL TODAY, V20, P398, DOI 10.1016/S0167-5699(99)01515-7; Virtanen T, 2012, CLIN EXP ALLERGY, V42, P494, DOI 10.1111/j.1365-2222.2011.03903.x; Virtanen T, 2014, ALLERGENS AND ALLERGEN IMMUNOTHERAPY: SUBCUTANEOUS, SUBLINGUAL,AND ORAL, 5TH EDITION, P217; Zeiler T, 1999, J IMMUNOL, V162, P1415	17	0	0	6	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2019	10								2266	10.3389/fimmu.2019.02266	http://dx.doi.org/10.3389/fimmu.2019.02266			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IZ6KJ	31620142	Green Published, gold			2022-12-18	WOS:000487190000001
J	Korf, H; Wiest, R; Jalan, R; van der Merwe, S				Korf, Hannelie; Wiest, Reiner; Jalan, Rajiv; van der Merwe, Schalk			Editorial: The Role of Myeloid-Derived Cells in the Progression of Liver Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						liver disease; innate immunity; myeloid-derived cells; inflammation; macrophage	SIGNALS		[Korf, Hannelie; van der Merwe, Schalk] Katholieke Univ Leuven, CHROMETA Dept, Lab Hepatol, Leuven, Belgium; [Wiest, Reiner] Univ Bern, Dept Biomed Res, Maurice Muller Labs, Bern, Switzerland; [Wiest, Reiner] Univ Bern, Bern Univ Hosp, Dept Visceral Surg & Med, Bern, Switzerland; [Jalan, Rajiv] UCL, Inst Liver Dis Hlth, Liver Failure Grp, London, England; [van der Merwe, Schalk] UZ Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium	KU Leuven; University of Bern; University of Bern; University Hospital of Bern; University of London; University College London; KU Leuven; University Hospital Leuven	Korf, H (corresponding author), Katholieke Univ Leuven, CHROMETA Dept, Lab Hepatol, Leuven, Belgium.	hannelie.korf@kuleuven.be		Van der Merwe, Schalk/0000-0002-9891-2686; Korf, Hannelie/0000-0003-3540-0138	International Liver Disease Award (Gilead Sciences, Inc)	International Liver Disease Award (Gilead Sciences, Inc)	HK was supported by an International Liver Disease Award (Gilead Sciences, Inc).	De Schepper S, 2018, CELL, V175, P400, DOI 10.1016/j.cell.2018.07.048; Guillot A, 2019, HEPATOL COMMUN, V3, P730, DOI 10.1002/hep4.1356; Hoeksema MA, 2019, ATHEROSCLEROSIS, V281, P159, DOI 10.1016/j.atherosclerosis.2018.10.005; Korf H, 2019, GUT, V68, P1872, DOI 10.1136/gutjnl-2018-316888; MacParland SA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06318-7; Okabe Y, 2014, CELL, V157, P832, DOI 10.1016/j.cell.2014.04.016; Sorribas M, 2019, BIORXIV, DOI 10.1016/j.jhep.2019.06.017; T'Jonck W, 2018, CELL IMMUNOL, V330, P43, DOI 10.1016/j.cellimm.2018.02.005	8	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 18	2019	10								2208	10.3389/fimmu.2019.02208	http://dx.doi.org/10.3389/fimmu.2019.02208			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IY4VQ	31620130	Green Published, gold			2022-12-18	WOS:000486391500001
J	Srivastava, BS; Singh, VK; Kashyap, VK; Srivastava, R; Khan, A; Jagannath, C				Srivastava, Brahm S.; Singh, Vipul K.; Kashyap, Vivek K.; Srivastava, Ranjana; Khan, Arshad; Jagannath, Chinnaswamy			Commentary: Bettering BCG: a tough task for a TB vaccine?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						LipY lipase from Mycobacterium tuberculosis; BCG-bacille calmette-guerin vaccine; M. tuberculosis; vaccine; booster antigen	MYCOBACTERIUM-TUBERCULOSIS; TRIACYLGLYCEROL; IDENTIFICATION; GENES; INFECTION; LIPY		[Srivastava, Brahm S.; Srivastava, Ranjana] Nextec Lifesci, Lucknow, Uttar Pradesh, India; [Singh, Vipul K.; Khan, Arshad; Jagannath, Chinnaswamy] Houston Methodist Res Inst, Dept Pathol & Genom Med, Houston, TX 77030 USA; [Kashyap, Vivek K.] Univ Texas Rio Grande Valley, Dept Immunol & Microbiol, Mcallen, TX USA	The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; University of Texas Rio Grande Valley	Singh, VK (corresponding author), Houston Methodist Res Inst, Dept Pathol & Genom Med, Houston, TX 77030 USA.	vsingh@houstonmethodist.org	Singh, Vipul Kumar/AAA-9302-2020; KASHYAP, VIVEK/ABF-1810-2021; Khan, Arshad/E-6855-2015	Khan, Arshad/0000-0003-3655-2854; Singh, Vipul Kumar/0000-0002-7146-7279				Bishai W, 2013, NAT MED, V19, P410, DOI 10.1038/nm.3153; Deb C, 2006, J BIOL CHEM, V281, P3866, DOI 10.1074/jbc.M505556200; Low KL, 2009, J BACTERIOL, V191, P5037, DOI 10.1128/JB.00530-09; Mishra KC, 2008, INFECT IMMUN, V76, P127, DOI 10.1128/IAI.00410-07; Parti RPS, 2005, MICROBES INFECT, V7, P349, DOI 10.1016/j.micinf.2004.11.006; Saxena A, 2008, TUBERCULOSIS, V88, P518, DOI 10.1016/j.tube.2008.01.003; Saxena AK, 2013, INT J ANTIMICROB AG, V42, P27, DOI 10.1016/j.ijantimicag.2013.03.007; Singh VK, 2016, EUR J CLIN MICROBIOL, V35, P535, DOI 10.1007/s10096-016-2579-y; Singh VK, 2014, TUBERCULOSIS, V94, P252, DOI 10.1016/j.tube.2014.02.001; Singh VK, 2011, VACCINE, V29, P4754, DOI 10.1016/j.vaccine.2011.04.086; Srivastava V, 2008, TUBERCULOSIS, V88, P171, DOI 10.1016/j.tube.2007.10.002; Srivastava V, 2007, MICROBIOL-SGM, V153, P659, DOI 10.1099/mic.0.2006/000547-0; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4	13	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 12	2019	10								2195	10.3389/fimmu.2019.02195	http://dx.doi.org/10.3389/fimmu.2019.02195			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IW8ZL	31572397	Green Published, gold			2022-12-18	WOS:000485282600001
J	Abbehusen, MMC; Cunha, J; Suarez, MS; Teixeira, C; Almeida, VD; Pereira, LD; Bordoni, M; Gil-Santana, L; Solca, MD; Fraga, DBM; Fischer, L; Bozza, PT; Veras, PST; Valenzuela, JG; Kamhawi, S; Andrade, BB; Brodskyn, CI				Costa Abbehusen, Melissa Moura; Cunha, Jurema; Suarez, Martha Sena; Teixeira, Clarissa; Almeida, Valter dos Anjos; Pereira, Lais da Silva; Bordoni, Marcelo; Gil-Santana, Leonardo; Solca, Manuela da Silva; Mote Fraga, Deborah Bittencourt; Fischer, Laurent; Bozza, Patricia Torres; Tavares Veras, Patricia Sampaio; Valenzuela, Jesus G.; Kamhawi, Shaden; Andrade, Bruno B.; Brodskyn, Claudia I.			Immunization of Experimental Dogs With Salivary Proteins From Lutzomyia longipalpis, Using DNA and Recombinant Canarypox Virus Induces Immune Responses Consistent With Protection Against Leishmania infantum (vol 9, 2558, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						vaccine; sand fly; canine visceral leishmaniasis; disease vectors; salivary proteins			[Costa Abbehusen, Melissa Moura; Cunha, Jurema; Suarez, Martha Sena; Almeida, Valter dos Anjos; Pereira, Lais da Silva; Bordoni, Marcelo; Gil-Santana, Leonardo; Solca, Manuela da Silva; Mote Fraga, Deborah Bittencourt; Tavares Veras, Patricia Sampaio; Andrade, Bruno B.; Brodskyn, Claudia I.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil; [Teixeira, Clarissa] Fundacao Oswaldo Cruz, Fiocruz Piaui, Teresina, Brazil; [Fischer, Laurent] Boerhinger Ingelheim, R&D, Lab Lyon Portes Alpes, Lyon, France; [Bozza, Patricia Torres; Kamhawi, Shaden] Fundacao Oswaldo Cruz, Inst Oswaldo, Lab Imunofarmacol, Rio De Janeiro, Brazil; [Valenzuela, Jesus G.] NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Andrade, Bruno B.] Fundacao Jose Silveira, Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil; [Andrade, Bruno B.] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil; [Andrade, Bruno B.] Laureate Univ, Univ Salvador UNIFACS, Salvador, BA, Brazil; [Brodskyn, Claudia I.] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil; [Brodskyn, Claudia I.] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil; [Brodskyn, Claudia I.] Nacl Ciencia & Tecnol Invest Imunol III INCT, Sao Paulo, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Escola Bahiana de Medicina e Saude Publica; Universidade Salvador (UNIFACS); Universidade Federal da Bahia; Universidade Federal da Bahia	Brodskyn, CI (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.; Brodskyn, CI (corresponding author), Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.; Brodskyn, CI (corresponding author), Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil.; Brodskyn, CI (corresponding author), Nacl Ciencia & Tecnol Invest Imunol III INCT, Sao Paulo, Brazil.	brodskyn@bahia.fiocruz.br	da Silva Solcà, Manuela/J-6386-2015; Veras, Patricia S T Sampaio Tavares/I-9632-2014; Andrade, Bruno/AAI-2248-2020; Bozza, Patricia T./AAM-4537-2021; Fraga, Deborah/AAL-5342-2021; Bozza, Patricia T./AAE-2933-2021	da Silva Solcà, Manuela/0000-0001-9014-8903; Veras, Patricia S T Sampaio Tavares/0000-0001-8308-9263; Bozza, Patricia T./0000-0001-8349-9529; Andrade, Bruno/0000-0001-6833-3811				Abbehusen MMC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02558	1	0	0	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 12	2019	10								1828	10.3389/fimmu.2019.01828	http://dx.doi.org/10.3389/fimmu.2019.01828			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IP9ZB	31431808	Green Published, gold			2022-12-18	WOS:000480408400001
J	Segovia-Mendoza, M; Morales-Montor, J				Segovia-Mendoza, M.; Morales-Montor, J.			Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology (vol 10, 348, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						immune infiltration; breast cancer; estrogen receptor; estrogen receptor inhibitors; tumor microenvironment							Montor, Jorge/B-1224-2012	Montor, Jorge/0000-0002-9461-610X				Segovia-Mendoza M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00348	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 9	2019	10								1868	10.3389/fimmu.2019.01868	http://dx.doi.org/10.3389/fimmu.2019.01868			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IP7WA		gold, Green Published			2022-12-18	WOS:000480257600001
J	Hartog, NL; Williams, KW; Abraham, RS				Hartog, Nicholas L.; Williams, Kelli W.; Abraham, Roshini S.			"The State of the Union": Current and Future Perspectives on Patient-Centric Care for Primary Immunodeficiencies and Immune Dysregulatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						primary immunodeficiencies (PI); patient-doctor relationship; specialty; alliance; global healthcare; immunoglobulin replacement therapy (IGRT); newborn screen (NBS)	ACCESS		[Hartog, Nicholas L.] Michigan State Coll Human Med, Div Allergy & Immunol, Grand Rapids, MI USA; [Hartog, Nicholas L.] Spectrum Hlth Helen DeVos Childrens Hosp, Grand Rapids, MI USA; [Williams, Kelli W.] Med Univ South Carolina, Div Pediat Pulmonol Sleep Med Allergy & Immunol, Dept Pediat, Charleston, SC 29425 USA; [Abraham, Roshini S.] Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH 43205 USA	Michigan State University; Michigan State University College of Human Medicine; Medical University of South Carolina; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Abraham, RS (corresponding author), Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH 43205 USA.	roshini.abraham@nationwidechildrens.org						Al-Herz W, 2008, J CLIN IMMUNOL, V28, P186, DOI 10.1007/s10875-007-9144-5; Bousfiha AA, 2013, J CLIN IMMUNOL, V33, P1, DOI 10.1007/s10875-012-9751-7; Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1; Chan A, 2011, CLIN IMMUNOL, V138, P3, DOI 10.1016/j.clim.2010.09.010; Chapel H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00627; Erwa Nahla H H, 2015, J Clin Immunol, V35, P517, DOI 10.1007/s10875-015-0179-8; Espinosa-Rosales FJ, 2016, J CLIN IMMUNOL, V36, P415, DOI 10.1007/s10875-016-0277-2; Fullman N, 2018, LANCET, V391, P2236, DOI [10.1016/S0140-6736(18)30994-2, 10.1016/s0140-6736(18)30994-2]; Gennery AR, 2018, J CLIN IMMUNOL, V38, P447, DOI 10.1007/s10875-018-0517-8; Gupta S, 2012, ANN NY ACAD SCI, V1250, P73, DOI 10.1111/j.1749-6632.2011.06353.x; Jindal AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00714; Lee PPW, 2011, ANN NY ACAD SCI, V1238, P33, DOI 10.1111/j.1749-6632.2011.06225.x; Leiva LE, 2011, ALLERGOL IMMUNOPATH, V39, P106, DOI 10.1016/j.aller.2010.10.007; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Mossialos E, 2014, INT PROFILES HLTH CA; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Stewart M, 2003, PATIENT CENTERED MED	18	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2019	10								1783	10.3389/fimmu.2019.01783	http://dx.doi.org/10.3389/fimmu.2019.01783			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IM1VT	31402922	Green Published, gold			2022-12-18	WOS:000477780500001
J	Garmendia, J; Gonzalo-Asensio, J				Garmendia, Junkal; Gonzalo-Asensio, Jesus			Editorial: Update on the Immune Mechanisms Against Respiratory Pathogens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						bacterial respiratory pathogens; viral airway pathogens; respiratory fungi; vaccines; antimicrobials; host immunity			[Garmendia, Junkal] Consejo Super Invest Cient IdAB CSIC Gobierno Nav, Inst Agrobiotecnol, Mutilva, Spain; [Garmendia, Junkal; Gonzalo-Asensio, Jesus] Ctr Invest Biomed Red Enfermedades Resp, Madrid, Spain; [Gonzalo-Asensio, Jesus] Univ Zaragoza, Grp Genet Micobacterias, Dept Microbiol Med Prevent & Salud Publ, Fac Med, Zaragoza, Spain; [Gonzalo-Asensio, Jesus] Inst Biocomputac & Fis Sistemas Complejos BIFI, Zaragoza, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-GN-UPNA - Instituto de Agrobiotecnologia (IDAB); CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Zaragoza	Garmendia, J (corresponding author), Consejo Super Invest Cient IdAB CSIC Gobierno Nav, Inst Agrobiotecnol, Mutilva, Spain.; Garmendia, J; Gonzalo-Asensio, J (corresponding author), Ctr Invest Biomed Red Enfermedades Resp, Madrid, Spain.; Gonzalo-Asensio, J (corresponding author), Univ Zaragoza, Grp Genet Micobacterias, Dept Microbiol Med Prevent & Salud Publ, Fac Med, Zaragoza, Spain.; Gonzalo-Asensio, J (corresponding author), Inst Biocomputac & Fis Sistemas Complejos BIFI, Zaragoza, Spain.	juncal.garmendia@csic.es; jagonzal@unizar.es	Gonzalo-Asensio, Jesús/E-4122-2013	Gonzalo-Asensio, Jesús/0000-0001-8841-6593	MINECO [SAF2015-66520-R, RTI2018-096369-B-I00, BFU2015-72190-EXP]; Health Department, Regional Govern from Navarra, Spain [03/2016]; SEPAR [31/2015]	MINECO(Spanish Government); Health Department, Regional Govern from Navarra, Spain; SEPAR	This work was supported by grants from MINECO SAF2015-66520-R and RTI2018-096369-B-I00, from Health Department, Regional Govern from Navarra, Spain, reference 03/2016, and from SEPAR 31/2015 to JG, and also from MINECO BFU2015-72190-EXP to JG-A. CIBER is an initiative from Instituto de Salud Carlos III (ISCIII), Madrid.	WHO, 2021, GLOBAL TUBERCULOSIS; WHO, 2018, GLOB HLTH EST 2019 D; WHO, 2017, GLOB PRIOR LIST ANT, DOI DOI 10.1016/S1473-3099(17)30753-3	3	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 23	2019	10								1730	10.3389/fimmu.2019.01730	http://dx.doi.org/10.3389/fimmu.2019.01730			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IK7FF	31396232	Green Published, gold			2022-12-18	WOS:000476753700001
J							Frontiers Editorial Off	RETRACTION: Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells (Retraction of Vol 9, art no 824, 2018)	FRONTIERS IN IMMUNOLOGY			English	Retraction																		Zhu LY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00824	1	0	0	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 16	2019	10								1770	10.3389/fimmu.2019.01770	http://dx.doi.org/10.3389/fimmu.2019.01770			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IJ3SU		gold, Green Published			2022-12-18	WOS:000475825600001
J	Grebennikov, D; Bouchnita, A; Volpert, V; Bessonov, N; Meyerhans, A; Bocharov, G				Grebennikov, Dmitry; Bouchnita, Anass; Volpert, Vitaly; Bessonov, Nikolay; Meyerhans, Andreas; Bocharov, Gennady			Spatial Lymphocyte Dynamics in Lymph Nodes Predicts the Cytotoxic T Cell Frequency Needed for HIV Infection Control (vol 10, 1213, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						lymphoid tissue; cell motility; HIV infection; cytotoxic T cell scanning; multicellular dynamics; dissipative particle dynamics; stochastic differential equation			[Grebennikov, Dmitry] Natl Res Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, Russia; [Grebennikov, Dmitry; Bocharov, Gennady] Russian Acad Sci, Marchuk Inst Numer Math, Moscow, Russia; [Grebennikov, Dmitry; Volpert, Vitaly] RUDN Univ, Peoples Friendship Univ Russia, Moscow, Russia; [Bouchnita, Anass] Uppsala Univ, Div Sci Comp, Dept Informat Technol, Uppsala, Sweden; [Volpert, Vitaly] Univ Lyon 1, UMR CNRS 5208, Inst Camille Jordan, Villeurbanne, France; [Volpert, Vitaly] INRIA Lyon La Doua, INRIA Team Dracula, Villeurbanne, France; [Bessonov, Nikolay] Russian Acad Sci, Inst Problems Mech Engn, St Petersburg, Russia; [Meyerhans, Andreas] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Infect Biol Lab, Barcelona, Spain; [Meyerhans, Andreas] ICREA, Barcelona, Spain; [Bocharov, Gennady] Sechenov First Moscow State Med Univ, Moscow, Russia	Moscow Institute of Physics & Technology; Russian Academy of Sciences; Peoples Friendship University of Russia; Uppsala University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Ecole Centrale de Lyon; Institut National des Sciences Appliquees de Lyon - INSA Lyon; Universite Jean Monnet; Russian Academy of Sciences; Pompeu Fabra University; ICREA; Sechenov First Moscow State Medical University	Grebennikov, D (corresponding author), Natl Res Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, Russia.; Grebennikov, D; Bocharov, G (corresponding author), Russian Acad Sci, Marchuk Inst Numer Math, Moscow, Russia.; Grebennikov, D (corresponding author), RUDN Univ, Peoples Friendship Univ Russia, Moscow, Russia.; Bocharov, G (corresponding author), Sechenov First Moscow State Med Univ, Moscow, Russia.	dmitry.ew@gmail.com; bocharov@m.inm.ras.ru	Bouchnita, Anass/AAW-2021-2021; Bocharov, Gennady/GSN-1705-2022; Bocharov, Gennady/AAN-7508-2020; Bocharov, Gennady/AGA-7312-2022; Volpert, Vitaly/E-2969-2019; Grebennikov, Dmitry/I-4310-2018	Bouchnita, Anass/0000-0002-2729-6484; Bocharov, Gennady/0000-0002-5049-0656; Bocharov, Gennady/0000-0002-5049-0656; Bocharov, Gennady/0000-0002-5049-0656; Grebennikov, Dmitry/0000-0002-7315-193X				Grebennikov D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01213	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 3	2019	10								1538	10.3389/fimmu.2019.01538	http://dx.doi.org/10.3389/fimmu.2019.01538			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IG1QI	31333669	Green Published, gold			2022-12-18	WOS:000473565900004
J	Eskandarian, Z; Fliegauf, M; Bulashevska, A; Proietti, M; Hague, R; Smulski, CR; Schubert, D; Warnatz, K; Grimbacher, B				Eskandarian, Zoya; Fliegauf, Manfred; Bulashevska, Alla; Proietti, Michele; Hague, Rosie; Smulski, Cristian Roberto; Schubert, Desiree; Warnatz, Klaus; Grimbacher, Bodo			Assessing the Functional Relevance of Variants in the IKAROS Family Zinc Finger Protein 1 (IKZF1) in a Cohort of Patients With Primary Immunodeficiency (vol 10, 568, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						CVID; monogenic defects; IKAROS; TRAIL; DNA binding; nuclear localization			[Eskandarian, Zoya; Fliegauf, Manfred; Bulashevska, Alla; Proietti, Michele; Schubert, Desiree; Grimbacher, Bodo] Albert Ludwigs Univ Freiburg, Inst Immunodeficiency, Ctr Chron Immunodeficiency, Med Ctr,Fac Med, Freiburg, Germany; [Eskandarian, Zoya] Albert Ludwigs Univ Freiburg, Fac Biol, Freiburg, Germany; [Fliegauf, Manfred; Grimbacher, Bodo] Albert Ludwigs Univ Freiburg, Ctr Integrat Biol Signalling Studies, Freiburg, Germany; [Hague, Rosie] Royal Hosp Children, Glasgow, Lanark, Scotland; [Smulski, Cristian Roberto] Consejo Nacl Invest Cient & Tecn, Dept Med Phys, Ctr Atom Bariloche, San Carlos De Bariloche, Rio Negro, Argentina; [Warnatz, Klaus] Albert Ludwigs Univ Freiburg, Med Ctr, Clin Rheumatol & Clin Immunol, Fac Med,CCI, Freiburg, Germany; [Grimbacher, Bodo] Hanover Med Sch, Satellite Ctr Freiburg, RESIST Cluster Excellence 2155, Freiburg, Germany; [Grimbacher, Bodo] German Ctr Infect Res, Satellite Ctr Freiburg, Freiburg, Germany; [Grimbacher, Bodo] UCL, Royal Free Hosp, Inst Immun & Transplantat, London, England	University of Freiburg; University of Freiburg; University of Freiburg; Comision Nacional de Energia Atomica (CNEA); Centro Atomico Bariloche; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Freiburg; Hannover Medical School; German Center for Infection Research; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Grimbacher, B (corresponding author), Albert Ludwigs Univ Freiburg, Inst Immunodeficiency, Ctr Chron Immunodeficiency, Med Ctr,Fac Med, Freiburg, Germany.; Grimbacher, B (corresponding author), Albert Ludwigs Univ Freiburg, Ctr Integrat Biol Signalling Studies, Freiburg, Germany.; Grimbacher, B (corresponding author), Hanover Med Sch, Satellite Ctr Freiburg, RESIST Cluster Excellence 2155, Freiburg, Germany.; Grimbacher, B (corresponding author), German Ctr Infect Res, Satellite Ctr Freiburg, Freiburg, Germany.; Grimbacher, B (corresponding author), UCL, Royal Free Hosp, Inst Immun & Transplantat, London, England.	bodo.grimbacher@uniklinik-freiburg.de	Warnatz, Klaus/AAD-3464-2022; Bulashevska, Alla/C-4910-2019					Eskandarian Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00568	1	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 28	2019	10								1490	10.3389/fimmu.2019.01490	http://dx.doi.org/10.3389/fimmu.2019.01490			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IF7LK	31316524	gold, Green Published			2022-12-18	WOS:000473265400002
J							Frontiers Editorial Off	RETRACTION: Stimulator of Interferon Genes in Classical Dendritic Cells Controls Mucosal Th17 Responses to Cyclic Dinucleotides for Host Defenses Against Microbial Infections in Gut (vol 9, 1085, 2018) (Retraction of Vol 9, art no 1085, 2018)	FRONTIERS IN IMMUNOLOGY			English	Retraction															NATIONAL CANCER INSTITUTE [U01CA242109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI133041, R01AI120714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE026736] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Liu S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01085	1	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 14	2019	10								1468	10.3389/fimmu.2019.01468	http://dx.doi.org/10.3389/fimmu.2019.01468			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ID8EU		gold, Green Published			2022-12-18	WOS:000471916800001
J	Wei, PH; Li, JJ				Wei, Penghui; Li, Jianjun			Commentary: CD22 blockade restores homeostatic microglial phagocytosis in ageing brains	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CD22 blockade; microglial phagocytosis; immunotherapy; neurodegenerative diseases; POCD	MOUSE		[Wei, Penghui; Li, Jianjun] Shandong Univ Qingdao, Dept Anesthesiol, Qilu Hosp, Qingdao, Shandong, Peoples R China	Shandong University	Li, JJ (corresponding author), Shandong Univ Qingdao, Dept Anesthesiol, Qilu Hosp, Qingdao, Shandong, Peoples R China.	ljj9573@163.com	Li, Jing/GYU-5036-2022; li, jian/GSE-0245-2022; LI, JIAN/GRY-2197-2022; Li, Jin/GYQ-5363-2022		People's Benefit Project of Science and Technology in Qingdao [18-6-1-74-nsh]; Scientific Research Foundation of Qilu Hospital of Shandong University (Qingdao) [QDKY2016QN01, QDKY2016ZD05]	People's Benefit Project of Science and Technology in Qingdao; Scientific Research Foundation of Qilu Hospital of Shandong University (Qingdao)	This work was supported by grants from People's Benefit Project of Science and Technology in Qingdao (18-6-1-74-nsh) and the Scientific Research Foundation of Qilu Hospital of Shandong University (Qingdao) (Grant Nos. QDKY2016QN01 and QDKY2016ZD05).	Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Constantinidou A, 2019, PHARMACOL THERAPEUT, V194, P84, DOI 10.1016/j.pharmthera.2018.09.008; Evered L, 2018, ANESTHESIOLOGY, V129, P872, DOI 10.1097/ALN.0000000000002334; Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737; Marsh SE, 2016, P NATL ACAD SCI USA, V113, pE1316, DOI 10.1073/pnas.1525466113; Obst J, 2018, BRAIN BEHAV IMMUN, V73, P708, DOI 10.1016/j.bbi.2018.08.006; Pluvinage JV, 2019, NATURE, V568, P187, DOI 10.1038/s41586-019-1088-4; Rosenzweig N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08352-5; Skvarc DR, 2018, NEUROSCI BIOBEHAV R, V84, P116, DOI 10.1016/j.neubiorev.2017.11.011; Wei PH, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00073; Xiang XW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00149; Xie ZC, 2013, ANN SURG, V258, P364, DOI 10.1097/SLA.0b013e318298b077	13	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 6	2019	10								1301	10.3389/fimmu.2019.01301	http://dx.doi.org/10.3389/fimmu.2019.01301			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IC5DH	31244847	Green Published, gold			2022-12-18	WOS:000470987200005
J	Bornancin, F; Snow, AL				Bornancin, Frederic; Snow, Andrew L.			CARMA Proteins: Playing a Hand of Four CARDs	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CARD9; CARD10; CARD11; CARD14; Bcl10; Malt1; CARMA; immunodeficiency			[Bornancin, Frederic] Novartis Inst BioMed Res, Autoimmun Transplantat & Inflammat, Basel, Switzerland; [Snow, Andrew L.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol & Mol Therapeut, Bethesda, MD 20814 USA	Novartis; Uniformed Services University of the Health Sciences - USA	Bornancin, F (corresponding author), Novartis Inst BioMed Res, Autoimmun Transplantat & Inflammat, Basel, Switzerland.; Snow, AL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol & Mol Therapeut, Bethesda, MD 20814 USA.	frederic.bornancin@novartis.com; andrew.snow@usuhs.edu	Bornancin, Frederic/AAA-2888-2021	Bornancin, Frederic/0000-0002-0152-6720					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 29	2019	10								1217	10.3389/fimmu.2019.01217	http://dx.doi.org/10.3389/fimmu.2019.01217			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	IA3AR	31231375	gold, Green Published			2022-12-18	WOS:000469435300003
J	Schonfeld, M; Knackmuss, U; Chandorkar, P; Hortnagl, P; Hope, TJ; Moris, A; Bellmann-Weiler, R; Lass-Florl, C; Posch, W; Wilflingseder, D				Schoenfeld, Manuela; Knackmuss, Ulla; Chandorkar, Parul; Hoertnagl, Paul; Hope, Thomas John; Moris, Arnaud; Bellmann-Weiler, Rosa; Lass-Floerl, Cornelia; Posch, Wilfried; Wilflingseder, Doris			Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity	FRONTIERS IN IMMUNOLOGY			English	Article						HIV-1; STIs; dendritic cell; complement; CTL	IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED-DISEASES; DENDRITIC CELLS; COMPLEMENT; TRANSMISSION; CAPTURE; OPSONIZATION; ACTIVATION; PROTECTION; RECEPTORS	Pathogenic bacteria and their microbial products activate dendritic cells (DCs) at mucosal surfaces during sexually transmitted infections (STIs) and therefore might also differently shape DC functions during co-infection with HIV-1. We recently illustrated that complement (C) coating of HIV-1 (HIV-C), as primarily found during the acute phase of infection before appearance of HIV-specific antibodies, by-passed SAMHD1-mediated restriction in DCs and therefore mediated an increased DC activation and antiviral capacity. To determine whether the superior antiviral effects of HIV-C-exposed DCs also apply during STIs, we developed a co-infection model in which DCs were infected with Chlamydia spp. simultaneously (HIV-C/Chlam-DCs or HIV/Chlam-DCs) or a sequential infection model, where DCs were exposed to Chlamydia for 3 or 24 h (Chlam-DCs) followed by HIV-1 infection. Co-infection of DCs with HIV-1 and Chlamydia significantly boosted the CTL-stimulatory capacity compared to HIV-1-loaded iDCs and this boost was independent on the opsonization pattern. This effect was lost in the sequential infection model, when opsonized HIV-1 was added delayed to Chlamydia-loaded DCs. The reduction in the CTL-stimulatory capacity of Chlam-DCs was not due to lower HIV-1 binding or infection compared to iDCs or HIV-C/Chlam-DCs, but due to altered fusion and internalizationmechanisms within DCs. The CTL-stimulatory capacity of HIV-C in Chlam-DCs correlated with significantly reduced viral fusion compared to iDCs and HIV-C/Chlam-DCs and illustrated considerably increased numbers of HIV-C-containing vacuoles than iDCs. The data indicate that Chlamydia co-infection of DCs mediates a transient boost of their HIV-specific CTL-stimulatory and antiviral capacity, while in the sequential infection model this is reversed and associated with hazard to the host.	[Schoenfeld, Manuela; Knackmuss, Ulla; Chandorkar, Parul; Lass-Floerl, Cornelia; Posch, Wilfried; Wilflingseder, Doris] Med Univ Innsbruck, Div Hyg & Med Microbiol, Innsbruck, Austria; [Hoertnagl, Paul] Med Univ Innsbruck, Cent Inst Blood Transfus & Immunol Dept, Innsbruck, Austria; [Hope, Thomas John] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Moris, Arnaud] Sorbonne Univ, INSERM, CNRS, Ctr Immunol & Microbial Infect CIMI Paris, Paris, France; [Moris, Arnaud] Univ Paris Saclay, Univ Paris Sud, CNRS, CEA,I2BC, Gif Sur Yvette, France; [Bellmann-Weiler, Rosa] Med Univ Innsbruck, Dept Internal Med 2, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Northwestern University; Feinberg School of Medicine; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Medical University of Innsbruck	Posch, W; Wilflingseder, D (corresponding author), Med Univ Innsbruck, Div Hyg & Med Microbiol, Innsbruck, Austria.	wilfried.posch@i-med.ac.at; doris.wilflingseder@i-med.ac.at	Lass-Flörl, Cornelia/AAA-8449-2020; Posch, Wilfried/AAH-6845-2019	Posch, Wilfried/0000-0001-8955-7654; Bellmann-Weiler, Rosa/0000-0002-5584-111X; Schonfeld, Manuela/0000-0002-0593-2419; Wilflingseder, Doris/0000-0002-5888-5118; Lass-Florl, Cornelia/0000-0002-2946-7785; Moris, Arnaud/0000-0002-5052-1678	Austrian Science Fund (MCBO graduate program) [P24598, P25389, W011010-21]; Oesterreichische Nationalbank Anniversary Fund [17614]; NIH [UM1AI068618]; Tyrolean Science Fund; ANRS; Sidaction; ANR; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI068618] Funding Source: NIH RePORTER	Austrian Science Fund (MCBO graduate program)(Austrian Science Fund (FWF)); Oesterreichische Nationalbank Anniversary Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tyrolean Science Fund; ANRS(ANRSFrench National Research Agency (ANR)); Sidaction; ANR(French National Research Agency (ANR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We would like to thank our technician Karolin Thurnes, Divison of Hygiene and Medical Microbiology, and Prof. Oliver Keppler, Max-von-Pettenkofer Institute, Munich, Germany, for supplying the HIV plasmids. We would like to thank the Austrian Science Fund (MCBO graduate program/W011010-21 and P24598 to DW, P25389 to WP) and the Oesterreichische Nationalbank Anniversary Fund (Project number: 17614 to WP) for supporting this work. Further, this publication was made possible with help from the HIV Vaccine Trials Network Mucosal Immunology Group Program, an NIH funded program (HVTN LC Grant UM1AI068618 to TJH and DW) and the Tyrolean Science Fund (to DW). AM is supported by ANRS, Sidaction and ANR fundings.	Alcaide ML, 2012, J GLOB INFECT DIS, V4, P141, DOI 10.4103/0974-777X.100566; Bachmann NL, 2014, TRENDS MICROBIOL, V22, P464, DOI 10.1016/j.tim.2014.04.013; Banki Z, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000891; Bellmann-Weiler R, 2010, IMMUNOBIOLOGY, V215, P842, DOI 10.1016/j.imbio.2010.05.021; Bennett AE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000591; Bouhlal H, 2002, J IMMUNOL, V169, P3301, DOI 10.4049/jimmunol.169.6.3301; Burton GF, 1997, IMMUNOL REV, V156, P185, DOI 10.1111/j.1600-065X.1997.tb00968.x; Campbell EM, 2008, J CELL BIOL, V180, P549, DOI 10.1083/jcb.200706154; Casartelli N, 2010, J EXP MED, V207, P39, DOI 10.1084/jem.20091933; Cavrois M, 2006, J VIROL, V80, P1992, DOI 10.1128/JVI.80.4.1992-1999.2006; Chen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059194; Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050; Doncel GF, 2011, AM J REPROD IMMUNOL, V65, P292, DOI 10.1111/j.1600-0897.2010.00931.x; EBENBICHLER CF, 1991, J EXP MED, V174, P1417, DOI 10.1084/jem.174.6.1417; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Hammonds JE, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006181; Hess C, 2002, LANCET, V359, P2230, DOI 10.1016/S0140-6736(02)09291-7; Hickey DK, 2011, J REPROD IMMUNOL, V88, P185, DOI 10.1016/j.jri.2011.01.005; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; Izquierdo-Useros N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004146; Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001448; Izquierdo-Useros N, 2011, TRAFFIC, V12, P1702, DOI 10.1111/j.1600-0854.2011.01281.x; Izquierdo-Useros N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000740; Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642; John EPS, 2007, CLIN IMMUNOL, V125, P95, DOI 10.1016/j.clim.2007.06.004; Kacani L, 2000, J VIROL, V74, P7997, DOI 10.1128/JVI.74.17.7997-8002.2000; Liechti GW, 2014, NATURE, V506, P507, DOI 10.1038/nature12892; Martinez-Picado J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01593; Martinez-Picado J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12412; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Moir S, 2000, J EXP MED, V192, P637, DOI 10.1084/jem.192.5.637; Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Pino M, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0160-x; Posch W, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005005; Posch W, 2012, J ALLERGY CLIN IMMUN, V130, P1368, DOI 10.1016/j.jaci.2012.08.025; Pruenster M, 2005, EUR J IMMUNOL, V35, P2691, DOI 10.1002/eji.200425940; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291; Puryear WB, 2013, ADV EXP MED BIOL, V762, P131, DOI 10.1007/978-1-4614-4433-6_5; Puryear WB, 2012, P NATL ACAD SCI USA, V109, P7475, DOI 10.1073/pnas.1201104109; Rodriguez-Plata MT, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-42; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Sanders RW, 2002, J VIROL, V76, P7812, DOI 10.1128/JVI.76.15.7812-7821.2002; Schifferli JA, 1996, RES IMMUNOL, V147, P109, DOI 10.1016/0923-2494(96)87183-5; Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5; Shen RZ, 2011, AM J REPROD IMMUNOL, V65, P261, DOI 10.1111/j.1600-0897.2010.00939.x; Sheung A, 2008, AIDS, V22, P1729, DOI 10.1097/QAD.0b013e32830baf5e; Slade J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146186; STOIBER H, 1995, AIDS, V9, P19, DOI 10.1097/00002030-199501000-00003; Stoiber H, 2008, VACCINE, V26, pI79, DOI 10.1016/j.vaccine.2008.11.050; Sullivan BL, 1996, J IMMUNOL, V157, P1791; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Wang JH, 2007, J VIROL, V81, P8933, DOI 10.1128/JVI.00878-07; Wang Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00078; Welsch S, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030036; Wilflingseder D, 2007, J IMMUNOL, V178, P7840, DOI 10.4049/jimmunol.178.12.7840; Wilflingseder D, 2015, J INFECT DIS, V212, P44, DOI 10.1093/infdis/jiv014; Wira CR, 2011, AM J REPROD IMMUNOL, V65, P196, DOI 10.1111/j.1600-0897.2011.00970.x; Yu HJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000134	64	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2019	10								1123	10.3389/fimmu.2019.01123	http://dx.doi.org/10.3389/fimmu.2019.01123			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HZ6AA	31178863	Green Published, gold			2022-12-18	WOS:000468932900001
J	Maze, EA; Ham, C; Kelly, J; Ussher, L; Almond, N; Towers, GJ; Berry, N; Belshaw, R				Maze, Emmanuel Atangana; Ham, Claire; Kelly, Jack; Ussher, Lindsay; Almond, Neil; Towers, Greg J.; Berry, Neil; Belshaw, Robert			Variable Baseline Papio cynocephalus Endogenous Retrovirus (PcEV) Expression Is Upregulated in Acutely SIV-Infected Macaques and Correlated to STAT1 Expression in the Spleen	FRONTIERS IN IMMUNOLOGY			English	Article						endogenous retrovirus; STAT1; macaque; PcEV; SIV; RNA; innate immunity	I INTERFERON RESPONSES; OLD-WORLD MONKEYS; W FAMILY; INNATE IMMUNITY; DNA; ELEMENTS; TRANSCRIPTION; EVOLUTIONARY; RETROELEMENTS; SEQUENCES	Retroviral replication leaves a DNA copy in the host cell chromosome, which over millions of years of infection of germline cells has led to 5% of the human genome sequence being comprised of endogenous retroviruses (ERVs), distributed throughout an estimated 100,000 loci. Over time these loci have accrued mutations such as premature stop codons that prevent continued replication. However, many loci remain both transcriptionally and translationally active and ERVs have been implicated in interacting with the host immune system. Using archived plasma and tissue samples from past macaque studies, experimentally infected with simian immunodeficiency virus (SIV), the expression of one macaque ERV in response to acute viral infection was explored together with a measure of the innate immune response. Specifically, RNA levels were determined for (a) Papio cynocephalus Endogenous Retrovirus (PcEV), an ERV (b) STAT1, a key gene in the interferon signaling pathway, and (c) SIV, an exogenous pathogen. Bioinformatic analysis of DNA sequences of the PcEV loci within the macaque reference genome revealed the presence of open reading frames (ORFs) consistent with potential protein expression but not ERV replication. Quantitative RT-PCR analysis of DNase-treated RNA extracts from plasma derived from acute SIV-infection detected PcEV RNA at low levels in 7 of 22 macaques. PcEV RNA levels were significantly elevated in PBMC and spleen samples recovered during acute SIV infection, but not in the thymus and lymph nodes. A strong positive correlation was identified between PcEV and STAT1 RNA levels in spleen samples recovered from SIV-positive macaques. One possibility is that SIV infection induces PcEV expression in infected lymphoid tissue that contributes to induction of an antiviral response.	[Maze, Emmanuel Atangana; Kelly, Jack; Ussher, Lindsay; Belshaw, Robert] Univ Plymouth, Fac Med & Dent, Sch Biomed Sci, Plymouth, Devon, England; [Maze, Emmanuel Atangana; Ham, Claire; Almond, Neil; Berry, Neil] Natl Inst Stand & Control NIBSC, Div Infect Dis Diagnost, Potters Bar, Herts, England; [Towers, Greg J.] UCL, Div Infect & Immun, London, England	University of Plymouth; University of London; University College London	Berry, N; Belshaw, R (corresponding author), Univ Plymouth, Fac Med & Dent, Sch Biomed Sci, Plymouth, Devon, England.; Berry, N (corresponding author), Natl Inst Stand & Control NIBSC, Div Infect Dis Diagnost, Potters Bar, Herts, England.	neil.berry@nibsc.org; robert.belshaw@plymouth.ac.uk	Atangana Maze, Emmanuel/HHC-2713-2022	Atangana Maze, Emmanuel/0000-0003-4632-6324; Kelly, Jack/0000-0003-2265-4649; Almond, Neil/0000-0001-6105-0616	NIBSC; University of Plymouth Ph.D. studentship; MRC [G0801172, MR/S023380/1] Funding Source: UKRI	NIBSC; University of Plymouth Ph.D. studentship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The project was supported by NIBSC and a University of Plymouth Ph.D. studentship.	Bannert N, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00178; Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021; Beck-Engeser GB, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-91; Belshaw R, 2004, P NATL ACAD SCI USA, V101, P4894, DOI 10.1073/pnas.0307800101; Berry N, 2008, J GEN VIROL, V89, P2240, DOI 10.1099/vir.0.2008/001693-0; Berry N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006083; Berry N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023092; Bhardwaj N, 2014, J VIROL, V88, P11108, DOI 10.1128/JVI.01623-14; Brattas PL, 2017, CELL REP, V18, P1, DOI 10.1016/j.celrep.2016.12.010; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Chuong EB, 2016, SCIENCE, V351, P1083, DOI 10.1126/science.aad5497; Contreras-Galindo R, 2007, AIDS RES HUM RETROV, V23, P116, DOI 10.1089/aid.2006.0117; Contreras-Galindo R, 2017, J VIROL, V91, DOI 10.1128/JVI.01309-17; Contreras-Galindo R, 2012, J VIROL, V86, P262, DOI 10.1128/JVI.00602-11; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Devonshire AS, 2014, ANAL BIOANAL CHEM, V406, P6499, DOI 10.1007/s00216-014-7835-3; Dube D, 2014, J VIROL, V88, P9673, DOI 10.1128/JVI.01147-14; Fan Y, 2015, CURR HIV RES, V13, P55, DOI 10.2174/1570162X13666150121115804; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fasching L, 2015, CELL REP, V10, P20, DOI 10.1016/j.celrep.2014.12.004; Ferguson D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104390; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Gonzalez-Hernandez MJ, 2014, J VIROL, V88, P8924, DOI 10.1128/JVI.00556-14; Gonzalez-Hernandez MJ, 2012, J VIROL, V86, P7790, DOI 10.1128/JVI.07215-11; Gough DJ, 2012, IMMUNITY, V36, P166, DOI 10.1016/j.immuni.2012.01.011; Grandi N, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00462; Ham C, 2010, J CLIN MICROBIOL, V48, P2582, DOI 10.1128/JCM.00082-10; Han K, 2007, SCIENCE, V316, P238, DOI 10.1126/science.1139462; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Hung T, 2015, SCIENCE, V350, P455, DOI 10.1126/science.aac7442; Hurst TP, 2015, J GEN VIROL, V96, P1207, DOI 10.1099/jgv.0.000017; Ishida T, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-69; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jacobs FMJ, 2014, NATURE, V516, P242, DOI 10.1038/nature13760; Jern P, 2008, ANNU REV GENET, V42, P709, DOI 10.1146/annurev.genet.42.110807.091501; Jiang J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154665; Karamitros T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33598; Kassiotis G, 2016, NAT REV IMMUNOL, V16, P207, DOI 10.1038/nri.2016.27; KATO S, 1987, JPN J GENET, V62, P127, DOI 10.1266/jjg.62.127; Katzourakis A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004214; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lanford RE, 2006, HEPATOLOGY, V43, P961, DOI 10.1002/hep.21167; Lavialle C, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0507; Lavie L, 2005, J VIROL, V79, P876, DOI 10.1128/JVI.79.2.876-883.2005; Lee WJ, 2003, J GEN VIROL, V84, P2229, DOI 10.1099/vir.0.19076-0; Li F, 2014, J VIROL, V88, P4328, DOI 10.1128/JVI.03628-13; Lu XY, 2014, NAT STRUCT MOL BIOL, V21, P423, DOI 10.1038/nsmb.2799; LUCIW PA, 1992, RETROVIRIDAE, V1, P159; Magiorkinis G, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0136-x; Mang R, 1999, J VIROL, V73, P7021, DOI 10.1128/JVI.73.8.7021-7026.1999; Manghera M, 2016, J VIROL, V90, P9338, DOI 10.1128/JVI.01503-16; Manghera M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-16; Marchi E, 2014, J VIROL, V88, P9529, DOI 10.1128/JVI.00919-14; Martins H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014745; Mattiuzzo G, 2013, J GEN VIROL, V94, P606, DOI 10.1099/vir.0.047795-0; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Nellaker C, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-44; Osada N, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-90; Parkin NT, 2014, AIDS REV, V16, P160; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rolland A, 2006, J IMMUNOL, V176, P7636, DOI 10.4049/jimmunol.176.12.7636; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Rowe HM, 2010, NATURE, V463, P237, DOI 10.1038/nature08674; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Stocking C, 2008, CELL MOL LIFE SCI, V65, P3383, DOI 10.1007/s00018-008-8497-0; Stoye JP, 2012, NAT REV MICROBIOL, V10, P395, DOI 10.1038/nrmicro2783; Strick R, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1122160; Subramanian RP, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-90; Subramanian S, 2003, GENOME RES, V13, P838, DOI 10.1101/gr.1152803; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Tanaka J, 2003, AIDS, V17, P167, DOI 10.1097/00002030-200301240-00005; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; Turner G, 2001, CURR BIOL, V11, P1531, DOI 10.1016/S0960-9822(01)00455-9; Uleri E, 2014, AIDS, V28, P2659, DOI 10.1097/QAD.0000000000000477; Utay Netanya S, 2016, Pathog Immun, V1, P107; Volkman HE, 2014, NAT IMMUNOL, V15, P415, DOI 10.1038/ni.2872; Wildschutte JH, 2016, P NATL ACAD SCI USA, V113, pE2326, DOI 10.1073/pnas.1602336113; Yi SJ, 2002, MOL BIOL EVOL, V19, P2191, DOI 10.1093/oxfordjournals.molbev.a004043; Young GR, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-59; Young GR, 2012, NATURE, V491, P774, DOI 10.1038/nature11599; Zimin AV, 2014, BIOL DIRECT, V9, DOI 10.1186/1745-6150-9-20	86	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 15	2019	10								901	10.3389/fimmu.2019.00901	http://dx.doi.org/10.3389/fimmu.2019.00901			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HY2RY	31156613	gold, Green Published			2022-12-18	WOS:000467971800001
J	Sorrentino, C; Hossain, F; Rodriguez, PC; Sierra, RA; Pannuti, A; Eld, SHF; Osborne, BA; Minter, LM; Miele, L; Morello, S				Sorrentino, Claudia; Hossain, Fokhrul; Rodriguez, Paulo C.; Sierra, Rosa A.; Pannuti, Antonio; Eld, Stephen Hat Fi; Osborne, Barbara A.; Minter, Lisa M.; Miele, Lucio; Morello, Silvana			Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells (vol 10, 162, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						adenosine; A2A adenosine receptor (A2AR); Notch1; CD8+T-cells; immunosuppression			[Sorrentino, Claudia; Morello, Silvana] Univ Salerno, Dept Pharm, Fisciano, Italy; [Hossain, Fokhrul; Pannuti, Antonio; Miele, Lucio] Louisiana State Univ, Dept Genet, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Hossain, Fokhrul; Pannuti, Antonio; Miele, Lucio] Louisiana State Univ, Stanley S Scott Canc Ctr, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Rodriguez, Paulo C.; Sierra, Rosa A.] HL Moffitt Comprehens Canc Ctr, Tampa, FL USA; [Eld, Stephen Hat Fi] Northeastern Univ, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA; [Osborne, Barbara A.; Minter, Lisa M.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Salerno; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; H Lee Moffitt Cancer Center & Research Institute; Northeastern University; University of Massachusetts System; University of Massachusetts Amherst	Morello, S (corresponding author), Univ Salerno, Dept Pharm, Fisciano, Italy.; Miele, L (corresponding author), Louisiana State Univ, Dept Genet, Hlth Sci Ctr, New Orleans, LA 70112 USA.; Miele, L (corresponding author), Louisiana State Univ, Stanley S Scott Canc Ctr, Hlth Sci Ctr, New Orleans, LA 70112 USA.	lmiele@lsuhsc.edu; smorello@unisa.it	Morello, Silvana/E-9328-2012; Rodríguez, Paulo/HDM-9539-2022	Morello, Silvana/0000-0002-6541-0997; Rodriguez, Paulo/0000-0001-7480-6566	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM104940] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Sorrentino C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00162	1	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2019	10								935	10.3389/fimmu.2019.00935	http://dx.doi.org/10.3389/fimmu.2019.00935			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HX3ZA	31130947	gold, Green Published			2022-12-18	WOS:000467333000002
J	Healy, LP; Rossi, GP; Rautela, J; Slade, CA; Huntington, ND; Winship, IM; Souza-Fonseca-Guimaraes, F				Healy, Lachlan P.; Rossi, Gustavo P.; Rautela, Jai; Slade, Charlotte A.; Huntington, Nicholas D.; Winship, Ingrid M.; Souza-Fonseca-Guimaraes, Fernando			Loss-of-Function in SMAD4 Might Not Be Critical for Human Natural Killer Cell Responsiveness to TGF-beta	FRONTIERS IN IMMUNOLOGY			English	Article						SMAD4; loss-of-function mutations; Hereditary Hemorrhagic Telangiectasia; NK cell; TGF-beta signaling; CD56(bright/dim) subsets	NK CELLS; CONVERSION	We characterized the NK cell phenotype and function in three family members with Hereditary Hemorrhagic Telangiectasia (HHT) due to heterozygous SMAD4 mutations. Loss-of-function mutation in this gene did not induce developmental effects to after CD56(bright) or CD56(dim) NK cell subset proportions in peripheral blood; and did not result in major differences in either their IL-15-induced proliferation, or their cytokine secretion response to TGF-beta 1. These data suggest that SMAD4 plays a redundant role in downstream TGF-beta signaling in NK cells.	[Healy, Lachlan P.; Winship, Ingrid M.] Royal Melbourne Hosp, Genet Med & Family Canc Clin, Parkville, Vic, Australia; [Healy, Lachlan P.; Winship, Ingrid M.] Univ Melbourne, Dept Med, Parkville, Vic, Australia; [Rossi, Gustavo P.; Rautela, Jai; Slade, Charlotte A.; Huntington, Nicholas D.; Souza-Fonseca-Guimaraes, Fernando] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Dept Med Biol, Div Immunol Mol Immunol, Parkville, Vic, Australia; [Rossi, Gustavo P.] Univ Fed Parana, Dept Cell Biol, Curitiba, Parana, Brazil; [Slade, Charlotte A.] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Melbourne, Vic, Australia; [Slade, Charlotte A.] Jeffrey Modell Diagnost & Res Ctr Primary Immunod, Melbourne, Vic, Australia; [Huntington, Nicholas D.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Souza-Fonseca-Guimaraes, Fernando] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia	Royal Melbourne Hospital; University of Melbourne; University of Melbourne; Walter & Eliza Hall Institute; Universidade Federal do Parana; Royal Melbourne Hospital; Monash University; University of Melbourne	Souza-Fonseca-Guimaraes, F (corresponding author), Univ Melbourne, Walter & Eliza Hall Inst Med Res, Dept Med Biol, Div Immunol Mol Immunol, Parkville, Vic, Australia.; Souza-Fonseca-Guimaraes, F (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia.	guimaraes.f@wehi.edu.au	Slade, Charlotte/ABC-5612-2020; Huntington, NICHOLAS/AAV-4704-2020; Guimarães, Fernando/AAQ-2535-2021	Huntington, NICHOLAS/0000-0002-5267-7211; Guimarães, Fernando/0000-0002-2718-8993; Rodrigues Rossi, Gustavo/0000-0002-7990-6977; Winship, Ingrid/0000-0001-8535-6003; Souza-Fonseca-Guimaraes, Fernando/0000-0002-2037-8946	National Health and Medical Research Council (NHMRC) of Australia [1124784, 1066770, 1057852, 1124907, 1140406]; NHMRC Early Career Fellowship [1088703]; National Breast Cancer Foundation (NBCF) Fellowship [PF-15-008]; Priority-driven Collaborative Cancer Research Scheme [1120725]; Cure Cancer Australia; Cancer Australia; Melanoma Research Grant from the Harry J Lloyd Charitable Trust; Melanoma Research Alliance Young Investigator Award; Ian Potter Foundation; CLIP grant from Cancer Research Institute; Matty's Soldiers MPhil scholarship; NHMRC postgraduate scholarship [1075666]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior postgraduate scholarship [PDSE-88881.188501/2018-01]	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Early Career Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation (NBCF) Fellowship; Priority-driven Collaborative Cancer Research Scheme; Cure Cancer Australia; Cancer Australia; Melanoma Research Grant from the Harry J Lloyd Charitable Trust; Melanoma Research Alliance Young Investigator Award; Ian Potter Foundation; CLIP grant from Cancer Research Institute; Matty's Soldiers MPhil scholarship; NHMRC postgraduate scholarship(National Health and Medical Research Council (NHMRC) of Australia); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior postgraduate scholarship	This work is supported by project grants from the National Health and Medical Research Council (NHMRC) of Australia (#1124784, #1066770, #1057852, #1124907 to NH; and #1140406 to FS-F-G). FS-F-G. was supported by a NHMRC Early Career Fellowship (1088703), a National Breast Cancer Foundation (NBCF) Fellowship (PF-15-008), a grant #1120725 awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Cure Cancer Australia with the assistance of Cancer Australia. NH is a NHMRC CDF2 Fellow (1124788), a recipient of a Melanoma Research Grant from the Harry J Lloyd Charitable Trust, Melanoma Research Alliance Young Investigator Award, Ian Potter Foundation equipment grant and a CLIP grant from Cancer Research Institute. This study was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institute Infrastructure Support scheme. LH is supported by a Matty's Soldiers MPhil scholarship. CS was supported by an NHMRC postgraduate scholarship (1075666). GR was supported by a Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior postgraduate scholarship (PDSE-88881.188501/2018-01).	Cerdeira AS, 2013, J IMMUNOL, V190, P3939, DOI 10.4049/jimmunol.1202582; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Govani FS, 2009, EUR J HUM GENET, V17, P860, DOI 10.1038/ejhg.2009.35; Hawkins ED, 2007, NAT PROTOC, V2, P2057, DOI 10.1038/nprot.2007.297; Huntington ND, 2007, NAT REV IMMUNOL, V7, P703, DOI 10.1038/nri2154; Juelke K, 2010, BLOOD, V116, P1299, DOI 10.1182/blood-2009-11-253286; Krasnova Y, 2017, CLIN IMMUNOL, V177, P50, DOI 10.1016/j.clim.2015.10.001; Lucarelli P, 2018, CELL SYST, V6, P75, DOI 10.1016/j.cels.2017.11.010; Lusty E, 2017, MOL IMMUNOL, V88, P138, DOI 10.1016/j.molimm.2017.06.025; Mace EM, 2014, IMMUNOL CELL BIOL, V92, P245, DOI 10.1038/icb.2013.96; Rautela J, 2018, IMMUNOL CELL BIOL, V96, P477, DOI 10.1111/imcb.12045; Rautela J, 2017, CURR OPIN IMMUNOL, V44, P1, DOI 10.1016/j.coi.2016.10.004; Souza-Fonseca-Guimaraes F, 2019, TRENDS IMMUNOL, V40, P142, DOI 10.1016/j.it.2018.12.003; Viant C, 2017, J EXP MED, V214, P491, DOI 10.1084/jem.20160869; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Wagner JA, 2017, J CLIN INVEST, V127, P4042, DOI 10.1172/JCI90387; Wilson EB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022842; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461; Zhang J, 2018, EUR J IMMUNOL, V48, P738, DOI 10.1002/eji.201747299; 1999, CYTOMETRY, V37, P197, DOI DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L	23	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 1	2019	10								904	10.3389/fimmu.2019.00904	http://dx.doi.org/10.3389/fimmu.2019.00904			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HW1UT	31118932	Green Published, gold			2022-12-18	WOS:000466468800001
J	Abudulai, LN; Fernandez, S; Corscadden, K; Kirkham, LA; Hunter, M; Post, JJ; French, MA				Abudulai, Laila N.; Fernandez, Sonia; Corscadden, Karli; Kirkham, Lea-Ann; Hunter, Michael; Post, Jeffrey J.; French, Marlyn A.			Production of IgG2 Antibodies to Pneumococcal Polysaccharides After Vaccination of Treated HIV Patients May Be Augmented by IL-7R alpha Signaling in ICOS+ Circulating T Follicular-Helper Cells	FRONTIERS IN IMMUNOLOGY			English	Article						T follicular cells; IgG2 antibodies; pneumococcal 23-polyvalent vaccine; HIV infection; IL-7 receptor	MEMORY B-CELLS; INTERLEUKIN-7 RECEPTOR; CONJUGATE VACCINE; IL-7; DEFICIENCY; ACTIVATION; SUBCLASSES; MECHANISM; RESPONSES	Greater understanding of factors influencing the maturation of antibody responses against pneumococcal polysaccharides (PcPs) may improve pneumococcal vaccination strategies. Although PcPs are type 2 T cell-independent antigens thought not to induce follicular immune responses, we have previously shown that IgG2 antibody responses against antigens in the 23-valent unconjugated PcP vaccine (PPV23) are associated with expansion of ICOS+ circulating T follicular helper (cT(FH)) cells in HIV seronegative subjects but not HIV patients. As IL-7R alpha signaling in CD4(+) T cells may affect T-FH cell function and is adversely affected by HIV-1 infection, we have examined the relationship of IL-7R alpha expression on ICOS+ cT(FH) cells with PcP-specific IgG2 antibody responses. PPV23 vaccination was undertaken in HIV patients receiving antiretroviral therapy (n = 25) and HIV seronegative subjects (n = 20). IL-7R alpha expression on ICOS+ and ICOS- cT(FH) cells was assessed at day(D) 0, 7, and 28. Fold increase between D0 and D28 in serum IgG1 and IgG2 antibodies to PcP serotypes 4, 6B, 9V, and 14 and the frequency of IgG1(+) and IgG2(+) antibody secreting cells (ASCs) at D7 were also assessed. Decline in IL-7R alpha expression on ICOS+ cT(FH) cells between D0 and D7 occurred in 75% of HIV seronegative subjects and 60% of HIV patients (Group A), with changes in IL-7R alpha expression being more pronounced in HIV patients. Group A patients exhibited abnormally high IL-7R alpha expression pre-vaccination, an association of serum IgG2, but not IgG1, antibody responses with a decline of IL-7R alpha expression on ICOS+ cT(FH) cells between D0 and D7, and an association of higher IgG2(+) ASCs with lower IL-7R alpha expression on ICOS+ cT(FH) cells at D7. As decline of IL-7R alpha expression on CD4(+) T cells is an indicator of IL-7R alpha signaling, our findings suggest that utilization of IL-7 by cT(FH) cells affects production of IgG2 antibodies to PPV23 antigens in some HIV patients.	[Abudulai, Laila N.; Fernandez, Sonia; Kirkham, Lea-Ann; French, Marlyn A.] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia; [Abudulai, Laila N.] Univ Western Australia, Ctr Microscopy Characterisat & Anal, Perth, WA, Australia; [Corscadden, Karli; Kirkham, Lea-Ann] Univ Western Australia, Wesfarmers Ctr Vaccine & Infect Dis Res, Telethon Kids Inst, Perth, WA, Australia; [Hunter, Michael] Royal Victoria Hosp, Dept Infect Dis, Belfast, Antrim, North Ireland; [Post, Jeffrey J.] Prince Wales Hosp, Dept Infect Dis, Sydney, NSW, Australia; [Post, Jeffrey J.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [French, Marlyn A.] Univ Western Australia, UWA Med Sch, Perth, WA, Australia	University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of New South Wales Sydney; University of Western Australia	French, MA (corresponding author), Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.; French, MA (corresponding author), Univ Western Australia, UWA Med Sch, Perth, WA, Australia.	martyn.french@uwa.edu.au	Kirkham, Lea-Ann S/A-5847-2013; Post, Jeffrey/AAL-7115-2020; Post, Jeffrey/AAF-4960-2020; Fernandez, Sonia/H-9176-2014	Kirkham, Lea-Ann S/0000-0001-5421-8126; Post, Jeffrey/0000-0003-1475-9272; Fernandez, Sonia/0000-0001-8753-466X; Abudulai, Laila/0000-0003-4083-0343; French, Martyn/0000-0002-4644-1982	National Health and Medical Research Council [510448]; Australian Postgraduate Award; Raine Medical Research Foundation	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Raine Medical Research Foundation	This study was supported by a grant (510448) from the National Health and Medical Research Council. LNA was supported by an Australian Postgraduate Award. SF was supported by the Raine Medical Research Foundation.	Abudulai LN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176641; Anttila M, 1999, CLIN EXP IMMUNOL, V118, P402; Bazdar DA, 2009, J INFECT DIS, V199, P1019, DOI 10.1086/597210; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Chiodi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00451; Choi YS, 2013, J IMMUNOL, V190, P4014, DOI 10.4049/jimmunol.1202963; Crum-Cianflone NF, 2010, J INFECT DIS, V202, P1114, DOI 10.1086/656147; de Jong BG, 2017, IMMUNOL CELL BIOL, V95, P744, DOI 10.1038/icb.2017.43; FRENCH MAH, 1995, CLIN EXP IMMUNOL, V100, P47; Gao JB, 2015, INT J MOL SCI, V16, P10267, DOI 10.3390/ijms160510267; Hartgring SAY, 2009, ARTHRITIS RHEUM-US, V60, P2595, DOI 10.1002/art.24754; Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152; Jackson KJL, 2014, IMMUNOL CELL BIOL, V92, P729, DOI 10.1038/icb.2014.44; Lee KY, 2014, HUM VACC IMMUNOTHER, V10, P3700, DOI 10.4161/hv.32247; Leggat DJ, 2013, VACCINE, V31, P4632, DOI 10.1016/j.vaccine.2013.07.030; Lim HW, 2007, J IMMUNOL, V179, P7448, DOI 10.4049/jimmunol.179.11.7448; Linterman Michelle A, 2016, F1000Res, V5, DOI 10.12688/f1000research.7388.1; Ma CS, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.17; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; Park JH, 2004, IMMUNITY, V21, P289, DOI 10.1016/j.immuni.2004.07.016; Seifert M, 2016, LEUKEMIA, V30, P2283, DOI 10.1038/leu.2016.226; Seifert M, 2015, P NATL ACAD SCI USA, V112, pE546, DOI 10.1073/pnas.1416276112; Seo YB, 2014, J VIROL, V88, P8998, DOI 10.1128/JVI.00534-14; Snapper CM, 2016, VACCINE, V34, P3542, DOI 10.1016/j.vaccine.2015.12.077; Tanaskovic S, 2014, AIDS, V28, P821, DOI 10.1097/QAD.0000000000000213; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081	28	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 24	2019	10								839	10.3389/fimmu.2019.00839	http://dx.doi.org/10.3389/fimmu.2019.00839			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HU6KY	31068934	Green Published, gold			2022-12-18	WOS:000465390200001
J	Theorell, J; Bileviciute-Ljungar, I; Tesi, B; Schlums, H; Johnsgaard, MS; Asadi-Azarbaijani, B; Strand, EB; Bryceson, YT				Theorell, Jakob; Bileviciute-Ljungar, Indre; Tesi, Bianca; Schlums, Heinrich; Johnsgaard, Mette Sophie; Asadi-Azarbaijani, Babak; Strand, Elin Bolle; Bryceson, Yenan T.			Unperturbed Cytotoxic Lymphocyte Phenotype and Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients (vol 8, 723, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						chronic fatigue syndrome; myalgic encephalomyelitis; natural killer cells; cytotoxic T cells; lymphocyte cytotoxicity; adaptive natural killer cells			[Theorell, Jakob; Schlums, Heinrich; Bryceson, Yenan T.] Karolinska Inst, Dept Med, Stockholm, Sweden; [Bileviciute-Ljungar, Indre] Karolinska Inst, Dept Rehabil Med, Stockholm, Sweden; [Bileviciute-Ljungar, Indre] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden; [Tesi, Bianca] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden; [Tesi, Bianca] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Mol Med & Surg, Ctr Mol Med,Clin Genet Unit, Stockholm, Sweden; [Johnsgaard, Mette Sophie] Balderklinikken, Oslo, Norway; [Asadi-Azarbaijani, Babak; Strand, Elin Bolle] Oslo Univ Hosp, Div Med, CFS ME Ctr, Oslo, Norway; [Asadi-Azarbaijani, Babak] VID Specialized Univ, Oslo, Norway; [Strand, Elin Bolle] Oslo Univ Hosp, Norwegian Natl Advisory Unit CFS ME, Oslo, Norway; [Bryceson, Yenan T.] Univ Bergen, Dept Clin Sci, Bergen, Norway	Karolinska Institutet; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Oslo; VID Specialised University; University of Oslo; University of Bergen	Theorell, J; Bryceson, YT (corresponding author), Karolinska Inst, Dept Med, Stockholm, Sweden.; Bryceson, YT (corresponding author), Univ Bergen, Dept Clin Sci, Bergen, Norway.	jakob.theorell@ki.se; yenan.bryceson@ki.se	Tesi, Bianca/AAH-6304-2021; Strand, Elin B/AAZ-1914-2020; Bryceson, Yenan/D-2121-2018	Tesi, Bianca/0000-0002-8253-2507; Schlums, Heinrich/0000-0002-2895-7766; Bryceson, Yenan/0000-0002-7783-9934				Theorell J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00723	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 11	2019	10								350	10.3389/fimmu.2019.00350	http://dx.doi.org/10.3389/fimmu.2019.00350			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO3CB	30915066	Green Published, gold			2022-12-18	WOS:000460794600001
J	Zhang, TY; Cheng, XQ; Yu, D; Lin, FY; Hou, N; Cheng, X; Hao, SS; Wei, JJ; Ma, L; Fu, YB; Ma, YH; Ren, LM; Han, HT; Yu, SY; Yang, X; Zhao, YF				Zhang, Tianyi; Cheng, Xueqian; Yu, Di; Lin, Fuyu; Hou, Ning; Cheng, Xuan; Hao, Shanshan; Wei, Jingjing; Ma, Li; Fu, Yanbin; Ma, Yonghe; Ren, Liming; Han, Haitang; Yu, Shuyang; Yang, Xiao; Zhao, Yaofeng			Genetic Removal of the CH1 Exon Enables the Production of Heavy Chain-Only IgG in Mice (vol 9, 2202, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						HcAbs; nanobody; CH1 domain; mouse; phage display; single domain antibodies			[Zhang, Tianyi; Cheng, Xueqian; Yu, Di; Hao, Shanshan; Wei, Jingjing; Ma, Li; Fu, Yanbin; Ma, Yonghe; Ren, Liming; Han, Haitang; Yu, Shuyang; Zhao, Yaofeng] China Agr Univ, State Key Lab Agrobiotechnol, Natl Engn Lab Anim Breeding, Coll Biol Sci, Beijing, Peoples R China; [Lin, Fuyu; Hou, Ning; Cheng, Xuan; Yang, Xiao] Beijing Inst Life, State Key Lab Prote, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, Beijing, Peoples R China; [Zhang, Tianyi] Cornell Univ, Dept Nutr Sci, Ithaca, NY USA	China Agricultural University; Cornell University	Yu, SY; Zhao, YF (corresponding author), China Agr Univ, State Key Lab Agrobiotechnol, Natl Engn Lab Anim Breeding, Coll Biol Sci, Beijing, Peoples R China.; Yang, X (corresponding author), Beijing Inst Life, State Key Lab Prote, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, Beijing, Peoples R China.	ysy@cau.edu.cn; yangx@bmi.ac.cn; yaofengzhao@cau.edu.cn	wei, jing/GXA-1455-2022	Fu, Yanbin/0000-0002-3424-4420				Janssens R, 2006, P NATL ACAD SCI USA, V103, P15130, DOI 10.1073/pnas.0601108103; Zhang TY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02202	2	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2019	10								398	10.3389/fimmu.2019.00398	http://dx.doi.org/10.3389/fimmu.2019.00398			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HO1VI	30906294	gold, Green Published			2022-12-18	WOS:000460699100001
J	Passos, LSA; Magalhaes, LMD; Soares, RP; Marques, AF; Alves, MLR; Giunchetti, RC; Nunes, MDP; Gollob, KJ; Dutra, WO				Araujo Passos, Livia Silva; Dias Magalhaes, Luisa Mourao; Soares, Rodrigo Pinto; Marques, Alexandre F.; Rodrigues Alves, Marina Luiza; Giunchetti, Rodolfo Cordeiro; Pereira Nunes, Maria do Carmo; Gollob, Kenneth J.; Dutra, Walderez Ornelas			Activation of Human CD11b(+) B1 B-Cells by Trypanosoma cruzi-Derived Proteins Is Associated With Protective Immune Response in Human Chagas Disease (vol 9, 3015, 2019)	FRONTIERS IN IMMUNOLOGY			English	Correction						B1 B-cells; Chagas disease; cardiomyopathy; Trypanosoma-cruzi; immunoregulation; cytokines			[Araujo Passos, Livia Silva; Dias Magalhaes, Luisa Mourao; Rodrigues Alves, Marina Luiza; Giunchetti, Rodolfo Cordeiro; Dutra, Walderez Ornelas] Inst Ciencias Biol, Dept Morfol, Lab Cell Cell Interact, Belo Horizonte, MG, Brazil; [Araujo Passos, Livia Silva; Dias Magalhaes, Luisa Mourao; Soares, Rodrigo Pinto; Marques, Alexandre F.; Giunchetti, Rodolfo Cordeiro; Dutra, Walderez Ornelas] Univ Fed Minas Gerais, Posgrad Parasitol, Belo Horizonte, MG, Brazil; [Soares, Rodrigo Pinto] Fundacao Oswaldo Cruz, Inst Rene Rachou, Lab Cellular & Mol Parasitol, FIOCRUZ, Belo Horizonte, MG, Brazil; [Pereira Nunes, Maria do Carmo] Univ Fed Minas Gerais, Dept Clin Med, Fac Med, Belo Horizonte, MG, Brazil; [Gollob, Kenneth J.] AC Camargo Canc Ctr, Ctr Int Res, Sao Paulo, Brazil; [Gollob, Kenneth J.; Dutra, Walderez Ornelas] Inst Nacl Ciencia & Tecnol Doencas Trop, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Universidade Federal de Minas Gerais; A.C.Camargo Cancer Center	Dutra, WO (corresponding author), Inst Ciencias Biol, Dept Morfol, Lab Cell Cell Interact, Belo Horizonte, MG, Brazil.; Dutra, WO (corresponding author), Univ Fed Minas Gerais, Posgrad Parasitol, Belo Horizonte, MG, Brazil.; Dutra, WO (corresponding author), Inst Nacl Ciencia & Tecnol Doencas Trop, Belo Horizonte, MG, Brazil.	waldutra@gmail.com	Marques, Alexandre F/K-3678-2013; Dutra, Walderez Ornelas/CAH-1502-2022; Gollob, Kenneth J/GPX-8434-2022; Soares, Rodrigo/S-5191-2019	Marques, Alexandre F/0000-0001-9416-3465; Dutra, Walderez Ornelas/0000-0002-7586-9996; Soares, Rodrigo/0000-0002-7966-3629	National Institute of Allergy and Infectious Diseases of the National Institute of Health (NIAID-NIH) [R01AI138230]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI138230] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases of the National Institute of Health (NIAID-NIH); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	In the original article, we neglected to include the funder "National Institute of Allergy and Infectious Diseases of the National Institute of Health (NIAID-NIH), R01AI138230" to WD.	Passos LSA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03015	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 5	2019	10								367	10.3389/fimmu.2019.00367	http://dx.doi.org/10.3389/fimmu.2019.00367			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HN6JT	30891038	Green Published, gold			2022-12-18	WOS:000460293000002
J	Leyshon, BJ; Ji, P; Caputo, MP; Matt, SM; Johnson, RW				Leyshon, Brian J.; Ji, Peng; Caputo, Megan P.; Matt, Stephanie M.; Johnson, Rodney W.			Dietary Iron Deficiency Impaired Peripheral Immunity but Did Not Alter Brain Microglia in PRRSV-Infected Neonatal Piglets	FRONTIERS IN IMMUNOLOGY			English	Article						iron; inflammation; microglia; infection; anemia; postnatal; iron deficiency; piglet	RESPIRATORY VIRAL-INFECTION; SYNDROME VIRUS PRRSV; CYTOKINE PRODUCTION; GLOBAL BURDEN; ACTIVATION; SICKNESS; SYSTEM; CELLS; HIPPOCAMPUS; BEHAVIOR	During the postnatal period the developing brain is vulnerable to insults including nutrient insufficiency and infection that may lead to disrupted development and cognitive dysfunction. Since iron deficiency (ID) often presents with immunodeficiency, the objective of this study was to investigate peripheral viremia and inflammation as well as brain microglial phenotype and function when ID and respiratory infection occur simultaneously in a neonatal piglet model. On postnatal day 2 (PD 2) male and female piglets were assigned to one of four treatments and fed either control or ID milk replacer. On PD 8 half the pigs on each diet were inoculated with either vehicle or porcine reproductive and respiratory syndrome virus (PRRSV; P-129). Blood samples were collected prior to inoculation (PD 7) and repeated once weekly. Rectal temperature, feeding score, and sickness behavior were measured daily until PD 28. Hematocrit, hemoglobin, and serum iron were reduced by ID but not PRRSV infection. PRRSV-infected piglets displayed viremia by PD 14; however, those fed control diet had lower viral titer on PD 28, while circulating virus remained elevated in those fed an ID diet, suggesting that ID either impaired immune function necessary for viral clearance or increased viral replication. ID piglets infected with PRRSV displayed reduced sickness behavior compared to those fed control diet on PD 13-15 and 18-20. While ID piglet sickness behavior progressively worsened, piglets fed control diet displayed improved sickness score after PD 21. Microglia isolated from PRRSV piglets had increased MHCII expression and phagocytic activity ex vivo compared to uninfected piglets. ID did not alter microglial activation or phagocytic activity. Similarly, microglial cytokine expression was increased by PRRSV but unaffected by ID, in stark contrast to peripheral blood mononuclear cell (PBMC) cytokine expression, which was increased by infection and generally decreased by ID. Taken together, these data suggest that ID decreases peripheral immune function leading to increased viremia, but immune activity in the brain is protected from acute ID.	[Leyshon, Brian J.; Caputo, Megan P.; Johnson, Rodney W.] Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; [Ji, Peng; Johnson, Rodney W.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; [Matt, Stephanie M.; Johnson, Rodney W.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Johnson, RW (corresponding author), Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA.; Johnson, RW (corresponding author), Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA.; Johnson, RW (corresponding author), Univ Illinois, Neurosci Program, Urbana, IL 61801 USA.	rwjohn@illinois.edu		Matt, Stephanie/0000-0002-4085-2385; Ji, Peng/0000-0002-7447-5688	NIH [HD069899]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD069899] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by NIH grant HD069899.	Beard JL, 2008, J NUTR, V138, P2534, DOI 10.1093/jn/138.12.2534; Bergman M, 2005, BIOMED PHARMACOTHER, V59, P307, DOI 10.1016/j.biopha.2004.11.009; Bergman M, 2004, CLIN IMMUNOL, V113, P340, DOI 10.1016/j.clim.2004.08.011; Chen XX, 2014, VET MICROBIOL, V170, P48, DOI 10.1016/j.vetmic.2014.01.031; Clouard C, 2015, J NUTR, V145, P2176, DOI 10.3945/jn.115.214650; Conrad MS, 2015, BRAIN BEHAV IMMUN, V44, P82, DOI 10.1016/j.bbi.2014.08.009; Conrad MS, 2012, DEV NEUROSCI-BASEL, V34, P291, DOI 10.1159/000339311; Council NR, 1998, NUTR REQ SWIN; Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013; Cusick SE, 2016, J PEDIATR-US, V175, P16, DOI 10.1016/j.jpeds.2016.05.013; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006; Duan X, 1997, VET MICROBIOL, V56, P9, DOI 10.1016/S0378-1135(96)01347-8; Elmore MRP, 2014, J NEUROSCI, V34, P2120, DOI 10.1523/JNEUROSCI.2180-13.2014; Ferkol Thomas, 2014, Ann Am Thorac Soc, V11, P404, DOI 10.1513/AnnalsATS.201311-405PS; Fretham SJB, 2011, ADV NUTR, V2, P112, DOI 10.3945/an.110.000190; Garcia-Nicolas O, 2014, VET IMMUNOL IMMUNOP, V160, P26, DOI 10.1016/j.vetimm.2014.03.008; Georgieff MK, 2017, AM J CLIN NUTR, V106, p1588S, DOI 10.3945/ajcn.117.155846; Golz A, 2001, AM J OTOLARYNG, V22, P391, DOI 10.1053/ajot.2001.28075; Gomez-Nicola D, 2015, NEUROSCIENTIST, V21, P169, DOI 10.1177/1073858414530512; Halbur PG, 2002, VET REC, V151, P344, DOI 10.1136/vr.151.12.344; Harvey L, 2014, BRAIN BEHAV IMMUN, V40, P27, DOI 10.1016/j.bbi.2014.06.005; Harvey L, 2014, BRAIN BEHAV IMMUN, V35, P144, DOI 10.1016/j.bbi.2013.09.009; Jason J, 2001, CLIN EXP IMMUNOL, V126, P466, DOI 10.1046/j.1365-2249.2001.01707.x; Ji P, 2016, BRAIN BEHAV IMMUN, V54, P243, DOI 10.1016/j.bbi.2016.02.010; Kaser T, 2011, DEV COMP IMMUNOL, V35, P1166, DOI 10.1016/j.dci.2011.04.006; Leyshon BJ, 2016, J NUTR, V146, P1420, DOI 10.3945/jn.115.223636; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603; Lozoff B, 2006, NUTR REV, V64, pS34, DOI 10.1301/nr.2006.may.S34-S43; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Nairz M, 2015, IMMUNOBIOLOGY, V220, P280, DOI 10.1016/j.imbio.2014.09.010; Nairz M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00152; Rytych JL, 2012, J NUTR, V142, P2050, DOI 10.3945/jn.112.165522; Schook L, 2005, ANIM BIOTECHNOL, V16, P183, DOI 10.1080/10495390500265034; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969	38	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 4	2019	9								3150	10.3389/fimmu.2018.03150	http://dx.doi.org/10.3389/fimmu.2018.03150			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HK0WG	30778359	Green Published, gold			2022-12-18	WOS:000457623500001
J	Eibel, H; Winkler, T; Ceredig, R				Eibel, Hermann; Winkler, Thomas; Ceredig, Rhodri			Editorial: Making Science Fun - A Tribute to Our Colleague and Friend, Prof. Antonius G. Rolink (1953-2017)	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lymphocyte development and function; B cells; T cells; hemopoiesis; graft versus host desease; BAFF - B-cell activating factor; treg cells; monoclonal antibodies	B-CELL-DEVELOPMENT; SURROGATE LIGHT-CHAIN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE BONE-MARROW; SYSTEMIC-LUPUS-ERYTHEMATOSUS; KAPPA-L-CHAIN; IMMUNOGLOBULIN HEAVY-CHAIN; GENE-EXPRESSION PROFILES; INNATE LYMPHOID-CELLS; LIVER ORGAN-CULTURES		[Eibel, Hermann] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Winkler, Thomas] Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum Mol Med, Erlangen, Germany; [Ceredig, Rhodri] Natl Univ Ireland, Coll Med & Nursing Hlth Sci, Discipline Physiol, Galway, Ireland	University of Freiburg; University of Erlangen Nuremberg; Ollscoil na Gaillimhe-University of Galway	Ceredig, R (corresponding author), Natl Univ Ireland, Coll Med & Nursing Hlth Sci, Discipline Physiol, Galway, Ireland.	rhodri.ceredig@nuigalway.ie						Alberti-Servera L, 2017, EMBO J, V36, P3619, DOI 10.15252/embj.201797105; ANDERSSON J, 1995, SCAND J IMMUNOL, V42, P21, DOI 10.1111/j.1365-3083.1995.tb03621.x; Ardouin L, 2005, EUR J IMMUNOL, V35, P977, DOI 10.1002/eji.200425836; Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Baerenwaldt A, 2016, J IMMUNOL, V196, P2561, DOI 10.4049/jimmunol.1501380; Balciunaite G, 2005, EUR J IMMUNOL, V35, P1292, DOI 10.1002/eji.200425822; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Balciunaite G, 2005, EUR J IMMUNOL, V35, P2019, DOI 10.1002/eji.200526318; Benard A, 2006, EUR J IMMUNOL, V36, P2324, DOI 10.1002/eji.200636434; Bessa J, 2015, PHARM RES-DORDR, V32, P2344, DOI 10.1007/s11095-015-1627-0; Bordon A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004007; Bornancin F, 2015, J IMMUNOL, V194, P3723, DOI 10.4049/jimmunol.1402254; Bosco N, 2008, EUR J IMMUNOL, V38, P381, DOI 10.1002/eji.200737665; Bosco N, 2006, J IMMUNOL, V177, P5014, DOI 10.4049/jimmunol.177.8.5014; Bosco N, 2010, EXP HEMATOL, V38, P222, DOI 10.1016/j.exphem.2009.12.006; Bosco N, 2008, EUR J IMMUNOL, V38, P3520, DOI 10.1002/eji.200838668; Bossen C, 2011, EUR J IMMUNOL, V41, P787, DOI 10.1002/eji.201040591; Brown G, 2007, TRENDS IMMUNOL, V28, P442, DOI 10.1016/j.it.2007.07.007; Brown G, 2015, CRIT REV CL LAB SCI, V52, P168, DOI 10.3109/10408363.2015.1021412; BRUNO L, 1995, EUR J IMMUNOL, V25, P1877, DOI 10.1002/eji.1830250713; Bruno L, 2002, CELLS TISSUES ORGANS, V171, P38, DOI 10.1159/000057690; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Calvo-Asensio I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01312; Cassani B, 2010, J EXP MED, V207, P1525, DOI 10.1084/jem.20091928; Cavelier P, 1997, EUR J IMMUNOL, V27, P1626, DOI 10.1002/eji.1830270706; Ceredig R, 2000, EUR J IMMUNOL, V30, P759, DOI 10.1002/1521-4141(200003)30:3<759::AID-IMMU759>3.0.CO;2-M; Ceredig R, 1999, CURR TOP MICROBIOL, V246, P11; Ceredig R, 2003, EUR J IMMUNOL, V33, P2567, DOI 10.1002/eji.200324134; Ceredig R, 1998, INT IMMUNOL, V10, P49, DOI 10.1093/intimm/10.1.49; Ceredig R, 1999, EUR J IMMUNOL, V29, P2797, DOI 10.1002/(SICI)1521-4141(199909)29:09<2797::AID-IMMU2797>3.3.CO;2-#; Ceredig R, 2007, EUR J IMMUNOL, V37, P830, DOI 10.1002/eji.200636728; Ceredig R, 2006, BLOOD, V108, P1216, DOI 10.1182/blood-2005-10-006643; Ceredig R, 2012, SEMIN IMMUNOL, V24, P159, DOI 10.1016/j.smim.2012.02.004; Ceredig R, 2009, NAT REV IMMUNOL, V9, P293, DOI 10.1038/nri2525; Chappaz S, 2007, BLOOD, V110, P3862, DOI 10.1182/blood-2007-02-074245; Choukrallah MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9324; Colonna M, 1998, J IMMUNOL, V160, P3096; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; DEVOS R, 1990, BIOCHEM BIOPH RES CO, V172, P570, DOI 10.1016/0006-291X(90)90711-U; DEVOS R, 1991, EUR J IMMUNOL, V21, P1315, DOI 10.1002/eji.1830210533; Dinkel A, 1998, J EXP MED, V188, P2215, DOI 10.1084/jem.188.12.2215; Duber S, 2003, MOL IMMUNOL, V40, P509, DOI 10.1016/S0161-5890(03)00226-8; Engel H, 1998, EUR J IMMUNOL, V28, P2289, DOI 10.1002/(SICI)1521-4141(199808)28:08<2289::AID-IMMU2289>3.0.CO;2-Y; Engel H, 1999, EUR J IMMUNOL, V29, P2167, DOI 10.1002/(SICI)1521-4141(199907)29:07<2167::AID-IMMU2167>3.3.CO;2-8; Faderl M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00016; Fazio G, 2013, LEUKEMIA, V27, P992, DOI 10.1038/leu.2012.281; Fazio G, 2017, BR J HAEMATOL; Fazio G, 2008, CANCER RES, V68, P181, DOI 10.1158/0008-5472.CAN-07-2778; Fazio G, 2018, BRIT J HAEMATOL, V182, P434, DOI 10.1111/bjh.14794; Felix K, 2003, MUTAT RES-FUND MOL M, V522, P135, DOI 10.1016/S0027-5107(02)00309-3; Gehre N, 2015, EUR J IMMUNOL, V45, P932, DOI 10.1002/eji.201444681; Ghia P, 1999, CURR TOP MICROBIOL, V246, P103; Ghia P, 2000, EXP GERONTOL, V35, P159, DOI 10.1016/S0531-5565(99)00095-9; Ghia P, 1996, J EXP MED, V184, P2217, DOI 10.1084/jem.184.6.2217; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; Ghia P, 2001, BLOOD, V98, P533, DOI 10.1182/blood.V98.3.533; GLEICHMANN E, 1984, IMMUNOL TODAY, V5, P324, DOI 10.1016/0167-5699(84)90126-9; Grawunder U, 1995, INT IMMUNOL, V7, P1915, DOI 10.1093/intimm/7.12.1915; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Grawunder U, 1996, J EXP MED, V183, P1731, DOI 10.1084/jem.183.4.1731; Gunthert U, 1998, ADV EXP MED BIOL, V451, P43; HAASNER D, 1994, INT IMMUNOL, V6, P21, DOI 10.1093/intimm/6.1.21; Harfst E, 2005, IMMUNOL LETT, V101, P173, DOI 10.1016/j.imlet.2005.05.013; Harmeier A, 2015, EUR NEUROPSYCHOPHARM, V25, P2049, DOI 10.1016/j.euroneuro.2015.08.011; Heiler S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00656; Hoffmann R, 2003, J IMMUNOL, V170, P1339, DOI 10.4049/jimmunol.170.3.1339; Hoffmann R, 2002, GENOME RES, V12, P98, DOI 10.1101/gr.201501; Hoffmann R, 2007, MOL BIOL EVOL, V24, P2610, DOI 10.1093/molbev/msm198; JESSBERGER R, 1995, J BIOL CHEM, V270, P6788, DOI 10.1074/jbc.270.12.6788; Kalberer CP, 1997, EUR J IMMUNOL, V27, P2400, DOI 10.1002/eji.1830270939; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; KARASUYAMA H, 1988, J EXP MED, V167, P1377, DOI 10.1084/jem.167.4.1377; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; Kim M, 2018, IMMUNOL LETT, V198, P60, DOI 10.1016/j.imlet.2018.04.008; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Kistler B, 1998, J IMMUNOL, V160, P2308; Kraus H, 2014, J IMMUNOL, V192, P1044, DOI 10.4049/jimmunol.1301815; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; KUDO A, 1992, INT IMMUNOL, V4, P831, DOI 10.1093/intimm/4.8.831; Kyaw T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060430; LERNHARDT W, 1987, IMMUNOL REV, V99, P241, DOI 10.1111/j.1600-065X.1987.tb01179.x; Maerki S, 2006, IMMUNOL LETT, V104, P110, DOI 10.1016/j.imlet.2005.11.002; Manoharan A, 2015, EUR J IMMUNOL, V45, P2343, DOI 10.1002/eji.201445035; Martensson IL, 2002, SEMIN IMMUNOL, V14, P335, DOI 10.1016/S1044-5323(02)00066-0; Massa S, 2006, EUR J IMMUNOL, V36, P526, DOI 10.1002/eji.200535760; Matthias P, 2005, NAT REV IMMUNOL, V5, P497, DOI 10.1038/nri1633; Melamed D, 1997, J IMMUNOL, V159, P1233; MELCHERS F, 1989, ADV EXP MED BIOL, V254, P87; Melchers F, 1999, SEMIN IMMUNOL, V11, P307, DOI 10.1006/smim.1999.0187; Melchers F, 2006, CURR TOP MICROBIOL, V305, P1, DOI 10.1007/3-540-29714-6_1; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; Melchers F, 1992, Curr Top Microbiol Immunol, V182, P3; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; MELCHERS F, 1992, ADV EXP MED BIOL, V323, P111; MELCHERS F, 1991, ADV EXP MED BIOL, V292, P201; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MELCHERS F, 1989, COLD SH Q B, V54, P183; Melchers F, 2007, ADV EXP MED BIOL, V596, P63; Mertsching E, 1996, EUR J IMMUNOL, V26, P28, DOI 10.1002/eji.1830260105; MITA S, 1991, INT IMMUNOL, V3, P665, DOI 10.1093/intimm/3.7.665; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; Mueller P, 2008, NAT IMMUNOL, V9, P424, DOI 10.1038/ni1570; Nobs SP, 2015, IMMUNITY, V43, P674, DOI 10.1016/j.immuni.2015.09.006; Nusser A, 2014, EUR J IMMUNOL, V44, P2893, DOI 10.1002/eji.201344408; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Nutt SL, 1999, COLD SPRING HARB SYM, V64, P51, DOI 10.1101/sqb.1999.64.51; OKA Y, 1995, EUR J IMMUNOL, V25, P1332, DOI 10.1002/eji.1830250530; Oka Y, 1996, INT IMMUNOL, V8, P1675, DOI 10.1093/intimm/8.11.1675; Okujava R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004187; OLTZ EM, 1992, EMBO J, V11, P2759, DOI 10.1002/j.1460-2075.1992.tb05341.x; Osmond DG, 1998, IMMUNOL TODAY, V19, P65, DOI 10.1016/S0167-5699(97)01203-6; PALACIOS R, 1989, EUR J IMMUNOL, V19, P347, DOI 10.1002/eji.1830190220; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; Pieper K, 2014, J ALLERGY CLIN IMMUN, V133, P1222, DOI 10.1016/j.jaci.2013.11.021; Rauch M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005456; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; ROLINK A, 1991, EUR J IMMUNOL, V21, P2895, DOI 10.1002/eji.1830211137; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; ROLINK A, 1991, EUR J IMMUNOL, V21, P2609, DOI 10.1002/eji.1830211044; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; ROLINK A, 1993, BLOOD, V81, P2290; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1994, IMMUNOL REV, V137, P185, DOI 10.1111/j.1600-065X.1994.tb00665.x; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Rolink A, 1995, Semin Immunol, V7, P155, DOI 10.1016/1044-5323(95)90043-8; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; Rolink A, 1996, IMMUNOL LETT, V54, P157, DOI 10.1016/S0165-2478(96)02666-1; Rolink A, 1996, Int Rev Immunol, V13, P341, DOI 10.3109/08830189609061757; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; ROLINK A, 1991, BIOCHEM SOC T, V19, P275, DOI 10.1042/bst0190275; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rolink A, 1999, COLD SPRING HARB SYM, V64, P21, DOI 10.1101/sqb.1999.64.21; ROLINK AG, 1990, EUR J IMMUNOL, V20, P1949, DOI 10.1002/eji.1830200912; ROLINK AG, 1983, J EXP MED, V158, P546, DOI 10.1084/jem.158.2.546; ROLINK AG, 1983, J IMMUNOL, V130, P209; ROLINK AG, 1987, J EXP MED, V165, P1675, DOI 10.1084/jem.165.6.1675; Rolink AG, 1999, CURR TOP MICROBIOL, V246, P39; Rolink AG, 2000, IMMUNOL REV, V175, P104, DOI 10.1034/j.1600-065X.2000.017512.x; ROLINK AG, 1989, J EXP MED, V169, P1693, DOI 10.1084/jem.169.5.1693; ROLINK AG, 1983, EUR J IMMUNOL, V13, P191, DOI 10.1002/eji.1830130303; ROLINK AG, 1988, SCAND J IMMUNOL, V28, P29, DOI 10.1111/j.1365-3083.1988.tb02412.x; ROLINK AG, 1988, MOL IMMUNOL, V25, P1217, DOI 10.1016/0161-5890(88)90159-9; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; ROLINK AG, 1982, J EXP MED, V155, P1501, DOI 10.1084/jem.155.5.1501; Rolink AG, 2004, IMMUNOL REV, V197, P41, DOI 10.1111/j.0105-2896.2004.0101.x; ROLINK AG, 1994, RES IMMUNOL, V145, P353, DOI 10.1016/S0923-2494(94)80199-1; Rolink AG, 2002, IMMUNOL LETT, V82, P35, DOI 10.1016/S0165-2478(02)00016-0; Rolink AG, 2002, IMMUNOL REV, V187, P87, DOI 10.1034/j.1600-065X.2002.18708.x; Rolink AG, 2002, CURR OPIN IMMUNOL, V14, P266, DOI 10.1016/S0952-7915(02)00332-1; Rolink AG, 2002, EUR J IMMUNOL, V32, P2004, DOI 10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5; Rolink AG, 2000, J EXP MED, V191, P23, DOI 10.1084/jem.191.1.23; Rolink AG, 2000, CURR TOP MICROBIOL, V251, P21; Rolink AG, 2001, CURR OPIN IMMUNOL, V13, P202, DOI 10.1016/S0952-7915(00)00205-3; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; Rolink AG, 1999, IMMUNITY, V10, P619, DOI 10.1016/S1074-7613(00)80061-8; Rolink AG, 1999, IMMUNOL LETT, V68, P89, DOI 10.1016/S0165-2478(99)00035-8; ROLINK AG, 1983, J EXP MED, V157, P755, DOI 10.1084/jem.157.2.755; Rolink AG, 2006, IMMUNOL LETT, V107, P50, DOI 10.1016/j.imlet.2006.07.005; Rolink Antonius G, 2004, Methods Mol Biol, V271, P271; Rolink AG, 2006, SWISS MED WKLY, V136, P679; Rolink Antonius G, 2007, Swiss Med Wkly, V137 Suppl 155, p20S; Santiago-Raber ML, 2010, J AUTOIMMUN, V34, P349, DOI 10.1016/j.jaut.2010.01.001; Schaniel C, 2002, BLOOD, V99, P472, DOI 10.1182/blood.V99.2.472; Schaniel C, 1999, CURR TOP MICROBIOL, V246, P95; Schaniel C, 2002, BLOOD, V99, P2760, DOI 10.1182/blood.V99.8.2760; Schaniel C, 2000, CURR TOP MICROBIOL, V251, P181; Schaniel C, 2001, ADV IMMUNOL, V78, P111, DOI 10.1016/S0065-2776(01)78003-0; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; Schaniel C, 1999, EUR J IMMUNOL, V29, P2934, DOI 10.1002/(SICI)1521-4141(199909)29:09<2934::AID-IMMU2934>3.3.CO;2-H; Schmutz S, 2009, J IMMUNOL, V183, P2217, DOI 10.4049/jimmunol.0802911; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart DB, 2000, J IMMUNOL, V164, P18, DOI 10.4049/jimmunol.164.1.18; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Seidl T, 2001, EUR J IMMUNOL, V31, P1999, DOI 10.1002/1521-4141(200107)31:7<1999::AID-IMMU1999>3.0.CO;2-K; Siwarski D, 1997, CURR TOP MICROBIOL, V224, P67; Smulski CR, 2017, CELL REP, V18, P2189, DOI 10.1016/j.celrep.2017.02.005; STRASSER A, 1989, J EXP MED, V170, P1973, DOI 10.1084/jem.170.6.1973; Swee LK, 2014, EUR J IMMUNOL, V44, P1299, DOI 10.1002/eji.201343840; Swee LK, 2010, IMMUNOL LETT, V131, P40, DOI 10.1016/j.imlet.2010.03.007; Swee LK, 2009, BLOOD, V113, P6277, DOI 10.1182/blood-2008-06-161026; Tardivel A, 2004, EUR J IMMUNOL, V34, P509, DOI 10.1002/eji.200324692; TARYLEHMANN M, 1990, J IMMUNOL, V145, P2092; ten Boekel E, 1999, CURR TOP MICROBIOL, V246, P3; ten Boekel E, 1998, IMMUNITY, V8, P199; tenBoekel E, 1997, IMMUNITY, V7, P357; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Terszowski G, 2001, EUR J IMMUNOL, V31, P832, DOI 10.1002/1521-4141(200103)31:3<832::AID-IMMU832>3.0.CO;2-D; Tiao JY, 2008, J BIOL CHEM, V283, P31005, DOI 10.1074/jbc.M804464200; Tsapogas P, 2017, INT J MOL SCI, V18; Tsapogas P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061115; Tsapogas P, 2014, HAEMATOLOGICA, V99, P638, DOI 10.3324/haematol.2013.089482; Turazzi N, 2018, BR J HAEMATOL; Tussiwand R, 2012, EUR J IMMUNOL, V42, P206, DOI 10.1002/eji.201141957; Tussiwand R, 2011, EUR J IMMUNOL, V41, P3371, DOI 10.1002/eji.201141824; Tussiwand R, 2009, EUR J IMMUNOL, V39, P2317, DOI 10.1002/eji.200939633; VANDERVEEN F, 1981, CLIN EXP IMMUNOL, V46, P589; VANDERVEEN FM, 1982, ADV EXP MED BIOL, V149, P669; VANDERVEEN JPW, 1981, J IMMUNOL, V127, P1281; VANELVEN EH, 1981, J IMMUNOL, V127, P2435; VANELVEN EH, 1981, J EXP MED, V153, P1474, DOI 10.1084/jem.153.6.1474; VANRAPPARDVANDERVEEN FM, 1982, J EXP MED, V155, P1555, DOI 10.1084/jem.155.5.1555; Venhoff N, 2014, AUTOIMMUNITY, V47, P401, DOI 10.3109/08916934.2014.914174; Vigano MA, 2014, EUR J IMMUNOL, V44, P1181, DOI 10.1002/eji.201344022; Vigolo M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03323-8; von Burg N, 2014, P NATL ACAD SCI USA, V111, P12835, DOI 10.1073/pnas.1406908111; von Muenchow L, 2017, EUR J IMMUNOL, V47, P394, DOI 10.1002/eji.201646638; von Muenchow L, 2016, P NATL ACAD SCI USA, V113, pE8122, DOI 10.1073/pnas.1613316113; von Muenchow L, 2014, IMMUNOL LETT, V160, P113, DOI 10.1016/j.imlet.2014.01.011; Wilhelmson AS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04408-0; WINKLER TH, 1995, EUR J IMMUNOL, V25, P446, DOI 10.1002/eji.1830250221; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; Yamagami T, 1999, IMMUNITY, V11, P309, DOI 10.1016/S1074-7613(00)80106-5; Yamagami T, 1999, IMMUNITY, V11, P317, DOI 10.1016/S1074-7613(00)80107-7; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287	229	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 19	2018	9								2915	10.3389/fimmu.2018.02915	http://dx.doi.org/10.3389/fimmu.2018.02915			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HF0QR	30619279	Green Published, gold			2022-12-18	WOS:000453867900001
J	Pinho, MP; Barbuto, JAM				Pinho, Mariana Pereira; Marzagao Barbuto, Jose Alexandre			Commentary: Soluble CD83 Alleviates Experimental Autoimmune Uveitis by Inhibiting Filamentous Actin-Dependent Calcium Release in Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CD83; calcium signaling; dendritic cells; T lymphocytes; T cell activation	CYTOSKELETON; STIMULATION; ORAI		[Pinho, Mariana Pereira; Marzagao Barbuto, Jose Alexandre] Univ Sao Paulo, Biomed Sci Inst, Immunol Dept, Tumor Immunol Lab, Sao Paulo, Brazil	Universidade de Sao Paulo	Barbuto, JAM (corresponding author), Univ Sao Paulo, Biomed Sci Inst, Immunol Dept, Tumor Immunol Lab, Sao Paulo, Brazil.	jbarbuto@icb.usp.br	Barbuto, Jose A. M./H-5299-2011; Pinho, Mariana/AAR-9604-2020	Barbuto, Jose A. M./0000-0001-9526-6781; Pinho, Mariana/0000-0002-5759-2436	Sao Paulo Research Foundation-FAPESP [2014/25988-1]; Coordination for the Improvement of Higher Education Personnel-CAPES; National Council for Scientific and Technological Development-CNPq [409825/2016-6, 308053/2017-6]	Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordination for the Improvement of Higher Education Personnel-CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Council for Scientific and Technological Development-CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The authors are supported by grants from the Sao Paulo Research Foundation-FAPESP (#2014/25988-1), the Coordination for the Improvement of Higher Education Personnel-CAPES, and from National Council for Scientific and Technological Development-CNPq (409825/2016-6, 308053/2017-6).	Beemiller P, 2013, IMMUNOL REV, V256, P148, DOI 10.1111/imr.12120; Eckhardt J, 2014, MUCOSAL IMMUNOL, V7, P1006, DOI 10.1038/mi.2013.119; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Kotzor N, 2004, IMMUNOBIOLOGY, V209, P129, DOI 10.1016/j.imbio.2004.04.003; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; Lin W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01567; Pinho MP, 2014, J LEUKOCYTE BIOL, V95, P755, DOI 10.1189/jlb.0413239; Prechtel AT, 2007, ARCH DERMATOL RES, V299, P59, DOI 10.1007/s00403-007-0743-z; Quintana A, 2011, EMBO J, V30, P3895, DOI 10.1038/emboj.2011.289; Senechal B, 2004, BLOOD, V103, P4207, DOI 10.1182/blood-2003-12-4350; Zinser E, 2004, J EXP MED, V200, P345, DOI 10.1084/jem.20030973	11	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2018	9								2659	10.3389/fimmu.2018.02659	http://dx.doi.org/10.3389/fimmu.2018.02659			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	HA3UJ	30498498	Green Published, gold			2022-12-18	WOS:000450181100001
J	Brennecke, AM; Duber, S; Roy, B; Thomsen, I; Garbe, AI; Klawonn, F; Pabst, O; Kretschmer, K; Weiss, S				Brennecke, Anne-Margarete; Dueber, Sandra; Roy, Bishnudeo; Thomsen, Irene; Garbe, Annette I.; Klawonn, Frank; Pabst, Oliver; Kretschmer, Karsten; Weiss, Siegfried			Induced B Cell Development in Adult Mice	FRONTIERS IN IMMUNOLOGY			English	Article						bone marrow; RAG; B cell development; B-2/B-1a/B-1b; antibodies; CSR; T-dependent/-independent; VH usage	CLASS-SWITCH RECOMBINATION; BONE-MARROW; T-CELLS; MOUSE; MECHANISM; RECEPTOR; LYMPHOPOIESIS; REPERTOIRE; MATURATION; SUBSETS	We employed the B-Indu-Rag1 model in which the coding exon of recombination-activating gene 1 (Rag1) is inactivated by inversion. It is flanked by inverted loxP sites. Accordingly, B cell development is stopped at the pro/pre B-I cell precursor stage. A B cell-specific Cre recombinase fused to a mutated estrogen receptor allows the induction of RAG1 function and B cell development by application of Tamoxifen. Since Rag1 function is recovered in a non-self-renewing precursor cell, only single waves of development can be induced. Using this system, we could determine that B cells minimally require 5 days to undergo development from pro/preB-I cells to the large and 6 days to the small preB-II cell stage. First immature transitional (T) 1 and T2 B cells could be detected in the bone marrow at day 6 and day 7, respectively, while their appearance in the spleen took one additional day. We also tested a contribution of adult bone marrow to the pool of B-1 cells. Sublethally irradiated syngeneic WT mice were adoptively transferred with bone marrow of B-Indu-Rag1 mice and B cell development was induced after 6 weeks. A significant portion of donor derived B-1 cells could be detected in such adult mice. Finally, early VH gene usage was tested after induction of B cell development. During the earliest time points the VH genes proximal to D/J were found to be predominantly rearranged. At later time points, the large family of the most distal VH prevailed.	[Brennecke, Anne-Margarete; Dueber, Sandra; Roy, Bishnudeo; Garbe, Annette I.; Kretschmer, Karsten; Weiss, Siegfried] Helmholtz Ctr Infect Res, Mol Immunol, Braunschweig, Germany; [Thomsen, Irene; Pabst, Oliver; Weiss, Siegfried] Med Sch Hannover, Inst Immunol, Hannover, Germany; [Garbe, Annette I.] Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden, Ctr Mol & Cellular Bioengn, Osteoimmunol, Dresden, Germany; [Klawonn, Frank] Helmholtz Ctr Infect Res, Biostat Grp, Braunschweig, Germany; [Pabst, Oliver] Rhein Westfal TH Aachen, Inst Mol Med, Aachen, Germany; [Kretschmer, Karsten] Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden, Ctr Mol & Cellular Bioengn, Mol & Cellular Immunol Immune Regulat, Dresden, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School; German Research Foundation (DFG); Technische Universitat Dresden; Helmholtz Association; Helmholtz-Center for Infection Research; RWTH Aachen University; German Research Foundation (DFG); Technische Universitat Dresden	Weiss, S (corresponding author), Helmholtz Ctr Infect Res, Mol Immunol, Braunschweig, Germany.; Weiss, S (corresponding author), Med Sch Hannover, Inst Immunol, Hannover, Germany.	siegfried.weiss@helmholtz-hzi.de	Garbe, Annette I/A-4824-2014; Roy, Bishnudeo/Q-2629-2018; Kretschmer, Karsten/E-8174-2010; Klawonn, Frank/HFH-5887-2022	Roy, Bishnudeo/0000-0002-7339-9556; Kretschmer, Karsten/0000-0001-6770-4078; Klawonn, Frank/0000-0001-9613-182X				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; Allman D, 2008, CURR OPIN IMMUNOL, V20, P149, DOI 10.1016/j.coi.2008.03.014; Barone F, 2009, MUCOSAL IMMUNOL, V2, P495, DOI 10.1038/mi.2009.106; Baumgarth N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00324; Baumgarth N, 2013, ADV EXP MED BIOL, V785, P57, DOI 10.1007/978-1-4614-6217-0_7; Carvalho TL, 2001, J EXP MED, V194, P1141, DOI 10.1084/jem.194.8.1141; Chevillard C, 2002, J IMMUNOL, V168, P5659, DOI 10.4049/jimmunol.168.11.5659; Chowdhury D, 2004, IMMUNOL REV, V200, P182, DOI 10.1111/j.0105-2896.2004.00177.x; Chowdhury D, 2001, EMBO J, V20, P6394, DOI 10.1093/emboj/20.22.6394; Chung JB, 2003, TRENDS IMMUNOL, V24, P343, DOI 10.1016/S1471-4906(03)00119-4; de Andres B, 2002, BLOOD, V100, P4074, DOI 10.1182/blood-2002-03-0809; Duber S, 2009, BLOOD, V114, P4960, DOI 10.1182/blood-2009-04-218156; Engel H, 1999, EUR J IMMUNOL, V29, P2167, DOI 10.1002/(SICI)1521-4141(199907)29:07<2167::AID-IMMU2167>3.3.CO;2-8; Esplin BL, 2009, P NATL ACAD SCI USA, V106, P5773, DOI 10.1073/pnas.0811632106; Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003; Hao ZY, 2001, J EXP MED, V194, P1151, DOI 10.1084/jem.194.8.1151; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hayakawa K, 2000, CURR OPIN IMMUNOL, V12, P346, DOI 10.1016/S0952-7915(00)00098-4; Holodick NE, 2016, J IMMUNOL, V196, P4348, DOI 10.4049/jimmunol.1600073; Holodick NE, 2009, EUR J IMMUNOL, V39, P2383, DOI 10.1002/eji.200838920; Ichii Michiko, 2014, World J Stem Cells, V6, P421, DOI 10.4252/wjsc.v6.i4.421; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.iy.11.040193.002441; Lang JL, 2013, J IMMUNOL, V190, P2090, DOI 10.4049/jimmunol.1202810; Lentz VM, 2000, INT IMMUNOL, V12, P1483, DOI 10.1093/intimm/12.11.1483; Lindner C, 2015, NAT IMMUNOL, V16, P880, DOI 10.1038/ni.3213; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; MALYNN BA, 1990, J EXP MED, V171, P843, DOI 10.1084/jem.171.3.843; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Montecino-Rodriguez E, 2006, NAT IMMUNOL, V7, P293, DOI 10.1038/ni1301; Nash JC, 2014, J STAT SOFTW, V60, P1; Pei WK, 2017, NATURE, V548, P456, DOI 10.1038/nature23653; Petro JB, 2002, J BIOL CHEM, V277, P48009, DOI 10.1074/jbc.M200305200; Pieper K, 2013, J ALLERGY CLIN IMMUN, V131, P959, DOI 10.1016/j.jaci.2013.01.046; RAFF MC, 1976, NATURE, V259, P224, DOI 10.1038/259224a0; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; Roy B, 2013, EUR J IMMUNOL, V43, P2023, DOI 10.1002/eji.201243070; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; tenBoekel E, 1997, IMMUNITY, V7, P357; Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; Wasserman R, 1998, J EXP MED, V187, P259, DOI 10.1084/jem.187.2.259; Yang Y, 2012, P NATL ACAD SCI USA, V109, P5382, DOI 10.1073/pnas.1121631109; Yoshimoto M, 2011, P NATL ACAD SCI USA, V108, P1468, DOI 10.1073/pnas.1015841108; Yuan J, 2012, SCIENCE, V335, P1195, DOI 10.1126/science.1216557; Zhou Y, 2015, J EXP MED, V212, P569, DOI 10.1084/jem.20141510	49	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 31	2018	9								2483	10.3389/fimmu.2018.02483	http://dx.doi.org/10.3389/fimmu.2018.02483			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GY8OV	30429851	Green Published, gold			2022-12-18	WOS:000448892700001
J	Ziegler, MC; Granana, FB; Garcia-Beltran, WF; zur Wiesch, JS; Hoffmann, C; Rechtien, A; Lunemann, S; Altfeld, M				Ziegler, Maja Christiane; Granana, Ferran Borras; Garcia-Beltran, Wilfredo F.; zur Wiesch, Julian Schulze; Hoffmann, Christian; Rechtien, Anne; Lunemann, Sebastian; Altfeld, Marcus			Stable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3(+) Natural Killer Cells Following Vaccination	FRONTIERS IN IMMUNOLOGY			English	Article						HLA; KIR; NK cells; HCV; HIV; YFV vaccine	HEPATITIS-C VIRUS; INHIBITORY RECEPTOR; NK CELLS; SEQUENCE VARIATIONS; ALTER BINDING; HLA; INFECTION; EXPANSION; PEPTIDE; KIR	Inhibitory KIRs play a central role in regulating NK cell activity. KIR2DL2/3 bind to HLA-C molecules, but the modulation of these interactions by viral infections and presentation of viral epitopes is not well-understood. We investigated whether the frequencies of KIR2DL2/3(+) NK cells recognizing HLA-C*03:04/viral peptide complexes were impacted by YFV vaccination or HIV-1 and HCV infection. Ex vivo HLA class I tetramer staining of primary human NK cells derived from YFV-vaccinated individuals, or HIV-1-or HCV-infected individuals revealed that the YFV/HLA-C*03:04-NS2A(4-13) - tetramer bound to a larger proportion of KIR2DL2/3(+) NK cells compared to HIV-1/HLA-C*03:04-Gag(296-304) - or HCV/HLA-C*03:04-Core136-144-tetramers. The YFV/HLA-C * 03: 04-NS2A4-13-tetramer also exhibited a stronger avidity to KIR2DL2/3 compared to the other tested tetramers. The proportional frequencies of KIR2DL2/3(+) NK cells binding to the three tested HLA-C*03:04 tetramers were identical between YFV-vaccinated individuals or HIV-1-or HCV-infected individuals, and remained stable following YFV vaccination. These data demonstrate consistent hierarchies in the frequency of primary KIR2DL2/3(+) NK cells binding HLA-C*03:04/peptide complexes that were determined by the HLA-C-presented peptide and not modulated by the underlying viral infection or vaccination.	[Ziegler, Maja Christiane; Granana, Ferran Borras; Garcia-Beltran, Wilfredo F.; Rechtien, Anne; Lunemann, Sebastian; Altfeld, Marcus] Heinrich Pette Inst, Leibniz Inst Expt Virol, Dept Virus Immunol, Hamburg, Germany; [Garcia-Beltran, Wilfredo F.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA; [zur Wiesch, Julian Schulze; Rechtien, Anne] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [Hoffmann, Christian] Infekt Med Ctr Hamburg, ICH Study Ctr, Hamburg, Germany; [Rechtien, Anne; Altfeld, Marcus] German Ctr Infect Res, Partner Site Hamburg Lubeck Borstel Riems, Hamburg, Germany	Heinrich Pette Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf; German Center for Infection Research	Altfeld, M (corresponding author), Heinrich Pette Inst, Leibniz Inst Expt Virol, Dept Virus Immunol, Hamburg, Germany.; Altfeld, M (corresponding author), German Ctr Infect Res, Partner Site Hamburg Lubeck Borstel Riems, Hamburg, Germany.	marcus.altfeld@leibniz-hpi.de	Ziegler, Maja C./AAG-8494-2021; Altfeld, Marcus/AAE-7306-2019; Wiesch, Julian Schulze zur/AAT-8452-2021	Ziegler, Maja C./0000-0003-3745-4834; Altfeld, Marcus/0000-0001-5972-2997; 				Alter G, 2009, J VIROL, V83, P6798, DOI 10.1128/JVI.00256-09; Beziat V, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00507; Beziat V, 2014, EUR J IMMUNOL, V44, P2192, DOI 10.1002/eji.201444464; Beziat V, 2013, BLOOD, V121, P4703, DOI 10.1182/blood-2012-10-461442; Beziat V, 2012, EUR J IMMUNOL, V42, P447, DOI 10.1002/eji.201141826; Bjorkstrom NK, 2011, J EXP MED, V208, P13, DOI 10.1084/jem.20100762; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Carrington M, 2003, CLIN TRANSPLANT, P1; Co MDT, 2009, IMMUNOLOGY, V128, pe718, DOI 10.1111/j.1365-2567.2009.03070.x; Colantonio AD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001316; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; Dokun AO, 2001, NAT IMMUNOL, V2, P951, DOI 10.1038/ni714; Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001; Fadda L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002805; Fausther-Bovendoa H, 2008, AIDS, V22, P217, DOI 10.1097/QAD.0b013e3282f46e7c; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Guma M, 2006, CURR TOP MICROBIOL, V298, P207; Holzemer A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001900; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kim S, 2008, P NATL ACAD SCI USA, V105, P3053, DOI 10.1073/pnas.0712229105; Knapp S, 2010, HEPATOLOGY, V51, P1168, DOI 10.1002/hep.23477; Lunemann S, 2016, J HEPATOL, V65, P252, DOI 10.1016/j.jhep.2016.03.016; Morishima C, 2006, HEPATOLOGY, V43, P573, DOI 10.1002/hep.21073; Rajagopalan S, 1997, J EXP MED, V185, P1523, DOI 10.1084/jem.185.8.1523; Rasmussen M, 2014, J IMMUNOL, V193, P4790, DOI 10.4049/jimmunol.1401689; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tarazona R, 2002, J CLIN IMMUNOL, V22, P176, DOI 10.1023/A:1015476114409; Thielens A, 2012, CURR OPIN IMMUNOL, V24, P239, DOI 10.1016/j.coi.2012.01.001; Townsley E, 2016, CLIN EXP IMMUNOL, V183, P419, DOI 10.1111/cei.12722; van Teijlingen NH, 2014, AIDS, V28, P1399, DOI 10.1097/QAD.0000000000000284; Vivian JP, 2011, NATURE, V479, P401, DOI 10.1038/nature10517; Vossen MTM, 2005, J INFECT DIS, V191, P198, DOI 10.1086/426866	36	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2018	9								2361	10.3389/fimmu.2018.02361	http://dx.doi.org/10.3389/fimmu.2018.02361			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GX1OW	30386333	Green Published, gold			2022-12-18	WOS:000447488300001
J	Campos, MP; Figueiredo, FB; Morgado, FN; Renzetti, ARD; de Souza, SMM; Pereira, SA; Rodrigues-Da-Silva, RN; Lima, JD; De Luca, PM				Campos, Monique Paiva; Figueiredo, Fabiano Borges; Morgado, Fernanda Nazare; dos Santos Renzetti, Alinne Rangel; Marques de Souza, Sara Maria; Pereira, Sandro Antonio; Rodrigues-Da-Silva, Rodrigo Nunes; Lima-Junior, Josue Da Costa; De Luca, Paula Mello			Leishmania infantum Virulence Factor A2 Protein: Linear B-Cell Epitope Mapping and Identification of Three Main Linear B-Cell Epitopes in Vaccinated and Naturally Infected Dogs (vol 9, 1690, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						canine visceral leishmaniasis; vaccines; A2 protein; serology test; epitope mapping; epitope prediction			[Campos, Monique Paiva; Marques de Souza, Sara Maria; Pereira, Sandro Antonio] Natl Inst Infectol Evandro Chagas Fiocruz, Lab Pesquisa Clin Dermatozoonoses Anim Domest, Rio De Janeiro, Brazil; [Campos, Monique Paiva; dos Santos Renzetti, Alinne Rangel; Marques de Souza, Sara Maria; Pereira, Sandro Antonio] Natl Inst Infectol Evandro Chagas Fiocruz, Rio De Janeiro, Brazil; [Figueiredo, Fabiano Borges] Fundacao Oswaldo Cruz, Inst Carlos Chagas, Curitiba, Parana, Brazil; [Morgado, Fernanda Nazare] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Pesquisa Leishmanioses, Rio De Janeiro, Brazil; [dos Santos Renzetti, Alinne Rangel; Rodrigues-Da-Silva, Rodrigo Nunes; Lima-Junior, Josue Da Costa; De Luca, Paula Mello] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunoparasitol, Rio De Janeiro, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Lima, JD; De Luca, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunoparasitol, Rio De Janeiro, Brazil.	josue@ioc.fiocruz.br; pmdeluca@ioc.fiocruz.br	Pereira, Sandro/C-5380-2013; Morgado, Fernanda/O-3577-2017; Morgado, Fernanda/AAV-4435-2021; da Costa Lima-Junior, Josue/AAI-4746-2021; Morgado, Fernanda N/K-2527-2013	Morgado, Fernanda/0000-0002-7188-251X; Morgado, Fernanda/0000-0002-7188-251X; da Costa Lima-Junior, Josue/0000-0002-5848-404X; Morgado, Fernanda N/0000-0002-7188-251X; Rodrigues-da-Silva, Rodrigo Nunes/0000-0002-9772-849X; Pereira, Sandro/0000-0002-0614-4713				CAMPOS MP, 2018, FRONTIERS IMMUNOLOGY, V9	1	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 12	2018	9								2245	10.3389/fimmu.2018.02245	http://dx.doi.org/10.3389/fimmu.2018.02245			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GW7EC	30349528	gold, Green Published			2022-12-18	WOS:000447128500001
J	Kloess, S; da Silva, AEV; Oberschmidt, O; Gardlowski, T; Matthies, N; Vyas, M; Arseniev, L; Heuser, M; von Strandmann, EP; Kohl, U				Kloess, Stephan; da Silva, Alessa Ede Valverde; Oberschmidt, Olaf; Gardlowski, Tanja; Matthies, Nadine; Vyas, Maulik; Arseniev, Lubomir; Heuser, Michael; von Strandmann, Elke Pogge; Koehl, Ulrike			Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset (vol 8, 1100, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						natural killer cells; natural killer group 2 member D; triplebodies; ULBP2; CD19; CD33; immunoligands; acute myeloid leukemia			[Kloess, Stephan; da Silva, Alessa Ede Valverde; Oberschmidt, Olaf; Gardlowski, Tanja; Matthies, Nadine; Arseniev, Lubomir; Koehl, Ulrike] Hannover Med Sch MHH, Inst Cellular Therapeut, IFB Tx, Hannover, Germany; [Vyas, Maulik] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany; [Heuser, Michael] Hannover Med Sch MHH, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany; [von Strandmann, Elke Pogge] Philipps Univ Marburg, Ctr Tumor Biol & Immunol, Expt Tumor Res, Marburg, Germany	Hannover Medical School; University of Cologne; Hannover Medical School; Philipps University Marburg	Kloess, S (corresponding author), Hannover Med Sch MHH, Inst Cellular Therapeut, IFB Tx, Hannover, Germany.	kloess.stephan@mh-hannover.de	Vyas, Maulik/ABG-6797-2021					Kloess S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01100	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 8	2018	9								2326	10.3389/fimmu.2018.02326	http://dx.doi.org/10.3389/fimmu.2018.02326			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GW0ZV	30344526	Green Published, gold			2022-12-18	WOS:000446599700001
J	Kurant, E; Ariel, A; Lauber, K				Kurant, Estee; Ariel, Amiram; Lauber, Kirsten			Apoptotic Cell Clearance in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						phagocytes; apoptosis; engulfment of debris; tissue maintenance; immuneregulation; efferocytosis			[Kurant, Estee; Ariel, Amiram] Univ Haifa, Fac Nat Sci, Dept Biol, Haifa, Israel; [Kurant, Estee; Ariel, Amiram] Univ Haifa, Fac Nat Sci, Dept Human Biol, Haifa, Israel; [Lauber, Kirsten] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiat Oncol, Munich, Germany	University of Haifa; University of Haifa; University of Munich	Kurant, E (corresponding author), Univ Haifa, Fac Nat Sci, Dept Biol, Haifa, Israel.; Kurant, E (corresponding author), Univ Haifa, Fac Nat Sci, Dept Human Biol, Haifa, Israel.	kurantestee@gmail.com	Kurant, Estee/ADQ-6246-2022	Kurant, Estee/0000-0003-4795-4074					0	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2018	9								2154	10.3389/fimmu.2018.02154	http://dx.doi.org/10.3389/fimmu.2018.02154			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GV4TL	30333821	Green Published, gold			2022-12-18	WOS:000446093400001
J	Findly, RC; Niagro, FD; Sweeney, RP; Camus, AC; Dickerson, HW				Findly, Robert Craig; Niagro, Frank D.; Sweeney, Ryan P.; Camus, Alvin C.; Dickerson, Harry W.			Rearranged T Cell Receptor Sequences in the Germline Genome of Channel Catfish Are Preferentially Expressed in Response to Infection	FRONTIERS IN IMMUNOLOGY			English	Article						T cell receptor; rearranged VDJ genes; germline genome; DNA transposition; channel catfish	ZEBRAFISH ANTIBODY REPERTOIRE; ICTALURUS-PUNCTATUS; V(D)J RECOMBINATION; RAG TRANSPOSON; TELEOST FISH; BETA LOCUS; B-CELLS; EVOLUTION; GENES; ORGANIZATION	Rearranged V(D)J genes coding for T cell receptor alpha and beta chains are integrated into the germline genome of channel catfish. Previous analysis of expressed TCR V beta 2 repertoires demonstrated that channel catfish express multiple public clonotypes, which were shared among all the fish, following infection with a common protozoan parasite. In each case a single DNA sequence was predominately used to code for a public clonotype. We show here that the rearranged VDJ genes coding for these expressed public V beta 2 clonotypes can be amplified by PCR from germline DNA isolated from oocytes and erythrocytes. Sequencing of the V beta 2 PCR products con firmed that these expressed public V beta 2 clonotypes are integrated into the germline. Moreover, sequencing of PCR products confirmed that all five V beta gene families and V alpha 1 have rearranged V(D)J genes with diverse CDR3 sequences integrated into the germline. Germline rearranged V beta 2 and V beta 4 genes retain the intron between the leader and V beta sequence. This suggests that the germline rearranged TCR V beta genes arose through VDJ rearrangement in T cells, and subsequently moved into the germline through DNA transposon mediated transposition. These results reveal a new dimension to the adaptive immune system of vertebrates, namely: the expression of evolutionarily conserved, rearranged V(D)J genes from the germline.	[Findly, Robert Craig; Niagro, Frank D.; Sweeney, Ryan P.; Dickerson, Harry W.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA; [Camus, Alvin C.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Findly, RC (corresponding author), Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.	rfindly@uga.edu			Agricultural and Food Research Initiative from the USDA National Institute of Food and Agriculture [2008-35204-04604, 1000626]	Agricultural and Food Research Initiative from the USDA National Institute of Food and Agriculture	This work was supported by Agricultural and Food Research Initiative grants 2008-35204-04604 and 1000626 from the USDA National Institute of Food and Agriculture (RF and HD). We thanks R. Tarleton for helpful comments.	Bengten E, 2015, RESULTS PROBL CELL D, V57, P193, DOI 10.1007/978-3-319-20819-0_9; Chen XH, 2016, GIGASCIENCE, V5, DOI 10.1186/s13742-016-0142-5; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Dooley H, 2006, DEV COMP IMMUNOL, V30, P43, DOI 10.1016/j.dci.2005.06.022; Findly RC, 2017, DEV COMP IMMUNOL, V68, P26, DOI 10.1016/j.dci.2016.11.010; Findly RC, 2013, DEV COMP IMMUNOL, V39, P302, DOI 10.1016/j.dci.2012.08.007; Fischer C, 2002, GENOMICS, V79, P241, DOI 10.1006/geno.2002.6688; Flajnik MF, 2016, CELL, V166, P11, DOI 10.1016/j.cell.2016.06.021; Flajnik MF, 2014, CURR BIOL, V24, pR1060, DOI 10.1016/j.cub.2014.09.070; Flajnik MF, 2010, NAT REV GENET, V11, P47, DOI 10.1038/nrg2703; Freeman JD, 2009, GENOME RES, V19, P1817, DOI 10.1101/gr.092924.109; Ghaffari SH, 1999, J IMMUNOL, V162, P1519; Huang SF, 2016, CELL, V166, P102, DOI 10.1016/j.cell.2016.05.032; Jiang N, 2011, P NATL ACAD SCI USA, V108, P5348, DOI 10.1073/pnas.1014277108; Kawakami K, 2000, P NATL ACAD SCI USA, V97, P11403, DOI 10.1073/pnas.97.21.11403; Korlach J, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix085; Krangel MS, 2009, CURR OPIN IMMUNOL, V21, P133, DOI 10.1016/j.coi.2009.03.009; Lee SS, 2000, J EXP MED, V191, P1637, DOI 10.1084/jem.191.10.1637; Liu ZJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11757; Ma CY, 2013, EUR J IMMUNOL, V43, P360, DOI 10.1002/eji.201242570; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Meeker ND, 2010, IMMUNOGENETICS, V62, P23, DOI 10.1007/s00251-009-0407-6; Nandi S, 2007, GENETICA, V131, P81, DOI 10.1007/s10709-006-9115-4; Parra ZE, 2007, P NATL ACAD SCI USA, V104, P9776, DOI 10.1073/pnas.0609106104; Richardson SR, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0061-2014; Robins HS, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001442; Roe D, 2017, GENES IMMUN, V18, P127, DOI 10.1038/gene.2017.10; Stuge TB, 2000, J IMMUNOL, V164, P2971, DOI 10.4049/jimmunol.164.6.2971; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Ventura-Holman T, 2002, MOL IMMUNOL, V38, P557, DOI 10.1016/S0161-5890(01)00075-X; Venturi V, 2006, P NATL ACAD SCI USA, V103, P18691, DOI 10.1073/pnas.0608907103; Warren RL, 2011, GENOME RES, V21, P790, DOI 10.1101/gr.115428.110; Weinstein JA, 2009, SCIENCE, V324, P807, DOI 10.1126/science.1170020; Wessler SR, 2006, P NATL ACAD SCI USA, V103, P17600, DOI 10.1073/pnas.0607612103; Wilson MR, 1998, MOL IMMUNOL, V35, P545, DOI 10.1016/S0161-5890(98)00037-6; Yazawa R, 2008, DEV COMP IMMUNOL, V32, P204, DOI 10.1016/j.dci.2007.05.002; Yuan ZH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197371; Zhao XG, 2008, DEV COMP IMMUNOL, V32, P500, DOI 10.1016/j.dci.2007.08.009; Zhou H, 2003, J IMMUNOL, V170, P2573, DOI 10.4049/jimmunol.170.5.2573	40	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2018	9								2117	10.3389/fimmu.2018.02117	http://dx.doi.org/10.3389/fimmu.2018.02117			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GV0QI	30319607	Green Published, gold			2022-12-18	WOS:000445766900001
J	Greaves, SA; Peterson, JN; Torres, RM; Pelanda, R				Greaves, Sarah A.; Peterson, Jacob N.; Torres, Raul M.; Pelanda, Roberta			Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance (vol 9, pg 707, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						B cells; B cell tolerance; BCR signaling; MAP kinase; ERK; B cell development; autoreactive B cells; mouse models			[Greaves, Sarah A.; Peterson, Jacob N.; Torres, Raul M.; Pelanda, Roberta] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA; [Torres, Raul M.; Pelanda, Roberta] Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health	Pelanda, R (corresponding author), Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA.; Pelanda, R (corresponding author), Natl Jewish Hlth, Dept Biomed Res, Denver, CO 80206 USA.	roberta.pelanda@ucdenver.edu			NIAID NIH HHS [R21 AI131639, R01 AI052310] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052310, R21AI131639] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Greaves SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00707	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 27	2018	9								2218	10.3389/fimmu.2018.02218	http://dx.doi.org/10.3389/fimmu.2018.02218			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GV0VC	30323810	Green Published, gold			2022-12-18	WOS:000445781300002
J	Ryu, S; Park, JS; Kim, HY; Kim, JH				Ryu, Seungwon; Park, Joon Seok; Kim, Hye Young; Kim, Ji Hyung			Lipid-Reactive T Cells in Immunological Disorders of the Lung	FRONTIERS IN IMMUNOLOGY			English	Review						pulmonary disorders; lipid antigens; CD1 molecules; CD1-restricted T cells; natural killer T cells	INVARIANT NKT CELLS; CD1 ANTIGEN PRESENTATION; INNATE IMMUNE-RESPONSE; A VIRUS-INFECTION; ALPHA-GALACTOSYLCERAMIDE; DENDRITIC CELLS; AIRWAY INFLAMMATION; PHASE-I; PULMONARY-FIBROSIS; POTENTIAL-ROLE	Regulation of T cell-mediated immunity in the lungs is critical for prevention of immune-related lung disorders and for host protection from pathogens. While the prevalent view of pulmonary T cell responses is based on peptide recognition by antigen receptors, called T cell receptors (TCR), on the T cell surface in the context of classical major histocompatibility complex (MHC) molecules, novel pathways involving the presentation of lipid antigens by cluster of differentiation 1 (CD1) molecules to lipid-reactive T cells are emerging as key players in pulmonary immune system. Whereas, genetic conservation of group II CD1 (CD1d) in mouse and human genomes facilitated numerous in vivo studies of CD1d-restricted invariant natural killer T (i NKT) cells in lung diseases, the recent development of human CD1-transgenic mice has made it possible to examine the physiological roles of group I CD1 (CD1a-c) molecules in lung immunity. Here, we discuss current understanding of the biology of CD1-reactive T cells with a specific focus on their roles in several pulmonary disorders.	[Ryu, Seungwon; Kim, Hye Young] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea; [Ryu, Seungwon; Kim, Hye Young] Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea; [Park, Joon Seok] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA USA; [Kim, Ji Hyung] Korea Univ, Coll Life Sci & Biotechnol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Harvard University; Harvard Medical School; Korea University	Kim, HY (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.; Kim, HY (corresponding author), Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea.; Kim, JH (corresponding author), Korea Univ, Coll Life Sci & Biotechnol, Seoul, South Korea.	hykim11@snu.ac.kr; jay_kim@korea.ac.kr	Kim, Hye Young/AAF-7609-2020	Kim, Hye Young/0000-0001-5978-512X; Kim, JI HYUNG/0000-0001-6785-2345; Park, Joon Seok/0000-0003-4001-6886; Ryu, Seungwon/0000-0003-2638-5749	Korea Healthcare Technology R&D Project, Ministry for Health and Welfare Affairs, Republic of Korea [HI15C1736]; National Research Foundation of Korea (NRF) - Ministry of Education [2018R1D1A1B07048813]	Korea Healthcare Technology R&D Project, Ministry for Health and Welfare Affairs, Republic of Korea; National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of Korea)	HK was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare Affairs, Republic of Korea (HI15C1736). JK was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1B07048813).	Adams EJ, 2014, CURR OPIN IMMUNOL, V26, P1, DOI 10.1016/j.coi.2013.09.005; Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Al Omar SY, 2012, INT IMMUNOL, V24, P409, DOI 10.1093/intimm/dxr122; Albacker LA, 2013, NAT MED, V19, P1297, DOI 10.1038/nm.3321; Ambrosino E, 2007, J IMMUNOL, V179, P5126, DOI 10.4049/jimmunol.179.8.5126; Bagchi S, 2017, J CLIN INVEST, V127, P2339, DOI 10.1172/JCI92217; Barnes PJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.76; Barral DC, 2007, NAT REV IMMUNOL, V7, P929, DOI 10.1038/nri2191; Barthelemy A, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00706-17; Bedel R, 2012, NAT IMMUNOL, V13, P705, DOI 10.1038/ni.2347; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, J EXP MED, V182, P2091, DOI 10.1084/jem.182.6.2091; Benlagha K, 2005, J EXP MED, V202, P485, DOI 10.1084/jem.20050456; Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017; Bilenki L, 2005, J IMMUNOL, V175, P3197, DOI 10.4049/jimmunol.175.5.3197; Bilenki L, 2004, EUR J IMMUNOL, V34, P345, DOI 10.1002/eji.200324303; Brennan PJ, 2014, P NATL ACAD SCI USA, V111, P13433, DOI 10.1073/pnas.1415357111; Brennan PJ, 2011, NAT IMMUNOL, V12, P1202, DOI 10.1038/ni.2143; Brigl M, 2011, J EXP MED, V208, P1163, DOI 10.1084/jem.20102555; Brooks CR, 2010, J ALLERGY CLIN IMMUN, V126, P882, DOI 10.1016/j.jaci.2010.06.041; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; Cernadas M, 2010, J IMMUNOL, V184, P1235, DOI 10.4049/jimmunol.0804140; Chandra S, 2015, NAT IMMUNOL, V16, P799, DOI 10.1038/ni.3203; Chang PP, 2012, NAT IMMUNOL, V13, P35, DOI 10.1038/ni.2166; Chang YJ, 2011, J CLIN INVEST, V121, P57, DOI 10.1172/JCI44845; Chen K, 2013, ANNU REV IMMUNOL, V31, P605, DOI 10.1146/annurev-immunol-032712-100019; Cheung KL, 2016, J EXP MED, V213, P2399, DOI 10.1084/jem.20160258; Christaki E, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/532717; Chuang YT, 2019, J ALLERGY CLIN IMMUN, V143, P565, DOI 10.1016/j.jaci.2018.03.022; Cotton RN, 2018, CURR OPIN IMMUNOL, V52, P93, DOI 10.1016/j.coi.2018.04.013; Cui JQ, 1999, J EXP MED, V190, P783, DOI 10.1084/jem.190.6.783; Das J, 2006, NAT MED, V12, P1345, DOI 10.1038/nm1206-1345; Dascher CC, 2003, INT IMMUNOL, V15, P915, DOI 10.1093/intimm/dxg091; Dasgupta S, 2016, IMMUNOGENETICS, V68, P665, DOI 10.1007/s00251-016-0930-1; de la Salle H, 2005, SCIENCE, V310, P1321, DOI 10.1126/science.1115301; de Lalla C, 2011, EUR J IMMUNOL, V41, P602, DOI 10.1002/eji.201041211; De Santo C, 2008, J CLIN INVEST, V118, P4036, DOI 10.1172/JCI36264; DeKruyff RH, 2014, IMMUNOL REV, V260, P235, DOI 10.1111/imr.12187; Dhodapkar MV, 2017, J IMMUNOL, V198, P1015, DOI 10.4049/jimmunol.1601399; Dougan SK, 2007, CURR TOP MICROBIOL, V314, P113; Dougan SK, 2005, J EXP MED, V202, P529, DOI 10.1084/jem.20050183; Facciotti F, 2011, P NATL ACAD SCI USA, V108, P14228, DOI 10.1073/pnas.1108809108; Faunce DE, 2005, J IMMUNOL, V175, P3102, DOI 10.4049/jimmunol.175.5.3102; Felio K, 2009, J EXP MED, V206, P2497, DOI 10.1084/jem.20090898; Gapin L, 2016, CURR OPIN IMMUNOL, V39, P68, DOI 10.1016/j.coi.2016.01.001; Germanov E, 2008, J IMMUNOL, V181, P81, DOI 10.4049/jimmunol.181.1.81; Grabarz F, 2018, INFLAMMOPHARMACOLOGY, V26, P491, DOI 10.1007/s10787-017-0383-7; Holzapfel KL, 2014, J IMMUNOL, V192, P5490, DOI 10.4049/jimmunol.1400722; Hwang SJ, 2006, J IMMUNOL, V177, P5258, DOI 10.4049/jimmunol.177.8.5258; Ishikawa A, 2005, CLIN CANCER RES, V11, P1910, DOI 10.1158/1078-0432.CCR-04-1453; Ivanov S, 2013, J VIROL, V87, P6911, DOI 10.1128/JVI.02943-12; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jarrett R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6833; Jing Y, 2007, EXP GERONTOL, V42, P719, DOI 10.1016/j.exger.2007.01.009; Joseph C, 2013, INFLUENZA OTHER RESP, V7, P105, DOI 10.1111/irv.12089; Kain L, 2014, IMMUNITY, V41, P543, DOI 10.1016/j.immuni.2014.08.017; KASINRERK W, 1993, J IMMUNOL, V150, P579; Kawano T, 1999, CANCER RES, V59, P5102; Kawashima T, 2003, J IMMUNOL, V170, P5345, DOI 10.4049/jimmunol.170.11.5345; Kelly H, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-4; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim JH, 2005, AM J PATHOL, V167, P1231, DOI 10.1016/S0002-9440(10)61211-4; Kim JH, 2016, NAT IMMUNOL, V17, P1159, DOI 10.1038/ni.3523; Kim JO, 2004, J ALLERGY CLIN IMMUN, V114, P1332, DOI 10.1016/j.jaci.2004.09.004; Kim PJ, 2006, J IMMUNOL, V177, P6650, DOI 10.4049/jimmunol.177.10.6650; Kimura T, 2004, J IMMUNOL, V172, P5782, DOI 10.4049/jimmunol.172.9.5782; Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380; Kinjo Y, 2011, NAT IMMUNOL, V12, P966, DOI 10.1038/ni.2096; Kobayashi C, 2012, J INVEST DERMATOL, V132, P241, DOI 10.1038/jid.2011.280; Kobayashi E, 1995, ONCOL RES, V7, P529; Koh YI, 2008, J IMMUNOL, V181, P4560, DOI 10.4049/jimmunol.181.7.4560; Kok WL, 2012, J LEUKOCYTE BIOL, V91, P357, DOI 10.1189/jlb.0411184; Konishi J, 2004, HUM IMMUNOL, V65, P1377, DOI 10.1016/j.humimm.2004.09.003; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kovalovsky D, 2008, NAT IMMUNOL, V9, P1055, DOI 10.1038/ni.1641; Kwon DI, 2017, IMMUNE NETW, V17, P365, DOI 10.4110/in.2017.17.6.365; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lee YJ, 2015, IMMUNITY, V43, P566, DOI 10.1016/j.immuni.2015.06.025; Lee YJ, 2013, NAT IMMUNOL, V14, P1146, DOI 10.1038/ni.2731; Leon L, 2012, P NATL ACAD SCI USA, V109, P4357, DOI 10.1073/pnas.1200764109; Li S, 2011, BLOOD, V118, P3870, DOI 10.1182/blood-2011-03-341941; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Lloyd CM, 2017, IMMUNITY, V46, P549, DOI 10.1016/j.immuni.2017.04.005; Lockridge JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021701; Lynch L, 2015, NAT IMMUNOL, V16, P85, DOI 10.1038/ni.3047; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Mathai SC, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6819; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; McCracken JL, 2017, JAMA-J AM MED ASSOC, V318, P279, DOI 10.1001/jama.2017.8372; McKnight CG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188221; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Moody DB, 2017, CURR OPIN IMMUNOL, V46, P127, DOI 10.1016/j.coi.2017.07.013; Moody DB, 2005, NAT REV IMMUNOL, V5, P387, DOI 10.1038/nri1605; Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Motohashi S, 2006, CLIN CANCER RES, V12, P6079, DOI 10.1158/1078-0432.CCR-06-0114; Motohashi S, 2009, J IMMUNOL, V182, P2492, DOI 10.4049/jimmunol.0800126; Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885; Mutalithas K, 2007, J ALLERGY CLIN IMMUN, V119, P1274, DOI 10.1016/j.jaci.2007.02.021; Nagarajan NA, 2007, J IMMUNOL, V178, P2706, DOI 10.4049/jimmunol.178.5.2706; Nagato K, 2012, J CLIN IMMUNOL, V32, P1071, DOI 10.1007/s10875-012-9697-9; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; O'Brien TF, 2016, MUCOSAL IMMUNOL, V9, P597, DOI 10.1038/mi.2015.78; Paget C, 2007, IMMUNITY, V27, P597, DOI 10.1016/j.immuni.2007.08.017; Paget C, 2012, J BIOL CHEM, V287, P8816, DOI 10.1074/jbc.M111.304758; Paget C, 2011, J IMMUNOL, V186, P5590, DOI 10.4049/jimmunol.1002348; Pai M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.76; Palucka KA, 1998, J IMMUNOL, V160, P4587; Parekh VV, 2004, J IMMUNOL, V173, P3693, DOI 10.4049/jimmunol.173.6.3693; Parlato S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189477; Paun A, 2014, RADIAT RES, V181, P369, DOI 10.1667/RR13581.1; Pellicci DG, 2002, J EXP MED, V195, P835, DOI 10.1084/jem.20011544; Pham-Thi N, 2006, J ALLERGY CLIN IMMUN, V117, P217, DOI 10.1016/j.jaci.2005.09.052; Pichavant M, 2014, MUCOSAL IMMUNOL, V7, P568, DOI 10.1038/mi.2013.75; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Porubsky S, 2007, P NATL ACAD SCI USA, V104, P5977, DOI 10.1073/pnas.0611139104; Pyszniak M, 2014, KARDIOCHIR TORAKOCHI, V11, P34, DOI 10.5114/kitp.2014.41928; Raghu G, 2015, AM J RESP CRIT CARE, V192, pE3, DOI 10.1164/rccm.201506-1063ST; Reinink P, 2016, IMMUNOGENETICS, V68, P515, DOI 10.1007/s00251-016-0926-x; Reynolds C, 2009, J ALLERGY CLIN IMMUN, V124, P860, DOI 10.1016/j.jaci.2009.07.022; Richeldi L, 2017, LANCET, V389, P1941, DOI 10.1016/S0140-6736(17)30866-8; Rosenzwajg M, 1996, BLOOD, V87, P535, DOI 10.1182/blood.V87.2.535.bloodjournal872535; Rougier N, 1998, EUR J CELL BIOL, V75, P287, DOI 10.1016/S0171-9335(98)80124-6; Sada-Ovalle I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000239; Sag D, 2014, J CLIN INVEST, V124, P3725, DOI 10.1172/JCI72308; Salio M, 2007, P NATL ACAD SCI USA, V104, P20490, DOI 10.1073/pnas.0710145104; Salio M, 2013, P NATL ACAD SCI USA, V110, pE4753, DOI 10.1073/pnas.1310050110; Savage AK, 2008, IMMUNITY, V29, P391, DOI 10.1016/j.immuni.2008.07.011; Scanlon ST, 2011, J EXP MED, V208, P2113, DOI 10.1084/jem.20110522; Sharma M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02229-7; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; SOLER P, 1989, AM REV RESPIR DIS, V139, P1112, DOI 10.1164/ajrccm/139.5.1112; Subramaniam S, 2016, EUR J IMMUNOL, V46, P242, DOI 10.1002/eji.201545869; Sugita M, 1999, IMMUNITY, V11, P743, DOI 10.1016/S1074-7613(00)80148-X; Szalay G, 1999, MICROBES INFECT, V1, P1153, DOI 10.1016/S1286-4579(99)00248-8; Taniguchi M, 2003, NAT IMMUNOL, V4, P1164, DOI 10.1038/ni1203-1164; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Terabe M, 2005, J EXP MED, V202, P1627, DOI 10.1084/jem.20051381; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Thomas SY, 2010, J ALLERGY CLIN IMMUN, V125, P980, DOI 10.1016/j.jaci.2010.01.032; Tsao CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147710; Ulrichs T, 2003, INFECT IMMUN, V71, P3076, DOI 10.1128/IAI.71.6.3076-3087.2003; Van Kaer L, 2016, TRENDS IMMUNOL, V37, P738, DOI 10.1016/j.it.2016.08.011; Van Pottelberge GR, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-35; Verhoeven GT, 2002, THORAX, V57, P694, DOI 10.1136/thorax.57.8.694; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Wang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058556; Watarai H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001255; Weng XF, 2014, EUR J IMMUNOL, V44, P3646, DOI 10.1002/eji.201444848; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229; Wun KS, 2018, NAT IMMUNOL, V19, P397, DOI 10.1038/s41590-018-0065-7; Young MH, 2011, EUR J IMMUNOL, V41, P592, DOI 10.1002/eji.201141408; YU CY, 1989, EMBO J, V8, P3727, DOI 10.1002/j.1460-2075.1989.tb08548.x; Zeissig S, 2010, J CLIN INVEST, V120, P2889, DOI 10.1172/JCI42703; Zhang GQ, 2011, AM J PHYSIOL-LUNG C, V301, pL975, DOI 10.1152/ajplung.00114.2011; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; Zhao J, 2015, ELIFE, V4, DOI 10.7554/eLife.08525; Zhao J, 2014, P NATL ACAD SCI USA, V111, P2674, DOI 10.1073/pnas.1323845111; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	167	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 26	2018	9								2205	10.3389/fimmu.2018.02205	http://dx.doi.org/10.3389/fimmu.2018.02205			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GU9JV	30319649	gold, Green Published			2022-12-18	WOS:000445662600002
J	Kim, M; Kim, M; Yoo, HJ; Lee, JH				Kim, Minjoo; Kim, Minkyung; Yoo, Hye Jin; Lee, Jong Ho			Natural Killer Cell Activity and Interleukin-12 in Metabolically Healthy versus Metabolically Unhealthy Overweight Individuals (vol 8, 1700, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						metabolically healthy overweight; metabolically unhealthy overweight; natural killer cell; interleukin-12; immune system			[Kim, Minjoo; Kim, Minkyung; Lee, Jong Ho] Yonsei Univ, Res Ctr Silver Sci, Inst Symbiot Life TECH, Seoul, South Korea; [Yoo, Hye Jin; Lee, Jong Ho] Yonsei Univ, Coll Human Ecol, Dept Food & Nutr, Brain Korea PLUS Project 21, Seoul, South Korea; [Lee, Jong Ho] Yonsei Univ, Coll Human Ecol, Dept Food & Nutr, Natl Leading Res Lab Clin Nutrigenet Nutrigen, Seoul, South Korea	Yonsei University; Yonsei University; Yonsei University	Lee, JH (corresponding author), Yonsei Univ, Res Ctr Silver Sci, Inst Symbiot Life TECH, Seoul, South Korea.; Lee, JH (corresponding author), Yonsei Univ, Coll Human Ecol, Dept Food & Nutr, Brain Korea PLUS Project 21, Seoul, South Korea.; Lee, JH (corresponding author), Yonsei Univ, Coll Human Ecol, Dept Food & Nutr, Natl Leading Res Lab Clin Nutrigenet Nutrigen, Seoul, South Korea.	jhleeb@yonsei.ac.kr						Kim M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01700	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 20	2018	9								2179	10.3389/fimmu.2018.02179	http://dx.doi.org/10.3389/fimmu.2018.02179			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GU2NW	30275818	gold, Green Published			2022-12-18	WOS:000445108000001
J	Dressel, R; Greinix, HT; Holler, E; Dickinson, AM				Dressel, Ralf; Greinix, Hildegard T.; Holler, Ernst; Dickinson, Anne M.			Editorial: Cellular Therapies: Past, Present and Future	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						animal models; biomarkers; genetic association; graft-vs.-host disease; graft-vs.-leukemia effects; hematopoietic stem cell transplantation; immunotherapies; reconstitution			[Dressel, Ralf] Univ Med Ctr Gottingen, Inst Cellular & Mol Immunol, Gottingen, Germany; [Greinix, Hildegard T.] Med Univ Graz, Div Haematol, Graz, Austria; [Holler, Ernst] Univ Hosp Regensburg, Dept Internal Med 3, Regensburg, Germany; [Dickinson, Anne M.] Newcastle Univ, Inst Cellular Med, Hematol Sci, Newcastle Upon Tyne, Tyne & Wear, England	University of Gottingen; Medical University of Graz; University of Regensburg; Newcastle University - UK	Dickinson, AM (corresponding author), Newcastle Univ, Inst Cellular Med, Hematol Sci, Newcastle Upon Tyne, Tyne & Wear, England.	anne.dickinson@newcastle.ac.uk	Dressel, Ralf/R-7065-2016	Dressel, Ralf/0000-0002-1651-1214	European Union [FP7-PEOPLE-2012-ITN-315963]	European Union(European Commission)	We thank our partners in the CELLEUROPE project S. Ahmed, R. Buhmann, I. Hromadnikova, M. Inngjerdingen, G. Multhoff, A. Richter, B. Rolstadt, E. Weissinger, and all other colleagues involved in the project. Margherita Boieri, Rihab Gam, Sakhila Ghimire, Dasaradha Jalapothu, Mateja Kralj-Juric, Shuang Li, Michael Lutteropp, Petra Mozes, Justyna Ogonek, Marsela Qesari, Monica Correia dos Reis, Pranali Shah, and Maxim Shevtsov were Marie Curie Fellows and supported by the European Union (FP7-PEOPLE-2012-ITN-315963).		0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 30	2018	9								1966	10.3389/fimmu.2018.01966	http://dx.doi.org/10.3389/fimmu.2018.01966			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GS0BZ	30214447	gold, Green Published			2022-12-18	WOS:000443149400001
J	Teku, GN; Vihinen, M				Teku, Gabriel Ndipagbornchi; Vihinen, Mauno			Simulation of the Dynamics of Primary Immunodeficiencies in B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; systems analysis; models; biological; B-cell network model; semi-quantitative network simulation; B-cell network simulation	HYPER-IGM SYNDROME; TRANSCRIPTION FACTOR; ECTODERMAL DYSPLASIA; MOLECULAR CHARACTERIZATION; DIFFERENTIAL ACTIVATION; ALPHA MUTATION; IMMUNE-SYSTEM; DISEASE GENES; RECEPTOR; PROTEIN	Primary immunodeficiencies (PIDs) are a group of over 300 hereditary, heterogeneous, and mainly rare disorders that affect the immune system. Various aspects of immune system and PID proteins and genes have been investigated and facilitate systems biological studies of effects of PIDs on B cell physiology and response. We reconstructed a B cell network model based on data for the core B cell receptor activation and response processes and performed semi-quantitative dynamic simulations for normal and B cell PID failure modes. The results for several knockout simulations correspond to previously reported molecular studies and reveal novel mechanisms for PIDs. The simulations for CD21, CD40, LYN, MS4A1, ORAI1, PLCG2, PTPRC, and STIM1 indicated profound changes to major transcription factor signaling and to the network. Significant effects were observed also in the BCL10, BLNK, BTK, loss-of-function CARD11, IKKB, MALT1, and NEMO, simulations whereas only minor effects were detected for PIDs that are caused by constitutively active proteins (PI3K, gain-of-function CARD11, KRAS, and NFKBIA). This study revealed the underlying dynamics of PID diseases, confirms previous observations, and identifies novel candidates for PID diagnostics and therapy.	[Teku, Gabriel Ndipagbornchi; Vihinen, Mauno] Lund Univ, Dept Expt Med Sci, BMC B13, Lund, Sweden	Lund University	Vihinen, M (corresponding author), Lund Univ, Dept Expt Med Sci, BMC B13, Lund, Sweden.	mauno.vihinen@med.lu.se	Teku, Gabriel/F-6146-2014; Vihinen, Mauno/A-8452-2012	Teku, Gabriel/0000-0001-6829-5501; Vihinen, Mauno/0000-0002-9614-7976	Vetenskapsradet; Alfred Osterlunds stiftelse	Vetenskapsradet(Swedish Research Council); Alfred Osterlunds stiftelse	This study is part of a published doctoral thesis (21). This study was funded by Vetenskapsradet and the Alfred Osterlunds stiftelse.	Al-Saud BK, 2013, J CLIN IMMUNOL, V33, P1325, DOI 10.1007/s10875-013-9951-9; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Baba Y, 2016, CURR TOP MICROBIOL, V393, P143, DOI 10.1007/82_2015_477; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Boole R. G., 1848, CAMBRIDGE DUBLIN MAT, V3, P183; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Compeer EB, 2015, ONCOTARGET, V6, P10759, DOI 10.18632/oncotarget.3577; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; Csardi G., 2006, INTERJOURNAL COMPLEX, V1695, P5; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; del Sol A, 2010, CURR OPIN BIOTECH, V21, P566, DOI 10.1016/j.copbio.2010.07.010; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; Garrett-Sinha LA, 2013, CELL MOL LIFE SCI, V70, P3375, DOI 10.1007/s00018-012-1243-7; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Granados EL, 2008, HUM MUTAT, V29, P861, DOI 10.1002/humu.20740; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hao SL, 2003, EMBO J, V22, P4166, DOI 10.1093/emboj/cdg401; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Harnett MA, 2005, IMMUNOL LETT, V98, P33, DOI 10.1016/j.imlet.2004.11.002; Hinman RM, 2007, J IMMUNOL, V178, P740, DOI 10.4049/jimmunol.178.2.740; Itan Y, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00142; Itan Y, 2013, P NATL ACAD SCI USA, V110, P5558, DOI [10.1073/pnas.1218167110, 10.1073/PNAS.1218167110]; Janssen R, 2004, J EXP MED, V200, P559, DOI 10.1084/jem.20040773; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Keerthikumar S, 2009, DNA RES, V16, P345, DOI 10.1093/dnares/dsp019; KLINMAN NR, 1975, TRANSPLANT REV, V24, P41; Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1_18; Krumsiek J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-233; Le DH, 2011, BIOINFORMATICS, V27, P2767, DOI 10.1093/bioinformatics/btr466; Leandro MJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3908; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Li FT, 2004, P NATL ACAD SCI USA, V101, P4781, DOI 10.1073/pnas.0305937101; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Luo W, 2014, J IMMUNOL, V193, P909, DOI 10.4049/jimmunol.1400666; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; Mendez A, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004696; Meyer-Bahlburg A, 2012, FRONT BIOSCI-LANDMRK, V17, P1499, DOI 10.2741/4000; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Ortutay C, 2007, IMMUNOGENETICS, V59, P333, DOI 10.1007/s00251-007-0191-0; Ortutay C, 2009, NUCLEIC ACIDS RES, V37, P622, DOI 10.1093/nar/gkn982; Ortutay Csaba, 2008, Immunome Res, V4, P4, DOI 10.1186/1745-7580-4-4; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Piirila H, 2006, HUM MUTAT, V27, P1200, DOI 10.1002/humu.20405; Piro RM, 2012, FEBS J, V279, P678, DOI 10.1111/j.1742-4658.2012.08471.x; Pratt D, 2015, CELL SYST, V1, P302, DOI 10.1016/j.cels.2015.10.001; R Development Core Team, 2021, LANG ENV STAT COMP; Rahman MM, 2011, J VIROL, V85, P12505, DOI 10.1128/JVI.00410-11; Rappaport N, 2017, NUCLEIC ACIDS RES, V45, pD877, DOI 10.1093/nar/gkw1012; Russell L, 2015, J IMMUNOL, V195, P3574, DOI 10.4049/jimmunol.1500776; Samarghitean Crina, 2007, Immunome Res, V3, P6, DOI 10.1186/1745-7580-3-6; Samarghitean C, 2009, J IMMUNOL, V183, P7569, DOI 10.4049/jimmunol.0901837; Sato S, 1997, J IMMUNOL, V159, P3278; Schmidlin H, 2009, TRENDS IMMUNOL, V30, P277, DOI 10.1016/j.it.2009.03.008; Sciammas R, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.25; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shifera AS, 2010, J CELL MOL MED, V14, P2404, DOI 10.1111/j.1582-4934.2010.01054.x; Singh SP, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0779-z; Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Szydlowski M, 2014, INT REV IMMUNOL, V33, P146, DOI 10.3109/08830185.2014.885022; Teku GN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176500; Teku NG, 2017, THESIS; Thakar J, 2009, J R SOC INTERFACE, V6, P599, DOI 10.1098/rsif.2008.0363; THOMAS R, 1973, J THEOR BIOL, V42, P563, DOI 10.1016/0022-5193(73)90247-6; Tibrewal N, 2008, J BIOL CHEM, V283, P3618, DOI 10.1074/jbc.M706906200; van der Burg M, 2011, EUR J PEDIATR, V170, P561, DOI 10.1007/s00431-011-1452-3; Vihinen M, 2015, ELS, P1; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Wilker PR, 2008, NAT IMMUNOL, V9, P603, DOI 10.1038/ni.1609; Wittmann DM, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-98; Xu WF, 2005, J INTERF CYTOK RES, V25, P113, DOI 10.1089/jir.2005.25.113; Yasuda T, 2008, IMMUNITY, V28, P499, DOI 10.1016/j.immuni.2008.02.015	79	0	0	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 2	2018	9								1785	10.3389/fimmu.2018.01785	http://dx.doi.org/10.3389/fimmu.2018.01785			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GP1PO	30116248	Green Published, gold			2022-12-18	WOS:000440588600001
J	Cai, ZM; Xie, CH; Qiao, W; Fei, XB; Guo, XX; Liu, HC; Li, XY; Fang, X; Xu, GQ; Dou, H; Deng, GM				Cai, Zhenming; Xie, Changhao; Qiao, Wei; Fei, Xibin; Guo, Xuanxuan; Liu, Huicheng; Li, Xiaoyan; Fang, Xiang; Xu, Guangqiong; Dou, Hui; Deng, Guo-Min			The Role of Estrogen Membrane Receptor (G Protein-Coupled Estrogen Receptor 1) in Skin Inflammation Induced by Systemic Lupus Erythematosus Serum IgG (vol 8, 1723, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						estrogen; systemic lupus erythematosus; IgG; skin inflammation; G protein-coupled estrogen receptor 1			[Cai, Zhenming; Xie, Changhao; Qiao, Wei; Fei, Xibin; Guo, Xuanxuan; Liu, Huicheng; Li, Xiaoyan; Fang, Xiang; Xu, Guangqiong; Dou, Hui; Deng, Guo-Min] Nanjing Med Univ, Minist Hlth, Key Lab Antibody Tech, Nanjing, Jiangsu, Peoples R China; [Deng, Guo-Min] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Deng, Guo-Min] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Deng, GM (corresponding author), Nanjing Med Univ, Minist Hlth, Key Lab Antibody Tech, Nanjing, Jiangsu, Peoples R China.; Deng, GM (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.; Deng, GM (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.	gmdeng@njmu.edu.cn	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022					Cai ZM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01723	1	0	0	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 31	2018	9								1732	10.3389/fimmu.2018.01732	http://dx.doi.org/10.3389/fimmu.2018.01732			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GO8JW	30116239	Green Published, gold			2022-12-18	WOS:000440335900001
J	Wang, TH; Hu, YF; Wangkahart, E; Liu, FG; Wang, A; Zahran, E; Maisey, KR; Liu, M; Xu, QQ; Imarai, M; Secombes, CJ				Wang, Tiehui; Hu, Yehfang; Wangkahart, Eakapol; Liu, Fuguo; Wang, Alex; Zahran, Eman; Maisey, Kevin R.; Liu, Min; Xu, Qiaoqing; Imarai, Monica; Secombes, Christopher J.			Interleukin (IL)-2 Is a Key Regulator of T Helper 1 and T Helper 2 Cytokine Expression in Fish: Functional Characterization of Two Divergent IL2 Paralogs in Salmonids	FRONTIERS IN IMMUNOLOGY			English	Article						salmonids; interleukin-2; expression; bioactivity; T cell growth factor; T helper 1; T helper 2; phagocytosis	TROUT ONCORHYNCHUS-MYKISS; TELEOST FISH; IFN-GAMMA; IN-VITRO; DIFFERENTIAL EXPRESSION; SIGNATURE CYTOKINES; PREDICTION SERVER; GENE-EXPRESSION; T-LYMPHOCYTES; FAMILY-MEMBER	Mammalian interleukin (IL)-2 is a cytokine centrally involved in the differentiation and survival of CD4+ T helper subsets and CD4+ T regulatory cells and in activation of cytotoxic effector lymphocytes. In bony fish, IL2 orthologs have been identified with an additional divergent IL2-Like gene on the same locus present in several fish species. We report here two divergent IL2 paralogs, IL2A and IL2B, in salmonids that originated from the whole genome duplication event in this fish lineage. The salmonid IL2 paralogs differ not only in sequence but also in exon sizes. The IL-2 isoforms that are encoded have disparate pl values and may have evolved to preferentially bind specific IL-2 receptors. Rainbow trout IL2 paralogs are highly expressed in thymus, spleen, gills, kidney and intestine, important tissues/organs in fish T cell development and function. Their expression in peripheral blood leukocytes (PBL) is low constitutively but can be upregulated by the mixed leukocyte reaction, by the T cell mitogen phytohemagglutinin and by signal mimics of T cell activation (phorbol 12-myristate 13 -acetate and calcium ionophore). Both trout IL-2 isoforms promoted PBL proliferation and sustained high-level expression of CD4 and CD8, suggesting that trout IL-2 isoforms are T cell growth/survival factors mainly expressed by activated T cells. The recombinant proteins for these two trout IL2 paralogs have been produced in E. coli and possess shared but also distinct bioactivities. IL-2A, but not IL-2B, induced ILI 2P35A1 and CXCR1 expression in PBL. IL-2B had a stronger effect on upregulation of the T helper 1 (Th1) cytokine interferon-gamma (1FN gamma) and could sustain CD8a and CD8 beta expression levels. Nevertheless, both cytokines upregulated key Th1 (IFN gamma 1, IFN gamma 2, TNF alpha 2 and IL12) and T helper 2 (Th2) cytokines (IL4/1381 and IL4/13B2), cytokine and chemokine receptors and the antimicrobial peptide cathelicidin-1 but had limited effects on T helper 17 cytokines and TGF beta 1 in PBL. They could also enhance PBL phagocytosis. These results suggest, for the first time in fish, that IL-2 isoforms may have an important role in regulating Th1 and Th2 cell development, and innate and adaptive host defenses in fish, and shed light on lineage-specific expansion, evolution, and functional diversification of IL2 in vertebrates.	[Wang, Tiehui; Hu, Yehfang; Wangkahart, Eakapol; Liu, Fuguo; Wang, Alex; Zahran, Eman; Liu, Min; Xu, Qiaoqing; Secombes, Christopher J.] Univ Aberdeen, Sch Biol Sci, Scottish Fish Immunol Res Ctr, Aberdeen, Scotland; [Wangkahart, Eakapol] Mahasarakham Univ, Fac Technol, Div Fisheries, Dept Agr Technol, Kantharawichai, Thailand; [Zahran, Eman] Mansoura Univ, Dept Internal Med Infect & Fish Dis, Fac Vet Med, Mansoura, Egypt; [Maisey, Kevin R.; Imarai, Monica] Univ Santiago Chile, Fac Quim & Biol, Dept Biol, Lab Immunol,Ctr Biotecnol Acuicola, Santiago, Chile; [Liu, Min] Northeast Agr Univ, Coll Anim Sci & Technol, Harbin, Heilongjiang, Peoples R China; [Xu, Qiaoqing] Yangtze Univ, Sch Anim Sci, Jingzhou, Peoples R China	University of Aberdeen; Mahasarakham University; Egyptian Knowledge Bank (EKB); Mansoura University; Universidad de Santiago de Chile; Northeast Agricultural University - China; Yangtze University	Wang, TH; Secombes, CJ (corresponding author), Univ Aberdeen, Sch Biol Sci, Scottish Fish Immunol Res Ctr, Aberdeen, Scotland.	t.h.wang@abdn.ac.uk; c.secombes@abdn.ac.uk	Wangkahart, Eakapol/AAM-5099-2020; Zahran, Eman/AAM-7733-2020	Zahran, Eman/0000-0003-2212-3688; Maisey, Kevin/0000-0002-7423-6329	Biotechnology and Biological Sciences Research Council (BBSRC) under the Newton Fund RCUK-CONICYT Research Partnerships call [BB/N024052/1]; Ministry of Education, Republic of China (Taiwan); Faculty of Technology, Mahasarakham University; Newton International Fellowship - Academy of Medical Sciences, UK (AMS) [NIF004\1036]; National Scholarship Council of China; European Commission [311993]; Academy of Medical Sciences (AMS) [NIF004\\1036] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council (BBSRC) under the Newton Fund RCUK-CONICYT Research Partnerships call(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Ministry of Education, Republic of China (Taiwan)(Ministry of Education, Taiwan); Faculty of Technology, Mahasarakham University; Newton International Fellowship - Academy of Medical Sciences, UK (AMS); National Scholarship Council of China; European Commission(European CommissionEuropean Commission Joint Research Centre); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS))	This work was funded by the Biotechnology and Biological Sciences Research Council (BBSRC, BB/N024052/1) under the Newton Fund RCUK-CONICYT Research Partnerships call. YH was supported by a PhD Studentship from the Ministry of Education, Republic of China (Taiwan). EW was supported financially by the Faculty of Technology, Mahasarakham University Grant Year 2018. FL was supported by a Newton International Fellowship funded by the Academy of Medical Sciences, UK (AMS, NIF004\1036). ML and QX were supported financially by the National Scholarship Council of China. This work was partially supported financially by European Commission contract No. 311993 (TargetFish).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Arenas-Ramirez N, 2015, TRENDS IMMUNOL, V36, P763, DOI 10.1016/j.it.2015.10.003; Berthelot C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4657; Bird S, 2005, IMMUNOGENETICS, V56, P909, DOI 10.1007/s00251-004-0741-7; Campanella JJ, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-29; Ceroni A, 2006, NUCLEIC ACIDS RES, V34, pW177, DOI 10.1093/nar/gkl266; Chen J, 2013, DEV COMP IMMUNOL, V41, P137, DOI 10.1016/j.dci.2013.05.006; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Costa MM, 2011, MOL IMMUNOL, V48, P1903, DOI 10.1016/j.molimm.2011.05.027; Crippen TL, 2001, J AQUAT ANIM HEALTH, V13, P234, DOI 10.1577/1548-8667(2001)013&lt;0234:AOSLPB&gt;2.0.CO;2; Diaz-Rosales P, 2009, FISH SHELLFISH IMMUN, V27, P414, DOI 10.1016/j.fsi.2009.06.008; Dijkstra JM, 2014, IMMUNOGENETICS, V66, P93, DOI 10.1007/s00251-013-0747-0; Drozdetskiy A, 2015, NUCLEIC ACIDS RES, V43, pW389, DOI 10.1093/nar/gkv332; Feau S, 2011, NAT IMMUNOL, V12, P908, DOI 10.1038/ni.2079; Gao Q, 2009, DEV COMP IMMUNOL, V33, P920, DOI 10.1016/j.dci.2009.03.001; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Harun NO, 2011, FISH SHELLFISH IMMUN, V31, P107, DOI 10.1016/j.fsi.2011.04.010; Hong S, 2013, J IMMUNOL, V191, P5959, DOI 10.4049/jimmunol.1301584; Hu Y, 2018, DEV COMP IMMUNOL, V88, P104, DOI 10.1016/j.dci.2018.07.010; Husain M, 2014, FISH SHELLFISH IMMUN, V41, P102, DOI 10.1016/j.fsi.2014.06.024; Husain M, 2012, DEV COMP IMMUNOL, V38, P431, DOI 10.1016/j.dci.2012.07.010; Jiang YS, 2015, MOL IMMUNOL, V66, P216, DOI 10.1016/j.molimm.2015.03.014; Kim HP, 2006, CYTOKINE GROWTH F R, V17, P349, DOI 10.1016/j.cytogfr.2006.07.003; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; Laing KJ, 2002, DEV COMP IMMUNOL, V26, P433, DOI 10.1016/S0145-305X(01)00092-1; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Louis A, 2013, NUCLEIC ACIDS RES, V41, pD700, DOI 10.1093/nar/gks1156; Macqueen DJ, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2881; Maehr T, 2013, FISH SHELLFISH IMMUN, V34, P420, DOI 10.1016/j.fsi.2012.11.011; MANGI RJ, 1975, YALE J BIOL MED, V48, P217; Mitra S, 2018, J LEUKOCYTE BIOL, V103, P643, DOI 10.1002/JLB.2RI0717-278R; Monte MM, 2013, INFECT IMMUN, V81, P340, DOI 10.1128/IAI.00599-12; Monte MM, 2012, FISH SHELLFISH IMMUN, V33, P365, DOI 10.1016/j.fsi.2012.05.023; Monte MM, 2011, CYTOKINE, V55, P62, DOI 10.1016/j.cyto.2011.03.015; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; NAU GJ, 1988, J IMMUNOL, V141, P3557; Pace CN, 2009, J BIOL CHEM, V284, P13285, DOI 10.1074/jbc.R800080200; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Ramsden SD, 2003, TRENDS ECOL EVOL, V18, P607, DOI 10.1016/j.tree.2003.09.020; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Secombes CJ, 2011, DEV COMP IMMUNOL, V35, P1336, DOI 10.1016/j.dci.2011.05.001; Stauber DJ, 2006, P NATL ACAD SCI USA, V103, P2788, DOI 10.1073/pnas.0511161103; Takizawa F, 2016, J IMMUNOL, V196, P4522, DOI 10.4049/jimmunol.1600222; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Turka LA, 2008, FRONT BIOSCI-LANDMRK, V13, P1440, DOI 10.2741/2773; Wang JT, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-96; Wang T, 2003, IMMUNOGENETICS, V55, P615, DOI 10.1007/s00251-003-0622-5; Wang TH, 2005, FEBS J, V272, P1136, DOI 10.1111/j.1742-4658.2005.04544.x; Wang T, 2007, J IMMUNOL, V179, P1475, DOI 10.4049/jimmunol.179.3.1475; Wang TH, 2016, ONCOTARGET, V7, P10917, DOI 10.18632/oncotarget.7295; Wang TH, 2015, IMMUNOGENETICS, V67, P395, DOI 10.1007/s00251-015-0838-1; Wang TH, 2014, DEV COMP IMMUNOL, V46, P194, DOI 10.1016/j.dci.2014.04.008; Wang TH, 2014, EUR J IMMUNOL, V44, P1541, DOI 10.1002/eji.201344273; Wang TH, 2013, FISH SHELLFISH IMMUN, V35, P1703, DOI 10.1016/j.fsi.2013.08.030; Wang TH, 2013, MOL IMMUNOL, V53, P398, DOI 10.1016/j.molimm.2012.09.008; Wang TH, 2011, FISH SHELLFISH IMMUN, V31, P673, DOI 10.1016/j.fsi.2011.05.016; Wang TH, 2011, IMMUNOGENETICS, V63, P235, DOI 10.1007/s00251-010-0508-2; Wang TH, 2011, J IMMUNOL, V186, P708, DOI 10.4049/jimmunol.1001203; Wang TH, 2010, MOL IMMUNOL, V47, P2563, DOI 10.1016/j.molimm.2010.06.015; Wang TH, 2010, FISH SHELLFISH IMMUN, V29, P705, DOI 10.1016/j.fsi.2010.06.016; Wang TH, 2010, DEV COMP IMMUNOL, V34, P491, DOI 10.1016/j.dci.2009.11.011; Wang TH, 2009, MOL IMMUNOL, V46, P2290, DOI 10.1016/j.molimm.2009.04.003; Wang TH, 2009, J IMMUNOL, V183, P962, DOI 10.4049/jimmunol.0802953; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; Wen Y, 2011, CELL MOL LIFE SCI, V68, P2615, DOI 10.1007/s00018-010-0574-5; Wuest SC, 2011, NAT MED, V17, P604, DOI 10.1038/nm.2365; Xu QQ, 2014, DEV COMP IMMUNOL, V45, P201, DOI 10.1016/j.dci.2014.03.002; YAMADA T, 1987, ARCH BIOCHEM BIOPHYS, V257, P194, DOI 10.1016/0003-9861(87)90558-3; Zhang XJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00388; Zhang YA, 2009, J IMMUNOL, V183, P83, DOI 10.4049/jimmunol.0900605; Zou J, 2005, J IMMUNOL, V175, P2484, DOI 10.4049/jimmunol.175.4.2484; Zou J, 2004, EUR J BIOCHEM, V271, P1913, DOI 10.1111/j.1432-1033.2004.04101.x; Zou Jun, 2016, Biology-Basel, V5, P23, DOI 10.3390/biology5020023	76	0	0	6	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 26	2018	9								1883	10.3389/fimmu.2018.016813	http://dx.doi.org/10.3389/fimmu.2018.016813			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GO2YB					2022-12-18	WOS:000439846000001
J	Abrahimians, EM; Elst, LV; Carlier, VA; Saint-Remy, JM				Abrahimians, Elin Malek; Elst, Luc Vander; Carlier, Vincent A.; Saint-Remy, Jean-Marie			Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model (vol 7, 67, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						type 1 diabetes; NOD mouse; cytolytic CD4(+) T cells; antigen-specific; MHC class II epitopes			[Abrahimians, Elin Malek; Elst, Luc Vander; Carlier, Vincent A.; Saint-Remy, Jean-Marie] Univ Leuven, Ctr Mol & Vasc Biol, Leuven, Belgium; [Abrahimians, Elin Malek; Elst, Luc Vander; Carlier, Vincent A.; Saint-Remy, Jean-Marie] ImCyse SA, Leuven, Belgium	KU Leuven	Saint-Remy, JM (corresponding author), Univ Leuven, Ctr Mol & Vasc Biol, Leuven, Belgium.; Saint-Remy, JM (corresponding author), ImCyse SA, Leuven, Belgium.	jean-marie.saint-remy@kuleuven.be			NATIONAL CANCER INSTITUTE [R21CA195433] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahimians EM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00067	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 9	2018	9								1600	10.3389/fimmu.2018.01600	http://dx.doi.org/10.3389/fimmu.2018.01600			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GM2BU		Green Published, gold			2022-12-18	WOS:000437883700001
J	Tuuminen, T; Rinne, K				Tuuminen, Tamara; Rinne, Kyosti			Response: Commentary: Severe Sequelae to Mold-Related Illness as Demonstrated in Two Finnish Cohorts	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						sick building syndrome; autoimmune conditions; multiple chemical syndrome; malignancies; environmental molds; indoor air; hypothyroidism; mold-related illness	MYCOTOXINS		[Tuuminen, Tamara] Univ Helsinki, Dept Bacteriol & Immunol, Med, Helsinki, Finland; [Rinne, Kyosti] KristinaMedi Oy, Kauhajoki, Finland	University of Helsinki	Tuuminen, T (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Med, Helsinki, Finland.	tamara.tuuminen@helsinki.fi	Tuuminen, Tamara/AAF-9723-2020					Andersson M, 2016, IND AIR SEM 16 3 201, P295; [Anonymous], 2018, VALT KANS JULK 2 201, V2, P16; Atosuo J, 2016, ASSESSING INDOOR AIR; Bennett JW, 2015, TOXINS, V7, P3785, DOI 10.3390/toxins7093785; Fromme H, 2016, INT J HYG ENVIR HEAL, V219, P143, DOI 10.1016/j.ijheh.2015.11.004; Salin JT, 2017, ENVIRON RES, V154, P234, DOI 10.1016/j.envres.2017.01.015; Salo J., 2015, P HLTH BUILD 2015 EU; Tampere Aattela E., 2017, SEM CONSTR PHYS 24 2, P535; Wong J, 2016, INT J CHRONIC OBSTR, V11, P1391, DOI 10.2147/COPD.S106009	9	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 11	2018	9								1220	10.3389/fimmu.2018.01220	http://dx.doi.org/10.3389/fimmu.2018.01220			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GI8SN	29942302	Green Published, gold			2022-12-18	WOS:000434795800001
J	Bjerregaard, AM; Nielsen, M; Jurtz, V; Barra, CM; Hadrup, SR; Szallasi, Z; Eklund, AC				Bjerregaard, Anne-Mette; Nielsen, Morten; Jurtz, Vanessa; Barra, Carolina M.; Hadrup, Sine Reker; Szallasi, Zoltan; Eklund, Aron Charles			An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes (vol 8, 1566, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						neoepitopes; neoantigens; prediction; immunogenicity; mutations; MHC binding			[Bjerregaard, Anne-Mette; Nielsen, Morten; Jurtz, Vanessa; Szallasi, Zoltan; Eklund, Aron Charles] Tech Univ Denmark, Dept Bio & Hlth Informat, Lyngby, Denmark; [Nielsen, Morten; Barra, Carolina M.] Univ Nacl San Martin, Inst Invest Biotecnol, Buenos Aires, DF, Argentina; [Hadrup, Sine Reker] Tech Univ Denmark, Natl Vet Inst, Sect Immunol & Vaccinol, Lyngby, Denmark; [Szallasi, Zoltan] Harvard Med Sch, Boston Childrens Hosp, CHIP, Boston, MA USA	Technical University of Denmark; Technical University of Denmark; Harvard University; Boston Children's Hospital; Harvard Medical School	Bjerregaard, AM; Eklund, AC (corresponding author), Tech Univ Denmark, Dept Bio & Hlth Informat, Lyngby, Denmark.	ambj@bioinformatics.dtu.dk; eklund@bioinformatics.dtu.dk	Barra, Carolina/AAF-1324-2019; Hadrup, Sine Reker/P-3388-2014	Barra, Carolina/0000-0002-6836-4906; Hadrup, Sine Reker/0000-0002-5937-4344				Bjerregaard AM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01566	1	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 14	2018	9								1007	10.3389/fimmu.2018.01007	http://dx.doi.org/10.3389/fimmu.2018.01007			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GF4WG	29795801	Green Published, gold			2022-12-18	WOS:000431964000001
J	Lin, JX; Chan, WFN; Boon, L; Anderson, CC				Lin, Jiaxin; Chan, William F. N.; Boon, Louis; Anderson, Colin C.			Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant	FRONTIERS IN IMMUNOLOGY			English	Article						chimerism; tolerance; hematopoietic stem cell; transplantation; T cell depletion; non-obese diabetic mice	ALLOGENEIC BONE-MARROW; VERSUS-HOST-DISEASE; MIXED CHIMERISM; HEMATOPOIETIC CHIMERISM; NOD MICE; ISLET ALLOGRAFTS; SPLIT TOLERANCE; MURINE MODEL; I-E; INDUCTION	Stable mixed hematopoietic chimerism is a robust method for inducing donor-specific tolerance with the potential to prevent rejection of donor islets in recipients with autoimmune type-1 diabetes. However, with reduced intensity conditioning, fully allogeneic chimerism in a tolerance resistant autoimmune-prone non-obese diabetic (NOD) recipient has rarely been successful. In this setting, successful multilineage chimerism has required either partial major histocompatability complex matching, mega doses of bone marrow, or conditioning approaches that are not currently clinically feasible. Irradiation free protocols with moderate bone marrow doses have not generated full tolerance; donor skin grafts were rejected. We tested whether more efficient recipient T cell depletion would generate a more robust tolerance. We show that a combination of donor-specific transfusion-cyclophosphamide and multiple T cell depleting antibodies could induce stable high levels of fully allogeneic chimerism in NOD recipients. Less effective T cell depletion was associated with instability of chimerism. Stable chimeras appeared fully donor-specific tolerant, with clonal deletion of allospecific T cells and acceptance of donor skin grafts, while recovering substantial immunocompetence. The loss of chimerism months after transplant was significantly associated with a lower level of chimerism and donor T cells within the first 2 weeks after transplant. Thus, rapid and robust recipient T cell depletion allows for stable high levels of fully allogeneic chimerism and robust donor-specific tolerance in the stringent NOD model while using a clinically feasible protocol. In addition, these findings open the possibility of identifying recipients whose chimerism will later fail, stratifying patients for early intervention.	[Lin, Jiaxin; Anderson, Colin C.] Univ Alberta, Dept Surg, Edmonton, AB, Canada; [Lin, Jiaxin; Chan, William F. N.; Anderson, Colin C.] Univ Alberta, Alberta Diabet & Transplant Inst, Edmonton, AB, Canada; [Boon, Louis] Bioceros BV, Utrecht, Netherlands; [Anderson, Colin C.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada	University of Alberta; University of Alberta; Bioceros B.V.; University of Alberta	Anderson, CC (corresponding author), Univ Alberta, Dept Surg, Edmonton, AB, Canada.; Anderson, CC (corresponding author), Univ Alberta, Alberta Diabet & Transplant Inst, Edmonton, AB, Canada.; Anderson, CC (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.	colinand@ualberta.ca	Boon, Laurence/HCI-3629-2022	Boon, Louis/0000-0002-0937-9171; Lin, Jiaxin/0000-0001-8636-294X; /0000-0003-1733-4237	Canadian Diabetes Association [OG-3-13-4183-CA]; Muttart Diabetes Research and Training Centre; Li Ka Shing Foundation (Sino-Canadian Exchange program); Alberta Innovates Health Solutions	Canadian Diabetes Association; Muttart Diabetes Research and Training Centre; Li Ka Shing Foundation (Sino-Canadian Exchange program); Alberta Innovates Health Solutions	We thank Perveen Anwar and HSLAS staff for assistance with animal care and Kristofor K. Ellestad for technical assistance. This work was supported by grants from the Canadian Diabetes Association (OG-3-13-4183-CA) and the Muttart Diabetes Research and Training Centre (to CA); JL is supported by a doctoral studentship from Li Ka Shing Foundation (Sino-Canadian Exchange program) and CA was supported by a senior scholar award from Alberta Innovates Health Solutions.	Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Al-Adra DP, 2012, AM J TRANSPLANT, V12, P3235, DOI 10.1111/j.1600-6143.2012.04260.x; Al-Adra David P, 2013, Chimerism, V4, P23, DOI 10.4161/chim.23350; Al-Adra David P, 2011, Chimerism, V2, P89, DOI 10.4161/chim.2.4.19017; Al-Adra DP, 2011, TRANSPLANTATION, V92, P977, DOI 10.1097/TP.0b013e3182313e70; Asari S, 2011, PANCREAS, V40, P846, DOI 10.1097/MPA.0b013e318215cdce; Baron F, 2017, HAEMATOLOGICA, V102, P224, DOI 10.3324/haematol.2016.148510; Beilhack GF, 2003, DIABETES, V52, P59, DOI 10.2337/diabetes.52.1.59; Benichou G, 2013, AM J TRANSPLANT, V13, P2500, DOI 10.1111/ajt.12366; Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Bigenzahn S, 2005, AM J TRANSPLANT, V5, P1237, DOI 10.1111/j.1600-6143.2005.00862.x; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; Blaha P, 2005, TRANSPLANTATION, V80, P237, DOI 10.1097/01.TP.0000164510.25625.70; Bozulic LD, 2011, EXP HEMATOL, V39, P977, DOI 10.1016/j.exphem.2011.06.008; Brode S, 2006, J IMMUNOL, V177, P6603, DOI 10.4049/jimmunol.177.10.6603; Chan WFN, 2008, J IMMUNOL, V180, P5177, DOI 10.4049/jimmunol.180.8.5177; Chhabra A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aae0501; Dai HH, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam6202; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; Elkin G, 2004, EXP HEMATOL, V32, P579, DOI 10.1016/j.exphem.2004.03.007; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; Gordon EJ, 2005, DIABETES, V54, P107, DOI 10.2337/diabetes.54.1.107; Guo Z, 2003, TRANSPLANTATION, V75, P909, DOI 10.1097/01.TP.0000057832.92231.F5; HERBERMAN RB, 1978, J IMMUNOL, V121, P304; Hotta K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86419; IKEHARA S, 1985, P NATL ACAD SCI USA, V82, P7743, DOI 10.1073/pnas.82.22.7743; Ildstad ST, 2005, BLOOD, V105, P2577, DOI 10.1182/blood-2004-04-1340; ILDSTAD ST, 1985, J EXP MED, V162, P231, DOI 10.1084/jem.162.1.231; Kanakry CG, 2014, BLOOD, V124, P3817, DOI 10.1182/blood-2014-07-587477; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kawai T, 2013, CURR OPIN ORGAN TRAN, V18, P402, DOI 10.1097/MOT.0b013e328363621d; Koehn BH, 2007, J IMMUNOL, V179, P2616, DOI 10.4049/jimmunol.179.4.2616; KORNGOLD R, 1978, J EXP MED, V148, P1687; Lee K, 2014, AM J TRANSPLANT, V14, P27, DOI 10.1111/ajt.12509; Leventhal J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003509; Leventhal JR, 2015, TRANSPLANTATION, V99, P288, DOI 10.1097/TP.0000000000000605; LI H, 1995, SURGERY, V118, P192, DOI 10.1016/S0039-6060(05)80323-X; Li H, 1996, J IMMUNOL, V156, P380; Liang YM, 2005, BLOOD, V105, P2180, DOI 10.1182/blood-2004-06-2411; Liu BL, 2006, AM J TRANSPLANT, V6, P933, DOI 10.1111/j.1600-6143.2006.01283.x; Luo B, 2007, ANN NY ACAD SCI, V1103, P94, DOI 10.1196/annals.1394.015; Luznik L, 2010, CURR OPIN HEMATOL, V17, P493, DOI 10.1097/MOH.0b013e32833eaf1b; MAEDA T, 1993, IMMUNOLOGY, V78, P113; Mahr B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01762; MAIN JM, 1955, J NATL CANCER I, V15, P1023; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; MCDUFFIE M, 1992, J IMMUNOL, V148, P2097; Menge T, 2014, NEUROLOGY, V83, P87, DOI 10.1212/WNL.0000000000000540; MIYAUCHI A, 1990, TOHOKU J EXP MED, V162, P147, DOI 10.1620/tjem.162.147; Neujahr DC, 2006, J IMMUNOL, V176, P4632, DOI 10.4049/jimmunol.176.8.4632; Nicosia M, 2017, AM J TRANSPLANT, V17, P1713, DOI 10.1111/ajt.14144; Nikolic B, 2004, DIABETES, V53, P376, DOI 10.2337/diabetes.53.2.376; Nikolic B, 2010, TRANSPLANTATION, V89, P23, DOI 10.1097/TP.0b013e3181c4692e; Oura Tetsu, 2015, Chimerism, V6, P21, DOI 10.1080/19381956.2015.1111975; Pearson T, 2003, J IMMUNOL, V171, P185, DOI 10.4049/jimmunol.171.1.185; Pearson T, 2003, DIABETES, V52, P321, DOI 10.2337/diabetes.52.2.321; Prigozhina TB, 2004, BLOOD CELL MOL DIS, V33, P238, DOI 10.1016/j.bcmd.2004.08.010; Racine JJ, 2013, J CLIN CELL IMMUNOL, P2, DOI 10.4172/2155-9899.S2-006; Resnick IB, 2017, IMMUNOTHERAPY MYTHS, DOI [10.5772/67604, DOI 10.5772/67604]; Ross D, 2013, BIOL BLOOD MARROW TR, V19, P1430, DOI 10.1016/j.bbmt.2013.06.019; Sachs DH, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015529; Serreze DV, 2006, J IMMUNOL, V177, P6675, DOI 10.4049/jimmunol.177.10.6675; Seung E, 2000, BLOOD, V95, P2175, DOI 10.1182/blood.V95.6.2175; Sharabi Y, 1993, PROGR IMMUNOLOGY, VVIII, P801, DOI [10.1007/978-3-642-51479-1, DOI 10.1007/978-3-642-51479-1]; SLAVIN S, 1977, J EXP MED, V146, P34, DOI 10.1084/jem.146.1.34; Soderdahl G, 1998, BONE MARROW TRANSPL, V21, P79, DOI 10.1038/sj.bmt.1701039; Swart JF, 2017, NAT REV RHEUMATOL, V13, P244, DOI 10.1038/nrrheum.2017.7; Wekerle T, 2002, TRANSPL INT, V15, P248, DOI 10.1007/s00147-002-0411-3; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Westerhuis G, 2005, BLOOD, V106, P2215, DOI 10.1182/blood-2005-04-1391; Wu ZH, 2004, NAT MED, V10, P87, DOI 10.1038/nm965; Zhang CY, 2007, P NATL ACAD SCI USA, V104, P2337, DOI 10.1073/pnas.0611101104; Zhang CY, 2010, DIABETES, V59, P2228, DOI 10.2337/db10-0450	73	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 24	2018	9								837	10.3389/fimmu.2018.00837	http://dx.doi.org/10.3389/fimmu.2018.00837			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GD8DK	29740442	Green Published, gold			2022-12-18	WOS:000430742800001
J	Volpini, X; Ambrosio, LF; Fozzatti, L; Insfran, C; Stempin, CC; Cervi, L; Motran, CC				Volpini, Ximena; Ambrosio, Laura F.; Fozzatti, Laura; Insfran, Constanza; Stempin, Cinthia C.; Cervi, Laura; Cristina Motran, Claudia			Trypanosoma cruzi Exploits Wnt Signaling Pathway to Promote Their Intracellular Replication in Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						Trypanosoma cruzi infection; Wnt proteins; beta-catenin; macrophages; cytokines; indoleamine 2,3-dioxygenase	INTERFERON-GAMMA; BETA-CATENIN; ALTERNATIVE ACTIVATION; CHAGAS-DISEASE; T-CELLS; EXPRESSION; RESPONSES; RESISTANCE; ALPHA; IDO	During the acute phase of Trypanosoma cruzi infection, macrophages can act as host cells for the parasites as well as effector cells in the early anti-parasitic immune response. Thus, the targeting of specific signaling pathways could modulate macrophages response to restrict parasite replication and instruct an appropriate adaptive response. Recently, it has become evident that Wnt signaling has immunomodulatory functions during inflammation and infection. Here, we tested the hypothesis that during T. cruzi infection, the activation of Wnt signaling pathway in macrophages plays a role in modulating the inflammatory/tolerogenic response and therefore regulating the control of parasite replication. In this report, we show that early after T. cruzi infection of bone marrow-derived macrophages (BMM), beta-catenin was activated and Wnt3a, Wnt5a, and some Frizzled receptors as well as Wnt/beta-catenin pathway's target genes were upregulated, with Wnt proteins signaling sustaining the activation of Wnt/beta-catenin pathway and then activating the Wnt/Ca+2 pathway. Wnt signaling pathway activation was critical to sustain the parasite's replication in BMM; since the treatments with specific inhibitors of beta-catenin transcriptional activation or Wnt proteins secretion limited the parasite replication. Mechanistically, inhibition of Wnt signaling pathway armed BMM to fight against T. cruzi by inducing the production of pro-inflammatory cytokines and indoleamine 2,3-dioxygenase activity and by downregulating arginase activity. Likewise, in vivo pharmacological inhibition of the Wnts' interaction with its receptors controlled the parasite replication and improved the survival of lethally infected mice. It is well established that T. cruzi infection activates a plethora of signaling pathways that ultimately regulate immune mediators to determine the modulation of a defined set of effector functions in macrophages. In this study, we have revealed a new signaling pathway that is activated by the interaction between protozoan parasites and host innate immunity, establishing a new conceptual framework for the development of new therapies.	[Volpini, Ximena; Ambrosio, Laura F.; Fozzatti, Laura; Insfran, Constanza; Stempin, Cinthia C.; Cervi, Laura; Cristina Motran, Claudia] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina; [Volpini, Ximena; Ambrosio, Laura F.; Fozzatti, Laura; Insfran, Constanza; Stempin, Cinthia C.; Cervi, Laura; Cristina Motran, Claudia] Consejo Nacl Invest Cient & Tecn, Ctr Invest Bioquim Clin & Inmunol CIBICI, Ciudad Univ, Cordoba, Argentina	National University of Cordoba; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Motran, CC (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, Cordoba, Argentina.; Motran, CC (corresponding author), Consejo Nacl Invest Cient & Tecn, Ctr Invest Bioquim Clin & Inmunol CIBICI, Ciudad Univ, Cordoba, Argentina.	cmotran@fcq.unc.edu.ar	Motran, Claudia/U-9106-2019	Motran, Claudia/0000-0002-8088-3901	Consejo Nacional de Investigaciones Cientificas y Tecnicas from Argentina (CONICET); Agencia Nacional de Promocion Cientifica y Tecnica [PICT 2016-0415, PICT 2015-2488]; Secretaria de Ciencia y Tecnica, Universidad Nacional de Cordoba	Consejo Nacional de Investigaciones Cientificas y Tecnicas from Argentina (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnica(ANPCyT); Secretaria de Ciencia y Tecnica, Universidad Nacional de Cordoba(Secretaria de Ciencia y Tecnologia (SECYT))	This work was supported by grants from Consejo Nacional de Investigaciones Cientificas y Tecnicas from Argentina (CONICET), Agencia Nacional de Promocion Cientifica y Tecnica (PICT 2016-0415, PICT 2015-2488), and Secretaria de Ciencia y Tecnica, Universidad Nacional de Cordoba (grants to CM). The funding bodies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Bansal K, 2011, J BIOL CHEM, V286, P37032, DOI 10.1074/jbc.M111.260414; Bergenfelz C, 2012, J IMMUNOL, V188, P5448, DOI 10.4049/jimmunol.1103378; Bergwelt-Baildon M, 2006, BLOOD, V108, P228, DOI DOI 10.1182/BLOOD-2005-08-3507; Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood-2005-12-5046; Brown JB, 2011, INFECT IMMUN, V79, P1863, DOI 10.1128/IAI.01025-10; BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; de Araujo FF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000992; Dejmek J, 2006, MOL CELL BIOL, V26, P6024, DOI 10.1128/MCB.02354-05; Dijksterhuis JP, 2015, J BIOL CHEM, V290, P6789, DOI 10.1074/jbc.M114.612648; Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174; Fiuza JA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000512; GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006; Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005; Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; Holtzhausen A, 2015, CANCER IMMUNOL RES, V3, P1082, DOI 10.1158/2326-6066.CIR-14-0167; Hong Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115941; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; Katoh M, 2007, INT J MOL MED, V19, P273; Kayama H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000514; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Knubel CP, 2017, ACS MED CHEM LETT, V8, P757, DOI 10.1021/acsmedchemlett.7b00169; Knubel CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026550; Le Loup G, 2011, CURR OPIN INFECT DIS, V24, P428, DOI 10.1097/QCO.0b013e32834a667f; Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510; Manoharan I, 2014, J IMMUNOL, V193, P4203, DOI 10.4049/jimmunol.1400614; Martin D, 2004, IMMUNOL REV, V201, P304, DOI 10.1111/j.0105-2896.2004.00183.x; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Motran CC, 2003, EUR J IMMUNOL, V33, P3007, DOI 10.1002/eji.200323993; Motran CC, 2002, J LEUKOCYTE BIOL, V72, P512; Munder M, 1998, J IMMUNOL, V160, P5347; Munn DH, 2004, TRENDS MOL MED, V10, P15, DOI 10.1016/j.molmed.2003.11.003; Neumann J, 2010, FASEB J, V24, P4599, DOI 10.1096/fj.10-160994; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Oderup C, 2013, J IMMUNOL, V190, P6126, DOI 10.4049/jimmunol.1203002; Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688; Oliveira AC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000870; Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366; Knubel CP, 2010, FASEB J, V24, P2689, DOI 10.1096/fj.09-150920; Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438; Pukrop T, 2008, J MOL MED, V86, P259, DOI 10.1007/s00109-007-0266-2; Reuter S, 2014, J IMMUNOL, V193, P485, DOI 10.4049/jimmunol.1400013; Robinson CM, 2005, J INTERF CYTOK RES, V25, P20, DOI 10.1089/jir.2005.25.20; Salvatella R, 2013, LANCET, V382, P395, DOI 10.1016/S0140-6736(13)61671-2; Schaale K, 2011, EUR J CELL BIOL, V90, P553, DOI 10.1016/j.ejcb.2010.11.004; Sen M, 2008, J IMMUNOL, V181, P4441, DOI 10.4049/jimmunol.181.7.4441; SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; Silva-Garcia O, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/310183; Soichot M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025470; Sosa-Estani S, 2006, CURR OPIN INFECT DIS, V19, P583, DOI 10.1097/01.qco.0000247592.21295.a5; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Stempin C, 2002, J LEUKOCYTE BIOL, V72, P727; TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992; Thaker AI, 2013, GASTROENTEROLOGY, V145, P416, DOI 10.1053/j.gastro.2013.05.002; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; Valencia J, 2011, J IMMUNOL, V187, P4129, DOI 10.4049/jimmunol.1101243; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Yoshida N, 2006, AN ACAD BRAS CIENC, V78, P87, DOI 10.1590/S0001-37652006000100010	63	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 23	2018	9								859	10.3389/fimmu.2018.00859	http://dx.doi.org/10.3389/fimmu.2018.00859			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GD5TR		Green Published, gold			2022-12-18	WOS:000430570100001
J	Lopez-Abente, J; Correa-Rocha, R; Pion, M				Lopez-Abente, Jacobo; Correa-Rocha, Rafael; Pion, Marjorie			Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune Suppression (vol 7, 192, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						Treg; HIV-infections; immunology; immune regulation; ICER			[Lopez-Abente, Jacobo; Correa-Rocha, Rafael; Pion, Marjorie] Gregorio Maranon Hlth Res Inst IISGM, Lab Immunoregulat, Madrid, Spain	General University Gregorio Maranon Hospital	Correa-Rocha, R; Pion, M (corresponding author), Gregorio Maranon Hlth Res Inst IISGM, Lab Immunoregulat, Madrid, Spain.	rafael.correa@iisgm.com; marjorie.pion@iisgm.com	Pion, Marjorie/D-8139-2012; Pion, Marjorie/AAB-5812-2022; Correa-Rocha, Rafael/C-8213-2011; Pion, Marjorie/D-8139-2012	Pion, Marjorie/0000-0003-1828-4745; Correa-Rocha, Rafael/0000-0003-3456-9986; Pion, Marjorie/0000-0002-6406-747X; Lopez-Abente, Jacobo/0000-0003-3640-4077				Lopez-Abente J, 2016, FRONT IMMUNOL, V7, DOI [10.3389/fimmu.2016.00192, 10.3389/fimmu.2016.00197]	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2018	9								792	10.3389/fimmu.2018.00792	http://dx.doi.org/10.3389/fimmu.2018.00792			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GD3SX	29713329	Green Published, gold			2022-12-18	WOS:000430425200002
J	Dugast, E; David, G; Oger, R; Danger, R; Judor, JP; Gagne, K; Chesneau, M; Degauque, N; Soulillou, JP; Paul, P; Picard, C; Guerif, P; Conchon, S; Giral, M; Gervois, N; Retiere, C; Brouard, S				Dugast, Emilie; David, Gaelle; Oger, Romain; Danger, Richard; Judor, Jean-Paul; Gagne, Katia; Chesneau, Melanie; Degauque, Nicolas; Soulillou, Jean-Paul; Paul, Pascale; Picard, Christophe; Guerif, Pierrick; Conchon, Sophie; Giral, Magali; Gervois, Nadine; Retiere, Christelle; Brouard, Sophie			Broad Impairment of Natural Killer Cells From Operationally Tolerant Kidney Transplanted Patients (vol 8, 1721, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						natural killer; cytotoxicity; tolerance; kidney; transplantation			[Dugast, Emilie; Danger, Richard; Judor, Jean-Paul; Chesneau, Melanie; Degauque, Nicolas; Soulillou, Jean-Paul; Guerif, Pierrick; Conchon, Sophie; Giral, Magali; Brouard, Sophie] Univ Nantes, Ctr Rech Transplantat & Immunol, INSERM, UMR1064, Nantes, France; [Dugast, Emilie; Danger, Richard; Judor, Jean-Paul; Chesneau, Melanie; Degauque, Nicolas; Soulillou, Jean-Paul; Guerif, Pierrick; Conchon, Sophie; Giral, Magali; Brouard, Sophie] CHU Nantes, ITUN, Nantes, France; [David, Gaelle; Gagne, Katia; Retiere, Christelle] Etab Francais Sang, Nantes, France; [David, Gaelle; Oger, Romain; Gagne, Katia; Gervois, Nadine; Retiere, Christelle] Univ Nantes, Univ Angers, CRCINA, INSERM, Nantes, France; [Gagne, Katia] Univ Strasbourg, LabEx Transplantex, Strasbourg, France; [Paul, Pascale] Aix Marseille Univ, Hosp Concept,INSERM, Assistance Publ Hop Paris,Vasc Res Ctr Marseille, Nephrol Dialysis Renal Transplantat Ctr,UMR 1076, Marseille, France; [Picard, Christophe] Etab Francais Sang Alpes Mediterranee, Marseille, France; [Picard, Christophe] Aix Marseille Univ, CNRS, EFS, ADES UMR 7268, Marseille, France; [Guerif, Pierrick] CHU Nantes, CIC Biotherapy, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Aix-Marseille Universite; Nantes Universite; CHU de Nantes	Brouard, S (corresponding author), Univ Nantes, Ctr Rech Transplantat & Immunol, INSERM, UMR1064, Nantes, France.; Brouard, S (corresponding author), CHU Nantes, ITUN, Nantes, France.	sophie.brouard@univ-nantes.fr	OGER, Romain/K-7423-2015; PAUL, Pascale/R-1484-2016; RETIERE, Christelle/L-5709-2015; Gervois, Nadine/K-6658-2015; Degauque, Nicolas/R-4944-2017; GAGNE, Katia K.G/L-5512-2015; PAUL, Pascale/AAI-1772-2020	PAUL, Pascale/0000-0002-6734-4479; RETIERE, Christelle/0000-0001-5943-6990; Gervois, Nadine/0000-0002-0092-3919; Degauque, Nicolas/0000-0003-2990-3513; GAGNE, Katia K.G/0000-0002-4467-5961; PAUL, Pascale/0000-0002-6734-4479; Conchon, Sophie/0000-0003-2602-3385; OGER, Romain/0000-0001-5012-6099; Dugast, Emilie/0000-0001-7439-1903				Dugast E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01721	1	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 26	2018	9								589	10.3389/fimmu.2018.00589	http://dx.doi.org/10.3389/fimmu.2018.00589			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GA4BN	29617012	Green Published, gold			2022-12-18	WOS:000428274700001
J	Baan, CC; de Graav, GN; Weimar, W; Hesselink, DA				Baan, Carla C.; de Graav, Gretchen N.; Weimar, Willem; Hesselink, Dennis A.			Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						belatacept; kidney transplantation; costimulation blockade; follicular helper T cells; rejection	HELPER-CELLS		[Baan, Carla C.; de Graav, Gretchen N.; Weimar, Willem; Hesselink, Dennis A.] Univ Med Ctr, Erasmus MC, Sect Nephrol & Transplantat, Dept Internal Med,Rotterdam Transplant Grp, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Baan, CC (corresponding author), Univ Med Ctr, Erasmus MC, Sect Nephrol & Transplantat, Dept Internal Med,Rotterdam Transplant Grp, Rotterdam, Netherlands.	c.c.baan@erasmusmc.nl		Baan, Carla/0000-0003-2274-2788				Baan CC, 2016, TRANSPLANTATION, V100, P2507, DOI 10.1097/TP.0000000000001518; Badell IR, 2018, AM J TRANSPLANT, V18, P89, DOI 10.1111/ajt.14400; Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; de Graav GN, 2015, CLIN EXP IMMUNOL, V180, P329, DOI 10.1111/cei.12576; de Graav GN, 2017, TRANSPLANTATION, V101, P2571, DOI 10.1097/TP.0000000000001755; de Graav Gretchen N, 2017, Front Immunol, V8, P641, DOI 10.3389/fimmu.2017.00641; de Graav GN, 2016, TRANSPLANTATION, V100, P1111, DOI 10.1097/TP.0000000000001004; de Graav GN, 2015, THER DRUG MONIT, V37, P560, DOI 10.1097/FTD.0000000000000179; de Leur K, 2018, CLIN EXP IMMUNOL, V192, P224, DOI 10.1111/cei.13099; de Leur Kitty, 2017, Front Immunol, V8, P306, DOI 10.3389/fimmu.2017.00306; Ford ML, 2016, AM J TRANSPLANT, V16, P2243, DOI 10.1111/ajt.13943; Kwun J, 2017, TRANSPLANTATION, V101, P704, DOI 10.1097/TP.0000000000001588; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Schroder PM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01615; Vincenti F, 2005, NEW ENGL J MED, V353, P770, DOI 10.1056/NEJMoa050085; Walters GD, 2016, TRANSPLANTATION, V100, P1650, DOI 10.1097/TP.0000000000001217; Yan L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01510	17	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2018	9								466	10.3389/fimmu.2018.00466	http://dx.doi.org/10.3389/fimmu.2018.00466			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FY5EL	29569634	Green Published, gold			2022-12-18	WOS:000426849100001
J	Gharagozloo, M; Gris, KV; Mahvelati, T; Amrani, A; Lukens, JR; Gris, D				Gharagozloo, M.; Gris, K., V; Mahvelati, T.; Amrani, A.; Lukens, J. R.; Gris, D.		Frontiers Prod Off	NLR-Dependent Regulation of Inflammation in Multiple Sclerosis (vol 8, 2012, 2018)	FRONTIERS IN IMMUNOLOGY			English	Correction						NLRs; multiple sclerosis; NLRP3; NLRP12; NLRX1; inflammation; astrocytes; microglia			[Gharagozloo, M.; Gris, K., V; Mahvelati, T.; Amrani, A.; Lukens, J. R.; Gris, D.; Frontiers Prod Off] Frontiers Media SA, Lausanne, Switzerland		Gharagozloo, M (corresponding author), Frontiers Media SA, Lausanne, Switzerland.	production.office@frontiersin.org	Gharagozloo, Marjan/ABH-6604-2020	Gharagozloo, Marjan/0000-0002-2166-4012				Gharagozloo M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02012	1	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 28	2018	9								404	10.3389/fimmu.2018.00404	http://dx.doi.org/10.3389/fimmu.2018.00404			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FX7SH		Green Published, gold			2022-12-18	WOS:000426290600001
J	Kratochvil, S; McKay, PF; Chung, AW; Kent, SJ; Gilmour, J; Shattock, RJ				Kratochvil, Sven; McKay, Paul F.; Chung, Amy W.; Kent, Stephen J.; Gilmour, Jill; Shattock, Robin J.			Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination (vol 8, 1883, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						allotype; G1m3; G1m1; HIV; vaccines			[Kratochvil, Sven; McKay, Paul F.; Shattock, Robin J.] Imperial Coll London, Med, London, England; [Chung, Amy W.; Kent, Stephen J.] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Kent, Stephen J.] Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Techn, Melbourne, Vic, Australia; [Kent, Stephen J.] Monash Univ, Melbourne Sexual Hlth Ctr, Dept Infect Dis, Alfred Hlth,Cent Clin Sch, Melbourne, Vic, Australia; [Gilmour, Jill] Imperial Coll London, IAVI Human Immunol Lab, London, England	Imperial College London; University of Melbourne; University of Melbourne; Monash University; Imperial College London; International AIDS Vaccine Initiative	Shattock, RJ (corresponding author), Imperial Coll London, Med, London, England.	r.shattock@imperial.ac.uk	Kent, Stephen/AAL-5101-2020	Kent, Stephen/0000-0002-8539-4891				Kratochvil S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01883	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 27	2018	9								342	10.3389/fimmu.2018.00342	http://dx.doi.org/10.3389/fimmu.2018.00342			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FX6OM	29508861	Green Published, gold			2022-12-18	WOS:000426205100001
J	Pineda, S; Sigdel, TK; Chen, JM; Jackson, AM; Sirota, M; Sarwal, MM				Pineda, Silvia; Sigdel, Tara K.; Chen, Jieming; Jackson, Annette M.; Sirota, Marina; Sarwal, Minnie M.			Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant (vol 8, 1687, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						kidney organ transplant; antibody-mediated rejection; exome sequencing; non-histocompatibility antigen; gene expression; machine learning			[Pineda, Silvia; Sigdel, Tara K.; Sarwal, Minnie M.] Univ Calif San Francisco, Dept Surg, Div Transplant Surg, San Francisco, CA 94143 USA; [Pineda, Silvia; Chen, Jieming; Sirota, Marina] Univ Calif San Francisco, Inst Computat Hlth Sci, San Francisco, CA 94143 USA; [Jackson, Annette M.] Johns Hopkins Univ, Sch Med, Dept Med, Div Immunogenet & Transplantat Immunol, Baltimore, MD 21205 USA; [Sirota, Marina] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; University of California System; University of California San Francisco	Sarwal, MM (corresponding author), Univ Calif San Francisco, Dept Surg, Div Transplant Surg, San Francisco, CA 94143 USA.; Sirota, M (corresponding author), Univ Calif San Francisco, Inst Computat Hlth Sci, San Francisco, CA 94143 USA.; Sirota, M (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.	marina.sirota@ucsf.edu; minnie.sarwal@ucsf.edu	Sigdel, Tara/AAV-5886-2020	Sigdel, Tara/0000-0001-8448-0328; Pineda SanJuan, Silvia/0000-0003-4017-1480				Pineda S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01687	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 31	2018	9								107	10.3389/fimmu.2018.00107	http://dx.doi.org/10.3389/fimmu.2018.00107			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FU2RA	29406538	Green Published, gold			2022-12-18	WOS:000423696500001
J	Michielsen, LA; Budding, K; Drop, D; van de Graaf, EA; Kardol-Hoefnagel, T; Verhaar, MC; van Zuilen, AD; Otten, HG				Michielsen, Laura A.; Budding, Kevin; Drop, Daniel; van de Graaf, Ed A.; Kardol-Hoefnagel, Tineke; Verhaar, Marianne C.; van Zuilen, Arjan D.; Otten, Henny G.			Reduced Expression of Membrane Complement Regulatory Protein CD59 on Leukocytes following Lung Transplantation.	FRONTIERS IN IMMUNOLOGY			English	Article						complement; CD59; lung transplantation; lymphocyte biology; accommodation	DECAY-ACCELERATING FACTOR; NF-KAPPA-B; ENDOTHELIAL-CELLS; ATTACK; ACCOMMODATION; MECHANISMS; INHIBITOR; COMPLEXES; GENE; CD46	Cellular protection against undesired effects of complement activation is provided by expression of membrane-bound complement regulatory proteins including CD59. This protein prevents membrane attack complex formation and is considered to be involved in graft accommodation. Also, CD59 downregulates CD4+ and CD8+ T-cell activation and proliferation. It is unknown whether CD59 expression is affected by transplantation. The aim of this study was to evaluate the quantitative CD59 antigen expression on distinct leukocyte subsets following lung transplantation (n = 26) and to investigate whether this differs from pretransplantation (n = 9). The results show that CD59 expression on leukocytes is significantly lower posttransplantation compared with healthy controls (p = 0.002) and pretransplantation (p < 0.0001). Moreover, the CD59 expression diminishes posttransplantation on all distinct lymphocyte subsets (p < 0.02). This effect appeared to be specific for CD59 since the expression of other surface markers remained stable or inclined following transplantation. The highest antigen expression posttransplantation was observed on CD4+ T cells and monocytes (p <= 0.002). These findings show that CD59 expression on leukocytes diminishes posttransplantation, which could result in decreased resistance against complement and enhanced T-cell activation. If such reduction in CD59 expression also occurs on endothelial cells from the transplanted organ, this could lead to a change into a prothrombotic and proinflammatory phenotype.	[Michielsen, Laura A.; Verhaar, Marianne C.; van Zuilen, Arjan D.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Nephrol & Hypertens, Utrecht, Netherlands; [Budding, Kevin; Drop, Daniel; Kardol-Hoefnagel, Tineke; Otten, Henny G.] Univ Utrecht, Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [van de Graaf, Ed A.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Resp Med, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Michielsen, LA (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Dept Nephrol & Hypertens, Utrecht, Netherlands.	l.a.michielsen@umcutrecht.nl	Verhaar, Marianne/AAM-6788-2020	Verhaar, Marianne/0000-0002-3276-6428; Michielsen, Laura/0000-0003-0382-143X	Astellas Pharma; Alexion	Astellas Pharma(Astellas Pharmaceuticals); Alexion	The authors would like to thank J. F. van Velzen, Laboratory of Translational Immunology, for his help with the set-up and analysis of our flow cytometry experiments. Parts of this research were presented as an abstract on the American Transplant Congress 2017 (38). This study was supported with financial support from Astellas Pharma and Alexion.	Alegretti AP, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/725684; Andreucci M, 2010, CHEM-BIOL INTERACT, V185, P253, DOI 10.1016/j.cbi.2010.03.019; Brodsky SV, 2009, TRANSPLANTATION, V88, P457, DOI 10.1097/TP.0b013e3181b0517d; Budding K, 2016, AM J TRANSPLANT, V16, P987, DOI 10.1111/ajt.13497; Budding K, 2014, TRANSPL IMMUNOL, V31, P260, DOI 10.1016/j.trim.2014.08.006; Chen S, 2011, AM J TRANSPLANT, V11, P2057, DOI 10.1111/j.1600-6143.2011.03646.x; Christmas SE, 2006, IMMUNOLOGY, V119, P522, DOI 10.1111/j.1365-2567.2006.02467.x; Du YQ, 2014, J BIOL CHEM, V289, P2711, DOI 10.1074/jbc.M113.525501; Eggleton P, 2003, CLIN EXP IMMUNOL, V134, P6, DOI 10.1046/j.1365-2249.2003.02263.x; Garcia-Valladares I, 2006, LUPUS, V15, P600, DOI 10.1177/0961203306071916; Griesemer AD, 2009, TRANSPLANTATION, V87, P1308, DOI 10.1097/TP.0b013e3181a19afc; Hayashida K, 2010, ANAT REC, V293, P925, DOI 10.1002/ar.20757; Jane-wit D, 2013, CIRCULATION, V128, P2504, DOI 10.1161/CIRCULATIONAHA.113.002972; Karpman D, 2015, ADV EXP MED BIOL, V865, P19, DOI 10.1007/978-3-319-18603-0_2; Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019; Lynch RJ, 2010, CURR OPIN ORGAN TRAN, V15, P481, DOI 10.1097/MOT.0b013e32833b9c25; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; MERI S, 1991, LAB INVEST, V65, P532; Nuutila J, 2013, HUM IMMUNOL, V74, P522, DOI [10.1016/j.humimm.2013.01.011, 10.]; Sivasankar B, 2009, J IMMUNOL, V182, P5203, DOI 10.4049/jimmunol.0804243; Subramanian V, 2014, AM J TRANSPLANT, V14, P2359, DOI 10.1111/ajt.12908; Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5; UESU T, 1995, LAB INVEST, V72, P587; Vakeva A, 2000, SCAND J IMMUNOL, V52, P411, DOI 10.1046/j.1365-3083.2000.00783.x; VARSANO S, 1995, AM J RESP CRIT CARE, V152, P1087, DOI 10.1164/ajrccm.152.3.7545058; Xie XH, 2012, CELL IMMUNOL, V274, P1, DOI 10.1016/j.cellimm.2012.02.013; Yamanaka K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148881	27	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 22	2018	8								2008	10.3389/fimmu.2017.02008	http://dx.doi.org/10.3389/fimmu.2017.02008			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FT2QK		Green Published, gold			2022-12-18	WOS:000422990900001
J	Meyer, N; Schuler, T; Zenclussen, AC				Meyer, Nicole; Schueler, Thomas; Zenclussen, Ana Claudia			Simultaneous Ablation of Uterine Natural Killer Cells and Uterine Mast Cells in Mice Leads to Poor Vascularization and Abnormal Doppler Measurements That Compromise Fetal Well-being	FRONTIERS IN IMMUNOLOGY			English	Article						angiogenesis; fetal development; intrauterine growth restriction; placenta; mast cells; natural killer cells; ultrasound imaging; Doppler measurements	INTRAUTERINE GROWTH-RETARDATION; BED SPIRAL ARTERIES; PLACENTAL DEVELOPMENT; CLINICAL-SIGNIFICANCE; PREGNANCY; RESTRICTION; MORTALITY; DISEASE; WEIGHT	Intrauterine growth restriction (IUGR) is a serious pregnancy complication with short- and long-term health consequences. The mechanisms underlying this condition are not well understood. Animal models are the basis for understanding the causes of IUGR and for developing useful therapeutic strategies. Here, we aimed to ascertain the in utero growth of fetuses from NK (natural killer cells)/MC (mast cells)-deficient mothers that give birth to growth restricted pups and to determine the time point at which IUGR starts. We used high frequency ultrasound imaging to follow-up fetal and placenta size and employed Doppler measurements to document blood supply to the fetus in females that were deficient for NK cells and MCs. In mice lacking NKs and MCs, we observed significantly reduced implantation sizes from mid gestation onward, which was further associated with smaller placentas. Additionally, NK/MC-deficiency was associated with absent and reversed end diastolic flow in umbilical arteries of the fetuses and an increased systolic/diastolic ratio as well as an elevated resistance index. Together, our results indicate that NKs/MCs promote blood flow, placental growth, and subsequent fetal development. The results of this study offer new insights as to how fetal growth is affected in vivo in NK/MC-deficient mice, whose pups are growth restricted at birth. The use of IUGR models and modern technologies enabling the in vivo follow-up of fetal development are important tools for understanding mechanisms behind pregnancy complications that in the future may lead to the development of effective therapies.	[Meyer, Nicole; Zenclussen, Ana Claudia] Otto von Guericke Univ, Expt Obstet & Gynecol Med Fac, Magdeburg, Germany; [Schueler, Thomas] Otto von Guericke Univ, Med Fac, Inst Mol & Clin Immunol, Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Zenclussen, AC (corresponding author), Otto von Guericke Univ, Expt Obstet & Gynecol Med Fac, Magdeburg, Germany.	ana.zenclussen@med.ovgu.de	Zenclussen, Ana C/G-2186-2013; Zenclussen, Ana/AAE-8760-2020	Zenclussen, Ana C/0000-0003-3544-4552; Zenclussen, Ana/0000-0003-3544-4552	Deutsche Forschungsgemeinschaft (DFG) [ZE526/6-1, AZ526/6-2]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This study was funded by grants from the Deutsche Forschungsgemeinschaft (DFG) to AZ (ZE526/6-1 and AZ526/6-2) that were granted within the priority program 1394 "Mast cells in health and disease."	Ball E, 2006, J PATHOL, V208, P535, DOI 10.1002/path.1927; BARKER DJP, 1989, LANCET, V2, P577; Chaddha Vandana, 2004, Semin Fetal Neonatal Med, V9, P357, DOI 10.1016/j.siny.2004.03.006; CHISWICK ML, 1985, BRIT MED J, V291, P845, DOI 10.1136/bmj.291.6499.845; Clark RH, 2003, PEDIATRICS, V111, P986, DOI 10.1542/peds.111.5.986; Croy BA, 2002, J REPROD IMMUNOL, V57, P151, DOI 10.1016/S0165-0378(02)00005-0; Faraci Marianna, 2011, J Prenat Med, V5, P31; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Gagnon R, 2003, EUR J OBSTET GYN R B, V110, pS99, DOI 10.1016/S0301-2115(03)00179-9; Giordano Rosalba, 2010, J Prenat Med, V4, P59; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; GOLDENBERG RL, 1989, AM J OBSTET GYNECOL, V161, P271, DOI 10.1016/0002-9378(89)90497-3; Janthanaphan Manop, 2006, Journal of the Medical Association of Thailand, V89, P130; Joo P, 2014, J IMMUNOL, V193, P5218, DOI 10.4049/jimmunol.1401096; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Menzies FM, 2011, HUM REPROD UPDATE, V17, P383, DOI 10.1093/humupd/dmq053; Meyer N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00711; Meyer N, 2017, SCI REP-UK, V7, DOI 10.1038/srep45106; NAEYE RL, 1987, HUM PATHOL, V18, P387, DOI 10.1016/S0046-8177(87)80170-3; OLOFSSON P, 1993, EUR J OBSTET GYN R B, V49, P161, DOI 10.1016/0028-2243(93)90265-E; Pijnenborg R, 2006, PLACENTA, V27, P939, DOI 10.1016/j.placenta.2005.12.006; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; Redline RW, 2000, J EXP MED, V192, pF1, DOI 10.1084/jem.192.2.F1; Resnik R, 2002, OBSTET GYNECOL, V99, P490, DOI 10.1016/S0029-7844(01)01780-X; Risnes KR, 2009, AM J EPIDEMIOL, V170, P622, DOI 10.1093/aje/kwp182; Schlembach D, 2016, HEBAMME, V29, P4, DOI [10.1055/s-0042-102011, DOI 10.1055/S-0042-102011]; TRUDINGER BJ, 1985, BRIT J OBSTET GYNAEC, V92, P23, DOI 10.1111/j.1471-0528.1985.tb01044.x; Whitley GSJ, 2009, J ANAT, V215, P21, DOI 10.1111/j.1469-7580.2008.01039.x; Woidacki K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13938; Woldacki K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.214; Zenclussen AC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00321	32	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 8	2018	8								1913	10.3389/fimmu.2017.01913	http://dx.doi.org/10.3389/fimmu.2017.01913			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FS0FL		gold, Green Published			2022-12-18	WOS:000419449200001
J	Iyer, SS				Iyer, Smita S.			Editorial: CD4 T Follicular Helper Cells in HIV	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						antibody; target cells; reservoirs; vaccine; prevention			[Iyer, Smita S.] Univ Calif Davis, Dept Pathol Microbiol & Immunol, Ctr Comparat Med, Calif Natl Primate Res Ctr, Davis, CA 95616 USA	University of California System; University of California Davis	Iyer, SS (corresponding author), Univ Calif Davis, Dept Pathol Microbiol & Immunol, Ctr Comparat Med, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.	smiyer@ucdavis.edu			NIH [KO1OD023034]; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [K01OD023034] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by NIH KO1OD023034.		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 22	2017	8								1894	10.3389/fimmu.2017.01894	http://dx.doi.org/10.3389/fimmu.2017.01894			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FQ8MV	29375558	Green Published, gold			2022-12-18	WOS:000418617800002
J	Zhou, ZJ; Wang, L; Feng, PP; Yin, LH; Wang, C; Zhi, SX; Dong, JY; Wang, JY; Lin, Y; Chen, DP; Xiong, YJ; Peng, JY				Zhou, Zijuan; Wang, Liang; Feng, Panpan; Yin, Lianhong; Wang, Chen; Zhi, Shengxu; Dong, Jianyi; Wang, Jingyu; Lin, Yuan; Chen, Dapeng; Xiong, Yongjian; Peng, Jinyong			Inhibition of Epithelial TNF-alpha Receptors by Purified Fruit Bromelain Ameliorates Intestinal Inflammation and Barrier Dysfunction in Colitis (vol 8, 1468, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						bromelain; purification; inflammation; cytokines; myosin light chain kinase; TNF-alpha receptor; inflammatory bowel disease; tight junction			[Zhou, Zijuan; Wang, Liang; Feng, Panpan; Dong, Jianyi; Wang, Jingyu; Chen, Dapeng] Dalian Med Univ, Lab Anim Ctr, Dalian, Peoples R China; [Yin, Lianhong; Lin, Yuan; Peng, Jinyong] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China; [Wang, Chen; Zhi, Shengxu] Dalian Med Univ, Dalian, Peoples R China; [Xiong, Yongjian] Dalian Med Univ, Affiliated Hosp 1, Cent Lab, Dalian, Peoples R China; [Xiong, Yongjian] Dalian Med Univ, Coll Integrat Med, Dalian, Peoples R China	Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University	Chen, DP (corresponding author), Dalian Med Univ, Lab Anim Ctr, Dalian, Peoples R China.; Peng, JY (corresponding author), Dalian Med Univ, Coll Pharm, Dalian, Peoples R China.; Xiong, YJ (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Cent Lab, Dalian, Peoples R China.; Xiong, YJ (corresponding author), Dalian Med Univ, Coll Integrat Med, Dalian, Peoples R China.	cdp.9527@163.com; private007@126.com; jinyongpeng2005@163.com	Chen, Dapeng/GZH-3314-2022	Wang, Liang/0000-0003-4812-8276				Zhou ZJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01468	1	0	0	0	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 13	2017	8								1769	10.3389/fimmu.2017.01769	http://dx.doi.org/10.3389/fimmu.2017.01769			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FP7IM	29266133	gold, Green Published			2022-12-18	WOS:000417806500001
J	Kim, JH; Sim, JH; Lee, S; Seol, MA; Ye, SK; Shin, HM; Lee, EB; Lee, YJ; Choi, YJ; Yoo, WH; Kim, JH; Kim, WU; Lee, DS; Kim, JH; Kang, I; Kang, SW; Kim, HR				Kim, Jin-Hee; Sim, Ji Hyun; Lee, Sunkyung; Seol, Min A.; Ye, Sang-Kyu; Shin, Hyun Mu; Lee, Eun Bong; Lee, Yun Jong; Choi, Yun Jung; Yoo, Wan-Hee; Kim, Jin Hyun; Kim, Wan-Uk; Lee, Dong-Sup; Kim, Jin-Hong; Kang, Insoo; Kang, Seong Wook; Kim, Hang-Rae			Interleukin-7 Induces Osteoclast Formation via STAT5, Independent of Receptor Activator of NF-kappaB Ligand (vol 8, 1376, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						osteoclast; intereleukin-7; intereleukin-7 receptor alpha; STAT5; RANKL; monocyte			[Kim, Jin-Hee; Sim, Ji Hyun; Lee, Sunkyung; Seol, Min A.; Shin, Hyun Mu; Lee, Dong-Sup; Kim, Hang-Rae] Seoul Natl Univ, Coll Med, Dept Anat & Cell Biol, Seoul, South Korea; [Kim, Jin-Hee] Cheongju Univ, Coll Hlth Sci, Dept Biomed Lab Sci, Cheongju, South Korea; [Seol, Min A.; Ye, Sang-Kyu; Shin, Hyun Mu; Lee, Dong-Sup; Kim, Hang-Rae] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea; [Seol, Min A.; Ye, Sang-Kyu; Shin, Hyun Mu; Lee, Dong-Sup; Kim, Hang-Rae] Seoul Natl Univ, Coll Med, Biomed Sci Project BK21Plus, Seoul, South Korea; [Ye, Sang-Kyu] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea; [Ye, Sang-Kyu; Shin, Hyun Mu; Lee, Eun Bong; Lee, Dong-Sup; Kim, Hang-Rae] Seoul Natl Univ, Coll Med, Med Res Inst, Seoul, South Korea; [Lee, Eun Bong; Lee, Yun Jong] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Choi, Yun Jung; Yoo, Wan-Hee] Chonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, South Korea; [Choi, Yun Jung; Yoo, Wan-Hee] Chonbuk Natl Univ Hosp, Res Inst Clin Med, Jeonju, South Korea; [Kim, Jin Hyun; Kang, Seong Wook] Chungnam Natl Univ, Sch Med, Dept Internal Med, Daejeon, South Korea; [Kim, Wan-Uk] Catholic Univ Korea, Dept Internal Med, Seoul, South Korea; [Kim, Jin-Hong] Seoul Natl Univ, Coll Nat Sci, Dept Biol Sci, Seoul, South Korea; [Kang, Insoo] Yale Univ, Sch Med, Dept Internal Med, Sect Rheumatol, New Haven, CT 06510 USA	Seoul National University (SNU); Cheongju University; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Jeonbuk National University; Jeonbuk National University; Jeonbuk National University Hospital; Chungnam National University; Catholic University of Korea; Seoul National University (SNU); Yale University	Kim, HR (corresponding author), Seoul Natl Univ, Coll Med, Dept Anat & Cell Biol, Seoul, South Korea.; Kim, HR (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.; Kim, HR (corresponding author), Seoul Natl Univ, Coll Med, Biomed Sci Project BK21Plus, Seoul, South Korea.; Kim, HR (corresponding author), Seoul Natl Univ, Coll Med, Med Res Inst, Seoul, South Korea.; Kang, SW (corresponding author), Chungnam Natl Univ, Sch Med, Dept Internal Med, Daejeon, South Korea.	kangsw@cnuh.co.kr; hangrae2@snu.ac.kr	Kim, Wan-Uk/AAO-8502-2020	Kim, Jin-Hong/0000-0002-6480-1929; Kim, Hang-Rae/0000-0002-3983-6193; Kim, Wan-Uk/0000-0001-8224-8496; Kang, Seong Wook/0000-0002-0076-0822; Lee, Darrall/0000-0002-6990-4441; Kim, Jinhyun/0000-0001-5235-2612				Kim JH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01376	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2017	8								1735	10.3389/fimmu.2017.01735	http://dx.doi.org/10.3389/fimmu.2017.01735			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FO9XL	29235580	Green Published, gold			2022-12-18	WOS:000417251700001
J	Vieillard, V; Foley, B; Lopez-Verges, SL				Vieillard, Vincent; Foley, Bree; Lopez-Verges, Sandra L.			Editorial: NK Cells in Human diseases: Friends or Foes?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						natural killer cells; anti-microbial response; antiviral response; antitumor response; transplantation; uterine natural killer cells	INFECTION; CYTOMEGALOVIRUS; CANCER		[Vieillard, Vincent] Pitie Salpetriere Hosp Paris, Ctr Immunol & Infect Dis, Paris, France; [Foley, Bree] Univ Western Australia, Telethon Kids Inst, Subiaco, WA, Australia; [Lopez-Verges, Sandra L.] Gorgas Mem Inst Hlth Studies, Panama City, Panama	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Telethon Kids Institute; University of Western Australia; Instituto Conmemorativo Gorgas de Estudios de la Salud	Vieillard, V (corresponding author), Pitie Salpetriere Hosp Paris, Ctr Immunol & Infect Dis, Paris, France.; Foley, B (corresponding author), Univ Western Australia, Telethon Kids Inst, Subiaco, WA, Australia.; Lopez-Verges, SL (corresponding author), Gorgas Mem Inst Hlth Studies, Panama City, Panama.	vincent.vieillard@upmc.fr; bree.foley@telethonkids.org.au; slopez@gorgas.gob.pa						Bjorkstrom NK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027664; Cerwenka A, 2016, NAT REV IMMUNOL, V16, P112, DOI 10.1038/nri.2015.9; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hendricks DW, 2014, J IMMUNOL, V192, P4492, DOI 10.4049/jimmunol.1303211; Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 7	2017	8								1737	10.3389/fimmu.2017.01737	http://dx.doi.org/10.3389/fimmu.2017.01737			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FO9XN	29270178	gold, Green Published			2022-12-18	WOS:000417251900001
J	Lozano, F; Martinez-Florensa, M				Lozano, Francisco; Martinez-Florensa, Mario			Commentary: The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain (vol 8, 366, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						SSc5D; S5D-SRCRB; scavenger receptor cysteine-rich; bacterial binding; CD6			[Lozano, Francisco; Martinez-Florensa, Mario] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Grp Immunoreceptors Sistema Innat & Adaptatiu, Barcelona, Spain; [Lozano, Francisco] Hosp Clin Barcelona, Serv Immunol, Barcelona, Spain; [Lozano, Francisco] Univ Barcelona, Fac Med, Dept Biomed, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona	Lozano, F (corresponding author), Inst Invest Biomed August Pi & Sunyer IDIBAPS, Grp Immunoreceptors Sistema Innat & Adaptatiu, Barcelona, Spain.; Lozano, F (corresponding author), Hosp Clin Barcelona, Serv Immunol, Barcelona, Spain.; Lozano, F (corresponding author), Univ Barcelona, Fac Med, Dept Biomed, Barcelona, Spain.	flozano@clinic.ub.es	LOZANO, FRANCISCO/AAB-7888-2019	LOZANO, FRANCISCO/0000-0003-1119-4368	Plan Nacional de I+D+I from the Spanish Ministerio de Economia y Competitividad [SAF2016-80535-R]; project SRecognite Infect from the Spanish Ministerio de Economia y Competitividad [ERA/0003/2015, PCIN-2015-070]	Plan Nacional de I+D+I from the Spanish Ministerio de Economia y Competitividad; project SRecognite Infect from the Spanish Ministerio de Economia y Competitividad	In the original article, we neglected to include the grants SAF2016-80535-R under Plan Nacional de I+D+I, and PCIN-2015-070 under the project SRecognite Infect-ERA/0003/2015 both from the Spanish Ministerio de Economia y Competitividad to FL. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.	Lozano F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00366	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 29	2017	8								1660	10.3389/fimmu.2017.01660	http://dx.doi.org/10.3389/fimmu.2017.01660			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FO0BC	29234322	Green Published, gold			2022-12-18	WOS:000416406800001
J	Benichou, G; Kim, J				Benichou, Gilles; Kim, James			Editorial: Allorecognition by Leukocytes of the Adaptive Immune System	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allorecognition; lymphocytes; transplantation immunology; tolerance; MHC			[Benichou, Gilles; Kim, James] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Benichou, G (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Ctr Transplantat Sci, Boston, MA 02115 USA.	gbenichou@partners.org			NIH [NIH R21 AI117466]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI102405, R21AI117466] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded through an NIH grant to GB, NIH R21 AI117466.		0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 15	2017	8								1555	10.3389/fimmu.2017.01555	http://dx.doi.org/10.3389/fimmu.2017.01555			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FM5NP	29187852	Green Published, gold			2022-12-18	WOS:000415082900001
J	Yoshimura, T; Imamichi, T; Weiss, JM; Sato, M; Li, LZ; Matsukawa, A; Wang, JM				Yoshimura, Teizo; Imamichi, Tomozumi; Weiss, Jonathan M.; Sato, Miwa; Li, Liangzhu; Matsukawa, Akihiro; Wang, Ji Ming			Induction of Monocyte Chemoattractant Proteins in Macrophages via the Production of Granulocyte/Macrophage Colony-Stimulating Factor by Breast Cancer Cells (vol 7, pg 2, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						monocytes/macrophages; chemokines; inflammation; tumor microenvironment; breast cancer			[Yoshimura, Teizo; Weiss, Jonathan M.; Wang, Ji Ming] NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA; [Yoshimura, Teizo; Sato, Miwa; Matsukawa, Akihiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol & Expt Med, Okayama, Japan; [Imamichi, Tomozumi] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, Lab Human Retrovirol & Immunoinformat, Frederick, MD USA; [Li, Liangzhu] Shanghai Jiao Tong Univ, Sch Pharm, Minist Educ, Engn Res Ctr Cell & Therapeut Antibody, Shanghai, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Okayama University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shanghai Jiao Tong University	Yoshimura, T (corresponding author), NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA.; Yoshimura, T (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol & Expt Med, Okayama, Japan.	yoshimut@okayama-u.ac.jp		Imamichi, Tomozumi/0000-0002-1474-1796; Matsukawa, Akihiro/0000-0002-5081-6089				Yoshimura T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00002	1	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 13	2017	8								1524	10.3389/fimmu.2017.01524	http://dx.doi.org/10.3389/fimmu.2017.01524			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FM3LQ	29151836	Green Published, gold			2022-12-18	WOS:000414907700001
J	Pai, S; Hickey, MJ; Weninger, W				Pai, Saparna; Hickey, Michael J.; Weninger, Wolfgang			Editorial: Inflammation in the CNS: Advancing the Field Using Intravital Imaging	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						intravital imaging; leucocytes; inflammation; brain; central nervous system disorders			[Pai, Saparna] James Cook Univ, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia; [Pai, Saparna; Weninger, Wolfgang] Centenary Inst, Immune Imaging Program, Newtown, NSW, Australia; [Pai, Saparna] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Hickey, Michael J.] Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, Melbourne, Vic, Australia; [Weninger, Wolfgang] Univ Sydney, Discipline Dermatol, Sydney, NSW, Australia; [Weninger, Wolfgang] Royal Prince Alfred Hosp, Dept Dermatol, Camperdown, NSW, Australia	James Cook University; University of Sydney; Centenary Institute; University of Sydney; Monash University; University of Sydney; University of Sydney	Pai, S (corresponding author), James Cook Univ, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia.; Pai, S (corresponding author), Centenary Inst, Immune Imaging Program, Newtown, NSW, Australia.; Pai, S (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.	saparna.pai@jcu.edu.au	Pai, Saparna/N-5609-2017; Hickey, Michael/A-5429-2012	Pai, Saparna/0000-0003-1571-3997; Hickey, Michael/0000-0003-2354-357X	National Health and Medical Research Council [1042775]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank Dr. Andreas Kupz, Australian Institute of Tropical Health and Medicine, James Cook University for his input. MH is an National Health and Medical Research Council Senior Research Fellow (Grant ID 1042775).	Abtin A, 2014, NAT IMMUNOL, V15, P45, DOI 10.1038/ni.2769; Clifford DB, 2017, MULT SCLER J, V23, P934, DOI 10.1177/1352458516670735; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051	5	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2017	8								1155	10.3389/fimmu.2017.01155	http://dx.doi.org/10.3389/fimmu.2017.01155			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI4SO	29038653	Green Accepted, gold, Green Published			2022-12-18	WOS:000411966200001
J	Speckmann, C; Sahoo, SS; Rizzi, M; Hirabayashi, S; Karow, A; Serwas, NK; Hoemberg, M; Damatova, N; Schindler, D; Vannier, JB; Boulton, SJ; Pannicke, U; Gohring, G; Thomay, K; Verdu-Amoros, JJ; Hauch, H; Woessmann, W; Escherich, G; Laack, E; Rindle, L; Seidl, M; Rensing-Ehl, A; Lausch, E; Jandrasits, C; Strahm, B; Schwarz, K; Ehl, SR; Niemeyer, C; Boztug, K; Wlodarski, MW				Speckmann, Carsten; Sahoo, Sushree Sangita; Rizzi, Marta; Hirabayashi, Shinsuke; Karow, Axel; Serwas, Nina Kathrin; Hoemberg, Marc; Damatova, Natalja; Schindler, Detlev; Vannier, Jean-Baptiste; Boulton, Simon J.; Pannicke, Ulrich; Goehring, Gudrun; Thomay, Kathrin; Verdu-Amoros, J. J.; Hauch, Holger; Woessmann, Wilhelm; Escherich, Gabriele; Laack, Eckart; Rindle, Liliana; Seidl, Maximilian; Rensing-Ehl, Anne; Lausch, Ekkehart; Jandrasits, Christine; Strahm, Brigitte; Schwarz, Klaus; Ehl, Stephan R.; Niemeyer, Charlotte; Boztug, Kaan; Wlodarski, Marcin W.			Clinical and Molecular Heterogeneity of RTE L1 Deficiency (vol 8, pg 449, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						RTE L1; dyskeratosis congenita; bone marrow failure; immunodeficiency; lymphopenia			[Speckmann, Carsten; Sahoo, Sushree Sangita; Hirabayashi, Shinsuke; Rindle, Liliana; Lausch, Ekkehart; Strahm, Brigitte; Ehl, Stephan R.; Niemeyer, Charlotte; Wlodarski, Marcin W.] Univ Freiburg, Med Ctr, Fac Med, Dept Pediat & Adolescent Med,Div Pediat Hematol &, Freiburg, Germany; [Speckmann, Carsten; Rizzi, Marta; Seidl, Maximilian; Rensing-Ehl, Anne; Ehl, Stephan R.] Univ Freiburg, Ctr Chron Immunodeficiency, Med Ctr, Fac Med, Freiburg, Germany; [Sahoo, Sushree Sangita] Univ Freiburg, Spemann Grad Sch Biol & Med, Freiburg, Germany; [Sahoo, Sushree Sangita] Univ Freiburg, Fac Biol, Freiburg, Germany; [Rizzi, Marta] Univ Freiburg, Dept Rheumatol & Clin Immunol, Med Ctr, Fac Med, Freiburg, Germany; [Karow, Axel] Univ Bern, Dept Pediat, Bern, Switzerland; [Serwas, Nina Kathrin; Boztug, Kaan] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Serwas, Nina Kathrin; Jandrasits, Christine; Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Hoemberg, Marc] Univ Cologne, Childrens Hosp, Dept Pediat Hematol & Oncol, Cologne, Germany; [Damatova, Natalja; Schindler, Detlev] Univ Wurzburg, Dept Med Genet, Biozentrum, Wurzburg, Germany; [Vannier, Jean-Baptiste; Boulton, Simon J.] London Inst Med Sci LMS, MRC, Telomere Replicat & Stabil Grp, London, England; [Pannicke, Ulrich; Schwarz, Klaus] Univ Ulm, German Red Cross Blood Serv Baden Wuerttemberg He, Inst Transfus Med, Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Germany; [Goehring, Gudrun] Hannover Med Sch, Dept Human Genet, Hannover, Germany; [Thomay, Kathrin; Verdu-Amoros, J. J.; Hauch, Holger; Woessmann, Wilhelm] Justus Liebig Univ, Dept Pediat Hematol & Oncol, Giessen, Germany; [Escherich, Gabriele] Univ Med Ctr Hamburg Eppendorf, Clin Pediat Hematol & Oncol, Hamburg, Germany; [Laack, Eckart] Hematooncol Clin Hamburg, Hamburg, Germany; [Seidl, Maximilian] Univ Freiburg, Inst Pathol, Med Ctr, Fac Med, Freiburg, Germany; [Niemeyer, Charlotte; Wlodarski, Marcin W.] German Canc Consortium DKTK, Freiburg, Germany; [Niemeyer, Charlotte; Wlodarski, Marcin W.] German Canc Res Ctr, Heidelberg, Germany; [Boztug, Kaan] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, St Anna Kinderspital, Dept Pediat & Adolescent Med, Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Bern; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; University of Cologne; University of Wurzburg; Ulm University; Hannover Medical School; Justus Liebig University Giessen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Vienna; Medical University of Vienna; Saint Anna Children's Hospital; Medical University of Vienna; Saint Anna Children's Hospital	Wlodarski, MW (corresponding author), Univ Freiburg, Med Ctr, Fac Med, Dept Pediat & Adolescent Med,Div Pediat Hematol &, Freiburg, Germany.; Wlodarski, MW (corresponding author), German Canc Consortium DKTK, Freiburg, Germany.; Wlodarski, MW (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	marcin.wlodarski@uniklinik-freiburg.de	Boztug, Kaan/AAM-4161-2021; Seidl, Maxmilian/ABF-3322-2021; Sahoo, Sushree/AAA-8361-2022; Rizzi, Marta/ABE-7264-2020; Ehl, Stephan/AAM-6006-2020	Boztug, Kaan/0000-0001-8387-9185; Seidl, Maxmilian/0000-0002-5559-4980; Rizzi, Marta/0000-0002-5153-6089; Speckmann, Carsten/0000-0002-6217-1556; Ehl, Stephan/0000-0002-9265-2721; VERDU AMOROS, JAIME/0000-0002-0900-0889	Excellence Initiative of the German Research Foundation; Spemann Graduate School [GSC-4]	Excellence Initiative of the German Research Foundation(German Research Foundation (DFG)); Spemann Graduate School	In the original article, we neglected to include the funder [Excellence Initiative of the German Research Foundation], [GSC-4, Spemann Graduate School] to [Sushree Sangita Sahoo]. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.	Speckmann C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00449	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2017	8								1250	10.3389/fimmu.2017.01250	http://dx.doi.org/10.3389/fimmu.2017.01250			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI4SW	28989339	Green Published, gold			2022-12-18	WOS:000411967200001
J	Weissert, R; Brilot, F				Weissert, Robert; Brilot, Fabienne			Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						multiple sclerosis; neuromyelitis optica spectrum disorder; autoimmune encephalitis; T cell; B cell; NMDA receptor; myelin oligodendrocyte glycoprotein; aquaporin-4	ASPARTATE RECEPTOR ENCEPHALITIS		[Weissert, Robert] Univ Regensburg, Dept Neurol, Regensburg, Germany; [Brilot, Fabienne] Univ Sydney, Childrens Hosp Westmead, Kids Res Inst,Brain & Mind Ctr, Brain Autoimmun Grp,Inst Neurosci & Muscle Res, Sydney, NSW, Australia	University of Regensburg; University of Sydney	Weissert, R (corresponding author), Univ Regensburg, Dept Neurol, Regensburg, Germany.; Brilot, F (corresponding author), Univ Sydney, Childrens Hosp Westmead, Kids Res Inst,Brain & Mind Ctr, Brain Autoimmun Grp,Inst Neurosci & Muscle Res, Sydney, NSW, Australia.	robert.weissert@ukr.de; fabienne.brilot@sydney.edu.au	Weissert, Robert/B-2585-2009; Brilot, Fabienne/AAT-3138-2020; Weissert, Robert/AAA-4791-2019	Weissert, Robert/0000-0002-1295-1271; Brilot, Fabienne/0000-0002-7025-2276; 				Castillo-Gomez E, 2016, ANN NEUROL, V79, P144, DOI 10.1002/ana.24545; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; LEBAR R, 1986, CLIN EXP IMMUNOL, V66, P423; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Moscato EH, 2014, ANN NEUROL, V76, P108, DOI 10.1002/ana.24195; Sato DK, 2014, NEUROLOGY, V82, P474, DOI 10.1212/WNL.0000000000000101; Schuster C, 2015, IMMUNITY, V42, P942, DOI 10.1016/j.immuni.2015.04.011	7	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 2	2017	8								1218	10.3389/fimmu.2017.01218	http://dx.doi.org/10.3389/fimmu.2017.01218			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FI4SR	29038655	Green Published, gold			2022-12-18	WOS:000411966500001
J	Lim, PS; Khanna, KK; Rao, S				Lim, Pek Siew; Khanna, Kum Kum; Rao, Sudha			Signaling to the Epigenome: New Insights into the Roles of Nuclear Signaling Kinases in the Context of the Immune System and Cancer	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						PKC; signaling kinase; epigenome; immune system; cancer; T cell; epigenetic regulation; transcription			[Lim, Pek Siew; Rao, Sudha] Univ Canberra, Canberra, ACT, Australia; [Khanna, Kum Kum] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia	University of Canberra; QIMR Berghofer Medical Research Institute	Lim, PS (corresponding author), Univ Canberra, Canberra, ACT, Australia.	chloe.lim@canberra.edu.au	Rao, Sudha/AAW-5192-2020	Rao, Sudha/0000-0001-9547-947X; Khanna, Kum Kum/0000-0001-8650-5381					0	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 21	2017	8								980	10.3389/fimmu.2017.00980	http://dx.doi.org/10.3389/fimmu.2017.00980			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FE2MY	28871255	Green Published, gold			2022-12-18	WOS:000408051600001
J	Johnson, HM; Larkin, J				Johnson, Howard M.; Larkin, Joseph, III			Editorial: the dynamic role of Suppressor of Cytokine Signaling Proteins in the regulation of immune and autoimmune responses	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cytokine; immune tolerance; suppressor of cytokine signaling proteins; inflammation; macrophages; T cell biology			[Johnson, Howard M.; Larkin, Joseph, III] Univ Florida, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Johnson, HM; Larkin, J (corresponding author), Univ Florida, Gainesville, FL 32611 USA.	johnsonh@ufl.edu; jlarkin3@ufl.edu		Larkin, Joseph/0000-0003-2066-6814	NIH [R01 AI 056152]; Lupus Research Institute; National Psoriasis Foundation; NIH/NIAID [U01AI101990]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056152, U01AI101990] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lupus Research Institute; National Psoriasis Foundation; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The research of HJ and JL is supported by NIH grant R01 AI 056152 to HJ, a grant to the University of Florida by HJ, a grant from Lupus Research Institute to JL, a grant from the National Psoriasis Foundation to JL, and a sub-award from NIH/NIAID U01AI101990 to JL.	McCormick SM, 2016, J BIOL CHEM, V291, P20574, DOI 10.1074/jbc.M116.746164	1	0	0	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 17	2017	8								825	10.3389/fimmu.2017.00825	http://dx.doi.org/10.3389/fimmu.2017.00825			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FA6JC	28769931	Green Published, gold			2022-12-18	WOS:000405548300001
J	Verrier, B; Paul, S; Terrat, C; Bastide, L; Ensinas, A; Phelip, C; Chanut, B; Bulens-Grassigny, L; Jospin, F; Guillon, C				Verrier, Bernard; Paul, Stephane; Terrat, Celine; Bastide, Liza; Ensinas, Agathe; Phelip, Capucine; Chanut, Blandine; Bulens-Grassigny, Laura; Jospin, Fabienne; Guillon, Christophe			Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Anti-body to Induce HIV-1 Neutralizing Responses In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						human immunodeficiency virus-1; gp41; p17; neutralizing antibodies; cross-reactivity; antigen engineering	T-CELL RESPONSES; MATRIX PROTEIN; MONOCLONAL-ANTIBODIES; EPITOPE-SCAFFOLDS; PLA NANOPARTICLES; VACCINE; TYPE-1; GP41; DESIGN; P24	Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro. The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro. Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity, Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model.	[Verrier, Bernard; Terrat, Celine; Ensinas, Agathe; Phelip, Capucine; Bulens-Grassigny, Laura] Univ Lyon, CNRS, Inst Biol & Chim Prot, Colloidal Vectors & Tissue Transport,UMR5305, Lyon, France; [Paul, Stephane; Ensinas, Agathe; Chanut, Blandine; Jospin, Fabienne] Univ Lyon, Fac Med Jacques Lisfranc, Grp Immunite Muqueuses & Agents Pathogenes, EA3064, St Etienne, France; [Bastide, Liza; Bulens-Grassigny, Laura; Guillon, Christophe] Univ Lyon, CNRS, Inst Biol & Chim Prot, Retroviruses & Struct Biochem,UMR5086, Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Guillon, C (corresponding author), Univ Lyon, CNRS, Inst Biol & Chim Prot, Retroviruses & Struct Biochem,UMR5086, Lyon, France.	christophe.guillon@ibcp.fr	Guillon, Christophe/A-4084-2015; verrier, bernard/J-4094-2017	Guillon, Christophe/0000-0001-6378-3303; paul, stephane/0000-0002-8830-4273; verrier, bernard/0000-0002-8478-7095	Agence Nationale de Recherche sur le SIDA (ANRS); Fondation Pierre Berge-Sidaction; FP7 European grant CUT'HIVAC [241904]; FP7 European grant ADITEC [280873]; HIVERA support (HIVNANOVA)	Agence Nationale de Recherche sur le SIDA (ANRS)(ANRSFrench National Research Agency (ANR)); Fondation Pierre Berge-Sidaction; FP7 European grant CUT'HIVAC; FP7 European grant ADITEC; HIVERA support (HIVNANOVA)	CG, BY, and SP were supported in part by the Agence Nationale de Recherche sur le SIDA (ANRS). SP and BY are supported by grants from the Fondation Pierre Berge-Sidaction, FP7 European grants CUT'HIVAC (No. 241904) and ADITEC (No. 280873), and HIVERA support (HIVNANOVA).	Benjelloun F, 2013, AIDS, V27, P1992, DOI 10.1097/QAD.0b013e3283632ea1; Buonaguro L, 2011, CLIN VACCINE IMMUNOL, V18, P2003, DOI 10.1128/CVI.05326-11; Buratti E, 1997, J VIROL, V71, P2457, DOI 10.1128/JVI.71.3.2457-2462.1997; Caccuri F, 2016, CURR DRUG TARGETS, V17, P23, DOI 10.2174/1389450116666150825110840; Connor RI, 1996, J VIROL, V70, P5306, DOI 10.1128/JVI.70.8.5306-5311.1996; Correia BE, 2010, STRUCTURE, V18, P1116, DOI 10.1016/j.str.2010.06.010; Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916; Dawood R, 2013, AIDS, V27, P717, DOI 10.1097/QAD.0b013e32835cfca5; deCamp A, 2014, J VIROL, V88, P2489, DOI 10.1128/JVI.02853-13; Dennison SM, 2009, J VIROL, V83, P10211, DOI 10.1128/JVI.00571-09; Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030; Fiorentini S, 2010, PHARMACOL THERAPEUT, V128, P433, DOI 10.1016/j.pharmthera.2010.08.005; Foucault M, 2010, PROTEINS, V78, P1441, DOI 10.1002/prot.22661; Gray ES, 2009, J VIROL, V83, P11265, DOI 10.1128/JVI.01359-09; Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060; Haynes BF, 2017, SCIENCE, V355, P1129, DOI 10.1126/science.aan0662; Hessell AJ, 2016, J IMMUNOL, V196, P3064, DOI 10.4049/jimmunol.1500527; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; Inagaki N, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-90; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kuiken C, 2010, HIV SEQUENCE COMPEND; Kwon YD, 2016, J VIROL, V90, P5899, DOI 10.1128/JVI.03246-15; Kwong PD, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007278; Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006; Lewis GK, 2014, P NATL ACAD SCI USA, V111, P15614, DOI 10.1073/pnas.1413550111; Mann JK, 2015, VIROL J, V12, DOI 10.1186/s12985-014-0221-0; McCoy LE, 2017, IMMUNOL REV, V275, P11, DOI 10.1111/imr.12484; McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827; Moore PL, 2015, TRENDS MICROBIOL, V23, P204, DOI 10.1016/j.tim.2014.12.007; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Muster T, 1994, J VIROL, V68, P4; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107; PAPSIDERO LD, 1989, J VIROL, V63, P267, DOI 10.1128/JVI.63.1.267-272.1989; Pavot V, 2016, BIOMATERIALS, V75, P327, DOI 10.1016/j.biomaterials.2015.10.034; Pavot V, 2014, NANOMEDICINE-UK, V9, P2703, DOI [10.2217/NNM.14.156, 10.2217/nnm.14.156]; Pegu A, 2017, IMMUNOL REV, V275, P296, DOI 10.1111/imr.12511; Quinnan GV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098060; Radebe M, 2015, AIDS, V29, P23, DOI 10.1097/QAD.0000000000000508; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Serriere J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-64; Serriere J, 2011, J MOL BIOL, V405, P33, DOI 10.1016/j.jmb.2010.10.033; Tagliamonte M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043318; Tang C, 2004, P NATL ACAD SCI USA, V101, P517, DOI 10.1073/pnas.0305665101; Wibmer CK, 2015, CURR OPIN HIV AIDS, V10, P135, DOI 10.1097/COH.0000000000000153; Wilkinson RA, 2005, J VIROL, V79, P13060, DOI 10.1128/JVI.79.20.13060-13069.2005; Yu XG, 2002, AIDS, V16, P321, DOI 10.1097/00002030-200202150-00002; Zhou TQ, 2017, CELL REP, V19, P719, DOI 10.1016/j.celrep.2017.04.013	49	0	0	1	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 30	2017	8								770	10.3389/fimmu.2017.00770	http://dx.doi.org/10.3389/fimmu.2017.00770			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EZ3BR	28713388	gold, Green Published			2022-12-18	WOS:000404585300004
J	Barghouthi, SA				Barghouthi, Sameer A.			The Epimmunity Theory: The Single Cell Defenses against Infectious and Genetic Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						erythrocytes; CD71 receptor; malaria; enucleation; cancer; extravasation; metastasis; reticulocyte	FACULTATIVE INTRACELLULAR PATHOGEN; ERYTHROCYTE-P-ANTIGEN; RED-BLOOD-CELLS; NEWCASTLE-DISEASE; CHICKEN ERYTHROCYTES; CRYPTOCOCCUS-NEOFORMANS; HEMOLYTIC INTERACTION; BARTONELLA-HENSELAE; OXYGEN-TRANSPORT; VIRUS-INFECTION	Single cell defense against diseases defines "epimmunity." Epimmunity is complementary to the immune system and can neither be substituted by innate nor by acquired immunity. Epimmunity, the proposed new branch of immunity, is further explored and analyzed for enucleated mature mammalian erythrocytes and nucleated erythrocytes of non-mammalian vertebrates leading to the development of "The Epimmunity Theory." Enucleation of mammalian erythroblast and inactivation of nuclei in erythrocytes of non-mammalian vertebrates are major contributors to the collective immunity: epimmunity, innate, and acquired. The fact that diseases of mature erythrocytes (MEs) are rare supports the notion that a single cell can resist microbial and genetic diseases; MEs are refractory to malaria and cancer. Nucleated cells, such as B-cells, T-cells, hepatocytes, and cell developmental stages are susceptible to genetic and specific microbial diseases depending on their nuclear activities and the receptors they express; such cells show lower epimmunity relative to MEs. Epimmunity is important as a disease insulator that prevents the spread of diseases from an infected tissue to the majority of other tissues. Breakdown of epimmunity may lead to disease development.	[Barghouthi, Sameer A.] Al Quds Univ, Fac Hlth Profess, Dept Med Lab Sci, Jerusalem, Palestine		Barghouthi, SA (corresponding author), Al Quds Univ, Fac Hlth Profess, Dept Med Lab Sci, Jerusalem, Palestine.	bargsam@yahoo.com	Barghouthi, Sameer A./AAC-6765-2019	Barghouthi, Sameer/0000-0002-0255-3712				Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; BASARAB JA, 1982, CAN J ANIM SCI, V62, P751, DOI 10.4141/cjas82-092; Baumann R, 2003, AM J PHYSIOL-REG I, V284, pR771, DOI 10.1152/ajpregu.00461.2002; BERNSTEI.MT, 1971, APPL MICROBIOL, V21, P84, DOI 10.1128/AEM.21.1.84-89.1971; BRADLEY MO, 1973, J CELL SCI, V12, P327; BRATT MA, 1972, APPL MICROBIOL, V23, P454, DOI 10.1128/AEM.23.3.454-460.1972; Brown C, 1999, VET PATHOL, V36, P125, DOI 10.1354/vp.36-2-125; BROWN KE, 1994, NEW ENGL J MED, V330, P1192, DOI 10.1056/NEJM199404283301704; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BULLIMAN BT, 1988, J THEOR BIOL, V134, P113, DOI 10.1016/S0022-5193(88)80306-0; Cabrales P, 2007, AM J PHYSIOL-HEART C, V293, pH1206, DOI 10.1152/ajpheart.00109.2007; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; Chen AY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002088; Ciuffetti G, 2005, EUR J CLIN INVEST, V35, P93, DOI 10.1111/j.1365-2362.2005.01437.x; CLAVELL LA, 1972, APPL MICROBIOL, V23, P461, DOI 10.1128/AEM.23.3.461-470.1972; Concha II, 1997, BLOOD, V89, P4190, DOI 10.1182/blood.V89.11.4190; COOK RF, 1979, INFECT IMMUN, V25, P396, DOI 10.1128/IAI.25.1.396-402.1979; Crandall M., 1991, J ADV MED, V4, P21; Erslev AJ, 1996, BLOOD REV, V10, P20, DOI 10.1016/S0268-960X(96)90017-X; Eze C. P., 2014, International Journal of Poultry Science, V13, P52; Feldmesser M, 2000, INFECT IMMUN, V68, P4225, DOI 10.1128/IAI.68.7.4225-4237.2000; GABUZDA TG, 1963, J CLIN INVEST, V42, P1678, DOI 10.1172/JCI104854; Gallagher PG, 2005, BLOOD CELL MOL DIS, V35, P345, DOI 10.1016/j.bcmd.2005.08.008; Garcia-Hermoso D, 1999, J CLIN MICROBIOL, V37, P3204, DOI 10.1128/JCM.37.10.3204-3209.1999; GASARYAN KG, 1982, INT REV CYTOL, V74, P95, DOI 10.1016/S0074-7696(08)61170-5; Gifford SC, 2006, BRIT J HAEMATOL, V135, P395, DOI 10.1111/j.1365-2141.2006.06279.x; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grove J, 2011, J CELL BIOL, V195, P1071, DOI 10.1083/jcb.201108131; HARRIS H, 1967, J CELL SCI, V2, P23; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Hopkins Jhons, 2016, VITAL SIGNS BODY TEM; INOUE J, 1985, EXP CELL RES, V158, P29, DOI 10.1016/0014-4827(85)90428-8; Jain T., 2015, INT RES J PURE APPL, V1, P21; Jelkmann W, 2011, J PHYSIOL-LONDON, V589, P1251, DOI 10.1113/jphysiol.2010.195057; Ji P, 2011, TRENDS CELL BIOL, V21, P409, DOI 10.1016/j.tcb.2011.04.003; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kabanova S, 2009, INT J MED SCI, V6, P156; Keerthivasan G, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/139851; Khoory J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0141206; Kim J., 2015, J CELL BIOTECHNOL, V1, P63, DOI [10.3233/JCB-15007, DOI 10.3233/JCB-15007]; Kocan KM, 2004, PARASITOLOGY, V129, pS285, DOI 10.1017/S0031182003004700; Kumar AA, 2015, AM J HEMATOL, V90, P31, DOI 10.1002/ajh.23860; Lam KM, 2003, AVIAN DIS, V47, P197, DOI 10.1637/0005-2086(2003)047[0197:NDVIDT]2.0.CO;2; Lelliott PM, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-100; LINDER S, 1981, P NATL ACAD SCI-BIOL, V78, P6286, DOI 10.1073/pnas.78.10.6286; Louisirirotchanakul S, 2007, J CLIN MICROBIOL, V45, P2284, DOI 10.1128/JCM.00921-07; Malleret B, 2015, BLOOD, V125, P1314, DOI 10.1182/blood-2014-08-596015; Mandle T, 2005, BLOOD, V106, P1215, DOI 10.1182/blood-2004-12-4670; MANGUM CP, 1985, AM J PHYSIOL, V248, pR505, DOI 10.1152/ajpregu.1985.248.5.R505; Martin-Jaular L, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-434; Means RT, 2016, BLOOD, V128, P2504, DOI 10.1182/blood-2016-05-717140; Mehock JR, 1998, INFECT IMMUN, V66, P3462, DOI 10.1128/IAI.66.7.3462-3466.1998; Minnick MF, 1996, TRENDS MICROBIOL, V4, P343, DOI 10.1016/0966-842X(96)10055-X; Mishra S, 2000, TROP ANIM HEALTH PRO, V32, P277, DOI 10.1023/A:1005260806046; Moraes PSA, 1998, ANN ALLERG ASTHMA IM, V81, P165, DOI 10.1016/S1081-1206(10)62804-9; Morera D, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-89; MORGAN HR, 1948, J EXP MED, V88, P503, DOI 10.1084/jem.88.5.503; Moyes CD, 2002, BBA-MOL CELL RES, V1591, P11, DOI 10.1016/S0167-4889(02)00224-0; MURAKAMI T, 1991, J VIROL METHODS, V32, P49; Muroya T, 2014, CRIT CARE MED, V42, pE364, DOI 10.1097/CCM.0000000000000231; MUTANDA LN, 1972, APPL MICROBIOL, V24, P939, DOI 10.1128/AEM.24.6.939-942.1972; Naissant B, 2016, BLOOD, V127, pE42, DOI 10.1182/blood-2016-01-690776; NELSON RA, 1953, SCIENCE, V118, P733, DOI 10.1126/science.118.3077.733; PETERSON PK, 1986, AM J KIDNEY DIS, V7, P146, DOI 10.1016/S0272-6386(86)80136-6; Pietras EM, 2011, J CELL BIOL, V195, P709, DOI 10.1083/jcb.201102131; RENTIER B, 1978, J VIROL, V28, P567, DOI 10.1128/JVI.28.2.567-577.1978; RINGERTZ NR, 1969, EXP CELL RES, V55, P205, DOI 10.1016/0014-4827(69)90482-0; Roy B, 2013, CURR GENOMICS, V14, P182, DOI 10.2174/1389202911314030004; Salama A, 2009, EXPERT OPIN DRUG SAF, V8, P73, DOI [10.1517/14740330802577351 , 10.1517/14740330802577351, 10.1182/asheducation-2009.1.73]; Seider K, 2011, J IMMUNOL, V187, P3072, DOI 10.4049/jimmunol.1003730; Silva MT, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00071; SMITH JE, 1987, VET PATHOL, V24, P471, DOI 10.1177/030098588702400601; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; Sosale NG, 2015, BLOOD, V125, P542, DOI 10.1182/blood-2014-06-585299; SPEERT DP, 1992, J CLIN INVEST, V90, P1085, DOI 10.1172/JCI115924; SPRINGER EL, 1974, J VIROL, V14, P1623, DOI 10.1128/JVI.14.6.1623-1626.1974; St Paul M, 2013, RES VET SCI, V95, P87, DOI 10.1016/j.rvsc.2013.01.024; Stier A, 2013, FRONT ZOOL, V10, DOI 10.1186/1742-9994-10-33; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Suthar MS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003168; Swanson K, 2010, VIROLOGY, V402, P372, DOI 10.1016/j.virol.2010.03.050; TAMM I, 1952, BIOL BULL, V102, P149, DOI 10.2307/1538703; Tanaka GD, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-4; Tefferi A, 2015, AM J HEMATOL, V90, P163, DOI 10.1002/ajh.23895; Terwilliger NB, 1998, J EXP BIOL, V201, P1085; Thom CS, 2014, DEV CELL, V30, P688, DOI 10.1016/j.devcel.2014.07.021; Udroiu I., 2014, ESTIMATION ERYTHROCY; van Holde KE, 2001, J BIOL CHEM, V276, P15563, DOI 10.1074/jbc.R100010200; Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0; Wassell J, 2000, Clin Lab, V46, P547; Wawrowski A, 2012, INSECT BIOCHEM MOLEC, V42, P603, DOI 10.1016/j.ibmb.2012.04.007; Weigel-Kelley KA, 2001, J VIROL, V75, P4110, DOI 10.1128/JVI.75.9.4110-4116.2001; WIERSMA PA, 1985, ARCH BIOCHEM BIOPHYS, V242, P90, DOI 10.1016/0003-9861(85)90483-7; Wynn JL, 2015, J IMMUNOL, V195, P1064, DOI 10.4049/jimmunol.1500771; Yamamoto D, 2006, BRAZ J MED BIOL RES, V39, P749, DOI 10.1590/S0100-879X2006000600007; YANG S-C, 1989, Taiwan yixuehui zazhi, V88, P1128; Zhu HJ, 2013, ANAL BIOANAL CHEM, V405, P4989, DOI 10.1007/s00216-013-6832-2	98	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 13	2017	8								694	10.3389/fimmu.2017.00694	http://dx.doi.org/10.3389/fimmu.2017.00694			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EX3EF	28659926	Green Published, gold			2022-12-18	WOS:000403114100001
J	Garcia-Valtanen, P; Martinez-Lopez, A; Lopez-Munoz, A; Bello-Perez, M; Medina-Gali, RM; Ortega-Villaizan, MD; Varela, M; Figueras, A; Mulero, V; Novoa, B; Estepa, A; Coll, J				Garcia-Valtanen, Pablo; Martinez-Lopez, Alicia; Lopez-Munoz, Azucena; Bello-Perez, Melissa; Medina-Gali, Regla M.; del Mar Ortega-Villaizan, Maria; Varela, Monica; Figueras, Antonio; Mulero, Victoriano; Novoa, Beatriz; Estepa, Amparo; Coll, Julio			Zebra Fish Lacking Adaptive immunity Acquire an Antiviral Alert State Characterized by Upregulated Gene expression of Apoptosis, Multigene Families, and interferon-related Genes (vol 8, pg 121, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						zebra fish rag1(-/-) adaptive deficient mutants; spring viremia carp viral infections; multigene families and apoptosis in resistance to viral infections; trained immunity NK/macrophages in fish; antiviral alert state			[Garcia-Valtanen, Pablo; Martinez-Lopez, Alicia; Bello-Perez, Melissa; Medina-Gali, Regla M.; del Mar Ortega-Villaizan, Maria; Estepa, Amparo] Univ Miguel Hernandez de Elche UMH, Dept Bioquim, Alicante, Spain; [Lopez-Munoz, Azucena; Mulero, Victoriano] Univ Murcia, IMIB Arrixaca, Fac Biol, Dept Biol Celular & Histol, Murcia, Spain; [Varela, Monica; Figueras, Antonio; Novoa, Beatriz] CSIC, IIM, Vigo, Spain; [Coll, Julio] Inst Nacl Invest & Tecnol Agr & Alimentaria INIA, Madrid, Spain	Hospital Clinico Universitario Virgen de la Arrixaca; University of Murcia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Marinas (IIM); Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Coll, J (corresponding author), Inst Nacl Invest & Tecnol Agr & Alimentaria INIA, Madrid, Spain.	juliocoll@inia.es	Figueras, Antonio/AAB-8921-2019; Coll, julio/M-6071-2019; Novoa, Beatriz/K-3785-2014; Del Mar Ortega-villaizan Romo, Maria/Q-9233-2018; Coll, Julio M/G-4533-2010; Gali, Regla María M Medina/D-6958-2018; Garcia Valtanen, Pablo/U-2921-2018	Figueras, Antonio/0000-0002-0617-0030; Coll, julio/0000-0001-8496-3493; Del Mar Ortega-villaizan Romo, Maria/0000-0003-2065-0601; Coll, Julio M/0000-0001-8496-3493; Gali, Regla María M Medina/0000-0001-9401-8292; Garcia Valtanen, Pablo/0000-0003-4382-6446; Novoa, Beatriz/0000-0003-4888-8419; Martinez Lopez, Alicia/0000-0003-3347-0394				Garcia-Valtanen P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00121	1	0	0	2	18	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 13	2017	8								668	10.3389/fimmu.2017.00668	http://dx.doi.org/10.3389/fimmu.2017.00668			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EX3DX	28616013	gold, Green Published			2022-12-18	WOS:000403113300001
J	Raimondi, G; Wood, KJ; Perelson, AS; Arciero, JC				Raimondi, Giorgio; Wood, Kathryn J.; Perelson, Alan S.; Arciero, Julia C.			Transplant Rejection and Tolerance-Advancing the Field through Integration of Computational and Experimental Investigation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						transplant rejection; transplant tolerance; theoretical modeling; big data and bioinformatics; mechanistic models; transplant immunology; biomarkers; systems biology			[Raimondi, Giorgio] Johns Hopkins Sch Med, Dept Plast & Reconstruct Surg, Vascularized & Composite Allotransplantat Lab, Baltimore, MD USA; [Wood, Kathryn J.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford, England; [Perelson, Alan S.] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM USA; [Arciero, Julia C.] Indiana Univ Purdue Univ, Dept Math Sci, Indianapolis, IN 46202 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Oxford; United States Department of Energy (DOE); Los Alamos National Laboratory; Indiana University System; Indiana University-Purdue University Indianapolis	Raimondi, G (corresponding author), Johns Hopkins Sch Med, Dept Plast & Reconstruct Surg, Vascularized & Composite Allotransplantat Lab, Baltimore, MD USA.; Arciero, JC (corresponding author), Indiana Univ Purdue Univ, Dept Math Sci, Indianapolis, IN 46202 USA.	g.raimondi@jhmi.edu; jarciero@iupui.edu	Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	National Institutes of Health [UL1TR000005, R21HL127355]; Burroughs Wellcome Fund BWF Collaborative Research; IUPUI School of Science Institute for Mathematical Modeling and Computational Science; NIH [R01-OD011095, R01-AI028433]; European Commission	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund BWF Collaborative Research(Burroughs Wellcome Fund); IUPUI School of Science Institute for Mathematical Modeling and Computational Science; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by a National Institutes of Health grant number UL1TR000005 in the form of a CTSI-PEIR and grant number R21HL127355 (to GR), Burroughs Wellcome Fund BWF Collaborative Research Travel Grant and the IUPUI School of Science Institute for Mathematical Modeling and Computational Science Grant to Enhance Interdisciplinary Research and Education (iM2CS-GEIRE) award (to JA), NIH grants R01-OD011095 and R01-AI028433 (to AP), and grant from the European Commission for the ONE Study and BioDRIM FP7 Consortia (to KW).	Germain RN, 2011, ANNU REV IMMUNOL, V29, P527, DOI 10.1146/annurev-immunol-030409-101317; Vodovotz Y, 2017, TRENDS IMMUNOL, V38, P116, DOI 10.1016/j.it.2016.11.006	2	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2017	8								616	10.3389/fimmu.2017.00616	http://dx.doi.org/10.3389/fimmu.2017.00616			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EW2ON	28611776	Green Submitted, Green Published, gold			2022-12-18	WOS:000402336000001
J	Bonavita, O; Poeta, VM; Setten, E; Massara, M; Bonecchi, R				Bonavita, Ornella; Poeta, Valeria Mollica; Setten, Elisa; Massara, Matteo; Bonecchi, Raffaella			ACKr2: An Atypical Chemokine Receptor Regulating Lymphatic Biology (vol 7, 691, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Bonavita, Ornella; Poeta, Valeria Mollica; Setten, Elisa; Massara, Matteo; Bonecchi, Raffaella] Humanitas Clin & Res Ctr, Rozzano, Italy; [Bonavita, Ornella; Setten, Elisa; Massara, Matteo] Univ Milan, Dept Med Biotechnol & Translat Med, Rozzano, Italy; [Poeta, Valeria Mollica; Bonecchi, Raffaella] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy	IRCCS Humanitas Research Hospital; University of Milan; Humanitas University; IRCCS Humanitas Research Hospital	Bonecchi, R (corresponding author), Humanitas Clin & Res Ctr, Rozzano, Italy.; Bonecchi, R (corresponding author), Humanitas Univ, Dept Biomed Sci, Rozzano, Italy.	raffaella.bonecchi@humanitasresearch.it	Bonecchi, Raffaella/ABI-2390-2020; Massara, Matteo/P-5023-2018	Massara, Matteo/0000-0001-6724-5633; Mollica Poeta, Valeria/0000-0002-7364-6297; Bonecchi, Raffaella/0000-0003-3346-5333				Bonavita O, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00691	1	0	1	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2017	8								520	10.3389/fimmu.2017.00520	http://dx.doi.org/10.3389/fimmu.2017.00520			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EU3RG	28496448	Green Published, gold			2022-12-18	WOS:000400948100001
J	Nissapatorn, V; Lau, YL; Yazar, S; Pelloux, H				Nissapatorn, Veeranoot; Lau, Yee-Ling; Yazar, Suleyman; Pelloux, Herve			Parasites in the tropic-A New Paradigm Shift	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Nissapatorn, Veeranoot; Lau, Yee-Ling] Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia; [Yazar, Suleyman] Erciyes Univ, Med Fac, Dept Med Parasitol, Kayseri, Turkey; [Pelloux, Herve] CHU Grenoble Alpes, Inst Biol & Pathol, Dept Agents Infect, PU PH Parasitol Mycol, Grenoble, France	Universiti Malaya; Erciyes University; CHU Grenoble Alpes	Nissapatorn, V (corresponding author), Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia.	nissapat@gmail.com	Lau, Yee Ling/C-6996-2009; Pelloux, Hervé/M-7132-2014	Lau, Yee Ling/0000-0002-2037-2165; Pelloux, Hervé/0000-0001-5727-5441					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 1	2017	8								509	10.3389/fimmu.2017.00509	http://dx.doi.org/10.3389/fimmu.2017.00509			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ET5IU	28507550	Green Published, gold			2022-12-18	WOS:000400318200001
J	Svegliati, S; Amico, D; Spadoni, T; Fischetti, C; Finke, D; Moroncini, G; Paolini, C; Tonnini, C; Grieco, A; Rovinelli, M; Funaro, A; Gabrielli, A				Svegliati, Silvia; Amico, Donatella; Spadoni, Tatiana; Fischetti, Colomba; Finke, Doreen; Moroncini, Gianluca; Paolini, Chiara; Tonnini, Cecilia; Grieco, Antonella; Rovinelli, Marina; Funaro, Ada; Gabrielli, Armando			Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro( vol 8, 75, 2017)	FRONTIERS IN IMMUNOLOGY			English	Correction						systemic sclerosis; autoantibodies; vascular smooth muscle cells; platelet-derived growth factor; synthetic phenotype			[Svegliati, Silvia; Amico, Donatella; Spadoni, Tatiana; Fischetti, Colomba; Finke, Doreen; Moroncini, Gianluca; Paolini, Chiara; Tonnini, Cecilia; Grieco, Antonella; Rovinelli, Marina; Gabrielli, Armando] Univ Politecn Marche, Clin Med, Dipartimento Sci Clin & Mol, Ancona, Italy; [Funaro, Ada] Univ Turin, Dipartimento Sci Med, Turin, Italy	Marche Polytechnic University; University of Turin	Gabrielli, A (corresponding author), Univ Politecn Marche, Clin Med, Dipartimento Sci Clin & Mol, Ancona, Italy.	a.gabrielli@univpm.it	Funaro, Ada/AAC-3203-2019; Gabrielli, Armando/AAC-3173-2019; SVEGLIATI BARONI, SILVIA/L-2614-2016; MORONCINI, Gianluca/K-6021-2016	SVEGLIATI BARONI, SILVIA/0000-0001-6863-2600; PAOLINI, Chiara/0000-0001-6364-7408; MORONCINI, Gianluca/0000-0002-0380-0105; Funaro, Ada/0000-0001-6341-1817				Svegliati S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00075	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2017	8								381	10.3389/fimmu.2017.00381	http://dx.doi.org/10.3389/fimmu.2017.00381			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ER7GZ	28405195	Green Published, gold			2022-12-18	WOS:000398979900001
J	Wong-Baeza, C; Resendiz-Mora, A; Donis-Maturano, L; Wong-Baeza, I; Zarate-Neira, L; Yam-Puc, JC; Calderon-Amador, J; Medina, Y; Wong, C; Baeza, I; Flores-Romo, L				Wong-Baeza, Carlos; Resendiz-Mora, Albany; Donis-Maturano, Luis; Wong-Baeza, Isabel; Zarate-Neira, Luz; Carlos Yam-Puc, Juan; Calderon-Amador, Juana; Medina, Yolanda; Wong, Carlos; Baeza, Isabel; Flores-Romo, Leopoldo			Anti-Lipid IgG Antibodies Are Produced via Germinal Centers in a Murine Model Resembling Human Lupus (vol 7, 396, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction						non-bilayer phospholipid arrangements; systemic lupus erythematosus; anti-lipid IgG antibodies; antigen-specific cells; autoimmune disease			[Wong-Baeza, Carlos; Donis-Maturano, Luis; Carlos Yam-Puc, Juan; Calderon-Amador, Juana; Flores-Romo, Leopoldo] IPN, CINVESTAV, Ctr Res & Adv Studies, Dept Cell Biol, Mexico City, DF, Mexico; [Wong-Baeza, Carlos; Resendiz-Mora, Albany; Zarate-Neira, Luz; Wong, Carlos; Baeza, Isabel] IPN, ENCB, Lab Biomembranas, Dept Bioquim, Mexico City, DF, Mexico; [Wong-Baeza, Isabel] IPN, ENCB, Lab Inmunol Mol 2, Dept Inmunol, Mexico City, DF, Mexico; [Medina, Yolanda] Inst Epidemiol Diag & Reference, Lab Monoclonal Antibodies, Mexico City, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico	Wong-Baeza, C; Flores-Romo, L (corresponding author), IPN, CINVESTAV, Ctr Res & Adv Studies, Dept Cell Biol, Mexico City, DF, Mexico.; Wong-Baeza, C (corresponding author), IPN, ENCB, Lab Biomembranas, Dept Bioquim, Mexico City, DF, Mexico.	charlywong@icloud.com; lefloresromo@gmail.com	Wong-Baeza, Isabel/A-3947-2013; Yam-Puc, Juan C/K-5122-2015; Yam-Puc, Juan C/CAF-4325-2022	Wong-Baeza, Isabel/0000-0002-2516-0081; Yam-Puc, Juan C/0000-0003-4395-8844; Yam-Puc, Juan C/0000-0003-4395-8844; Donis Maturano, Luis/0000-0001-8430-5669				Wong-Baeza C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00396	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 12	2017	8								440	10.3389/fimmu.2017.00440	http://dx.doi.org/10.3389/fimmu.2017.00440			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	ER7HD	28405196	gold, Green Published			2022-12-18	WOS:000398980400001
J	Pira, GL; Di Cecca, S; Biagini, S; Girolami, E; Cicchetti, E; Bertaina, V; Quintarelli, C; Caruana, I; Lucarelli, B; Merli, P; Pagliara, D; Brescia, LP; Bertaina, A; Montanari, M; Locatelli, F				Pira, Giuseppina Li; Di Cecca, Stefano; Biagini, Simone; Girolami, Elia; Cicchetti, Elisabetta; Bertaina, Valentina; Quintarelli, Concetta; Caruana, Ignazio; Lucarelli, Barbarella; Merli, Pietro; Pagliara, Daria; Brescia, Letizia Pomponia; Bertaina, Alice; Montanari, Mauro; Locatelli, Franco			Preservation of antigen-specific Functions of alpha beta T cells and B cells removed from hematopoietic stem cell Transplants suggests Their Use as an alternative cell source for advanced Manipulation and adoptiveimmunotherapy Immunotheraphy	FRONTIERS IN IMMUNOLOGY			English	Article						HLA-haploidentical transplantation; graft manipulation; alpha beta T cells; alloreactivity; antigen-induced activation; B-cell presentation	CHRONIC MYELOGENOUS LEUKEMIA; DONOR LYMPHOCYTE INFUSION; BARR-VIRUS EBV; ADOPTIVE TRANSFER; SELECTIVE DEPLETION; IMMUNE-RESPONSES; HEALTHY DONORS; THERAPY; RECIPIENTS; PRODUCTS	Hematopoietic stem cell transplantation is standard therapy for numerous hematological diseases. The use of haploidentical donors, sharing half of the HLA alleles with the recipient, has facilitated the use of this procedure as patients can rely on availability of a haploidentical donor within their family. Since HLA disparity increases the risk of graft-versus-host disease, T-cell depletion has been used to remove alloreactive lymphocytes from the graft. Selective removal of alpha beta T cells, which encompass the alloreactive repertoire, combined with removal of B cells to prevent EBV-related lymphoproliferative disease, proved safe and effective in clinical studies. Depleted alpha beta T cells and B cells are generally discarded as by-products. Considering the possible use of donor T cells for donor lymphocyte infusions or for generation of pathogen- specific T cells as mediators of graft-versus-infection effect, we tested whether cells in the discarded fractions were functionally intact. Response to alloantigens and to viral antigens comparable to that of unmanipulated cells indicated a functional integrity of alpha beta T cells, in spite of the manipulation used for their depletion. Furthermore, B cells proved to be efficient antigen-presenting cells, indicating that antigen uptake, processing, and presentation were fully preserved. Therefore, we propose that separated alpha beta T lymphocytes could be employed for obtaining pathogen- specific T cells, applying available methods for positive selection, which eventually leads to indirect allodepletion. In addition, these functional T cells could undergo additional manipulation, such as direct allodepletion or genetic modification.	[Pira, Giuseppina Li; Di Cecca, Stefano; Biagini, Simone; Girolami, Elia; Cicchetti, Elisabetta; Bertaina, Valentina; Quintarelli, Concetta; Caruana, Ignazio; Lucarelli, Barbarella; Merli, Pietro; Pagliara, Daria; Brescia, Letizia Pomponia; Bertaina, Alice; Montanari, Mauro; Locatelli, Franco] IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol & Oncol, Rome, Italy; [Quintarelli, Concetta] Univ Naples Federico II, Dept Med Clin & Chirurg, Naples, Italy; [Locatelli, Franco] Univ Pavia, Dept Pediat, Pavia, Italy	IRCCS Bambino Gesu; University of Naples Federico II; University of Pavia	Pira, GL (corresponding author), IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol & Oncol, Rome, Italy.	giuseppina.lipira@opbg.net	Biagini, Simone/AAR-9149-2021; Lucarelli, Barbarella/AAB-5245-2020; Merli, Pietro/K-3132-2018; Caruana, Ignazio/AAW-7904-2020; di cecca, stefano/AAE-4175-2022; cicchetti, elisabetta/AAD-7238-2022; Bertaina, Valentina/AAH-9522-2019; Girolami, Elia/AAR-9162-2021; Quintarelli, Concetta/K-6056-2016; Pira, Giuseppina Li/F-7105-2012	Merli, Pietro/0000-0001-6426-4046; Caruana, Ignazio/0000-0002-9250-0605; Quintarelli, Concetta/0000-0002-4343-9705; Pira, Giuseppina Li/0000-0002-6293-4314; di cecca, stefano/0000-0003-2595-9261	AIRC (Associazione Italiana Ricerca sul Cancro, progetto 5xmille); IRCCS Bambino Ges Children's Hospital [201602P003745]; Bambino Gesu Children's Hospital [201602T003704]; AIRC [MFAG 15925]	AIRC (Associazione Italiana Ricerca sul Cancro, progetto 5xmille)(Fondazione AIRC per la ricerca sul cancro); IRCCS Bambino Ges Children's Hospital; Bambino Gesu Children's Hospital; AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was partially supported by grants from AIRC (Associazione Italiana Ricerca sul Cancro, progetto 5xmille) and IRCCS Bambino Ges Children's Hospital to FL (# 201602P003745), by a grant from Bambino Gesu Children's Hospital to GLP (# 201602T003704), and by a grant from AIRC (MFAG 15925) to AB.	Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Alyea E, 2001, BLOOD, V98, P934, DOI 10.1182/blood.V98.4.934; Anasetti C., 1999, HEMATOPOIETIC CELL T, P904; Appelbaum FR, 2003, ANNU REV MED, V54, P491, DOI 10.1146/annurev.med.54.101601.152456; Arpinati M, 2000, BLOOD, V95, P2484, DOI 10.1182/blood.V95.8.2484; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; Barrett AJ, 1997, STEM CELLS, V15, P248, DOI 10.1002/stem.150248; Beloki L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0515-z; Beloki L, 2014, CYTOTHERAPY, V16, P1390, DOI 10.1016/j.jcyt.2014.05.009; Bernardo ME, 2016, EBMT; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; Bleakley M, 2015, J CLIN INVEST, V125, P2677, DOI 10.1172/JCI81229; Bleakley M, 2014, BIOL BLOOD MARROW TR, V20, P705, DOI 10.1016/j.bbmt.2014.01.032; Bloor AJC, 2008, BIOL BLOOD MARROW TR, V14, P50, DOI 10.1016/j.bbmt.2007.04.013; Bollard CM, 2016, BLOOD, V127, P3331, DOI 10.1182/blood-2016-01-628982; Bollard CM, 2014, J CLIN ONCOL, V32, P798, DOI 10.1200/JCO.2013.51.5304; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Bunse CE, 2016, CLIN EXP IMMUNOL, V185, P107, DOI 10.1111/cei.12794; Bunse CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077925; Capolunghi F, 2008, J IMMUNOL, V180, P800, DOI 10.4049/jimmunol.180.2.800; Chaleff S, 2007, CYTOTHERAPY, V9, P746, DOI 10.1080/14653240701644000; Ciurea SO, 2015, BLOOD REV, V29, P63, DOI 10.1016/j.blre.2014.09.009; Clancy LE, 2013, BIOL BLOOD MARROW TR, V19, P725, DOI 10.1016/j.bbmt.2013.01.021; Cobbold M, 2005, J EXP MED, V202, P379, DOI 10.1084/jem.20040613; Comoli P, 2002, BLOOD, V99, P2592, DOI 10.1182/blood.V99.7.2592; Di Stasi A, 2011, NEW ENGL J MED, V365, P1673, DOI 10.1056/NEJMoa1106152; Feuchtinger T, 2006, BRIT J HAEMATOL, V134, P64, DOI 10.1111/j.1365-2141.2006.06108.x; Feuchtinger T, 2004, EXP HEMATOL, V32, P282, DOI 10.1016/j.exphem.2003.12.009; Gill S, 2015, IMMUNOL REV, V263, P68, DOI 10.1111/imr.12243; GOLDMAN JM, 1993, BLOOD, V82, P2235; Graef P, 2014, IMMUNITY, V41, P116, DOI 10.1016/j.immuni.2014.05.018; Gratama JW, 2001, BLOOD, V98, P1358, DOI 10.1182/blood.V98.5.1358; HALE G, 1988, TRANSPLANTATION, V45, P753, DOI 10.1097/00007890-198804000-00018; Handgretinger R, 2012, SEMIN ONCOL, V39, P664, DOI 10.1053/j.seminoncol.2012.09.007; Hartung T, 1999, CLIN PHARMACOL THER, V66, P415, DOI 10.1053/cp.1999.v66.a101210; Heslop HE, 2002, CYTOTHERAPY, V4, P433, DOI 10.1080/146532402320776071; Holtappels R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00232; HOROWITZ MM, 1990, BLOOD, V75, P555; Kelderman S, 2016, EUR J IMMUNOL, V46, P1351, DOI 10.1002/eji.201545849; Kern F, 2005, TRENDS IMMUNOL, V26, P477, DOI 10.1016/j.it.2005.07.005; KITABAYASHI A, 1995, BLOOD, V86, P2220, DOI 10.1182/blood.V86.6.2220.bloodjournal8662220; Knabel M, 2002, NAT MED, V8, P631, DOI 10.1038/nm0602-631; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475; Levine BL, 2013, NATURE, V498, pS17, DOI 10.1038/498S17a; Li Pira G, 2016, BIOL BLOOD MARROW TR, V22, P2056, DOI 10.1016/j.bbmt.2016.08.006; Li Pira G, 2016, BLOOD REV, V30, P297, DOI 10.1016/j.blre.2016.03.001; Mackinnon S, 2008, BLOOD CELL MOL DIS, V40, P63, DOI 10.1016/j.bcmd.2007.07.003; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Marktel S, 2003, BLOOD, V101, P1290, DOI 10.1182/blood-2002-08-2351; MARTIN PJ, 1988, BONE MARROW TRANSPL, V3, P445; Maschan M, 2016, BONE MARROW TRANSPL, V51, P668, DOI 10.1038/bmt.2015.343; Montoro J, 2016, EBMT; Moosmann A, 2010, BLOOD, V115, P2960, DOI 10.1182/blood-2009-08-236356; Naik S, 2016, J ALLERGY CLIN IMMUN, V137, P1498, DOI 10.1016/j.jaci.2015.12.1311; Nauerth M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005958; Odendahl M, 2014, CYTOTHERAPY, V16, P1245, DOI 10.1016/j.jcyt.2014.05.023; Or-Geva N, 2016, BRIT J HAEMATOL, V172, P667, DOI 10.1111/bjh.13868; Pahl-Seibert MF, 2005, J VIROL, V79, P5400, DOI 10.1128/JVI.79.9.5400-5413.2005; Pan LP, 1999, BLOOD, V93, P4071, DOI 10.1182/blood.V93.12.4071.412k41_4071_4078; PATTERSON J, 1986, BRIT J HAEMATOL, V63, P221; Peggs KS, 2011, CLIN INFECT DIS, V52, P49, DOI 10.1093/cid/ciq042; Pira GL, 2009, CURR OPIN IMMUNOL, V21, P549, DOI 10.1016/j.coi.2009.08.006; Ramirez N, 2013, BONE MARROW TRANSPL, V48, P1265, DOI 10.1038/bmt.2012.262; Rauser G, 2004, BLOOD, V103, P3565, DOI 10.1182/blood-2003-09-3056; REISNER Y, 1981, LANCET, V2, P327; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Roskrow MA, 1998, BLOOD, V91, P2925, DOI 10.1182/blood.V91.8.2925.2925_2925_2934; Rutella S, 1997, BONE MARROW TRANSPL, V20, P355, DOI 10.1038/sj.bmt.1700899; Rutella S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0240-z; Saglio F, 2014, CYTOTHERAPY, V16, P149, DOI 10.1016/j.jcyt.2013.11.010; Samuel ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085911; Samuel ER, 2013, BRIT J HAEMATOL, V160, P87, DOI 10.1111/bjh.12082; Schober K, 2016, EUR J IMMUNOL, V46, P1335, DOI 10.1002/eji.201646436; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Schumm M, 2013, CYTOTHERAPY, V15, P1253, DOI 10.1016/j.jcyt.2013.05.014; Sica S, 1996, J Hematother, V5, P391, DOI 10.1089/scd.1.1996.5.391; Simula MP, 2007, LEUKEMIA, V21, P943, DOI 10.1038/sj.leu.2404641; Sloand EM, 2000, BLOOD, V95, P2269, DOI 10.1182/blood.V95.7.2269.007k37_2269_2274; Stemberger C, 2014, BLOOD, V124, P628, DOI 10.1182/blood-2013-12-547349; Tayebi H, 2001, EXP HEMATOL, V29, P458, DOI 10.1016/S0301-472X(01)00613-0; Teschner D, 2014, BONE MARROW TRANSPL, V49, P138, DOI 10.1038/bmt.2013.114; Tischer S, 2012, INT IMMUNOL, V24, P561, DOI 10.1093/intimm/dxs059; Truitt R L, 1995, Biol Blood Marrow Transplant, V1, P61; Tzannou I, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.2; Uhlin M, 2012, CLIN INFECT DIS, V55, P1064, DOI 10.1093/cid/cis625; van Esser JWJ, 2001, BLOOD, V98, P972, DOI 10.1182/blood.V98.4.972; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384; Zand MS, 2005, AM J TRANSPLANT, V5, P76, DOI 10.1111/j.1600-6143.2003.00637.x	90	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 23	2017	8								332	10.3389/fimmu.2017.00332	http://dx.doi.org/10.3389/fimmu.2017.00332			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EP1LI		gold, Green Published			2022-12-18	WOS:000397146000002
J	Xue, D; Desjardins, M; Kaufman, GN; Beland, M; Al-Tamemi, S; Ahmed, E; Tao, S; Friedel, RH; Mourad, W; Mazer, BD				Xue, Di; Desjardins, Marylin; Kaufman, Gabriel N.; Beland, Marianne; Al-Tamemi, Salem; Ahmed, Eisha; Tao, Shao; Friedel, Roland H.; Mourad, Walid; Mazer, Bruce D.			Semaphorin 4C: A Novel Component of B-Cell Polarization in Th2-Driven Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Correction									[Xue, Di; Desjardins, Marylin; Kaufman, Gabriel N.; Beland, Marianne; Ahmed, Eisha; Tao, Shao; Mazer, Bruce D.] McGill Univ, Ctr Hlth, Res Inst, Translat Res Resp Dis, Montreal, PQ, Canada; [Desjardins, Marylin; Al-Tamemi, Salem; Mazer, Bruce D.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada; [Al-Tamemi, Salem] Sultan Qaboos Univ Hosp, Muscat, Oman; [Friedel, Roland H.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Mourad, Walid] Univ Montreal, Dept Med, Montreal, PQ, Canada	McGill University; McGill University; Sultan Qaboos University; Icahn School of Medicine at Mount Sinai; Universite de Montreal	Mazer, BD (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Translat Res Resp Dis, Montreal, PQ, Canada.; Mazer, BD (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada.	bruce.mazer@mcgill.ca	Al-Tamemi, Salem/T-7687-2017	Al-Tamemi, Salem/0000-0002-7232-2629	Natural Sciences and Engineering Research Council (NSERC) [47480]; Canadian Institute for Health Research (CIHR) [MOP142247]; Research Institute of the McGill University Health Center (RI-MUHC); Montreal Chest Institute; Costello Foundation; Strauss Family Foundation; Immunodeficiency Canada; Allergen-NCE Clinician Scientist Award	Natural Sciences and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Research Institute of the McGill University Health Center (RI-MUHC); Montreal Chest Institute; Costello Foundation; Strauss Family Foundation; Immunodeficiency Canada; Allergen-NCE Clinician Scientist Award	The authors acknowledge the financial support of Natural Sciences and Engineering Research Council (NSERC) Grant 47480, the Canadian Institute for Health Research (CIHR) Grant MOP142247, The Research Institute of the McGill University Health Center (RI-MUHC), Montreal Chest Institute, Costello Foundation, the Strauss Family Foundation and we thank the Immunodeficiency Canada for providing grant support for part of the study via the Chaim Roifman Award Program. BM was a Chercheur National of the Fonds de Recherche du Quebec-Sante. MD was the recipient of a Strauss Fellowship from McGill University and the Allergen-NCE Clinician Scientist Award.	Xue D, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00558	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 8	2017	8								213	10.3389/fimmu.2017.00213	http://dx.doi.org/10.3389/fimmu.2017.00213			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EN0GU	28275378	gold, Green Submitted, Green Published			2022-12-18	WOS:000395689100001
J	Kenngott, EE; Pfeil, J; Hoffmann, U; Lauer, U; Kuhl, AA; Rigby, A; Pernthaner, A; Hamann, A				Kenngott, Elisabeth E.; Pfeil, Jennifer; Hoffmann, Ute; Lauer, Uta; Kuehl, Anja A.; Rigby, Anne; Pernthaner, Anton; Hamann, Alf			Facilitated Peptide Transport via the Mucosal Epithelium: Impact on Tolerance Induction	FRONTIERS IN IMMUNOLOGY			English	Article						oral tolerance; peptide vaccination; targeted delivery; mucosa; regulatory T cells; mucosal uptake	DELAYED-TYPE HYPERSENSITIVITY; REGULATORY T-CELLS; ORAL TOLERANCE; DENDRITIC CELLS; SMALL-INTESTINE; RETINOIC-ACID; IN-VIVO; ANTIGEN; DELIVERY; MICE	A hallmark of autoimmunity is the breakdown of tolerance and generation of effector responses against self-antigens. Re-establishment of tolerance in autoimmune disorders was always the most desired treatment option; however, despite many efforts, clinical trials have been largely unsuccessful. This also applies to the generation of oral tolerance, which seems to be a default response type of the mucosa-associated lymphoid tissues to harmless antigens. In this study, we report improved efficacy of oral tolerance induction by coupling antigen with the newly identified mucosal carrier peptide 13C. Antigen coupled to 13C is efficiently taken up in the gastrointestinal tract and could be visualized in cells of the lamina propria. Oral, rectal, or nasal treatment effectively induced the proliferation of antigen-specific T cells with some increase in the frequency of regulatory T cells. In a model of delayed-type hypersensitivity, especially intrarectal tolerization treatment resulted in reduced footpad swelling, demonstrating a moderate tolerogenic effect of mucosal treatment with 13C coupled antigen. Coupling of antigens to a transmucosal carrier, therefore, is a promising tool to improve the efficacy of vaccination via mucosal surfaces.	[Kenngott, Elisabeth E.; Pfeil, Jennifer; Hoffmann, Ute; Lauer, Uta; Hamann, Alf] Deutsch Rheuma Forschungszentrum, Expt Rheumatol, Berlin, Germany; [Kenngott, Elisabeth E.] Charite, Dept Gastroenterol Infectiol & Rheumatol, Rheumatol, Berlin, Germany; [Pfeil, Jennifer; Rigby, Anne; Hamann, Alf] Charite, Expt Rheumatol, Dept Rheumatol & Clin Immunol, Berlin, Germany; [Kuehl, Anja A.] Charite, Res Ctr ImmunoSci, Dept Med, Div Gastroenterol Infectiol & Rheumatol, Berlin, Germany; [Pernthaner, Anton] AgResearch Ltd, Hopkirk Res Inst, Grasslands Res Inst, Palmerston North, New Zealand	Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; AgResearch - New Zealand	Hamann, A (corresponding author), Deutsch Rheuma Forschungszentrum, Expt Rheumatol, Berlin, Germany.; Hamann, A (corresponding author), Charite, Expt Rheumatol, Dept Rheumatol & Clin Immunol, Berlin, Germany.	hamann@drfz.de		Kuhl, Anja/0000-0003-2293-5387	Deutsche Forschungsgemeinschaft [SFB633, SFB650]; AgResearch Ltd; ZIBI graduate school	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); AgResearch Ltd; ZIBI graduate school	This work was supported by the Deutsche Forschungsgemeinschaft (SFB633 and SFB650) and partly funded by AgResearch Ltd. EK was supported by the ZIBI graduate school.	Blumenthal-Barby F, 2008, CELL IMMUNOL, V253, P110, DOI 10.1016/j.cellimm.2008.05.004; Chen YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/pnas.93.1.388; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Faria AMC, 2006, CLIN DEV IMMUNOL, V13, P143, DOI 10.1080/17402520600876804; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; Hanninen A, 2001, DIABETES, V50, P771, DOI 10.2337/diabetes.50.4.771; Issa F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00254; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kenngott EE, 2016, MOL PHARMACEUT, V13, P202, DOI 10.1021/acs.molpharmaceut.5b00635; Knoop KA, 2015, MUCOSAL IMMUNOL, V8, P198, DOI 10.1038/mi.2014.58; LI L, 1994, J IMMUNOL, V153, P3967; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Siewert C, 2008, J IMMUNOL, V180, P146, DOI 10.4049/jimmunol.180.1.146; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x	18	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 6	2017	8								216	10.3389/fimmu.2017.00216	http://dx.doi.org/10.3389/fimmu.2017.00216			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EM8EY	28321216	Green Published, gold			2022-12-18	WOS:000395545400001
J	Cotta-de-Almeida, V; Dupre, L; Savino, W				Cotta-de-Almeida, Vinicius; Dupre, Loic; Savino, Wilson			Editorial: T-Cell Migration in Health and Disease	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; migration; motility; immunity; endothelial cells; antigen-presenting cells			[Cotta-de-Almeida, Vinicius; Savino, Wilson] Fiocruz MS, Inst Oswaldo Cruz, Lab Thymus Res, Rio De Janeiro, Brazil; [Dupre, Loic] INSERM, Ctr Physiopathol Toulouse Purpan, UMR 1043, Toulouse, France; [Dupre, Loic] Univ Toulouse III Paul Sabatier, Toulouse, France; [Dupre, Loic] CNRS, UMR 5282, Toulouse, France	Fundacao Oswaldo Cruz; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cotta-de-Almeida, V (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Thymus Res, Rio De Janeiro, Brazil.	vca@ioc.fiocruz.br	Cotta-de-Almeida, Vinicius/G-3939-2012; dupre, loic/L-8174-2014; Cotta-de-Almeida, Vinicius/AAC-3721-2019	dupre, loic/0000-0002-7278-6503; Cotta-de-Almeida, Vinicius/0000-0002-6753-3480	Oswaldo Cruz Foundation; Brazilian Research Council (CNPq); Rio de Janeiro State Foundation (FAPERJ); French "Agence Nationale de la Recherche" [ANR-13-BSV1-0031]	Oswaldo Cruz Foundation; Brazilian Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro State Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); French "Agence Nationale de la Recherche"(French National Research Agency (ANR))	This article is funded by the Oswaldo Cruz Foundation (VC-d-A and WS), Brazilian Research Council (CNPq; VC-d-A and WS), Rio de Janeiro State Foundation for Research Funding (FAPERJ; VC-d-A and WS), and the French "Agence Nationale de la Recherche" (ANR-13-BSV1-0031 to LD).	Krummel MF, 2016, NAT REV IMMUNOL, V16, P193, DOI 10.1038/nri.2015.16; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442	2	0	0	1	8	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 13	2017	8								132	10.3389/fimmu.2017.00132	http://dx.doi.org/10.3389/fimmu.2017.00132			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EK3LH	28243238	Green Published, gold			2022-12-18	WOS:000393827400001
J	Jankovic, A; Maslarevic-Radovic, V; Djuric, P; Tosic-Dragovic, J; Bulatovic, A; Simovic, N; Mitrovic, M; Stankovic-Popovic, V; Dopudja-Pantic, V; Arandjelovic, S; Dimkovic, N				Jankovic, Aleksandar; Maslarevic-Radovic, Vesna; Djuric, Petar; Tosic-Dragovic, Jelena; Bulatovic, Ana; Simovic, Nikola; Mitrovic, Milos; Stankovic-Popovic, Verica; Dopudja-Pantic, Vesna; Arandjelovic, Snezana; Dimkovic, Nada			Onset of Microscopic Polyangiitis in Binephrectomied Patient on Chronic Hemodialysis-Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						microscopic polyangiitis; chronic hemodialysis; binephrectomy; MPO-ANCA; puimo	ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; AUTOANTIBODIES; VASCULITIS; ANCA	Introduction: Microscopic polyangiitis (MPA) is one of the causes of the pulmonary-renal syndrome associated with elevated non-specific markers of inflammation and antineu-trophil cytoplasmic autoantibody (ANCA) positivity in 50-75%. De novo occurrence of the disease in patients on chronic hemodialysis (HD) has not been described. Case presentation: We presented patient who developed MPO-ANCA-associated MPA with lung and musculoskeletal involvement after 4 years on regular HD due to bilateral nephrectomy. After excluding the other causes of MPO-ANCA positivity, diagnosis was confirmed even without renal biopsy. Patient received standard immunosuppression therapy and he is still in remission after 27 months. Conclusion: The onset of immune-mediated disease could be observed even after introduction of renal replacement therapy, which may be a diagnostic problem. Early recognition and traditional immunosuppressive regiment may provide successful outcome.	[Jankovic, Aleksandar; Maslarevic-Radovic, Vesna; Djuric, Petar; Tosic-Dragovic, Jelena; Bulatovic, Ana; Simovic, Nikola; Mitrovic, Milos; Stankovic-Popovic, Verica; Dimkovic, Nada] Univ Med Ctr Zvezdara, Clin Dept Nephrol Dialysis, Belgrade, Serbia; [Dopudja-Pantic, Vesna] Univ Med Ctr Zvezdara, Clin Dept Pulmonol, Belgrade, Serbia; [Arandjelovic, Snezana] Clin Ctr Serbia, Inst Allergol & Immunol, Belgrade, Serbia; [Dimkovic, Nada] Univ Belgrade, Fac Med, Belgrade, Serbia	Clinical Centre of Serbia; University of Belgrade	Jankovic, A (corresponding author), Univ Med Ctr Zvezdara, Clin Dept Nephrol Dialysis, Belgrade, Serbia.	sashajan22@yahoo.com						Andreini B, 2000, INT J ARTIF ORGANS, V23, P97, DOI 10.1177/039139880002300206; Bauer A, 2004, CLIN NEPHROL, V62, P144; Brimnes J, 1997, CLIN EXP IMMUNOL, V110, P250; Choi HK, 2000, ARTHRITIS RHEUM, V43, P405, DOI 10.1002/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5; Chung SA, 2010, RHEUM DIS CLIN N AM, V36, P545, DOI 10.1016/j.rdc.2010.04.003; Guillevin L, 1999, ARTHRITIS RHEUM-US, V42, P421, DOI 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6; Guillevin L, 2008, VASCULITIS, P355; Hermann J, 2005, ANN RHEUM DIS, V64, P641, DOI 10.1136/ard.2004.024877; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; MERTZ L E, 1992, Current Opinion in Rheumatology, V4, P39; Mojcik CF, 1996, AM J MED, V101, P100, DOI 10.1016/S0002-9343(96)00074-5; POOL MO, 1993, GUT, V34, P46, DOI 10.1136/gut.34.1.46; Savige J, 2000, KIDNEY INT, V57, P846, DOI 10.1046/j.1523-1755.2000.057003846.x; Stone JH, 2000, ARTHRIT CARE RES, V13, P424, DOI 10.1002/1529-0131(200012)13:6<424::AID-ART14>3.0.CO;2-Q	15	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 13	2017	8								111	10.3389/fimmu.2017.00111	http://dx.doi.org/10.3389/fimmu.2017.00111			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EK3KM	28243232	Green Published, gold			2022-12-18	WOS:000393825200002
J	Ingle, NB; Virkar, RG; Arankalle, VA				Ingle, Nilesh B.; Virkar, Rashmi G.; Arankalle, Vidya A.			Inter-Clade Protection Offered by Mw-Adjuvanted Recombinant HA, NP Proteins, and M2e Peptide Combination Vaccine in Mice Correlates with Cellular Immune Response	FRONTIERS IN IMMUNOLOGY			English	Article						H5N1; Mw; adjuvant; vaccine; immunophenotyping; protection; heterologous challenge; M2e	MYCOBACTERIUM-INDICUS-PRANII; MONOCLONAL-ANTIBODY; H5N1 INFLUENZA; T-CELLS; VIRUS; IMMUNOGENICITY; HEMAGGLUTININ; NUCLEOPROTEIN; GENE; RESISTANCE	We documented earlier that Mw (heat-killed suspension of Mycobacterium indicus pranii) adjuvant when used with conserved antigens, nucleoprotein (NP), and ectodomain of matrix (M2) protein (M2e) provided complete protection against homologous (Glade 2.2) virus challenge in mice. The present study extends these observations to inter-Glade challenge (Glade 2.3.2.1) H5N1 virus and attempts to understand preliminary immunologic basis for the observed protection. Female BALB/c mice immunized with a single or two doses of vaccine formulations (Glade 2.2 antigens) were challenged with 100LD50 homologous or heterologous (Glade 2.3.2.1) virus. To understand the preliminary immunologic mechanism, we studied proportions of selected immune cell types, immune response gene expression, and Th1iTh2 cytokines induced by antigen-stimulated splenocytes from immunized mice, at different time points. Complete protection was conferred by Mw-HA, Mw-HA + NP, and Mw-HA + NP + M2e against homologous challenge. The protection correlated with IgG2a antibody titers indicating important role of Th1 response. Despite high inter-cladal antigenic differences, complete protection against the heterologous strain was achieved with Mw-HA + NP + M2e. Of note, a single dose with higher antigen concentrations (50 mu g HA + 50 mu g NP + 50 mu g M2e) led to 80% protection against Glade 2.3.2.1 strain. The protection conferred by Mw-HNM correlated with induction of IFN-gamma, CD8(+) T cytotoxic cells, and CD4(+) T helper cells. Mw-adjuvanted HA + NP + M2e combination represents a promising vaccine candidate deserving further evaluation.	[Ingle, Nilesh B.; Virkar, Rashmi G.; Arankalle, Vidya A.] Natl Inst Virol, Hepatitis Div, Pune, Maharashtra, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Virology (NIV)	Arankalle, VA (corresponding author), Natl Inst Virol, Hepatitis Div, Pune, Maharashtra, India.	varankalle@yahoo.com		INGLE, NILESH/0000-0001-5853-3588; Arankalle, Vidya/0000-0002-9940-3437; VIRKAR, RASHMI/0000-0002-3764-9626	National Institute of Virology (NIV), Indian Council of Medical Research (ICMR), India	National Institute of Virology (NIV), Indian Council of Medical Research (ICMR), India	The study was funded by National Institute of Virology (NIV), Indian Council of Medical Research (ICMR), India.	[Anonymous], 2002, MAN AN INFL DIAGN SU, P28; Arankalle VA, 2010, CLIN VACCINE IMMUNOL, V17, P1481, DOI 10.1128/CVI.00223-10; Bhat S, 2015, MICROB PATHOGENESIS, V88, P87, DOI 10.1016/j.micpath.2015.08.010; Bright RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001501; Chan PKS, 2002, CLIN INFECT DIS, V34, pS58, DOI 10.1086/338820; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Deshmukh TM, 2007, VACCINE, V25, P4350, DOI 10.1016/j.vaccine.2007.03.040; El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147; Epstein SL, 2005, VACCINE, V23, P5404, DOI 10.1016/j.vaccine.2005.04.047; Fan JA, 2004, VACCINE, V22, P2993, DOI 10.1016/j.vaccine.2004.02.021; Fiers W, 2004, VIRUS RES, V103, P173, DOI 10.1016/j.virusres.2004.02.030; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Hessel A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088340; Hillaire MLB, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/939860; Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062; Ikeno D, 2011, VACCINE, V29, P4156, DOI 10.1016/j.vaccine.2011.03.084; Ingle NB, 2016, VIRAL IMMUNOL, V29, P478, DOI 10.1089/vim.2016.0021; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; Kim EH, 2014, J VIROL, V88, P9693, DOI 10.1128/JVI.00823-14; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Kumar P, 2014, IMMUNOLOGY, V143, P258, DOI 10.1111/imm.12306; Lalor PA, 2008, J INFECT DIS, V197, P1643, DOI 10.1086/588431; LaMere MW, 2011, J VIROL, V85, P5027, DOI 10.1128/JVI.00150-11; Le QM, 2005, NATURE, V437, P1108, DOI 10.1038/4371108a; Liu WL, 2003, FEMS IMMUNOL MED MIC, V35, P141, DOI 10.1016/S0928-8244(03)00009-9; Mozdzanowska K, 2003, VACCINE, V21, P2616, DOI 10.1016/S0264-410X(03)00040-9; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Patil DR, 2012, MICROBES INFECT, V14, P457, DOI 10.1016/j.micinf.2011.12.008; Pedersen GK, 2014, VACCINE, V32, P4550, DOI 10.1016/j.vaccine.2014.06.009; Purswani S, 2011, VACCINE, V29, P2341, DOI 10.1016/j.vaccine.2010.11.069; Rao SS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009812; Saini V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006263; Saravanabalaji S, 2009, INTERVIROLOGY, V52, P78, DOI 10.1159/000214862; SHU LL, 1993, J VIROL, V67, P2723, DOI 10.1128/JVI.67.5.2723-2729.1993; SINGH IG, 1992, INFECT IMMUN, V60, P257, DOI 10.1128/IAI.60.1.257-263.1992; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Suguitan AL, 2006, PLOS MED, V3, P1541, DOI 10.1371/journal.pmed.0030360; Talwar G P, 1999, Int Rev Immunol, V18, P229, DOI 10.3109/08830189909043027; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; TREANOR JJ, 1990, J VIROL, V64, P1375, DOI 10.1128/JVI.64.3.1375-1377.1990; WHO, 2015, CUM NUMB CONF HUM CA; WHO/FAO/OIE H5N1 Evolution Working Group, 2012, FAO OIE WHO TECHN UP; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; World Health Organization (WHO), 2007, OPT US HUM H5N1 INFL; Xue CY, 2015, VIRUS RES, V195, P35, DOI 10.1016/j.virusres.2014.09.018; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988	46	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 9	2017	7								674	10.3389/fimmu.2016.00674	http://dx.doi.org/10.3389/fimmu.2016.00674			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EG9GV	28119689	Green Published, gold			2022-12-18	WOS:000391367800001
J	Asgari, S; McLaren, PJ; Peake, J; Wong, M; Wong, R; Bartha, I; Francis, JR; Abarca, K; Gelderman, KA; Agyeman, P; Aebi, C; Berger, C; Fellay, J; Schlapbach, LJ				Asgari, Samira; McLaren, Paul J.; Peake, Jane; Wong, Melanie; Wong, Richard; Bartha, Istvan; Francis, Joshua R.; Abarca, Katia; Gelderman, Kyra A.; Agyeman, Philipp; Aebi, Christoph; Berger, Christoph; Fellay, Jacques; Schlapbach, Luregn J.		Swiss Pediat Sepsis Study	Exome Sequencing reveals Primary immunodeficiencies in Children with Community-Acquired Pseudomonas aeruginosa Sepsis (vol 7, 357, 2016)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Asgari, Samira; Bartha, Istvan; Fellay, Jacques] Ecole Polytech Fed Lausanne, Sch Life Sci, Global Hlth Inst, Lausanne, Switzerland; [Asgari, Samira; Bartha, Istvan; Fellay, Jacques] Swiss Inst Bioinformat, Lausanne, Switzerland; [McLaren, Paul J.] Publ Hlth Agcy Canada, Natl HIV & Retrovirol Lab, Winnipeg, MB, Canada; [McLaren, Paul J.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada; [Peake, Jane; Schlapbach, Luregn J.] Lady Cilento Childrens Hosp, Brisbane, Qld, Australia; [Wong, Melanie] Childrens Hosp Westmead, Sydney, NSW, Australia; [Wong, Richard] Royal Brisbane & Womens Hosp, Pathol Queensland Cent Lab, Brisbane, Qld, Australia; [Francis, Joshua R.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia; [Francis, Joshua R.] Royal Darwin Hosp, Darwin, NT, Australia; [Abarca, Katia] Pontificia Univ Catolica Chile, Escuela Med, Dept Enfermedades Infecciosas & Inmunol Pediat, Santiago, Chile; [Gelderman, Kyra A.] Sanquin Diagnost Serv, Amsterdam, Netherlands; [Agyeman, Philipp; Aebi, Christoph; Schlapbach, Luregn J.] Univ Bern, Univ Hosp Bern, Dept Pediat, Inselspital, Bern, Switzerland; [Berger, Christoph] Univ Childrens Hosp Zurich, Zurich, Switzerland; [Schlapbach, Luregn J.] Univ Queensland, PCCRG, Mater Res, Brisbane, Qld, Australia	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute of Bioinformatics; Public Health Agency of Canada; University of Manitoba; University of Sydney; Royal Brisbane & Women's Hospital; Charles Darwin University; Menzies School of Health Research; Pontificia Universidad Catolica de Chile; University of Bern; University Hospital of Bern; University Children's Hospital Zurich; Mater Research; University of Queensland	Fellay, J (corresponding author), Ecole Polytech Fed Lausanne, Sch Life Sci, Global Hlth Inst, Lausanne, Switzerland.; Fellay, J (corresponding author), Swiss Inst Bioinformat, Lausanne, Switzerland.; Schlapbach, LJ (corresponding author), Lady Cilento Childrens Hosp, Brisbane, Qld, Australia.; Schlapbach, LJ (corresponding author), Univ Bern, Univ Hosp Bern, Dept Pediat, Inselspital, Bern, Switzerland.; Schlapbach, LJ (corresponding author), Univ Queensland, PCCRG, Mater Res, Brisbane, Qld, Australia.	jacques.fellay@epfl.ch; l.schlapbach@uq.edu.au	ABARCA, KATIA/HDM-9351-2022; Agyeman, Philipp/AAG-3510-2019; Schlapbach, Luregn J/F-7465-2017	Schlapbach, Luregn J/0000-0003-2281-2598; Peake, Jane/0000-0001-9003-5861; Gelderman, Kyra/0000-0002-7815-032X				Asgari S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00357	1	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2016	7								447	10.3389/fimmu.2016.00447	http://dx.doi.org/10.3389/fimmu.2016.00447			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	EA1YR	27790221	Green Published, gold			2022-12-18	WOS:000386388700001
J	Harris, J; Morand, EF				Harris, James; Morand, Eric F.			Editorial: Focus on Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						SLE; inflammation; autoimmune diseases; autoantibodies; cytokines; cell death			[Harris, James; Morand, Eric F.] Monash Univ, Monash Hlth, Sch Clin Sci, Dept Med, Clayton, Vic, Australia	Monash University	Harris, J (corresponding author), Monash Univ, Monash Hlth, Sch Clin Sci, Dept Med, Clayton, Vic, Australia.	jim.harris@monash.edu	Morand, Eric/AAT-3259-2021; Morand, Eric F/I-4718-2013	Morand, Eric/0000-0002-9507-3338; Morand, Eric F/0000-0002-9507-3338; Harris, James/0000-0002-5634-9637					0	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 3	2016	7								400	10.3389/fimmu.2016.00400	http://dx.doi.org/10.3389/fimmu.2016.00400			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DX8EZ	27752255	Green Published, gold			2022-12-18	WOS:000384622200001
J	Martinet, J; Bourdenet, G; Meliani, A; Jean, L; Adriouch, S; Cohen, JL; Mingozzi, F; Boyer, O				Martinet, Jeremie; Bourdenet, Gwladys; Meliani, Amine; Jean, Laetitia; Adriouch, Sahil; Cohen, Jose L.; Mingozzi, Federico; Boyer, Olivier			Induction of Hematopoietic Microchimerism by Gener-Modified BMT Elicits Antigen-Specific B and T Cell Unresponsiveness toward Gene Therapy Products	FRONTIERS IN IMMUNOLOGY			English	Article						gene therapy; hemophilia B; tolerance; microchimerism; animal model	MURINE HEMOPHILIA-A; FACTOR-IX; LENTIVIRAL VECTORS; IMMUNE-RESPONSES; VIRAL VECTORS; CONDITIONING REGIMENS; TOLERANCE; MICE; TRANSPLANTATION; IMMUNOSUPPRESSION	Background: Gene therapy is a promising treatment option for hemophilia and other protein deficiencies. However, immune responses against the transgene product represent an obstacle to safe and effective gene therapy, urging for the implementation of tolerization strategies. Induction of a hematopoietic chimerism via bone marrow transplantation (BMT) is a potent means for inducing immunological tolerance in solid organ transplantation. Objectives: We reasoned, here, that the same viral vector could be used, first, to transduce BM cells for inducing chimerism-associated transgene-specific immune tolerance and, second, for correcting protein deficiencies by vector-mediated systemic production of the deficient coagulation factor. Methods: Evaluation of strategies to induce B and T cell tolerance was performed using ex vivo gene transfer with lentiviral (LV) vectors encoding coagulation factor IX (FIX) or the SIINFEKL epitope of ovalbumin. Following induction of microchimerism via BMT, animals were challenged with in vivo gene transfer with LV vectors. Results: The experimental approach prevented humoral immune response against FIX, resulting in persistence of therapeutic levels of circulating FIX, after LV-mediated gene transfer in vivo. In an ovalbumin model, we also demonstrated that this approach effectively tolerized the CD8(+) T cell compartment in an antigen-specific manner. Conclusion: These results provide the proof-of-concept that inducing a microchimerism by gene-modified BMT is a powerful tool to provide transgene-specific B and T cell tolerance in a gene therapy setting.	[Martinet, Jeremie; Bourdenet, Gwladys; Jean, Laetitia; Adriouch, Sahil; Boyer, Olivier] Normandie Univ, UNIROUEN, Pathophysiol & Biotherapy Inflammatory & Autoimmu, INSERM,CHU Rouen, Rouen, France; [Meliani, Amine; Mingozzi, Federico] Univ Paris 06, INSERM, U974, Paris, France; [Meliani, Amine; Mingozzi, Federico] Genethon, Evry, France; [Cohen, Jose L.] INSERM, Team 21 U955, Creteil, France	CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Boyer, O (corresponding author), Normandie Univ, UNIROUEN, Pathophysiol & Biotherapy Inflammatory & Autoimmu, INSERM,CHU Rouen, Rouen, France.	olivier.boyer@chu-rouen.fr	Bourdenet, Gwladys/G-1512-2018; ADRIOUCH, Sahil/G-8999-2012; Boyer, Olivier/N-6552-2013; Cohen, José/Q-4816-2018	ADRIOUCH, Sahil/0000-0002-0265-7773; Boyer, Olivier/0000-0002-7591-307X; Cohen, José/0000-0002-5077-6726; Martinet, Jeremie/0000-0002-3895-2731	Immunology-Hematology-Pneumology (IHP) ITMO collaborative grant from Inserm	Immunology-Hematology-Pneumology (IHP) ITMO collaborative grant from Inserm	This work was funded in part by an Immunology-Hematology-Pneumology (IHP) ITMO collaborative grant from Inserm.	Adriouch S, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00199; Annoni A, 2013, EMBO MOL MED, V5, P1684, DOI 10.1002/emmm.201302857; Annoni A, 2013, TRANSL RES, V161, P230, DOI 10.1016/j.trsl.2012.12.018; Astermark J, 2008, HAEMOPHILIA, V14, P36, DOI 10.1111/j.1365-2516.2008.01711.x; Bigger BW, 2006, GENE THER, V13, P117, DOI 10.1038/sj.gt.3302638; Brown BD, 2007, BLOOD, V110, P4144, DOI 10.1182/blood-2007-03-078493; Brown BD, 2007, BLOOD, V109, P2797, DOI 10.1182/blood-2006-10-049312; Chen J, 2006, MOL THER, V13, P260, DOI 10.1016/j.ymthe.2005.10.006; Childs R, 1999, BLOOD, V94, P3234, DOI 10.1182/blood.V94.9.3234.421k16_3234_3241; Crudele JM, 2015, BLOOD, V125, P1553, DOI 10.1182/blood-2014-07-588194; DiMichele DM, 2012, BRIT J HAEMATOL, V159, P123, DOI 10.1111/bjh.12028; Fields PA, 2001, MOL THER, V4, P201, DOI 10.1006/mthe.2001.0441; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Forman D, 2006, J IMMUNOL, V176, P3410, DOI 10.4049/jimmunol.176.6.3410; Gay V, 2012, ARCH VIROL, V157, P217, DOI 10.1007/s00705-011-1150-5; Grimm D, 2003, BLOOD, V102, P2412, DOI 10.1182/blood-2003-02-0495; Gyurkocza B, 2014, BLOOD, V124, P344, DOI 10.1182/blood-2014-02-514778; Hardet R, 2016, MOL THER, V24, P87, DOI 10.1038/mt.2015.146; High KA, 2012, BLOOD, V120, P4482, DOI 10.1182/blood-2012-05-423210; Ide LM, 2007, BLOOD, V110, P2855, DOI 10.1182/blood-2007-04-082602; Jiang HY, 2006, BLOOD, V108, P3321, DOI 10.1182/blood-2006-04-017913; Jindra PT, 2013, GENE THER, V20, P478, DOI 10.1038/gt.2012.57; Kang ES, 2002, J IMMUNOL, V169, P1930, DOI 10.4049/jimmunol.169.4.1930; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Lei TC, 2005, BLOOD, V105, P4865, DOI 10.1182/blood-2004-11-4274; Markusic DM, 2013, EMBO MOL MED, V5, P1698, DOI 10.1002/emmm.201302859; Mendell JR, 2010, NEW ENGL J MED, V363, P1429, DOI 10.1056/NEJMoa1000228; Mingozzi F, 2003, J CLIN INVEST, V111, P1347, DOI 10.1172/JCI200316887; Moayeri M, 2005, MOL THER, V12, P1034, DOI 10.1016/j.ymthe.2005.09.007; Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148; Ramezani A, 2011, THROMB HAEMOSTASIS, V105, P676, DOI 10.1160/TH10-11-0725; Rogers GL, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-25; van der Ploeg AT, 2008, LANCET, V372, P1342, DOI 10.1016/S0140-6736(08)61555-X; Vandendriessche T, 2007, J THROMB HAEMOST, V5, P16, DOI 10.1111/j.1538-7836.2006.02220.x; Verhoeyen E, 2012, HUM GENE THER, V23, P754, DOI 10.1089/hum.2012.020; Wang L, 2005, GENE THER, V12, P1453, DOI 10.1038/sj.gt.3302539; Wang XF, 2015, MOL THER, V23, P617, DOI 10.1038/mt.2015.20; Yu YYL, 2002, J IMMUNOL, V168, P3145, DOI 10.4049/jimmunol.168.7.3145	38	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2016	7								360	10.3389/fimmu.2016.00360	http://dx.doi.org/10.3389/fimmu.2016.00360			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DW0HH	27695454	gold, Green Published			2022-12-18	WOS:000383321000001
J	Van Regenmortel, MHV				Van Regenmortel, Marc H. V.			Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HIV vaccines; reverse vaccinology; philosophy of science; bioethics of vaccine trials; reductionism	ANTIBODY-ANTIGEN RECOGNITION; POLYSPECIFICITY; SPECIFICITY; VACCINES; TRIALS		[Van Regenmortel, Marc H. V.] Univ Strasbourg, Sch Biotechnol, CNRS, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Van Regenmortel, MHV (corresponding author), Univ Strasbourg, Sch Biotechnol, CNRS, Strasbourg, France.	vanregen@unistra.fr						Andrieu JM, 2014, J AIDS CLIN RES, V5, P281, DOI [10.4172/2155-6113.1000281, DOI 10.4172/2155-6113.1000281]; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Chalmers A.F., 1999, WHAT IS THIS THING C, V3rd ed.; Eisen HN, 2010, P NATL ACAD SCI USA, V107, P22373, DOI 10.1073/pnas.1012051108; Gandhi RT, 2009, VACCINE, V27, P6088, DOI 10.1016/j.vaccine.2009.05.016; Greek R, 2011, J PHILOS SCI LAW, V10, P1, DOI [10.5840/jpsl20111133, DOI 10.5840/JPSL20111133]; Horrobin DF, 2003, NAT REV DRUG DISCOV, V2, P151, DOI 10.1038/nrd1012; King MR, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00042; Klee R, 1997, INTRO PHILOS SCI, P212; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; Palma P, 2014, VACCINES, V2, P563, DOI 10.3390/vaccines2030563; Shanks Niall, 2009, Philos Ethics Humanit Med, V4, P2, DOI 10.1186/1747-5341-4-2; Shedlock DJ, 2009, NAT REV IMMUNOL, V9, P717, DOI 10.1038/nri2636; Van Regenmortel MHV, 2015, AIMS PUBLIC HEALTH, V2, P183, DOI 10.3934/publichealth.2015.2.183; Van Regenmortel MHV, 2014, J MOL RECOGNIT, V27, P627, DOI 10.1002/jmr.2394; Van Regenmortel MHV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00194; Van Regenmortel MHV, 2012, ARCH VIROL, V157, P1, DOI 10.1007/s00705-011-1145-2; Van Regenmortel MHV, 2011, VACCINE, V29, P7875, DOI 10.1016/j.vaccine.2011.08.063; Van Regenmortel MHV, 2004, EMBO REP, V5, P1016, DOI 10.1038/sj.embor.7400284; Wucherpfennig KW, 2007, SEMIN IMMUNOL, V19, P216, DOI 10.1016/j.smim.2007.02.012	21	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 5	2016	7								266	10.3389/fimmu.2016.00266	http://dx.doi.org/10.3389/fimmu.2016.00266			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DQ3QZ	27458032	gold, Green Published			2022-12-18	WOS:000379118300001
J	Rajnavolgyi, E				Rajnavolgyi, Eva			Editorial: The Emerging Role of Monocyte-Derived Cells in the Central Nervous System	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						monocyte-macrophage precursor cells; monocyte-derived macrophages; monocyte-derived dendritic cells; neuroimmunomodulation; neuroimmune interactions			[Rajnavolgyi, Eva] Univ Debrecen, Dept Immunol, Fac Med, Debrecen, Hungary	University of Debrecen	Rajnavolgyi, E (corresponding author), Univ Debrecen, Dept Immunol, Fac Med, Debrecen, Hungary.	evaraj@med.unideb.hu						Hildebrand DG, 2013, J IMMUNOL, V190, P4812, DOI 10.4049/jimmunol.1300089; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432	2	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 7	2016	7								223	10.3389/fimmu.2016.00223	http://dx.doi.org/10.3389/fimmu.2016.00223			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DN6BS	27375621	Green Published, gold			2022-12-18	WOS:000377156800001
J							Frontiers Prod Off	Defining Mononuclear Phagocyte Subset Homology across Several Distant Warm-Blooded Vertebrates through Comparative Transcriptomics (vol 6, 299, 2015)	FRONTIERS IN IMMUNOLOGY			English	Correction						comparative biology; immunology; dendritic cells; monocytes; macrophages; genomic and bio-informatic methods			[Frontiers Prod Off] Frontiers Prod Off, Frontiers, Switzerland		Frontiers Prod Off, Frontiers, Switzerland.							Robbins SH, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r17	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2016	7								143	10.3389/fimmu.2016.00143	http://dx.doi.org/10.3389/fimmu.2016.00143			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DK5HZ		Green Published, gold			2022-12-18	WOS:000374952300001
J	Jonuleit, H; Bopp, T				Jonuleit, Helmut; Bopp, Tobias			Editorial: Current Concepts of Cellular and Biological drugs to Modulate regulatory T Cell activity in the Clinic	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						regulatory T cells; dendritic cells; immunoregulation; autoimmunity; autoimmune diseases; clinical studies	TOLERANCE		[Jonuleit, Helmut] Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Dept Dermatol, D-55122 Mainz, Germany; [Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Inst Immunol, D-55122 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Jonuleit, H (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr Mainz, Dept Dermatol, D-55122 Mainz, Germany.	helmut.jonuleit@unimedizin-mainz.de	Bopp, Tobias/A-4328-2018; Jonuleit, Helmut/D-8059-2011	Bopp, Tobias/0000-0002-3232-8065; Jonuleit, Helmut/0000-0002-5672-9365				QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839	3	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2016	7								141	10.3389/fimmu.2016.00141	http://dx.doi.org/10.3389/fimmu.2016.00141			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DJ3UX	27148261	Green Published, gold			2022-12-18	WOS:000374133300001
J	Chirumbolo, S				Chirumbolo, Salvatore			Commentary: Mutual interaction of basophils and T cells in chronic inflammatory diseases	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						leukotriene B4; cysteinyl leukotriene; basophils; allergy and immunology; T cells	CYSTEINYL LEUKOTRIENE RECEPTOR; MAST-CELLS; ACTIVATION; EXPRESSION; 15-HETE; TIME; 5-LIPOXYGENASE; ALLERGY; ASTHMA		[Chirumbolo, Salvatore] Policlin GB Rossi, Univ Lab Med Res LURM Est, Dept Med, Unit Geriatry, Verona, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Chirumbolo, S (corresponding author), Policlin GB Rossi, Univ Lab Med Res LURM Est, Dept Med, Unit Geriatry, Verona, Italy.	salvatore.chirumbolo@univr.it						Brunnstrom A, 2015, PROSTAG OTH LIPID M, V121, P83, DOI 10.1016/j.prostaglandins.2015.04.010; Chirumbolo S, 2012, INT ARCH ALLERGY IMM, V158, P99, DOI 10.1159/000331312; Chirumbolo S, 2012, BLOOD TRANSFUS-ITALY, V10, P148, DOI 10.2450/2011.0020-11; Fujimura Y, 2002, BIOCHEM BIOPH RES CO, V297, P193, DOI 10.1016/S0006-291X(02)02139-3; Gauvreau GM, 2005, J ALLERGY CLIN IMMUN, V116, P80, DOI 10.1016/j.jaci.2005.03.014; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Iikura M, 2005, J ALLERGY CLIN IMMUN, V116, P578, DOI 10.1016/j.jaci.2005.04.029; Jarvis B, 2000, DRUGS, V59, P891, DOI 10.2165/00003495-200059040-00015; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Laidlaw TM, 2012, CLIN EXP ALLERGY, V42, P1313, DOI 10.1111/j.1365-2222.2012.03982.x; Michalak A, 2015, POSTEP DERM ALERGOL, V32, P262, DOI 10.5114/pdia.2015.52741; Moon TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108595; O'Sullivan S, 1999, ACTA PHYSIOL SCAND, V166, P1; Prinz I, 2005, J IMMUNOL, V175, P713, DOI 10.4049/jimmunol.175.2.713; Saito H, 2004, IMMUNOLOGY, V113, P246, DOI 10.1111/j.1365-2567.2004.01944.x; Sarfati M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00399; Siracusa MC, 2013, J ALLERGY CLIN IMMUN, V132, P789, DOI 10.1016/j.jaci.2013.07.046; Theron AJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/608930; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; Thivierge M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/384780; Uyttebroek AP, 2014, EXPERT REV CLIN IMMU, V10, P1325, DOI 10.1586/1744666X.2014.959498; VONAKIS BM, 1992, J BIOL CHEM, V267, P23625	23	0	1	0	6	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 8	2016	7								135	10.3389/fimmu.2016.00135	http://dx.doi.org/10.3389/fimmu.2016.00135			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DI6PQ	27092145	Green Published, gold			2022-12-18	WOS:000373622300001
J	Chirumbolo, S				Chirumbolo, Salvatore			Commentary: Sublingual allergen Immunotherapy in HIV-Positive Patients	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						allergy and immunology; basophils; asthma; HIV; anti-retroviral therapy; immunotherapy; SLIT	INFECTION; TH17; CELLS		[Chirumbolo, Salvatore] Univ Verona, Dept Med, Unit Geriatry, I-37100 Verona, Italy	University of Verona	Chirumbolo, S (corresponding author), Univ Verona, Dept Med, Unit Geriatry, I-37100 Verona, Italy.	salvatore.chirumbolo@univr.it						Bixler SL, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/852418; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; ElHed A, 2010, CURR OPIN HIV AIDS, V5, P146, DOI 10.1097/COH.0b013e32833647a8; Fodeman J, 2010, ANN ALLERG ASTHMA IM, V105, P320, DOI 10.1016/j.anai.2010.06.017; Gingo MR, 2012, J ALLERGY CLIN IMMUN, V129, P708, DOI 10.1016/j.jaci.2011.11.015; Iemoli E, 2016, ALLERGY, V71, P412, DOI 10.1111/all.12713; Kim CJ, 2013, J IMMUNOL, V191, P2164, DOI 10.4049/jimmunol.1300829; Ramirez-Velazquez C, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-23; Singh A, 2014, J MED VIROL, V86, P372, DOI 10.1002/jmv.23810; Steiner UC, 2009, WORLD ALLERGY ORGAN, V2, P57, DOI 10.1097/WOX.0b013e31819bcae7; Valiathan R, 2016, IMMUNOBIOLOGY, V221, P670, DOI 10.1016/j.imbio.2016.01.002; Wakashin H, 2009, INT ARCH ALLERGY IMM, V149, P108, DOI 10.1159/000211382	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAR 31	2016	7								132	10.3389/fimmu.2016.00132	http://dx.doi.org/10.3389/fimmu.2016.00132			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DI2QA	27066011	Green Published, gold			2022-12-18	WOS:000373340300001
J							Frontiers Production Office	Novel Immune Check-Point Regulators in Tolerance Maintenance (vol 6, 421, 2015)	FRONTIERS IN IMMUNOLOGY			English	Correction						B7; butyrophilin; immune tolerance			[Frontiers Production Office] Frontiers, Frontiers Prod Off, Lausanne, Switzerland									Guo TX, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00247; Pawar RD, 2015, CLIN EXP IMMUNOL, V179, P329, DOI 10.1111/cei.12452	2	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 8	2016	7								38	10.3389/fimmu.2016.00038	http://dx.doi.org/10.3389/fimmu.2016.00038			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	DC8QM		Green Published, gold			2022-12-18	WOS:000369484800002
J	Venketaraman, V				Venketaraman, Vishwanath			Editorial: Causes for increased susceptibility to Mycobacterium tuberculosis - a close view of the immune system	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tuberculosis; host-pathogen interactions; host immune responses; pathogenesis; adaptive immunity			[Venketaraman, Vishwanath] Western Univ Hlth Sci, Dept Basic Med Sci, Coll Osteopath Med Pacific, Pomona, CA 91766 USA	Western University of Health Sciences	Venketaraman, V (corresponding author), Western Univ Hlth Sci, Dept Basic Med Sci, Coll Osteopath Med Pacific, Pomona, CA 91766 USA.	vvenketaraman@westernu.edu	venketaraman, Vishwanath/AAW-6945-2020	venketaraman, Vishwanath/0000-0002-2586-1160				Allen M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00508; BoseDasgupta S, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00455; Cruz A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00498; Deng WY, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00613; Fennelly KP, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00313; Lozza L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00324	6	0	0	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 22	2015	6								545	10.3389/fimmu.2015.00545	http://dx.doi.org/10.3389/fimmu.2015.00545			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CX9BH	26557122	Green Published, gold			2022-12-18	WOS:000365999200001
J	Fennelly, KP; Jones-Lopez, EC				Fennelly, Kevin P.; Jones-Lopez, Edward C.			Quantity and quality of inhaled dose predicts immunopathology in tuberculosis (vol 6, 313, 2015)	FRONTIERS IN IMMUNOLOGY			English	Correction						tuberculosis; inhaled dose; pathology; inoculum; immune response			[Fennelly, Kevin P.] Univ Florida, Dept Med, Emerging Pathogens Inst, Gainesville, FL 32611 USA; [Jones-Lopez, Edward C.] Boston Univ, Sch Med, Boston Med Ctr, Sect Infect Dis, Boston, MA 02118 USA	State University System of Florida; University of Florida; Boston Medical Center; Boston University	Fennelly, KP (corresponding author), Univ Florida, Dept Med, Emerging Pathogens Inst, Gainesville, FL 32611 USA.	kevin.fennelly@verizon.net		Jones Lopez, Edward/0000-0001-6323-286X				Fennelly KP, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00313	1	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 1	2015	6								511	10.3389/fimmu.2015.00511	http://dx.doi.org/10.3389/fimmu.2015.00511			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CS5KC	26483797	gold, Green Published			2022-12-18	WOS:000362115900001
J	Ambuel, Y; Young, G; Brewoo, JN; Paykel, J; Weisgrau, K; Rakasz, EG; Haller, AA; Royals, M; Huang, CYH; Capuano, S; Stinchcomb, DT; Partidos, CD; Oso-Rio, JE				Ambuel, Y.; Young, G.; Brewoo, J. N.; Paykel, J.; Weisgrau, K.; Rakasz, E. G.; Haller, A. A.; Royals, M.; Huang, C. Y. H.; Capuano, S.; Stinchcomb, D. T.; Partidos, C. D.; Oso-rio, J. E.		Frontiers Prod Off	A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates (vol 5, 263, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction									Frontiers Prod Off, Frontiers, Switzerland		Ambuel, Y (corresponding author), Frontiers Prod Off, Frontiers, Switzerland.							Ambuel Y, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00263	1	0	0	0	12	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 15	2015	5								436	10.3389/fimmu.2014.00436	http://dx.doi.org/10.3389/fimmu.2014.00436			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0RN		gold, Green Published			2022-12-18	WOS:000354445600001
J	Hargadon, KM				Hargadon, Kristian Michael			Whole genome expression microarray analysis of highly versus poorly tumorigenic murine melanoma cell lines provides insights into factors that regulate tumor growth, metastasis, and immunogenicity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						melanoma; gene expression; microarray; pathway analysis; tumorigenicity	CD8(+) T-CELLS; DIFFERENTIATION		Hampden Sydney Coll, Hargadon Lab, Dept Biol, Hampden Sydney, VA 23943 USA		Hargadon, KM (corresponding author), Hampden Sydney Coll, Hargadon Lab, Dept Biol, Box 837, Hampden Sydney, VA 23943 USA.	khargadon@hsc.edu						American Cancer Society, 2015, CANC FACTS FIG 2015; Anichini A, 2003, J IMMUNOL, V171, P2134, DOI 10.4049/jimmunol.171.4.2134; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Guy GP, 2015, AM J PREV MED, V48, P183, DOI 10.1016/j.amepre.2014.08.036; Hargadon KM, 2012, AM J IMMUNOL, V8, P179, DOI DOI 10.3844/AJISP.2012.179.190; Hargadon KM, 2006, J IMMUNOL, V177, P6081, DOI 10.4049/jimmunol.177.9.6081; Hargadon KM, 2016, IMMUNOL CELL BIOL, V94, P24, DOI 10.1038/icb.2015.58; Hargadon KM, 2012, CELL IMMUNOL, V272, P275, DOI 10.1016/j.cellimm.2011.10.003; Howlader N, 2015, SEER CANC STAT REV 1; Leung AM, 2012, CANCER J, V18, P176, DOI 10.1097/PPO.0b013e31824bc981; Lucas R., 2006, ENV BURDEN DIS SERIE, V13; Mortarini R, 2003, CANCER RES, V63, P2535; Nonaka M, 2008, J IMMUNOL, V180, P3347, DOI 10.4049/jimmunol.180.5.3347; Overwijk W W, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2001s39; Riker AI, 2010, OCHSNER J, V10, P56; VAN DE VELDE H, 1991, NATURE, V351, P662; Ya Zhiya, 2015, Curr Protoc Immunol, V108, DOI 10.1002/0471142735.im2001s108; Zippelius A, 2004, CANCER RES, V64, P2865, DOI 10.1158/0008-5472.CAN-03-3066	18	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 14	2015	6									10.3389/fiimmu.2015.00452	http://dx.doi.org/10.3389/fiimmu.2015.00452			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CR8WJ					2022-12-18	WOS:000361634600001
J	Smith, KA				Smith, Kendall A.			Commentary: Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cell growth factor (TCGF); interleukin-2 (IL-2); T cell clones; IL-2 receptor	CELL GROWTH-FACTOR; FETAL LIVER-CELLS; ERYTHROPOIETIN		Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA.	kasmith@med.cornell.edu						BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; FREDRICKSON TN, 1977, EXP HEMATOL, V5, P254; GILLIS S, 1978, J IMMUNOL, V120, P2027; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; ROBB RJ, 1981, MOL IMMUNOL, V18, P1087, DOI 10.1016/0161-5890(81)90024-9; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; SMITH KA, 1983, J IMMUNOL, V131, P1808; SMITH KA, 1977, EXP HEMATOL, V5, P333; Smith KA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00194; Smith KA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00001	10	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 2	2015	6								454	10.3389/fimmu.2015.00454	http://dx.doi.org/10.3389/fimmu.2015.00454			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CR3PA	26388876	gold, Green Published			2022-12-18	WOS:000361244200001
J	Robert, PA				Robert, Philippe A.			Commentary: "Can selective MHC downregulation explain the specificity and genetic diversity of NK cell receptors?"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						iNKR; co-evolution; viral evasion strategies; computational model; population model			[Robert, Philippe A.] Helmholtz Ctr Infect Res, Dept Syst Immunol, Braunschweig, Germany; [Robert, Philippe A.] Helmholtz Ctr Infect Res, Braunschweig Integrated Ctr Syst Biol, Braunschweig, Germany; [Robert, Philippe A.] Inst Genet Mol Montpellier, CNRS, UMR5535, Montpellier, France; [Robert, Philippe A.] Univ Montpellier, F-34059 Montpellier, France	Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Robert, PA (corresponding author), Helmholtz Ctr Infect Res, Dept Syst Immunol, Braunschweig, Germany.	philippe.robert@ens-lyon.org	Robert, Philippe A./Z-2816-2019	Robert, Philippe A./0000-0003-1345-5015				Borhis G, 2011, ATLAS GENET CYTOGENE, V15, P787, DOI [10.4267/2042/46021, DOI 10.4267/2042/46021]; Carrillo-Bustamante P, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00311; Carrillo-Bustamante P, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003264; Lanier LL, 2008, NAT REV IMMUNOL, V8, P259, DOI 10.1038/nri2276; Sivori S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00105	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 31	2015	6								444	10.3389/fimmu.2015.00444	http://dx.doi.org/10.3389/fimmu.2015.00444			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CQ1BT	26379675	Green Published, gold			2022-12-18	WOS:000360333000001
J	von Hoven, G; Neukirch, C; Meyenburg, M; Fuser, S; Petrivna, MB; Rivas, AJ; Ryazanov, A; Kaufman, RJ; Aroian, RV; Husmann, M				von Hoven, Gisela; Neukirch, Claudia; Meyenburg, Martina; Fueser, Sabine; Petrivna, Maria Bidna; Rivas, Amable J.; Ryazanov, Alexey; Kaufman, Randal J.; Aroian, Raffi V.; Husmann, Matthias			eIF2 alpha confers cellular tolerance to S. aureus alpha-toxin	FRONTIERS IN IMMUNOLOGY			English	Article						pore forming toxins; S. aureus alpha-toxin; cellular tolerance; EIF2AK4; MAPK	PORE-FORMING TOXINS; ACTIVATED PROTEIN-KINASE; PLASMA-MEMBRANE; TRANSLATION INITIATION; LISTERIOLYSIN-O; CELLS; STRESS; DEPHOSPHORYLATION; PHOSPHORYLATION; RESISTANCE	We report on the role of conserved stress-response pathways for cellular tolerance to a pore forming toxin. First, we observed that small molecular weight inhibitors including of eIF2 alpha-phosphatase, jun-N-terminal kinase (JNK), and PI3-kinase sensitized normal mouse embryonal fibroblasts (MEFs) to the small pore forming S. aureus alpha-toxin. Sensitization depended on expression of mADAM10, the murine ortholog of a proposed high-affinity receptor for alpha-toxin in human cells. Similarly, eIF2 alpha(S51A/S51A) MEFs, which harbor an Ala knock-in mutation at the regulated Ser51 phosphorylation site of eukaryotic translation initiation factor 2 alpha, were hyper-sensitive to alpha-toxin. Inhibition of translation with cycloheximide did not mimic the tolerogenic effect of eIF2 alpha-phosphorylation. Notably, eIF2 alpha-dependent tolerance of MEFs was toxin-selective, as wild-type MEFs and eIF2 alpha(S51A/S51A) MEFs exhibited virtually equal sensitivity to Vibrio cholerae cytolysin. Binding of S. aureus alpha-toxin to eIF2 alpha(S51A/S51A) MEFs and toxicity in these cells were enhanced as compared to wild-type cells. This led to the unexpected finding that the mutant cells carried more ADAM10. Because basal phosphorylation of eIF2 alpha in MEFs required amino acid deprivation-activated eIF2 alpha-kinase 4/GCN2, the data reveal that basal activity of this kinase mediates tolerance of MEFs to alpha-toxin. Further, they suggest that modulation of ADAM10 is involved. During infection, bacterial growth may cause nutrient shortage in tissues, which might activate this response. Tolerance to alpha-toxin was robust in macrophages and did not depend on GCN2. However, JNKs appeared to play a role, suggesting differential cell type and toxin selectivity of tolerogenic stress responses. Understanding their function or failure will be important to comprehend anti-bacterial immune responses.	[von Hoven, Gisela; Neukirch, Claudia; Meyenburg, Martina; Fueser, Sabine; Petrivna, Maria Bidna; Rivas, Amable J.; Husmann, Matthias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Microbiol & Hyg, Mainz, Germany; [Ryazanov, Alexey] Rutgers Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ USA; [Kaufman, Randal J.] Sanford Burnham Med Res Inst, Degenerat Dis Program, La Jolla, CA USA; [Aroian, Raffi V.] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA	Johannes Gutenberg University of Mainz; Rutgers State University New Brunswick; Rutgers State University Medical Center; Sanford Burnham Prebys Medical Discovery Institute; University of Massachusetts System; University of Massachusetts Worcester	Aroian, RV (corresponding author), Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.	raffi.aroian@umassmed.edu; husmann@uni-mainz.de	von Hoven, Gisa/AAP-4044-2021; ryazanov, alexey/J-8081-2017		National Institutes of Health NIH/NIFMS [7-R0I-GM071603-09, DK042394, DK088227, HL052173]; University Medical Center Mainz	National Institutes of Health NIH/NIFMS; University Medical Center Mainz	Research reported in this publication was supported by the National Institutes of Health NIH/NIFMS under award number 7-R0I-GM071603-09 to RA and MH (subrecipient); DK042394, DK088227, and HL052173 to RK; MH and GH received support by University Medical Center Mainz. We like to thank Dr. H. Harding and Dr. D. Ron for generously providing Ppp1r15b<SUP>-/-</SUP>MEFs, Dr. P. Saftig for ADAM10<SUP>-/-</SUP> MEFs, and Dr. B. Bruegger for a large scale lipid analysis. Further, we gratefully acknowledge support by Dr. A. Diefenbach.	Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Agerer F, 2004, J MICROBIOL METH, V59, P23, DOI 10.1016/j.mimet.2004.05.008; Arguello RJ, 2015, CURR OPIN IMMUNOL, V32, P28, DOI 10.1016/j.coi.2014.12.001; Aroian R, 2007, CURR OPIN MICROBIOL, V10, P57, DOI 10.1016/j.mib.2006.12.008; Babiychuk EB, 2011, CELL DEATH DIFFER, V18, P80, DOI 10.1038/cdd.2010.81; BHAKDI S, 1986, MICROB PATHOGENESIS, V1, P5, DOI 10.1016/0882-4010(86)90027-6; Bischofberger M, 2012, CELL HOST MICROBE, V12, P266, DOI 10.1016/j.chom.2012.08.005; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Castro-Gomes T, 2014, TRENDS BIOCHEM SCI, V39, P307, DOI 10.1016/j.tibs.2014.06.001; Chakrabarti S, 2012, CELL HOST MICROBE, V12, P60, DOI 10.1016/j.chom.2012.06.001; Chu HP, 2014, DEV CELL, V28, P561, DOI 10.1016/j.devcel.2014.01.027; Corrotte M, 2013, ELIFE, V2, DOI 10.7554/eLife.00926; Corrotte M, 2012, TRAFFIC, V13, P483, DOI 10.1111/j.1600-0854.2011.01323.x; De Filippi L, 2007, CURR GENET, V52, P171, DOI 10.1007/s00294-007-0151-0; De S, 2011, P NATL ACAD SCI USA, V108, P7385, DOI 10.1073/pnas.1017442108; Deloche O, 2004, MOL CELL, V13, P357, DOI 10.1016/S1097-2765(04)00008-5; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; Dunbar TL, 2012, CELL HOST MICROBE, V11, P375, DOI 10.1016/j.chom.2012.02.008; Gonzalez MR, 2008, CELL MOL LIFE SCI, V65, P493, DOI 10.1007/s00018-007-7434-y; Gonzalez MR, 2011, CELL MICROBIOL, V13, P1026, DOI 10.1111/j.1462-5822.2011.01600.x; Hamon MA, 2011, INFECT IMMUN, V79, P2839, DOI 10.1128/IAI.01243-10; Harding HP, 2009, P NATL ACAD SCI USA, V106, P1832, DOI 10.1073/pnas.0809632106; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Haugwitz U, 2006, CELL MICROBIOL, V8, P1591, DOI 10.1111/j.1462-5822.2006.00733.x; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Husmann M, 2006, BIOCHEM BIOPH RES CO, V344, P1128, DOI 10.1016/j.bbrc.2006.03.241; Husmann M, 2009, FEBS LETT, V583, P337, DOI 10.1016/j.febslet.2008.12.028; Iacovache I, 2008, BBA-BIOMEMBRANES, V1778, P1611, DOI 10.1016/j.bbamem.2008.01.026; Idone V, 2008, J CELL BIOL, V180, P905, DOI 10.1083/jcb.200708010; Imre G, 2012, EMBO J, V31, P2615, DOI 10.1038/emboj.2012.93; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; Kao CY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001314; Kloft N, 2012, J BIOL CHEM, V287, P35299, DOI 10.1074/jbc.M112.379883; Kloft N, 2010, MED MICROBIOL IMMUN, V199, P299, DOI 10.1007/s00430-010-0163-0; Kloft N, 2009, BIOCHEM BIOPH RES CO, V385, P503, DOI 10.1016/j.bbrc.2009.05.121; Lemaitre B, 2013, NAT REV MICROBIOL, V11, P365, DOI 10.1038/nrmicro3029; Los FCO, 2013, MICROBIOL MOL BIOL R, V77, P173, DOI 10.1128/MMBR.00052-12; Maurer K, 2015, CELL HOST MICROBE, V17, P429, DOI 10.1016/j.chom.2015.03.001; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Nagahama M, 2013, INFECT IMMUN, V81, P3703, DOI 10.1128/IAI.00579-13; Porta H, 2011, PEPTIDES, V32, P601, DOI 10.1016/j.peptides.2010.06.012; Raberg L, 2009, PHILOS T R SOC B, V364, P37, DOI 10.1098/rstb.2008.0184; Richter E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122089; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/nmeth.1314, 10.1038/NMETH.1314]; Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432; Stassen M, 2003, INFECT IMMUN, V71, P6171, DOI 10.1128/IAI.71.11.6171-6177.2003; Stuart LM, 2013, NAT REV IMMUNOL, V13, P199, DOI 10.1038/nri3398; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tam C, 2010, J CELL BIOL, V189, P1027, DOI 10.1083/jcb.201003053; Tattoli I, 2012, CELL HOST MICROBE, V11, P563, DOI 10.1016/j.chom.2012.04.012; THELESTAM M, 1983, TOXICON, V21, P805, DOI 10.1016/0041-0101(83)90069-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vadia S, 2014, INFECT IMMUN, V82, P1084, DOI 10.1128/IAI.01067-13; von Hoven G, 2012, MED MICROBIOL IMMUN, V201, P409, DOI 10.1007/s00430-012-0271-0; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107	64	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2015	6								383	10.3389/fimmu.2015.00383	http://dx.doi.org/10.3389/fimmu.2015.00383			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	VF6CK		Green Published, gold			2022-12-18	WOS:000443241800001
J	von Hoven, G; Neukirch, C; Meyenburg, M; Fuser, S; Petrivna, MB; Rivas, AJ; Ryazanov, A; Kaufman, RJ; Aroian, RV; Husmann, M				von Hoven, Gisela; Neukirch, Claudia; Meyenburg, Martina; Fueser, Sabine; Petrivna, Maria Bidna; Rivas, Amable J.; Ryazanov, Alexey; Kaufman, Randal J.; Aroian, Raffi V.; Husmann, Matthias			eIF2 alpha confers cellular tolerance to S. aureus alpha-toxin	FRONTIERS IN IMMUNOLOGY			English	Article						pore forming toxins; S. aureus alpha-toxin; cellular tolerance; EIF2AK4; MAPK	PORE-FORMING TOXINS; ACTIVATED PROTEIN-KINASE; PLASMA-MEMBRANE; TRANSLATION INITIATION; LISTERIOLYSIN-O; CELLS; STRESS; DEPHOSPHORYLATION; PHOSPHORYLATION; RESISTANCE	We report on the role of conserved stress-response pathways for cellular tolerance to a pore forming toxin. First, we observed that small molecular weight inhibitors including of eIF2 alpha-phosphatase, jun-N-terminal kinase (JNK), and PI3-kinase sensitized normal mouse embryonal fibroblasts (MEFs) to the small pore forming S. aureus alpha-toxin. Sensitization depended on expression of mADAM10, the murine ortholog of a proposed high-affinity receptor for alpha-toxin in human cells. Similarly, eIF2 alpha(S51A/S51A) MEFs, which harbor an Ala knock-in mutation at the regulated Ser51 phosphorylation site of eukaryotic translation initiation factor 2 alpha, were hyper-sensitive to alpha-toxin. Inhibition of translation with cycloheximide did not mimic the tolerogenic effect of eIF2 alpha-phosphorylation. Notably, eIF2 alpha-dependent tolerance of MEFs was toxin-selective, as wild-type MEFs and eIF2 alpha(S51A/S51A) MEFs exhibited virtually equal sensitivity to Vibrio cholerae cytolysin. Binding of S. aureus alpha-toxin to eIF2 alpha(S51A/S51A) MEFs and toxicity in these cells were enhanced as compared to wild-type cells. This led to the unexpected finding that the mutant cells carried more ADAM10. Because basal phosphorylation of eIF2 alpha in MEFs required amino acid deprivation-activated eIF2 alpha-kinase 4/GCN2, the data reveal that basal activity of this kinase mediates tolerance of MEFs to alpha-toxin. Further, they suggest that modulation of ADAM10 is involved. During infection, bacterial growth may cause nutrient shortage in tissues, which might activate this response. Tolerance to alpha-toxin was robust in macrophages and did not depend on GCN2. However, JNKs appeared to play a role, suggesting differential cell type and toxin selectivity of tolerogenic stress responses. Understanding their function or failure will be important to comprehend anti-bacterial immune responses.	[von Hoven, Gisela; Neukirch, Claudia; Meyenburg, Martina; Fueser, Sabine; Petrivna, Maria Bidna; Rivas, Amable J.; Husmann, Matthias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Microbiol & Hyg, Mainz, Germany; [Ryazanov, Alexey] Rutgers Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ USA; [Kaufman, Randal J.] Sanford Burnham Med Res Inst, Degenerat Dis Program, La Jolla, CA USA; [Aroian, Raffi V.] Univ Massachusetts, Med Sch, Worcester, MA 01605 USA	Johannes Gutenberg University of Mainz; Rutgers State University New Brunswick; Rutgers State University Medical Center; Sanford Burnham Prebys Medical Discovery Institute; University of Massachusetts System; University of Massachusetts Worcester	Aroian, RV (corresponding author), Univ Massachusetts, Med Sch, Worcester, MA 01605 USA.	raffi.aroian@umassmed.edu; husmann@uni-mainz.de	von Hoven, Gisa/AAP-4044-2021		National Institutes of Health NIH/NIFMS [7-R0I-GM071603-09, DK042394, DK088227, HL052173]; University Medical Center Mainz	National Institutes of Health NIH/NIFMS; University Medical Center Mainz	Research reported in this publication was supported by the National Institutes of Health NIH/NIFMS under award number 7-R0I-GM071603-09 to RA and MH (subrecipient); DK042394, DK088227, and HL052173 to RK; MH and GH received support by University Medical Center Mainz. We like to thank Dr. H. Harding and Dr. D. Ron for generously providing Ppplrl5b<SUP>-/-</SUP> MEFs, Dr. P. Saftig for ADAM10<SUP>-/-</SUP> MEFs, and Dr. B. Bruegger for a large scale lipid analysis. Further, we gratefully acknowledge support by Dr. A. Diefenbach.	Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Agerer F, 2004, J MICROBIOL METH, V59, P23, DOI 10.1016/j.mimet.2004.05.008; Arguello RJ, 2015, CURR OPIN IMMUNOL, V32, P28, DOI 10.1016/j.coi.2014.12.001; Aroian R, 2007, CURR OPIN MICROBIOL, V10, P57, DOI 10.1016/j.mib.2006.12.008; Babiychuk EB, 2011, CELL DEATH DIFFER, V18, P80, DOI 10.1038/cdd.2010.81; BHAKDI S, 1986, MICROB PATHOGENESIS, V1, P5, DOI 10.1016/0882-4010(86)90027-6; Bischofberger M, 2012, CELL HOST MICROBE, V12, P266, DOI 10.1016/j.chom.2012.08.005; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Castro-Gomes T, 2014, TRENDS BIOCHEM SCI, V39, P307, DOI 10.1016/j.tibs.2014.06.001; Chakrabarti S, 2012, CELL HOST MICROBE, V12, P60, DOI 10.1016/j.chom.2012.06.001; Chu HP, 2014, DEV CELL, V28, P561, DOI 10.1016/j.devcel.2014.01.027; Corrotte M, 2013, ELIFE, V2, DOI 10.7554/eLife.00926; Corrotte M, 2012, TRAFFIC, V13, P483, DOI 10.1111/j.1600-0854.2011.01323.x; De Filippi L, 2007, CURR GENET, V52, P171, DOI 10.1007/s00294-007-0151-0; De S, 2011, P NATL ACAD SCI USA, V108, P7385, DOI 10.1073/pnas.1017442108; Deloche O, 2004, MOL CELL, V13, P357, DOI 10.1016/S1097-2765(04)00008-5; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027; Dunbar TL, 2012, CELL HOST MICROBE, V11, P375, DOI 10.1016/j.chom.2012.02.008; Gonzalez MR, 2008, CELL MOL LIFE SCI, V65, P493, DOI 10.1007/s00018-007-7434-y; Gonzalez MR, 2011, CELL MICROBIOL, V13, P1026, DOI 10.1111/j.1462-5822.2011.01600.x; Hamon MA, 2011, INFECT IMMUN, V79, P2839, DOI 10.1128/IAI.01243-10; Harding HP, 2009, P NATL ACAD SCI USA, V106, P1832, DOI 10.1073/pnas.0809632106; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Haugwitz U, 2006, CELL MICROBIOL, V8, P1591, DOI 10.1111/j.1462-5822.2006.00733.x; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Husmann M, 2006, BIOCHEM BIOPH RES CO, V344, P1128, DOI 10.1016/j.bbrc.2006.03.241; Husmann M, 2009, FEBS LETT, V583, P337, DOI 10.1016/j.febslet.2008.12.028; Iacovache I, 2008, BBA-BIOMEMBRANES, V1778, P1611, DOI 10.1016/j.bbamem.2008.01.026; Idone V, 2008, J CELL BIOL, V180, P905, DOI 10.1083/jcb.200708010; Imre G, 2012, EMBO J, V31, P2615, DOI 10.1038/emboj.2012.93; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; Kao CY, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001314; Kloft N, 2012, J BIOL CHEM, V287, P35299, DOI 10.1074/jbc.M112.379883; Kloft N, 2010, MED MICROBIOL IMMUN, V199, P299, DOI 10.1007/s00430-010-0163-0; Kloft N, 2009, BIOCHEM BIOPH RES CO, V385, P503, DOI 10.1016/j.bbrc.2009.05.121; Lemaitre B, 2013, NAT REV MICROBIOL, V11, P365, DOI 10.1038/nrmicro3029; Los FCO, 2013, MICROBIOL MOL BIOL R, V77, P173, DOI 10.1128/MMBR.00052-12; Maurer K, 2015, CELL HOST MICROBE, V17, P429, DOI 10.1016/j.chom.2015.03.001; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Nagahama M, 2013, INFECT IMMUN, V81, P3703, DOI 10.1128/IAI.00579-13; Porta H, 2011, PEPTIDES, V32, P601, DOI 10.1016/j.peptides.2010.06.012; Raberg L, 2009, PHILOS T R SOC B, V364, P37, DOI 10.1098/rstb.2008.0184; Richter E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122089; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/nmeth.1314, 10.1038/NMETH.1314]; Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432; Stassen M, 2003, INFECT IMMUN, V71, P6171, DOI 10.1128/IAI.71.11.6171-6177.2003; Stuart LM, 2013, NAT REV IMMUNOL, V13, P199, DOI 10.1038/nri3398; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tam C, 2010, J CELL BIOL, V189, P1027, DOI 10.1083/jcb.201003053; Tattoli I, 2012, CELL HOST MICROBE, V11, P563, DOI 10.1016/j.chom.2012.04.012; THELESTAM M, 1983, TOXICON, V21, P805, DOI 10.1016/0041-0101(83)90069-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vadia S, 2014, INFECT IMMUN, V82, P1084, DOI 10.1128/IAI.01067-13; von Hoven G, 2012, MED MICROBIOL IMMUN, V201, P409, DOI 10.1007/s00430-012-0271-0; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107	64	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 27	2015	6								383	10.3389/fimmu.2015.00383	http://dx.doi.org/10.3389/fimmu.2015.00383			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	VF9QL		Green Published, gold			2022-12-18	WOS:000444173200001
J	Agostino, M; Yuriev, E				Agostino, Mark; Yuriev, Elizabeth			Editorial: Structural and computational glycobiology - immunity and infection	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						glycobiology; structural biology; infection; cancer immunotherapy; molecular modeling; molecular recognition; lectins; signaling			[Agostino, Mark] Curtin Univ, Sch Biomed Sci, CHIRI Biosci, Perth, WA 6845, Australia; [Agostino, Mark] Curtin Univ, Sch Biomed Sci, Curtin Inst Computat, Perth, WA 6845, Australia; [Agostino, Mark] Burnet Inst, Ctr Biomed Res, Melbourne, Vic, Australia; [Yuriev, Elizabeth] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Melbourne, Vic 3004, Australia	Curtin University; Curtin University; Burnet Institute; Monash University	Agostino, M (corresponding author), Curtin Univ, Sch Biomed Sci, CHIRI Biosci, Perth, WA 6845, Australia.	mark.agostino@curtin.edu.au; elizabeth.yuriev@monash.edu	Yuriev, Elizabeth/A-7132-2016; Agostino, Mark/H-5481-2019	Yuriev, Elizabeth/0000-0002-3909-0379; Agostino, Mark/0000-0002-1799-0392				Agirre J, 2015, NAT CHEM BIOL, V11, P303, DOI 10.1038/nchembio.1798; Agostino M, 2013, J MOL GRAPH MODEL, V40, P80, DOI 10.1016/j.jmgm.2013.01.001; Agostino M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035457; Ahmed M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00372; Aretz J, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00323; Brockhausen I, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00492; Eid S, 2014, J COMPUT AID MOL DES, V28, P1191, DOI 10.1007/s10822-014-9794-3; Kerzmann A, 2008, J CHEM INF MODEL, V48, P1616, DOI 10.1021/ci800103u; Kieber-Emmons T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00308; Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820; Krengel U, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00325; Lee LY, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00404; Makeneni S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00397; Perez Serge, 2015, Methods Mol Biol, V1273, P241, DOI 10.1007/978-1-4939-2343-4_18; Richardson MB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00288; Tessier MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054874; Varki A., 2009, ESSENTIALS GLYCOBIOL; Yuriev E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00300	18	0	0	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 14	2015	6								359	10.3389/fimmu.2015.00359	http://dx.doi.org/10.3389/fimmu.2015.00359			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CO1YY	26236314	Green Published, gold			2022-12-18	WOS:000358953500002
J	Dalai, SK; Yadav, N; Patidar, M; Patel, H; Singh, AP				Dalai, Sarat Kumar; Yadav, Naveen; Patidar, Manoj; Patel, Hardik; Singh, Agam Prasad			Liver-stage specific response among endemic populations: diet and immunity (6, pg 125, 2015)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Dalai, Sarat Kumar; Yadav, Naveen; Patidar, Manoj; Patel, Hardik] Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India; [Singh, Agam Prasad] Natl Inst Immunol, Infect Dis Lab, New Delhi 110067, India	Nirma University; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Dalai, SK (corresponding author), Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India.	sarat.dalai@nirmauni.ac.in	Patel, Hardik/AAH-2217-2021	Patel, Hardik/0000-0003-0716-4510				Dalai SK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00125; Egan TJ, 2005, J INORG BIOCHEM, V99, P1532, DOI 10.1016/j.jinorgbio.2005.04.013; Trotta RF, 2004, BIOCHEMISTRY-US, V43, P4885, DOI 10.1021/bi0499258	3	0	0	0	3	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 22	2015	6								324	10.3389/fimmu.2015.00324	http://dx.doi.org/10.3389/fimmu.2015.00324			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CL9DS	26157440	Green Published, gold			2022-12-18	WOS:000357276300001
J	Anderson, J; Casorati, G				Anderson, John; Casorati, Giulia			Pnosphoantigen presentation to TCR gamma delta cells, a conundrum getting less gray zones	FRONTIERS IN IMMUNOLOGY			English	Review						antigen presentation; gamma delta TCR; butyrophilin 3A1; infection control; tumor surveillance	PRENYL PYROPHOSPHATE ANTIGENS; HUMAN T-LYMPHOCYTES; NONPEPTIDE ANTIGENS; CRYSTAL-STRUCTURE; MYCOBACTERIUM-TUBERCULOSIS; PHOSPHORYLATED ANTIGENS; PERIPHERAL-BLOOD; LYMPHOMA-CELLS; TUMOR-CELLS; RECOGNITION	The mechanistic requirements of antigen recognition by T cells expressing a gamma delta TCR has revealed important differences with those of alpha beta TCR cells and, despite impressive new data generated in the very recent years, they remain poorly understood. Based on the structure of the TCR chains and the tissue distribution, gamma delta cells are represented in a variety of populations. The major subset of human peripheral blood gamma delta cells express V gamma 9V gamma delta TCR heterodimers and are all stimulated by phosphorylated metabolites (commonly called phosphoantigens). Phosphoantigens are molecules with a very small mass and only stimulate V gamma 9V gamma delta cells in the presence of antigen-presenting cells, suggesting a strict requirement for dedicated antigen-presenting molecules. Recent studies have identified butyrophilin (BIN) 3A1 as the molecule necessary to stimulate V gamma 9V gamma delta cells. BTN3A1 extracellular, transmembrane, and cytoplasmic domains have different functions, including cognate interaction with the V gamma 9V gamma delta TCR, binding of the phosphoantigens, and interaction with cytoplasmic proteins. This review mainly discusses the known molecular mechanisms of BTN3A1-mediated antigen presentation to gamma delta cells and proposes a model of phosphoantigen presentation, which integrates past and recent studies. Keywords: antigen presentation, gamma delta TCR, butyrophilin 3A1, infection control, tumor surveillance	[Anderson, John] UCL, London WC1E 6BT, England; [Casorati, Giulia] Ist Sci San Raffaele, Milan, Italy	University of London; University College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Anderson, J (corresponding author), UCL, London WC1E 6BT, England.		Casorati, Giulia/J-7141-2018		European Union FP7 NEWTBVAC program, Swiss National Foundation Grant, A-STAR [310030_149571]	European Union FP7 NEWTBVAC program, Swiss National Foundation Grant, A-STAR	We thank Paula Cullen for reading the manuscript. This work was supported by the European Union FP7 NEWTBVAC program, Swiss National Foundation Grant 310030_149571, A-STAR	AbdelMotal UM, 1996, EUR J IMMUNOL, V26, P544, DOI 10.1002/eji.1830260307; Abeler-Dorner L, 2012, TRENDS IMMUNOL, V33, P34, DOI 10.1016/j.it.2011.09.007; Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Allison TJ, 2002, MOL IMMUNOL, V38, P1051, DOI 10.1016/S0161-5890(02)00034-2; Allison TJ, 2001, NATURE, V411, P820, DOI 10.1038/35081115; Arnett HA, 2014, NAT REV IMMUNOL, V14, P559, DOI 10.1038/nri3715; Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; Belmant C, 2000, FASEB J, V14, P1669, DOI 10.1096/fj.99-0909fje; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; Born WK, 2013, CELL MOL IMMUNOL, V10, P13, DOI 10.1038/cmi.2012.45; Boyden LM, 2008, NAT GENET, V40, P656, DOI 10.1038/ng.108; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Bruder J, 2012, J BIOL CHEM, V287, P20986, DOI 10.1074/jbc.M112.356709; Burk MR, 1997, J EXP MED, V185, P91, DOI 10.1084/jem.185.1.91; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; CASORATI G, 1989, J EXP MED, V170, P1521, DOI 10.1084/jem.170.5.1521; CICCONE E, 1989, EUR J IMMUNOL, V19, P1267, DOI 10.1002/eji.1830190718; Compte E, 2004, EUR J IMMUNOL, V34, P2089, DOI 10.1002/eji.200425227; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; DAVIS MM, 1995, IMMUNOL TODAY, V16, P316, DOI 10.1016/0167-5699(95)80143-X; DAVODEAU F, 1993, J IMMUNOL, V151, P1214; DAVODEAU F, 1993, EUR J IMMUNOL, V23, P804, DOI 10.1002/eji.1830230405; DELIBERO G, 1991, CURR TOP MICROBIOL, V173, P235; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; DELPORTO P, 1994, J IMMUNOL, V153, P3093; Espinosa E, 2001, J BIOL CHEM, V276, P18337, DOI 10.1074/jbc.M100495200; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; Favier B, 2003, J IMMUNOL, V171, P5027, DOI 10.4049/jimmunol.171.10.5027; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; FRANKE WW, 1981, J CELL BIOL, V89, P485, DOI 10.1083/jcb.89.3.485; Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; Hintz M, 2001, FEBS LETT, V509, P317, DOI 10.1016/S0014-5793(01)03191-X; HOHLFELD R, 1991, NEW ENGL J MED, V324, P877, DOI 10.1056/NEJM199103283241303; HOLOSHITZ J, 1992, J CLIN INVEST, V89, P308, DOI 10.1172/JCI115577; Hsiao CHC, 2014, CHEM BIOL, V21, P945, DOI 10.1016/j.chembiol.2014.06.006; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; Jeong J, 2009, J BIOL CHEM, V284, P22444, DOI 10.1074/jbc.M109.020446; Karunakaran MM, 2014, IMMUNOGENETICS, V66, P243, DOI 10.1007/s00251-014-0763-8; Kato Y, 2003, J IMMUNOL, V170, P3608, DOI 10.4049/jimmunol.170.7.3608; KAUR I, 1993, J IMMUNOL, V150, P2046; Kistowska M, 2008, EUR J IMMUNOL, V38, P2200, DOI 10.1002/eji.200838366; KORNBERG RD, 1972, P NATL ACAD SCI USA, V69, P1508, DOI 10.1073/pnas.69.6.1508; KOZBOR D, 1989, J EXP MED, V169, P1847, DOI 10.1084/jem.169.5.1847; Laad AD, 1999, INT J CANCER, V80, P709, DOI 10.1002/(SICI)1097-0215(19990301)80:5<709::AID-IJC14>3.3.CO;2-I; LANG F, 1995, J IMMUNOL, V154, P5986; Luoma AM, 2013, IMMUNITY, V39, P1032, DOI 10.1016/j.immuni.2013.11.001; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600-065X.2006.00479.x; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; OHMEN JD, 1991, J IMMUNOL, V147, P3353; Palakodeti A, 2012, J BIOL CHEM, V287, P32780, DOI 10.1074/jbc.M112.384354; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PLUSCHKE G, 1992, J EXP MED, V176, P1785, DOI 10.1084/jem.176.6.1785; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; RAULET DH, 1989, NATURE, V339, P342, DOI 10.1038/339342a0; Riano F, 2014, EUR J IMMUNOL, V44, P2571, DOI 10.1002/eji.201444712; RIVAS A, 1989, J IMMUNOL, V142, P1840; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Rojas RE, 2002, INFECT IMMUN, V70, P4019, DOI 10.1128/IAI.70.8.4019-4027.2002; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Scotet E, 2005, IMMUNITY, V22, P71, DOI 10.1016/j.immuni.2004.11.012; Sireci G, 2001, EUR J IMMUNOL, V31, P1628, DOI 10.1002/1521-4141(200105)31:5<1628::AID-IMMU1628>3.0.CO;2-T; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; Speir JA, 1999, IMMUNITY, V10, P51, DOI 10.1016/S1074-7613(00)80006-0; SPITS H, 1990, J IMMUNOL, V144, P4156; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; Uldrich AP, 2013, NAT IMMUNOL, V14, P1137, DOI 10.1038/ni.2713; VANKAER L, 1991, IMMUNOL REV, V120, P89, DOI 10.1111/j.1600-065X.1991.tb00589.x; Vavassori S, 2013, NAT IMMUNOL, V14, P908, DOI 10.1038/ni.2665; Wang H, 2003, J IMMUNOL, V170, P3696, DOI 10.4049/jimmunol.170.7.3696; Wang H, 2010, J IMMUNOL, V184, P6209, DOI 10.4049/jimmunol.1000231; Wiemer DF, 2014, BIOCHEM PHARMACOL, V89, P301, DOI 10.1016/j.bcp.2014.03.009; Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394; Woo JS, 2006, EMBO J, V25, P1353, DOI 10.1038/sj.emboj.7600994; Xi XY, 2013, CLIN VACCINE IMMUNOL, V20, P530, DOI 10.1128/CVI.00584-12; Xu B, 2011, P NATL ACAD SCI USA, V108, P2414, DOI 10.1073/pnas.1015433108; Zeng X, 2014, ELIFE, V3, DOI 10.7554/eLife.03609; Zeng X, 2012, IMMUNITY, V37, P524, DOI 10.1016/j.immuni.2012.06.011	84	0	0	0	15	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 15	2015	5								679	10.3389/fimmu.2014.00679	http://dx.doi.org/10.3389/fimmu.2014.00679			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI2TX		Green Published, gold			2022-12-18	WOS:000354601200001
J	Toubert, A; Einsele, H				Toubert, Antoine; Einsele, Hermann			From immunomonitoring to immune intervention	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HSCT; immune reconstitution; thymic function; cell therapy; Haplo-SCT			[Toubert, Antoine] Univ Paris Diderot, AP HP, Lab Immunol & Histocompatibil, Immunol Histocompatibil,Lab Jean Dausse,INSERM, Paris, France; [Einsele, Hermann] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany	Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Wurzburg	Einsele, H (corresponding author), Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany.	einsele_h@ukw.de						Clave E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00054; Danby R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00068; Eiz-Vesper B, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00410; Forcina A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00071; Fuji S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00330; Fuji S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00276; Locatelli F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00015; Seidel UJE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00076; Zinocker S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00355	9	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 6	2015	5								669	10.3389/fimmu.2014.00669	http://dx.doi.org/10.3389/fimmu.2014.00669			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI2TD	25610438	Green Published, gold			2022-12-18	WOS:000354599000001
J	Carrillo-Bustamante, P; Kesmir, C; De Boer, RJ				Carrillo-Bustamante, Paola; Kesmir, Can; De Boer, Rob J.			Quant fying tne protection of activating and inhibiting NK cell receptors during infection with a CMV-Iike virus (vol 5, 20, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction									[Carrillo-Bustamante, Paola; Kesmir, Can; De Boer, Rob J.] Univ Utrecht, Dept Biol, Theoret Biol & Bioinformat, Utrecht, Netherlands	Utrecht University	Carrillo-Bustamante, P (corresponding author), Univ Utrecht, Dept Biol, Theoret Biol & Bioinformat, Utrecht, Netherlands.	p.carrillobustamante@uu.nl	de Boer, Rob/B-6050-2011; Kesmir, Can/B-9410-2011	de Boer, Rob/0000-0002-2130-691X; Carrillo-Bustamante, Paola/0000-0001-8322-8286				Carrillo-Bustamante P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00020	1	0	0	0	3	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2015	5								663	10.3389/fimmu.2014.00663	http://dx.doi.org/10.3389/fimmu.2014.00663			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI2SU	25599749	Green Published, gold			2022-12-18	WOS:000354598100001
J	Michaeli, M; Tabibian-Keissar, H; Schiby, G; Shahaf, G; Pickman, Y; Hazanov, L; Rosenblatt, K; Dunn-Walters, DK; Barshack, I; Mehr, R				Michaeli, Miri; Tabibian-Keissar, Huila; Schiby, Ginette; Shahaf, Gitit; Pickman, Yishai; Hazanov, Lena; Rosenblatt, Kinneret; Dunn-Walters, Deborah K.; Barshack, Iris; Mehr, Ramit			Immunoglobulin gene repertoire diversification and selection in the stomach - from gastritis to gastric lymphomas (vol 5, 264 , 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction						B-cells; Ig gene; repertoire; somatic hypermutation; diversity			[Michaeli, Miri; Tabibian-Keissar, Huila; Shahaf, Gitit; Pickman, Yishai; Hazanov, Lena; Mehr, Ramit] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel; [Tabibian-Keissar, Huila; Schiby, Ginette; Rosenblatt, Kinneret; Barshack, Iris] Chaim Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel; [Dunn-Walters, Deborah K.] Kings Coll London, Sch Med, Div Immunol Infect & Inflammatory Dis, London WC2R 2LS, England; [Barshack, Iris] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Bar Ilan University; Chaim Sheba Medical Center; University of London; King's College London; Tel Aviv University; Sackler Faculty of Medicine	Mehr, R (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel.	ramit.mehr@biu.ac.il		Dunn-Walters, Deborah/0000-0002-7172-3893				Chao A, 2008, BIOMETRICS, V64, P1178, DOI 10.1111/j.1541-0420.2008.01010.x; Chao TJ, 2003, PROGRAM USERS GUIDE; Jost L, 2007, ECOLOGY, V88, P2427, DOI 10.1890/06-1736.1; Michaeli M, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00264	4	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JAN 5	2015	5								666	10.3389/fimmu.2014.00666	http://dx.doi.org/10.3389/fimmu.2014.00666			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI2SW		Green Published, gold			2022-12-18	WOS:000354598300001
J	Levin-Klein, R; Bergman, Y				Levin-Klein, Rena; Bergman, Yehudit			Epigenetic regulation of monoallelic rearrangement (allelic exclusion) of antigen receptor genes	FRONTIERS IN IMMUNOLOGY			English	Review						asynchronous replication; immunoglobulin; V(D)J recombination; DNA methylation; hematopoietic development	CELL-SPECIFIC DEMETHYLATION; KAPPA-CHAIN LOCUS; ASYNCHRONOUS REPLICATION; DNA METHYLATION; V(D)J RECOMBINATION; PLANT HOMEODOMAIN; MAMMALIAN-CELLS; IMMUNE-SYSTEM; TCRB ALLELES; EXPRESSION	While most genes in the mammalian genome are transcribed from both parental chromosomes in cells where they are expressed, approximately 10% of genes are expressed monoallelically, so that any given cell will express either the paternal or maternal allele, but not both. The antigen receptor genes in B and T cells are well-studied examples of a gene family, which is expressed in a monoallelic manner, in a process coined "allelic exclusion." During lymphocyte development, only one allele of each antigen receptor undergoesV(D)J rearrangement at a time, and once productive rearrangement is sensed, rearrangement of the second allele is prevented. In this mini review, we discuss the epigenetic processes, including asynchronous replication, nuclear localization, chromatin condensation, histone modifications, and DNA methylation, which appear to regulate the primary rearrangement of a single allele, while blocking the rearrangement of the second allele.	[Levin-Klein, Rena; Bergman, Yehudit] Hebrew Univ Jerusalem, Sch Med, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bergman, Y (corresponding author), Hebrew Univ Jerusalem, Sch Med, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, POB 12272, IL-91120 Jerusalem, Israel.	yehudit.bergman@huji.ac.il			Israel Academy of Sciences (ISF); NIH; Israel Cancer Research Foundation; United States-Israel Bi-national Science Foundation; I-CORE Program of ISF [1796/12]	Israel Academy of Sciences (ISF)(Israel Science Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Israel Cancer Research Foundation; United States-Israel Bi-national Science Foundation(US-Israel Binational Science Foundation); I-CORE Program of ISF	This work was supported by research grants from the Israel Academy of Sciences (ISF, Yehudit Bergman), NIH (Yehudit Bergman), the Israel Cancer Research Foundation (Yehudit Bergman), the United States-Israel Bi-national Science Foundation (Yehudit Bergman), and the I-CORE Program of ISF (grant no. 1796/12).	CEBRA JJ, 1966, J EXP MED, V123, P547, DOI 10.1084/jem.123.3.547; Cedar H, 2008, CURR OPIN IMMUNOL, V20, P308, DOI 10.1016/j.coi.2008.02.002; Chan EAW, 2013, P NATL ACAD SCI USA, V110, pE4628, DOI 10.1073/pnas.1310846110; Chaumeil J, 2013, CELL REP, V3, P359, DOI 10.1016/j.celrep.2013.01.024; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chess A, 2012, NAT REV GENET, V13, P421, DOI 10.1038/nrg3239; Deng QL, 2014, SCIENCE, V343, P193, DOI 10.1126/science.1245316; Di Ruscio A, 2013, NATURE, V503, P371, DOI 10.1038/nature12598; Eckersley-Maslin MA, 2014, DEV CELL, V28, P351, DOI 10.1016/j.devcel.2014.01.017; Farago M, 2012, NATURE, V490, P561, DOI 10.1038/nature11496; Farkash-Amar S, 2008, GENOME RES, V18, P1562, DOI 10.1101/gr.079566.108; Fraenkel S, 2007, NAT IMMUNOL, V8, P715, DOI 10.1038/ni1476; Gendre AV, 2014, DEV CELL, V28, P366, DOI 10.1016/j.devcel.2014.01.016; Goldmit M, 2002, EMBO J, V21, P5255, DOI 10.1093/emboj/cdf518; Goldmit M, 2005, NAT IMMUNOL, V6, P198, DOI 10.1038/ni1154; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hewitt SL, 2009, NAT IMMUNOL, V10, P655, DOI 10.1038/ni.1735; Inlay M, 2002, NAT IMMUNOL, V3, P463, DOI 10.1038/ni790; Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483; Ji YH, 2010, J EXP MED, V207, P2809, DOI 10.1084/jem.20101136; Ji YH, 2010, CELL, V141, P419, DOI 10.1016/j.cell.2010.03.010; Ji YH, 2003, P NATL ACAD SCI USA, V100, P7557, DOI 10.1073/pnas.0932635100; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; Levin-Klein R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00240; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Liu Y, 2007, IMMUNITY, V27, P561, DOI 10.1016/j.immuni.2007.09.005; Matthews AGW, 2007, NATURE, V450, P1106, DOI 10.1038/nature06431; Mendez J, 2009, CRIT REV BIOCHEM MOL, V44, P343, DOI 10.1080/10409230903232618; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Nakase H, 2003, EMBO REP, V4, P774, DOI 10.1038/sj.embor.embor904; Nemazee D, 2003, CURR OPIN IMMUNOL, V15, P182, DOI 10.1016/S0952-7915(03)00008-6; Pelanda R, 2014, CURR OPIN IMMUNOL, V27, P53, DOI 10.1016/j.coi.2014.01.012; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Plasschaert RN, 2014, DEVELOPMENT, V141, P1805, DOI 10.1242/dev.101428; Ramon-Maiques S, 2007, P NATL ACAD SCI USA, V104, P18993, DOI 10.1073/pnas.0709170104; Rodriguez I, 2013, CELL, V155, P274, DOI 10.1016/j.cell.2013.09.032; Schlimgen RJ, 2008, NAT IMMUNOL, V9, P802, DOI 10.1038/ni.1624; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; Schulz EG, 2013, CURR OPIN GENET DEV, V23, P109, DOI 10.1016/j.gde.2013.01.008; Selimyan R, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001475; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Skok JA, 2007, NAT IMMUNOL, V8, P378, DOI 10.1038/ni1448; Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; Steinel NC, 2013, J EXP MED, V210, P233, DOI 10.1084/jem.20121605; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Winter M, 2014, IMMUNOL CELL BIOL, V92, P409, DOI 10.1038/icb.2013.105; Zhou XR, 2010, J IMMUNOL, V185, P7544, DOI 10.4049/jimmunol.1002665; Zwemer LM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r10	55	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 5	2014	5									10.3389/fimmu.2014.00625	http://dx.doi.org/10.3389/fimmu.2014.00625			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1WA		Green Published, gold			2022-12-18	WOS:000354534500001
J	Mills, CD				Mills, Charles Dudley			Spatial, temporal, and functional aspects of macrophages during "The Good, the Bad, and the Ugly" phases of inflammation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						macrophage activation; M1/M2 macrophages; microenvironment; phenotype; immunotherapy; adoptive	DIFFERENT TUMOR MICROENVIRONMENTS; MULTIPLE-SCLEROSIS; ADOPTIVE TRANSFER; ANALYSIS REVEALS; ACTIVATION; POLARIZATION; MONOCYTES; SPECTRUM; M2; PHENOTYPE		BioMed Consultants, Skokie, IL 60077 USA		Mills, CD (corresponding author), BioMed Consultants, Skokie, IL 60077 USA.		Harris, Robert A./I-6234-2019	Harris, Robert A./0000-0003-4990-509X				Andersson A, 2004, J LEUKOCYTE BIOL, V76, P1118, DOI 10.1189/jlb.0704385; BARTH MW, 1995, J LEUKOCYTE BIOL, V57, P361, DOI 10.1002/jlb.57.3.361; Bonnet A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-417; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Hoeffel G, 2012, J EXP MED, V209, P1167, DOI 10.1084/jem.20120340; Kuang DM, 2007, BLOOD, V110, P587, DOI 10.1182/blood-2007-01-068031; Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196; Lee J, 2014, EXP MOL PATHOL, V96, P118, DOI 10.1016/j.yexmp.2013.09.004; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110; Mia S, 2014, SCAND J IMMUNOL, V79, P305, DOI 10.1111/sji.12162; MILLS CD, 1992, J IMMUNOL, V149, P2709; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; MORLAND B, 1977, EXP CELL RES, V108, P279, DOI 10.1016/S0014-4827(77)80035-9; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Mukherjee Sumana, 2013, Methods Mol Biol, V1002, P71, DOI 10.1007/978-1-62703-360-2_6; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Parsa R, 2012, DIABETES, V61, P2881, DOI 10.2337/db11-1635; Redente EF, 2010, J LEUKOCYTE BIOL, V88, P159, DOI 10.1189/jlb.0609378; Schouppe E, 2012, ONCOIMMUNOLOGY, V1, P1135, DOI 10.4161/onci.21566; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Stoger JL, 2012, ATHEROSCLEROSIS, V225, P461, DOI 10.1016/j.atherosclerosis.2012.09.013; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Vogel DYS, 2014, IMMUNOBIOLOGY, V219, P695, DOI 10.1016/j.imbio.2014.05.002; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Wang BF, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-43; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yin Y, 2013, CANCER IMMUNOL RES, V1, P256, DOI 10.1158/2326-6066.CIR-13-0073; Zaynagetdinov R, 2011, J IMMUNOL, V187, P5703, DOI 10.4049/jimmunol.1100558; Zhang XM, 2014, GLIA, V62, P804, DOI 10.1002/glia.22643	32	0	0	0	7	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 3	2014	5								612	10.3389/fimmu.2014.00612	http://dx.doi.org/10.3389/fimmu.2014.00612			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1VV		gold, Green Published			2022-12-18	WOS:000354534000001
J	Kisielow, P				Kisielow, Pawel			Demonstration of functional heterogeneity of T lymphocytes and identification of their two major subsets	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T lymphocytes; CD4(+)8(-) and CD4(-)8(+) subsets; CD4(+)8(+) thymocytes; positive selection; negative selection	THYMUS-DERIVED LYMPHOCYTES; CELL-MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY; POSITIVE SELECTION; CD4+8+ THYMOCYTES; ANTIGENS; RECEPTOR; MICE; EXPRESSION; PHENOTYPE		Ludwik Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland	Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences	Kisielow, P (corresponding author), Ludwik Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland.	kisielow@iitd.pan.wroc.pl						Boyse EA, 1968, P ROY SOC LOND B BIO, V178, P175, DOI [10.1098/rspb.1968.0032, DOI 10.1098/RSPB.1968.0032]; Cantor EA, 1975, J EXP MED, V141, P1376, DOI [10.1084/jem.141.6.1376, DOI 10.1084/JEM.141.6.1376]; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DRABER P, 1981, EUR J IMMUNOL, V11, P1, DOI 10.1002/eji.1830110102; GOWANS JL, 1966, J EXP MED, V124, P1017, DOI 10.1084/jem.124.5.1017; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; KISIELOW P, 1995, J EXP MED, V181, P1975, DOI 10.1084/jem.181.6.1975; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1975, NATURE, V253, P219, DOI 10.1038/253219a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MILLER JFA, 1967, NATURE, V216, P659, DOI 10.1038/216659a0; MITCHELL GF, 1968, J EXP MED, V128, P821, DOI 10.1084/jem.128.4.821; PARROTT DMV, 1962, NATURE, V195, P347, DOI 10.1038/195347a0; RAFF MC, 1969, NATURE, V224, P378, DOI 10.1038/224378a0; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; SHIKU H, 1975, J EXP MED, V141, P227, DOI 10.1084/jem.141.1.227; SHIKU H, 1975, J NATL CANCER I, V54, P415; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	23	0	0	0	3	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	DEC 1	2014	5								609	10.3389/fimmu.2014.00609	http://dx.doi.org/10.3389/fimmu.2014.00609			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1VN	25520718	Green Published, gold			2022-12-18	WOS:000354533200001
J	Silva, RDE; de Castro, MCAB; Rezende, AM; Pereira, VRA				Silva, Rafael de Freitas e; Accioly Brelaz de Castro, Maria Carolina; Rezende, Antonio Mauro; Alves Pereira, Valeria Rego			Targeting dencritic cells as a good alternative to combat Leishmania spp.	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						dendritic cells; vaccine; neglected diseases; leishmaniasis	MURINE VISCERAL LEISHMANIASIS; DENDRITIC CELLS; BALB/C MICE; CUTANEOUS LEISHMANIASIS; PARASITIC DISEASES; IMMUNE-RESPONSE; IN-VIVO; VACCINATION; PROTECTION; INFECTION		[Silva, Rafael de Freitas e] Univ Pernambuco, Dept Nat Sci, Garanhuns, Brazil; [Silva, Rafael de Freitas e; Accioly Brelaz de Castro, Maria Carolina; Alves Pereira, Valeria Rego] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Dept Immunol, Recife, PE, Brazil; [Rezende, Antonio Mauro] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Dept Microbiol, Recife, PE, Brazil	Universidade de Pernambuco (UPE); Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Silva, RDE (corresponding author), Univ Pernambuco, Dept Nat Sci, Garanhuns, Brazil.	rafael.silva@upe.br	de Castro, Maria Carolina Accioly Brelaz/AAV-5606-2020; Rezende, Antonio M/S-2126-2018; de Freitas e Silva, Rafael/AAH-6028-2020	de Castro, Maria Carolina Accioly Brelaz/0000-0003-2205-0618; Rezende, Antonio M/0000-0003-4775-1779; de Freitas e Silva, Rafael/0000-0001-7343-5986				Brelaz-de-Castro MCA, 2012, CELL IMMUNOL, V279, P180, DOI 10.1016/j.cellimm.2012.11.006; Agallou M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00268; Agallou M, 2012, VACCINE, V30, P5086, DOI 10.1016/j.vaccine.2012.05.075; Agallou M, 2011, VACCINE, V29, P5053, DOI 10.1016/j.vaccine.2011.04.089; Ahuja SS, 1999, J IMMUNOL, V163, P3890; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beaumier CM, 2013, TRANSL RES, V162, P144, DOI 10.1016/j.trsl.2013.03.006; Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Cohn L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00255; Das S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008222; Do Y, 2012, VACCINE, V30, P6359, DOI 10.1016/j.vaccine.2012.08.051; Flower Darren R, 2010, Immunome Res, V6 Suppl 2, pS1, DOI 10.1186/1745-7580-6-S2-S1; Garcia F, 2013, HUM VACC IMMUNOTHER, V9, P2445, DOI 10.4161/hv.25876; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Ghosh M, 2003, J IMMUNOL, V170, P5625, DOI 10.4049/jimmunol.170.11.5625; Gupta G, 2011, MED MICROBIOL IMMUN, V200, P241, DOI 10.1007/s00430-011-0197-y; Gupta G, 2009, J INFECT DIS, V200, P1300, DOI 10.1086/605895; Hotez PJ, 2006, VACCINE, V24, P5787, DOI 10.1016/j.vaccine.2006.05.008; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kopf M, 1996, J EXP MED, V184, P1127, DOI 10.1084/jem.184.3.1127; Majumder S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048727; Masic A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001721; Matos I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067453; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Okwor I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00128; Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139; Remer KA, 2007, EUR J IMMUNOL, V37, P2463, DOI 10.1002/eji.200636780; Sacks DL, 2014, NAT IMMUNOL, V15, P403, DOI 10.1038/ni.2853; Schnitzer JK, 2010, VACCINE, V28, P5785, DOI 10.1016/j.vaccine.2010.06.077; Schwarz T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003476; Stager S, 2010, IMMUNOL RES, V47, P14, DOI 10.1007/s12026-009-8135-4; Tel J, 2013, J IMMUNOL, V191, P5005, DOI 10.4049/jimmunol.1300787; Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x; Tsagozis P, 2004, INT J IMMUNOPATH PH, V17, P343, DOI 10.1177/039463200401700314; Tu H, 2014, J IMMUNOL METHODS, V413, P69, DOI 10.1016/j.jim.2014.07.008; Warren TL, 2000, J IMMUNOL, V165, P6244, DOI 10.4049/jimmunol.165.11.6244	43	0	0	0	6	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 26	2014	5								604	10.3389/fimmu.2014.00604	http://dx.doi.org/10.3389/fimmu.2014.00604			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1UR		gold, Green Published			2022-12-18	WOS:000354530900002
J	Raff, MC				Raff, Martin C.			Defining cell-surface antigenic markers for mouse T and B cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T cells; B cells; cell-surface markers; thy1; Ig; carrier effect; pre-B cells	LYMPHOCYTES		UCL, MRC Lab Mol Cell Biol, London, England	MRC Laboratory Molecular Biology; University of London; University College London	Raff, MC (corresponding author), UCL, MRC Lab Mol Cell Biol, London, England.	m.raff@ucl.ac.uk						Fink PJ, 2008, J IMMUNOL, V180, P4351, DOI 10.4049/jimmunol.180.7.4351; FLORSHEI.GL, 1969, NATURE, V222, P854, DOI 10.1038/222854a0; LEVEY RH, 1966, P NATL ACAD SCI USA, V56, P1130, DOI 10.1073/pnas.56.4.1130; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; Mitchison NA, 2004, NAT REV IMMUNOL, V4, P308, DOI 10.1038/nri1334; OWEN JJT, 1974, NATURE, V249, P361, DOI 10.1038/249361a0; Raff M C, 1970, Nature, V226, P1257, DOI 10.1038/2261257a0; RAFF MC, 1976, NATURE, V259, P224, DOI 10.1038/259224a0; RAFF MC, 1970, IMMUNOLOGY, V18, P931; RAFF MC, 1970, NATURE, V225, P553, DOI 10.1038/225553a0; RAFF MC, 1969, NATURE, V224, P378, DOI 10.1038/224378a0; RAFF MC, 1970, IMMUNOLOGY, V19, P637; RAFF MC, 1984, CC/LIFE SCI, V27, P21; REIF AE, 1966, NATURE, V209, P521, DOI 10.1038/209521b0; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; SCHLESIN.M, 1969, SCIENCE, V164, P1412, DOI 10.1126/science.164.3886.1412; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; WILLIAMS AF, 1984, NATURE, V308, P108, DOI 10.1038/308108a0	18	0	0	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 20	2014	5								559	10.3389/fimmu.2014.00559	http://dx.doi.org/10.3389/fimmu.2014.00559			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1TB	25477877	gold, Green Published			2022-12-18	WOS:000354526300001
J	Dinarello, C				Dinarello, Charles			Arginase in the vascular endothelium: friend or foe?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						arginase inhibitors; eNOS; reactive oxygen species; microvascular permeability; impaired vasorelaxation; vessel wall remodeling; I-citrulline	NITRIC-OXIDE; CELLS; DYSFUNCTION; INJURY		Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Dinarello, C (corresponding author), Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA.							Bagi Z, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00293; Chen F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00184; Durante W, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00111; Gao X, 2007, ARTERIOSCL THROM VAS, V27, P1269, DOI 10.1161/ATVBAHA.107.142521; Johnson FK, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00119; Katusic ZS, 2007, CIRC RES, V101, P640, DOI 10.1161/CIRCRESAHA.107.162701; Kuo L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00237; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Liu YL, 2013, EXP MOL PATHOL, V94, P160, DOI 10.1016/j.yexmp.2012.10.015; Lucas R, 1997, J LEUKOCYTE BIOL, V61, P551, DOI 10.1002/jlb.61.5.551; Lucas R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00228; Madigan M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00174; Ochoa JB, 2001, ANN SURG, V233, P393, DOI 10.1097/00000658-200103000-00014; Patel C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00173; Pernow J, 2013, CARDIOVASC RES, V98, P334, DOI 10.1093/cvr/cvt036; Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004; Romero MJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00480; Schulman SP, 2006, JAMA-J AM MED ASSOC, V295, P58, DOI 10.1001/jama.295.1.58; Steppan J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00278; Toque HA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00219; Yang ZH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00149	21	0	0	0	4	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	NOV 17	2014	5								589	10.3389/fimmu.2014.00589	http://dx.doi.org/10.3389/fimmu.2014.00589			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1SQ		Green Published, gold			2022-12-18	WOS:000354525100001
J	Dutton, RW				Dutton, Richard W.			In vitro studies of the antibody response: antibodies of different specificity are made in different populations of cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						in vitro culture; lymphocyte proliferation; clonal selection	PROTEIN-SYNTHESIS; MOUSE SPLEEN; AMINO-ACIDS; 8-AZAGUANINE; STIMULATION; ANTIGEN; INVITRO		Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Dutton, RW (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA.	Richard.Dutton@umassmed.edu						Burnet F. Macfarlane, 1956, ENZYME ANTIGEN VIRUS; Burnet M., 1959, CLONAL SELECTION THE; CREASER EH, 1956, BIOCHEM J, V64, P539, DOI 10.1042/bj0640539; DUTTON RW, 1978, IMMUNOL REV, V42, P20, DOI 10.1111/j.1600-065X.1978.tb00257.x; DUTTON RW, 1967, J EXP MED, V126, P443, DOI 10.1084/jem.126.3.443; DUTTON RW, 1973, J EXP MED, V138, P1496, DOI 10.1084/jem.138.6.1496; DUTTON RW, 1960, BIOCHEM J, V75, P230, DOI 10.1042/bj0750230; DUTTON RW, 1961, NATURE, V192, P462, DOI 10.1038/192462a0; DUTTON RW, 1958, NATURE, V182, P1377, DOI 10.1038/1821377a0; DUTTON RW, 1962, NATURE, V194, P93, DOI 10.1038/194093a0; DUTTON RW, 1971, PROGR IMMUNOLOGY, P355; HERSHEY AD, 1951, J GEN PHYSIOL, V34, P305, DOI 10.1085/jgp.34.3.305; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; MISHELL RI, 1967, J EXP MED, V126, P423, DOI 10.1084/jem.126.3.423; NOVELLI GD, 1957, J CELL COMPAR PHYSL, V50, P173, DOI 10.1002/jcp.1030500413; PAUL WE, 1968, J EXP MED, V127, P25, DOI 10.1084/jem.127.1.25; RICHARDSON M, 1964, SCIENCE, V146, P655, DOI 10.1126/science.146.3644.655; SCHWEET RS, 1957, J CELL COMPAR PHYSL, V50, P199, DOI 10.1002/jcp.1030500414; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P7101, DOI 10.1073/pnas.78.11.7101; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TALMAGE DW, 1957, ANNU REV MED, V8, P239, DOI 10.1146/annurev.me.08.020157.001323; VAUGHAN JH, 1960, J IMMUNOL, V84, P258	22	0	0	0	6	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 28	2014	5								515	10.3389/fimmu.2014.00515	http://dx.doi.org/10.3389/fimmu.2014.00515			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1NX	25389424	gold, Green Published			2022-12-18	WOS:000354512000001
J	Gray, CM; Addo, M; Schmidt, RE				Gray, Clive M.; Addo, Marylyn; Schmidt, Reinhold E.		Clinical Immunology Comm IUIS	A dead-end host: is there a way out? A position piece on the Ebola virus outbreak by the International Union of Immunology Societies	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccines; Ebolavirus; immunotherapies; clinical trials; immunopathogenesis	DISEASE		[Gray, Clive M.] Univ Cape Town, Natl Hlth Lab Serv, Inst Infect Dis & Mol Med, Div Immunol, ZA-7925 Cape Town, South Africa; [Addo, Marylyn] Univ Med Ctr Hamburg Eppendorf, Div Emerging Infect Trop Med, Dept Med, Hamburg, Germany; [Schmidt, Reinhold E.] Leibniz Univ Hannover, Div Rheumatol & Immunol, D-30167 Hannover, Germany	University of Cape Town; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leibniz University Hannover	Gray, CM (corresponding author), Univ Cape Town, Natl Hlth Lab Serv, Inst Infect Dis & Mol Med, Div Immunol, ZA-7925 Cape Town, South Africa.	clive.gray@uct.ac.za	Addo, Marylyn M./GNP-2548-2022	Addo, Marylyn/0000-0003-2836-9224; Gray, Clive/0000-0002-9293-901X				Aylward B, 2014, NEW ENGL J MED, V371, P1481, DOI 10.1056/NEJMoa1411100; Bavier J., 2014, REUTERS; Falzarano D, 2011, EXPERT REV VACCINES, V10, P63, DOI [10.1586/erv.10.152, 10.1586/ERV.10.152]; Farrar JJ, 2014, NEW ENGL J MED, V371, P1545, DOI 10.1056/NEJMe1411471; Fauci AS, 2014, NEW ENGL J MED, V371, P1084, DOI 10.1056/NEJMp1409494; Gatherer D, 2014, J GEN VIROL, V95, P1619, DOI 10.1099/vir.0.067199-0; Geisbert TW, 2011, J INFECT DIS, V204, pS1075, DOI 10.1093/infdis/jir349; Gunther S, 2011, J INFECT DIS, V204, pS785, DOI 10.1093/infdis/jir298; Kanapathipillai R, 2014, NEW ENGL J MED, V371, P2249, DOI 10.1056/NEJMp1412166; Marzi Andrea, 2011, J Bioterror Biodef, VS1; Olinger GG, 2012, P NATL ACAD SCI USA, V109, P18030, DOI 10.1073/pnas.1213709109; Owen Michael, 2014, Nurs Stand, V29, P32, DOI 10.7748/ns.29.4.32.s43; Paessler S, 2013, ANNU REV PATHOL-MECH, V8, P411, DOI 10.1146/annurev-pathol-020712-164041; Pigott DM, 2014, ELIFE, V3, DOI 10.7554/eLife.04395; Pollack A., 2014, NEW YORK TIMES; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Reed DS, 2004, VIRAL IMMUNOL, V17, P390, DOI 10.1089/vim.2004.17.390; Wahl-Jensen VM, 2005, J VIROL, V79, P10442, DOI 10.1128/JVI.79.16.10442-10450.2005; World Health Organization, 1978, B WORLD HEALTH ORGAN, P271; World Health Organization, 2014, EXP EB VACC WHO CONS; Zhang APP, 2012, VIRULENCE, V3, P440, DOI 10.4161/viru.21302	21	0	0	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2014	5								562	10.3389/fimmu.2014.00562	http://dx.doi.org/10.3389/fimmu.2014.00562			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1NV	25400640	Green Published, gold			2022-12-18	WOS:000354511800001
J	Oppenheim, JJ				Oppenheim, Joost J.			Evolution of the serendipitous discovery of macrophage-lymphocyte interactions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						lymphocytes; dendritic cells; macrophages; antigen presentation; chronic lymphocytic leukemic cells	PIG T-LYMPHOCYTES; ANTIGEN RECOGNITION; BOUND ANTIGENS; TRANSFORMATION; CELLS		NCI, Lab Mol Immunol, NIH, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Oppenheim, JJ (corresponding author), NCI, Lab Mol Immunol, NIH, Frederick, MD 21701 USA.	oppenhej@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC009369] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; HERSH EM, 1968, J IMMUNOL, V100, P1184; OPPENHEIM JJ, 1968, J IMMUNOL, V101, P262; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; SEEGER RC, 1972, J IMMUNOL, V109, P255; SEEGER RC, 1970, J EXP MED, V132, P44, DOI 10.1084/jem.132.1.44; SEEGER RC, 1972, J IMMUNOL, V109, P244; SHEVACH EM, 1973, J EXP MED, V138, P1213, DOI 10.1084/jem.138.5.1213; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Zhong YM, 2014, SEMIN HEMATOL, V51, P206, DOI 10.1053/j.seminhematol.2014.05.007	10	0	0	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 27	2014	5								530	10.3389/fimmu.2014.00530	http://dx.doi.org/10.3389/fimmu.2014.00530			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1IV	25386177	Green Published, gold			2022-12-18	WOS:000354498100001
J	Mosier, DE				Mosier, Donald E.			The story behind "a requirement for two cell types for antibody formation in vitro"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cell interactions; antibody response; early career; mentoring; history			Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA	Scripps Research Institute	Mosier, DE (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	dmosier@scripps.edu						ASKONAS BA, 1965, NATURE, V205, P470, DOI 10.1038/205470a0; COOPER MD, 1965, NATURE, V205, P143, DOI 10.1038/205143a0; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; MISHELL RI, 1966, SCIENCE, V153, P1004, DOI 10.1126/science.153.3739.1004; MOSIER DE, 1967, SCIENCE, V158, P1573, DOI 10.1126/science.158.3808.1573; MOSIER DE, 1970, NATURE, V225, P276, DOI 10.1038/225276a0; MOSIER DE, 1968, P NATL ACAD SCI USA, V61, P542, DOI 10.1073/pnas.61.2.542; RABINOWITZ Y, 1964, BLOOD, V23, P811, DOI 10.1182/blood.V23.6.811.811	8	0	0	0	5	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 17	2014	5						1	2	495	10.3389/fimmu.2014.00495	http://dx.doi.org/10.3389/fimmu.2014.00495			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1HK	25368614	gold, Green Published			2022-12-18	WOS:000354494300001
J	Bleackley, RC				Bleackley, R. Chris			Cloning CTL-specific genes (and now for something completely differential)	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						granzymes; proteases; immunology; gene expression; cytotoxic T lymphocyte; natural killer cells	CYTOTOXIC T-LYMPHOCYTES; MOUSE CHROMOSOME-14; SERINE PROTEASE; GRANZYME-B; GRANULES; CDNA; ACTIVATION; CLONES; CELLS		Univ Alberta, Dept Biochem, Edmonton, AB, Canada	University of Alberta	Bleackley, RC (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB, Canada.	chris.bleackley@ualberta.ca						BLEACKLEY RC, 1982, J IMMUNOL, V128, P758; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HENKART PA, 1986, J IMMUNOL, V137, P2611; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; TEH HS, 1985, J IMMUNOL, V135, P1582; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3	17	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	OCT 14	2014	5								509	10.3389/fimmu.2014.00509	http://dx.doi.org/10.3389/fimmu.2014.00509			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI1HD	25352849	Green Published, gold			2022-12-18	WOS:000354493500001
J							Frontiers Prod Off	Distinct migration and contact dynamics of resting and IL-2-activated human natural killer cells (vol 5, pg 80, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction						natural killer cells; cell migration; single-cell; fluorescence imaging; microchip			Frontiers Prod Off, Frontiers, Switzerland		Frontiers Prod Off, Frontiers, Switzerland.							Khorshidi MA, 2011, INTEGR BIOL-UK, V3, P770, DOI 10.1039/c1ib00007a; Olofsson PE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00080	2	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	SEP 22	2014	5						1	2	451	10.3389/fimmu.2014.00451	http://dx.doi.org/10.3389/fimmu.2014.00451			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0SR		Green Published, gold			2022-12-18	WOS:000354448700001
J	Marrella, V; Poliani, PL; Notarangelo, LD; Grassi, F; Villa, A				Marrella, Veronica; Poliani, Pietro Luigi; Notarangelo, Luigi Daniele; Grassi, Fabio; Villa, Anna			Rag defects and thymic stroma: lessons from animal models (vol 5, 259, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction						hymus; rag deficiency; omenn and leaky SCID models; central tolerance; thymic reconstitution; thymic crosstalk			[Marrella, Veronica; Villa, Anna] CNR, Inst Genet & Biomed Res, Milan Unit, Milan, Italy; [Marrella, Veronica; Villa, Anna] Ist Ricovero & Cura Carattere Sci, Ist Clin Humanitas, Rozzano, Italy; [Poliani, Pietro Luigi] Univ Brescia, Dept Mol & Translat Med, Pathol Unit, Brescia, Italy; [Notarangelo, Luigi Daniele] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Grassi, Fabio] Inst Res Biomed, Bellinzona, Switzerland	Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); IRCCS Humanitas Research Hospital; University of Brescia; Harvard University; Boston Children's Hospital; Universita della Svizzera Italiana	Villa, A (corresponding author), CNR, Inst Genet & Biomed Res, Milan Unit, Milan, Italy.	anna.villa@hsr.it	Marrella, Veronica/ABI-1285-2020; Notarangelo, Luigi D/F-9718-2016; POLIANI, Pietro Luigi/E-8145-2010	Marrella, Veronica/0000-0003-4035-8106; Notarangelo, Luigi D/0000-0002-8335-0262; Villa, Anna/0000-0003-4428-9013; GRASSI, FABIO/0000-0003-3348-1712; POLIANI, Pietro Luigi/0000-0002-5662-8978				Marrella V, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00259	1	0	0	0	0	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 25	2014	5								407	10.3389/fimmu.2014.00407	http://dx.doi.org/10.3389/fimmu.2014.00407			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0BH		gold, Green Accepted			2022-12-18	WOS:000354400100001
J	[Anonymous]				[Anonymous]			Expression of concern: Co-receptor CD8-mediated moculation of T-cell receptor functional sensitivity and epitope recognition degeneracy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material																			0	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	AUG 18	2014	5						1	1		10.3389/fimmu.2014.00401	http://dx.doi.org/10.3389/fimmu.2014.00401			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0AD		Green Published, gold			2022-12-18	WOS:000354397000001
J	Smith, KA				Smith, Kendall A.			Articles from he 15th ICI meeting Milan, Italy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						ICI2013; immunology; IUIS; Milan; SIICA			Cornell Univ, Weill Med College, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med College, Dept Med, Div Immunol, New York, NY 10021 USA.	kasmith@med.cornell.edu							0	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUL 28	2014	5								356	10.3389/fimmu.2014.00356	http://dx.doi.org/10.3389/fimmu.2014.00356			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH9VH	25120542	Green Published, gold			2022-12-18	WOS:000354384000001
J	Lane, PJL; McConnell, FM; Gaspal, FM; Nawaf, MG; Withers, DR; Anderson, G				Lane, Peter J. L.; McConnell, Fiona M.; Gaspal, Fabrina M.; Nawaf, Maher G.; Withers, David R.; Anderson, Graham			Evolving strategies for cancer and autoimmunity: back to the future (vol 5, 154, 2014)	FRONTIERS IN IMMUNOLOGY			English	Correction						CD4T cell; autoimmunity; tolerance mechanisms; cancer; regulation; memory			[Lane, Peter J. L.; McConnell, Fiona M.; Gaspal, Fabrina M.; Nawaf, Maher G.; Withers, David R.; Anderson, Graham] Univ Birmingham Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Lane, PJL (corresponding author), Univ Birmingham Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England.	p.j.l.lane@bham.ac.uk		Nawaf, Maher/0000-0003-2827-2967	Medical Research Council [G1000213] Funding Source: Medline; MRC [G1000213] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Lane PJL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00154	1	0	0	0	3	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 13	2014	5						1	1	286	10.3389/fimmu.2014.00286	http://dx.doi.org/10.3389/fimmu.2014.00286			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CH8JA	24982660	Green Published, gold			2022-12-18	WOS:000354281400001
J	Acuto, O				Acuto, Oreste			Bench, bedside, toolbox: T-cells deliver on every level	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						T-cells; pMHC; TCR; cancer immunotherapy; immunosuppression			Univ Oxford, Oxford OX1 2JD, England	University of Oxford	Acuto, O (corresponding author), Univ Oxford, Oxford OX1 2JD, England.							Blanchfield JL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00170; Burrows SR, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00229; Cole DK, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00168; Hebeisen M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00154; Holland CJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00172; Hombach AA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00135; Kerkar SP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00304; Kunert A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00363; Li YL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00206; Lloyd A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00221; Pentier JM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00133; Schaft N, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00270; Schmidt J, 2013, FRONT IMMUNOL, V4, P218, DOI DOI 10.3389/FIMMU.2013.00218; Stone JD, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00244; Szomolay B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00329; van den Berg HA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00250; Wooldridge L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00199; Zoete V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00268	18	0	0	0	2	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	FEB 3	2014	5								31	10.3389/fimmu.2014.00031	http://dx.doi.org/10.3389/fimmu.2014.00031			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	CI0VN	24550915	Green Published, gold			2022-12-18	WOS:000354457300001
J	Belz, GT; Cretney, E				Belz, Gabrielle T.; Cretney, Erika			Keeping memories alive	FRONTIERS IN IMMUNOLOGY			English	Editorial Material							T-CELL DIFFERENTIATION; IMMUNITY; EFFECTOR		[Belz, Gabrielle T.; Cretney, Erika] Walter & Eliza Hall Inst Med Res, Div Mol Immunol, Melbourne, Vic 3050, Australia; [Belz, Gabrielle T.; Cretney, Erika] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Belz, GT (corresponding author), Walter & Eliza Hall Inst Med Res, Div Mol Immunol, Melbourne, Vic 3050, Australia.	belz@wehi.edu.au	Belz, Gabrielle T/C-9350-2013	Belz, Gabrielle T/0000-0002-9660-9587				Buchholz VR, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00031; Gebhardt T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00340; Hamilton SE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00353; Kedzierska K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00357; Kim EH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00020; Krzych U, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00370; Kurtulus S, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00404; Rossy J, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00352; Russ BE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00371; Vasconcelos JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00358	10	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								21	10.3389/fimmu.2013.00021	http://dx.doi.org/10.3389/fimmu.2013.00021			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23378845	Green Published, gold			2022-12-18	WOS:000209374100021
J	Glenn, LL				Glenn, L. Lee			Limited effectiveness of psoralen- and ultraviolet-inactivated vaccinia virus on SHIV infection	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HIV-1 vaccine; pathogenic SHIV; non-human primate; envelope cocktail; ultraviolet-inactivated vaccinia virus			E Tennessee State Univ, Inst Quantitat Biol, Johnson City, TN 37614 USA	East Tennessee State University	Glenn, LL (corresponding author), E Tennessee State Univ, Inst Quantitat Biol, Johnson City, TN 37614 USA.	glennl@etsu.edu						HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Jones BG, 2012, VACCINE, V30, P3188, DOI 10.1016/j.vaccine.2012.03.001	2	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 327	10.3389/fimmu.2013.00327	http://dx.doi.org/10.3389/fimmu.2013.00327			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	24130561	Green Published, gold			2022-12-18	WOS:000209374100321
J	Kemper, C				Kemper, Claudia			Deciphering new molecular mechanisms of mast cell activation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									Kings Coll London, London WC2R 2LS, England	University of London; King's College London	Kemper, C (corresponding author), Kings Coll London, London WC2R 2LS, England.			Blank, Ulrich/0000-0002-2661-2983; Benhamou, Marc/0000-0001-7763-3795				Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Beghdadi W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00037; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Blank U, 2007, IMMUNOL REV, V217, P79, DOI 10.1111/j.1600-065X.2007.00503.x; Cavalcante MCM, 2002, J STRUCT BIOL, V137, P313, DOI 10.1016/S1047-8477(02)00007-2; Draber P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00130; Freichel M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00150; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Gri G, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00120; Halova I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00119; Koberle M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00106; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; Lorentz A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00143; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Migalovich-Sheikhet H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00238; Sandig H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00185; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Woidacki K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00029; Zierau O, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00169	22	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 100	10.3389/fimmu.2013.00100	http://dx.doi.org/10.3389/fimmu.2013.00100			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23630529	Green Published, gold			2022-12-18	WOS:000209374100099
J	Schilderink, R; Verseijden, C; de Jonge, WJ				Schilderink, R.; Verseijden, C.; de Jonge, W. J.			Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis (vol 4, 226, 2013)	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Schilderink, R.; Verseijden, C.; de Jonge, W. J.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Schilderink, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Tytgat Inst Liver & Intestinal Res, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	r.schilderink@amc.uva.nl						Schilderink R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00226	1	0	0	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 414	10.3389/fimmu.2013.00414	http://dx.doi.org/10.3389/fimmu.2013.00414			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS		gold, Green Published, Green Accepted			2022-12-18	WOS:000209374100402
J	Smith, KA				Smith, Kendall A.			Scientific scholarship and impact factors	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA.	kasmith@med.cornell.edu						Bach F H, 1970, Cell Immunol, V1, P219, DOI 10.1016/0008-8749(70)90009-2; Dutton R W, 1970, Cell Immunol, V1, P196, DOI 10.1016/0008-8749(70)90007-9; GERY I, 1972, J EXP MED, V136, P128, DOI 10.1084/jem.136.1.128; GERY I, 1972, J EXP MED, V136, P143, DOI 10.1084/jem.136.1.143; GILLIS S, 1978, J IMMUNOL, V120, P2027; GORDON J, 1965, NATURE, V208, P795, DOI 10.1038/208795a0; HOFFMANN M, 1971, SCIENCE, V172, P1047, DOI 10.1126/science.172.3987.1047; KASAKURA S, 1965, NATURE, V208, P794, DOI 10.1038/208794a0; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; PLATE JMD, 1976, NATURE, V260, P329, DOI 10.1038/260329a0; ROBB RJ, 1981, MOL IMMUNOL, V18, P1087, DOI 10.1016/0161-5890(81)90024-9; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROSENWASSER LJ, 1979, J EXP MED, V150, P709, DOI 10.1084/jem.150.3.709; SCHIMPL A, 1972, NATURE-NEW BIOL, V237, P15, DOI 10.1038/newbio237015a0; SMITH KA, 1980, J EXP MED, V151, P1551, DOI 10.1084/jem.151.6.1551; SMITH KA, 1980, MOL IMMUNOL, V17, P579, DOI 10.1016/0161-5890(80)90156-X; SMITH KA, 1980, NATURE, V287, P853, DOI 10.1038/287853a0; SMITH KA, 1983, J IMMUNOL, V131, P1808; Smith KA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00369; Smith KA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00364; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0	21	0	0	0	0	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2013	4								UNSP 79	10.3389/fimmu.2013.00079	http://dx.doi.org/10.3389/fimmu.2013.00079			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V38WS	23544031	Green Published, gold			2022-12-18	WOS:000209374100078
J	Craig, AWB				Craig, Andrew W. B.			The family infighting continues: dualling Src family kinases now linked to activating IgG receptor signaling and anaphylaxis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada	Queens University - Canada	Craig, AWB (corresponding author), Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.	andrew.craig@queensu.ca	Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				Falanga YT, 2012, J IMMUNOL, V188, P4360, DOI 10.4049/jimmunol.1003223; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Pullen NA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00117	6	0	0	0	0	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2012	3								137	10.3389/fimmu.2012.00137	http://dx.doi.org/10.3389/fimmu.2012.00137			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TQ	22685445	Green Published, gold			2022-12-18	WOS:000209501300134
J	Fridman, WH				Fridman, Wolf-Herve			Frontiers in Tumor Immunity: Grand Challenge "cancer and immunity: a family drama"	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Fridman, Wolf-Herve] Cordeliers Res Ctr, Paris, France; [Fridman, Wolf-Herve] Hop Europeen Georges Pompidou, Paris, France; [Fridman, Wolf-Herve] Univ Paris 05, Paris, France; [Fridman, Wolf-Herve] Univ Paris 06, Paris, France; [Fridman, Wolf-Herve] INSERM, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Fridman, WH (corresponding author), Cordeliers Res Ctr, Paris, France.	herve.fridman@crc.jussieu.fr		fridman, wolf herman/0000-0002-1332-0973					0	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2								34	10.3389/fimmu.2011.00034	http://dx.doi.org/10.3389/fimmu.2011.00034			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566824	Green Published, gold			2022-12-18	WOS:000209501400034
J	Le Moine, A; Jones, ND				Le Moine, Alain; Jones, Nick D.			A common biomarker signature for tolerated allografts and self tissues	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Le Moine, Alain] Univ Libre Bruxelles, Inst Med Immunol, Hop Erasme, Dept Nephrol Transplantat & Dialysis, Brussels, Belgium; [Jones, Nick D.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Transplantat Res Immunol Grp, Oxford OX3 9DU, England	Universite Libre de Bruxelles; University of Oxford	Le Moine, A (corresponding author), Univ Libre Bruxelles, Inst Med Immunol, Hop Erasme, Dept Nephrol Transplantat & Dialysis, Brussels, Belgium.	alemoine@ulb.ac.be						Cobbold SP, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00009; Martinez-Llordella M, 2008, J CLIN INVEST, V118, P2845, DOI 10.1172/JCI35342; Sagoo P, 2010, J CLIN INVEST, V120, P1848, DOI 10.1172/JCI39922; Sanchez-Fueyo A, 2011, GASTROENTEROLOGY, V140, P51, DOI 10.1053/j.gastro.2010.10.059; Waldmann H, 2010, NAT REV NEPHROL, V6, P569, DOI 10.1038/nrneph.2010.108	5	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2								11	10.3389/fimmu.2011.00011	http://dx.doi.org/10.3389/fimmu.2011.00011			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566802	gold, Green Published			2022-12-18	WOS:000209501400011
J	Moser, B				Moser, Bernhard			Grand challenges	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Moser, Bernhard] Cardiff Univ, Dept Infect Immun & Biochem, Cardiff CF10 3AX, S Glam, Wales	Cardiff University	Moser, B (corresponding author), Cardiff Univ, Dept Infect Immun & Biochem, Cardiff CF10 3AX, S Glam, Wales.	moserb@cardiff.ac.uk		Moser, Bernhard/0000-0002-4354-4572					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2									10.3389/fimmu.2011.00001	http://dx.doi.org/10.3389/fimmu.2011.00001			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566792	Green Published, gold			2022-12-18	WOS:000209501400001
J	Toubert, A				Toubert, Antoine			Grand challenges in alloimmunity and transplantation	FRONTIERS IN IMMUNOLOGY			English	Editorial Material									[Toubert, Antoine] Univ Paris Diderot, Sorbonne Paris Cite, Hop St Louis,Lab Jean Dausset, AP HP,Inst Univ Hematol,INSERM UMR940,Lab Immunol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Toubert, A (corresponding author), Univ Paris Diderot, Sorbonne Paris Cite, Hop St Louis,Lab Jean Dausset, AP HP,Inst Univ Hematol,INSERM UMR940,Lab Immunol, Paris, France.	antoine.toubert@univ-paris-diderot.fr	Toubert, Antoine/Q-3404-2017	Toubert, Antoine/0000-0002-7308-7317				Brouard S, 2011, TRANSPLANTATION, V91, P691, DOI 10.1097/TP.0b013e31820c4559; Charron D, 2009, J CARDIOVASC TRANSL, V2, P130, DOI 10.1007/s12265-008-9062-9; Dickinson AM, 2008, BEST PRACT RES CL HA, V21, P149, DOI 10.1016/j.beha.2008.03.004; Duquesnoy RJ, 2011, TISSUE ANTIGENS, V77, P525, DOI 10.1111/j.1399-0039.2011.01646.x; Krenger W, 2011, BLOOD, V117, P6768, DOI 10.1182/blood-2011-02-334623; Le Bas-Bernardet S, 2008, GENE THER, V15, P1247, DOI 10.1038/gt.2008.119; Levitsky J, 2011, LIVER TRANSPLANT, V17, P222, DOI 10.1002/lt.22265; Lupo-Stanghellini MT, 2010, HUM GENE THER, V21, P241, DOI 10.1089/hum.2010.014; Sagoo P, 2010, J CLIN INVEST, V120, P1848, DOI 10.1172/JCI39922; SNELL GD, 1986, IMMUNOGENETICS, V24, P339, DOI 10.1007/BF00377948; Tichelli A, 2009, EXPERT REV HEMATOL, V2, P583, DOI 10.1586/EHM.09.48; Velardi A, 2008, CURR OPIN IMMUNOL, V20, P581, DOI 10.1016/j.coi.2008.07.004	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.		2011	2									10.3389/fimmu.2011.00038	http://dx.doi.org/10.3389/fimmu.2011.00038			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	V40TR	22566828	Green Published, gold			2022-12-18	WOS:000209501400038
